CA2350730A1 - N-ureidoalkyl-piperidines as modulators of chemokine receptor activity - Google Patents

N-ureidoalkyl-piperidines as modulators of chemokine receptor activity Download PDF

Info

Publication number
CA2350730A1
CA2350730A1 CA002350730A CA2350730A CA2350730A1 CA 2350730 A1 CA2350730 A1 CA 2350730A1 CA 002350730 A CA002350730 A CA 002350730A CA 2350730 A CA2350730 A CA 2350730A CA 2350730 A1 CA2350730 A1 CA 2350730A1
Authority
CA
Canada
Prior art keywords
alkyl
occurrence
substituted
cycloalkyl
piperidinyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002350730A
Other languages
French (fr)
Inventor
George V. Delucca
Soo S. Ko
Jeffrey G. Varnes
Paul S. Watson
John V. Duncia
Dean A. Wacker
Joseph B. Santella, Iii
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Pharma Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2350730A1 publication Critical patent/CA2350730A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Abstract

The present application describes modulators of CCR3 of formula (I), or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.

Description

DEMANDES OU BREVETS VOLUMINEUX
LA PRESEN'fE PARTIE DE CETTE DEMANDS OU_ CE BREVET
COMPREND PLUS D'UN TOME.
CEC! EST LE TOME _ ~-DE c~
NOTE: Pour les tomes additionels, veuillez contacter le Bureau canadien des brevets JUMBO APPLlCATIONSIPATENTS
THIS SECTION ~F THE APPLICATION/PATENT CONTAINS MORE
THIS 1S VOLUME ~ _'OF -NOTE..For additional volumes please contact'the Canadian Patent Offfice ~::. _ :.v . , ',' ~wv. .~ ~ : ~ ~ . v° - v- . :.':' .......: , -.:~' ,. . :<' ~. ~. __ TITLE
N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE
RECF;PTOR ACTIVITY
FIELD OF THE INVENTION
This invention relates generally to modulators of ' chemokine receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and prevention of inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis.
BACKGROUND OF THE INVENTION
Chemokines are chemotactic cytokines, of molecular weight 6-15 kDa, that are released by a wide variety of cells to attract and activate, among other cell types, macrophages, T and B lymphocytes, eosinophils, basophils and neutrophils (reviewed in Luster, New Eng. J Med., 338, 436-445 (1998) and Rollins, Blood, 90, 909-928 (1997)).
There are two major classes of chemokines, CXC and CC, depending on whether the first two cysteines in the amino acid sequence are separated by a single amino acid (CXC) or are adjacent (CC). The CXC chemokines, such as interleukin-8 (IL-8), neutrophil-activating protein-2 (NAP-2) and melanoma growth stimulatory activity protein (MGSA) are chemotactic primarily for neutrophils and T
lymphocytes, whereas the CC chemokines, such as RANTES, MIP-10L, MIP-1~, the monocyte chemotactic proteins (MCP-1, MCP-2, MCP-3, MCP-4, and MCP-5) and the eotaxins (-1,-2, and -3) are chemotactic for, among other cell types, macrophages, T lymphocytes, eosinophils, dendritic cells, and basophils. There also exist the chemokines lymphotactin-l, lymphotactin-2 (both C chemokines), and fractalkine (a CXXXC chemokine) that do not fall into either of the major chemokine subfamilies.

The chemokines bind to specific cell-surface receptors belonging to the family of G-protein-coupled seven-transmembrane-domain proteins (reviewed in Horuk, Trends Pharm. Sci., 15, 159-165 (1994)) which are termed "chemokine receptors." pn binding their cognate ligands, chemokine receptors transduce an intracellular signal through the associated trimeric G proteins, resulting in, among other responses, a rapid increase in intracellular calcium concentration, changes in cell shape, increased expression of cellular adhesion molecules, degranulation, and promotion of cell migration. There are at least ten human chemokine receptors that bind or respond to CC
chemokines with the following characteristic patterns: CCR-1 (or "CKR-1" or "CC-CKR-1") [MIP-loc, MCP-3, MCP-4, RANTES]
(Ben-Barruch, et al., Cell, 72, 415-425 (1993), Luster, New Eng. J. Med., 338, 436-445 (1998)); CCR-2A and CCR-2B (or "CKR-2A"/"CKR-2B" or "CC-CKR-2A"/"CC-CKR-2B") (MCP-1, MCP-2, MCP-3, MCP-4, MCP-5] (Charo et al., Proc. Natl. Acad.
Sci. USA, 91, 2752-2756 (1994), Luster, New Eng. J. Med., 338, 436-445 (1998)); CCR-3 (or "CKR-3" or "CC-CKR-3") (eotaxin-1, eotaxin-2, RANTES, MCP-3, MCP-4] (Combadiere, et al., J. Biol. Chem., 270, 16491-16494 (1995), Luster, New Eng. J. Med., 338, 436-445 (1998)); CCR-4 (or "CKR-4~
or "CC-CKR-4") [TARC, MIP-la, RANTES, MCP-1] (Power et al., J. Biol. Chem., 270, 19495-19500 (1995), Luster, New Eng.
J. Med., 338, 436-445 (1998)); CCR-5 (or "CKR-5" OR "CC-CKR-5") [MIP-lOf" RANTES, MIP-1~] (Sanson, et al., Biochemistry, 35, 3362-3367 (1996)); CCR-6 (or "CKR-6~ or "CC-CKR-6") [LARC] (Baba et al., J. Biol. Chem., 272, 14893-14898 (1997)); CCR-7 (or "CKR-7" or "CC-CRR-7") [ELC]
(Yoshie et al., J. Leukoc. Biol. 62, 634-644 (1997)); CCR-8 (or "CKR-8" or "CC-CKR-8") [I-309, TARO, MIP-1~]
(Napolitano et al., J. Immunol., 157, 2759-2763 (1996), Bernardini et al., Eur. J. Immunol., 28, 582-588 (1998));
and CCR-10 (or "CKR-20" or "CC-CKR-10") [MCP-1, MCP-3]
(Bonini et al, DNA and Cell Biol., 16, 1249-1256 (1997)).

In addition to the mammalian chemokine receptors, mammalian cytomegaloviruses, herpesviruses and poxviruses have been shown to express, in infected cells, proteins with the binding properties of chemokine receptors (reviewed by Wells and Schwartz, Curr. Opin. Biotech., 8, 741-748 (1997)). Human CC chemokines, such as RANTES and MCP-3, can cause rapid mobilization of calcium via these virally encoded receptors. Receptor expression may be permissive for infection by allowing for the subversion of normal immune system surveillance and response to infection. Additionally, human chemokine receptors, such as CXCR4, CCR2, CCR3, CCRS and CCR8, can act as co-receptors for the infection of mammalian cells by microbes as with, for example, the human immunodeficiency viruses (HIV).
Chemokine receptors have been implicated as being important mediators of inflammatory, infectious, and immunoregulatory disorders and diseases, including asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. For example, the chemokine receptor CCR-3 plays a pivotal role in attracting eosinophils to sites of allergic inflammation and in subsequently activating these cells. The chemokine ligands for CCR-3 induce a rapid increase in intracellular calcium concentration, increased expression of cellular adhesion molecules, cellular degranulation, and the promotion of eosinophil migration. Accordingly, agents which modulate chemokine receptors would be useful in such disorders and diseases. In addition, agents which modulate chemokine receptors would also be useful in infectious diseases such as by blocking infection of CCR3 expressing cells by HIV or in preventing the manipulation of immune cellular responses by viruses such as cytomegaloviruses.
A substantial body of art has accumulated over the past several decades with respect to substituted piperidines and pyrrolidines. These compounds have implicated in the treatment of a variety of disorders.
4 describes spiro-substituted azacycles which are useful as modulators of chemokine receptors:
~m wherein R1 is C1_6 alkyl, optionally substituted with functional groups such as -NR6CONHR~, wherein R6 and R~ may be phenyl further substituted with hydroxy, alkyl, cyano, halo and haloalkyl. Such spiro compounds are not 20 considered part of the present invention.
WO 95/13069 is directed to certain piperidine, pyrrolidine, and hexahydro-1H-azepine compounds of general formula:
wherein A may be substituted alkyl or Z-substituted alkyl, with Z=NR6a or O. Compounds of this type are claimed to promote the release of growth hormone in humans and animals.
WO 93/06108 discloses pyrrolobenzoxazine derivatives as 5-hydroxytryptamine (5-HT) agonists and antagonists:
wherein A is lower alkylene and R4 may be phenyl optionally substituted with halogen.

U.S. Pat. No. 5,668,151 discloses Neuropeptide Y (NPY) antagonists comprising 1,4-dihydropyridines with a piperidinyl or tetrahydropyridinyl-containing moiety attached to the 3-position of the 4-phenyl ring:
~C O-B-(C H~,f- ~.
wherein B may be NH, NR1, O, or a bond, and R~ may be substituted phenyl, benzyl, phenethyl and the like.
These reference compounds are readily distinguished structurally by either the nature of the urea functionality, the attachment chain, or the possible substitution of the present invention. The prior art does not disclose nor suggest the unique combination of structural fragments which embody these novel piperidines and pyrrolidines as having activity toward the chemokine receptors.
SUN~IARY OF THE INVENTION
Accordingly, one object of the present invention is to provide novel agonists or antagonists of CCR-3, or pharmaceutically acceptable salts or prodrugs thereof.
It is another object of the present invention to provide pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt or prodrug form thereof.
It is another object of the present invention to . 30 provide a method for treating inflammatory diseases and allergic disorders comprising administering to a host in need of such treatment a therapeutically effective amount of at least one of the compounds of the present invention WO 00/35451 PCT/fJS99/30332 or a pharmaceutically acceptable salt or prodrug form thereof .
It is another object of the present invention to provide novel N-ureidoalkyl-piperidines for use in therapy.
It is another object~.of the present invention to provide the use of novel N-ureidoalkyl-piperidines for the manufacture of a medicament for the treatment of allergic disorders.
In another embodiment, the present invention provides novel N-ureidoalkyl-piperidines for use in therapy.
In another embodiment, the present invention provides the use of novel N-ureidoalkyl-piperidines for the manufacture of a medicament for the treatment of allergic disorders.
These and other objects, which will become apparent during the following detailed description, have been achieved by the inventors~ discovery that compounds of formula (I):
_R3 2 0 L-0 Ri R2 (I) or stereoisomers or pharmaceutically acceptable salts thereof, wherein E, Z, M, J, K, L, Q, R1, R2, R3, and R4 are defined below, are effective modulators of chemokine activity.
DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS
[ll Thus, in a first embodiment, the present invention provides novel compounds of formula (I):

L-Gl Rt R2 (I) or stereoisomers or pharmaceutically acceptable salts thereof, wherein:
M is absent or selected from CH2, CHR5, CHR13, CR13R13, and CRSR13 ;
Q is selected from CH2, CHRS, CHR13, CR13R13, and CR5R13;
J, K, and L are independently selected from CH2, CHRS, CHR6, CR6R6 and CR5R6;
with the provisos:
1) at least one of M, J, K, L, or Q contains an R5;
and 2) when M is absent, J is selected from CH2, CHRS, CHR13 , arid CR5R13 ;
Z is selected from O and S;
E is - ( CHR' ) - ( CHR' ) ~- ( CHRll ) - ;
R1 and Rz are independently selected from H, C1_g alkyl, CZ_g alkenyl, C2_8 alkynyl, (CH2)rC3-s cycloalkyl, and a (CH2)r-C3-to carbocyclic residue substituted with 0-5 Ra:
Ra, at each occurrence, is selected from Ci_q alkyl, C2_8 alkenyl, C2_g alkynyl, (CH2)rC3-6 cYcloalkyl, C1, Br, I, F. (CF2)rCF3. N02, CN, (CHZ)rNRbRb, (CH2)rOH, (CH2)rOR~, (CH2)rSH, (CH2)rSR~, (CH2)rC(O)Rb, (CH2)rC(0)NRbRb.
( CH2 ) rNRbC ( O ) Rb, ( CH2 ) rC ( O ) ORb. ( CH2 ) rOC ( 0 ) R~ , ( CH2 ) rCH ( =NRb ) NRbR~' . ( CH 2 ) rNHC ( =NRb ) NRbRb . ( CH2 ) rS ( 0 ) pR~ , (CH2)rS(O)2NRbRb, (CHz)rNRbS(O)2R~, and (CH2)rphenyl;
Rb, at each occurrence, is selected from H, Cl_6 alkyl, C3-s cycloalkyl, and phenyl;
Rte, at each occurrence, is selected from CI_6 alkyl, C3-s cycloalkyl, and phenyl;
alternatively, RZ and R3 join to form a 5, 6, or 7-membered ring substituted with 0-3 Ra;
R3 is selected from a (CR3'R3")r-C3-to carbocyclic residue substituted with 0-5 R15 and a (CR3'R3")r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, 0, and S, substituted with 0-3 R15;
R3' and R3", at each occurrence, are selected from H, C1_s alkyl, (CH2)rC3-6 cYcloalkyl, and phenyl;
R4 is absent, taken with the nitrogen to which it is attached to form an N-oxide, or selected from C1_8 alkyl, C2_8 alkenyl, C2_8 alkynyl, (CHZ)rC3-6 cycloalkyl, (CH2)qC(O)R4b, (CH2)qC(O)NR4aR4a~
(CH2)qC(O)OR4b, and a (CH2)r-C
3-to carbocyclic residue substituted with 0-3 R4c R4a and R4a', at each occurrence, are selected from H, C1_5 alkyl, (CH2)rC3-s cYcloalkyl, and phenyl;
R4b. at each occurrence, is selected from C~_6 alkyl, alkenyl, (CH2)rC3-6 cYcloalkyl, C2_8 alkynyl, and phenyl;
R4~, at each occurrence, is selected from C1_6 alkyl, C
alkenyl, C2_8 alkynyl, C3-6 cycloalkyl, C1, F, Br, I, CN, N02, (CF2)YCF3. (CH2)rOCl_5 alkyl, (CH2)rOH, (CH2)rSCl_5 alkyl, (CH2)rNR4aR4a' and (CH2)rphenyl;
alternatively, R4 joins with R~, R9, or R~l to form a 5, 6 or 7 membered piperidinium spirocycle or p~rrrolidinium spirocycle substituted with 0-3 Ra;
R5 is selected from a (CRS~'R5" ) t-C3-to carbocyclic residue substituted with 0-5 R16 and a (CRS'RS")t-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R16;
R5' and R5", at each occurrence, are selected from H, C1_s alkyl, (CHZ)rC3-s cYcloalkyl, and phenyl;
R6, at each occurrence, is selected from C1_6 alkyl, C2_g alkenyl, C2_8 alkynyl, (CH2)rC3-6 cYcloalkyl, (CFZ)rCF3, CN, (CH2)rNR6aR6a'. (CH2)rOH, (CH2)rOR6b, (CH2)rSH, (CH2)rSR6b, (CH2)rC(p)OH, (CH2)rC(O)R6b, (CH2)rC(O)NR6aR6a'. (CH2)rNR6dC(O)R6a, (CH2)rC(p)OR6b, (CH2)rOC(O)R6b, (CH2)rS(O)pR6b~ (CH2)rS(O)2NR6aR6a'.
(CH2)rNR6dS(O)2R6b~ and (CH2)tphenyl substituted with 0-3 RSc;
R6a ~d Rsa' , at each occurrence, are selected from H, C1_s alkyl, C3_6 cycloalkyl, and phenyl substituted with 0-3 R6c R6b. at each occurrence, is selected from C1_6 alkyl, C3_s cycloalkyl, and phenyl substituted with 0-3 R6c R6c, at each occurrence, is selected from C1_6 alkyl, C3-6 cycloalkyl, C1, F, Br, I, CN, N02, (CF2)rCF3, (CH2)rOCi-5 alkyl, (CH2)rOH, (CH2)rSCl-5 alkyl, and (CHZ)rNR6dR6d;
R6d, at each occurrence, is selected from H, C1_6 alkyl, and C3-s cycloalkyl;
with the proviso that when any of J, K, or L is CR6R6 and R6 is halogen, cyano, nitro, or bonded to the carbon to which it is attached through a heteroatom, the other R6 is not halogen, cyano, or bonded to the carbon to which it is attached through a heteroatom;
R' at each occurrence, is selected from H or alternatively R' joins with R° to form a 5, 6, or 7 membered piperidinium spirocycle or pyrrolidinium spirocycle substituted with 0-3R°;
R' at each occurrence,, is selected from H or alternatively R' joins with R° to form a 5, 6, or 7 membered piperidinium spirocycle or pyrrolidinium spirocycle substituted with 0-3R°;
R11 at each occurrence, is selected from H, C1_6alkyl, C2_ Balkenyl , C2_8alkynyl , and a (CH2 ) r-C3_lo carbocyclic residue substituted with 0-5 Rl~c, or alternatively R11 joins with R° to form a 5, 6, or 7 membered piperidinium spirocycle or pyrrolidinium spirocycle substituted with 0-3R°;
Rlia ~d Rlla~~ at each occurrence, are selected from H, alkyl, C2_8 alkenyl, C2_8 alkynyl, a (CH2) r-C3-1o carbocyclic residue substituted with 0-5 Rlle, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 Rlle;
Rllb, at each occurrence, is selected from C1_6 alkyl, C2_e alkenyl, C2_a alkynyl, a (CH2)r-C3-s carbocyclic residue substituted with 0-2 Rlle, and a (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 Rlle.
' Rllc, at each occurrence, is selected from Ci_6 alkyl, C2_8 alkenyl, C2_g alkynyl, (CH2)rC3-6 cycloalkyl, Cl, Br, I, F, (CF2 ) rCF3. N02. CN, (CH2 ) rNRllfRllf ~ (CH2 ) rOH, (CH2)rOCl_4 alkyl, (CH2)rSCl_4 alkyl, (CHz)rC(O)OH, (CH2)rC(O)Rllb~ (CH2)rC(O)NRllfRllf~ (CH2)rNRllfC(O)Rlla~
(CH2)rC(O)OC1_4 alkyl, (CH2)rOC(0)Rllb~
(CH2 ) rC (=NRllf ) ~llfRllf ~ (CH2 ) rNHC (-NRllf ) ~llfRllf (CHZ)rS(0)pRllb, (CH2)rS(O)2NR11fRllf~
(CH2)rNRllfS(O)2Rilb~ and (CH2)rphenyl substituted with 0-3 Rlle;
RIIe~ at each occurrence, is selected from Cl_6 alkyl, C
alkenyl, C2_8 alkynyl, C3_6 cycloalkyl, C1, F, Br, I, CN, N02, (CF2)rCF3, (CH2)rOCl_5 alkyl, OH, SH, (CH2)rSCl_ 5 alkyl, (CH2)rNRllfRllf~ ~d (CH2)rphenyl;
Rllf~ at each occurrence, is selected from H, C1_6 alkyl, and C3_6 cycloalkyl;
R13, at each occurrence, is selected from C1_6 alkyl, C2_8 alkenyl, C2_8 alkynyl, C3_6 cycloalkyl, (CF2)wCF3, (CH2)NR13aR13a'. (CH2)qOH, (CH2)QORl3b~ (CHZ)qSH, (CH2)qSRl3b, (CH2)wC(O)OH, (CH2)~",C(O)Rl3b~
(CH2)wC(O)NR13aR13a', (CH2)qI~TRI3dC(0)Rl3a~
(CH2)wC(0)ORl3b, (CH2)QOC(O)Rl3b, (CH2)wS(O)pRl3b~
(CH2 ) wS (p) 2NR13aR13a' . (CH2 ) qNRl3dS (O) 2R13b, and (CH2 ) w_ phenyl substituted with 0-3 Rl3c;
RI3a and Rl3a' , at each occurrence, are selected from H, C1_6 alkyl, C3_6 cycloalkyl, and phenyl substituted with 0-3 Rl3c;
Rl3b~ at each occurrence, is selected from Cl_6 alkyl, C3_s cycloalkyl, and phenyl substituted with 0-3 Rl3c Rl3c~ at each occurrence, is selected from C1_6 alkyl, C3_6 cycloalkyl, C1, F, Br, I, CN, N02, (CF2)rCF3, (CHZ)rOCl-5 alkyl, (CH2) rOH, (CH2 ) rSCl_5 alkyl, and (CHz)rNR13dR13d.

Rl3d, at each occurrence, is selected from H, C1_6 alkyl, and C3-6 cycloalkyl;
R15, at each occurrence, is selected from C1_g alkyl, (CH2)rC3-6 cycloalkyl, C1, Br, I, F, N02, CN, (CHR')rNR15aR15a', (CHR')rOH, (CHR')r0(CHR')rRlSd, (CHR' ) rSH, (CHR' ) rC (O) H, (CHR' ) rS (CHR~ ) rRl5d, ( CHR' ) rC ( 0 ) OH , ( CHR' ) rC ( O ) ( CHR' ) rRlSb, (CHR' ) rC (0) NR15aR15a' . (CHR' ) rNRlSfC (O) (CHR' ) rRlSb, (CHR' ) rNRlSfC (O) NR15fR15f, (CHR' ) rC (O) 0 (CHR' ) rRlSd, (CHR' ) rOC (O) (CHR' ) rRlSb, (CHR' ) rC (=NRl5f ) ~15aR15a' .
(CHR')rNHC(=NRl5f)~15fR15f, (CHR')rS(O)p(CHR')rRlSb, (CHR' ) rS (0) 2NR15aR15a' , (CHR' ) rNRlSfS (0) 2 (CHR' ) rRlSb~ C1-5 haloalkyl, C2_8 alkenyl substituted with 0-3 R', C2_8 alkynyl substituted with 0-3 R', (CHR')rphenyl substituted with 0-3 RlSe, and a (CHZ)r-5-IO membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 RlSe R', at each occurrence, is selected from H, C1_6 alkyl, C2_8 alkenyl, C2_g alkynyl, (CH2)rC3-6 cycloalkyl, and (CH2)rphenyl substituted with RlSe;
RlSa and RlSa~, at each occurrence, are selected from H, C1_s alkyl, C2_8 alkenyl, C2_g alkynyl, a (CHZ)r-C3-to carbocyclic residue substituted with 0-5 RlSe, and a (CHZ)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, 0, and S, substituted with 0-2 RlSe RlSb, at each occurrence, is selected from C1_6 alkyl, CZ_8 alkenyl, C2_a alkynyl, a (CH2)r-C3-6 carbocyclic residue substituted with 0-3 RlSe~ and (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 RlSe RlSd~ at each occurrence, is selected from C2_8 alkenyl, C2_a alkynyl, C1_6 alkyl substituted with 0-3 RlSe, a (CH2)r-C3-to carbocyclic residue substituted with 0-3 RISe, and a (CH2)r5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 RlSe;
RlSe~ at each occurrence, is selected from C1_6 alkyl, C2_8 alkenyl, C2_8 alkynyl, (CHZ)rC3-6 cYcloalkyl, C1, F, Br, I, CN, N02, (CF2)rCF3, (CH2)rOCl_5 alkyl, OH, SH, (CH2)rSCl_5 alkyl, (CH2)rNR15fR15f~ and (CH2)rphenyl;
RlSf~ at each occurrence, is selected from H, C1_6 alkyl, C3-6 cycloalkyl, and phenyl;
R16, at each occurrence, is selected from C1_g alkyl, C2_8 alkenyl, CZ_g alkynyl, (CH2)rC3_6 cycloalkyl, C1, Br, I, F, N02, CN, (CHR')rNR16aR16a'~ (CHR')rOH, (CHR')r0(CHR')rRl6d, (CHR')rSH, (CHR')rC(O)H, (CHR')rS(CHR')rRl6d, (CHR')rC(O)OH, ( CHR' ) rC ( O ) ( CHR' ) rRl6b, ( CHR' ) rC ( O ) NR16aR16a' (CHR' ) rNRl6fC (O) (CHR' ) rRl6b~ (CHR' ) rC (O) O (CHR' ) rRl6d~
( CHR' ) rOC ( O ) ( CHR' ) rRl6b , ( CHR' ) rC ( =X16 f ) ~16aR16a' (CHR')rNHC(=NRl6f)NR16fR16f~ (CHR')rS(O)p(CHR')rRl6b~
(CHR')rS(0)2NR16aR16a', (CHR')rNRl6fS(O)2(CHR')rRl6b, C1_6 haloalkyl, C2_g alkenyl substituted with 0-3 R', C2_8 alkynyl substituted with 0-3 R', and (CHR')rphenyl substituted with 0-3 Rlse Rl6a and Rl6a' , at each occurrence, are selected from H, C1_6 alkyl, C2_g alkenyl, C2_g alkynyl, a (CH2)r-C3-10 carbocyclic residue substituted with 0-5 Rlse, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 Rl6e WO 00/35451 PCTlUS99/30332 Rl6b~ at each occurrence, is selected from C1_6 alkyl, C2_g alkenyl, CZ_e alkynyl, a (CH2)rC3-6 carbocyclic residue substituted with 0-3 Rl6e, and a (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, 0, and S, substituted with 0-2 Rise;
Rl6d~ at each occurrence, is selected from C2_8 alkenyl, C2_8 alkynyl, CI_s alkyl substituted with 0-3 Rlse, a (CH2)r-C3-to carbocyclic residue substituted with 0-3 Rl6e, and a (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 Rl6e Rl6e~ at each occurrence, is selected from C1_6 alkyl, C2_8 alkenyl, C2_8 alkynyl, (CH2)rC3_s cycloalkyl, C1, F, Br, I, CN, N02, (CF2)rCF3, (CH2)rOC1_5 alkyl, OH, SH, (CH2)rSC1_5 alkyl, (CH2)rNR16fR16f~ ~d (CH2)rphenyl;
Rl6f~ at each occurrence, is selected from H, C1-5 alkyl, and C3-6 cycloalkyl, and phenyl;
v is selected from 2 and 2;
t is selected from 1 and 2;
w is selected from 0 and 1;
r is selected from 0, 1, 2, 3, 4, and 5;
q is selected from 1, 2, 3, 4, and 5; and p is selected from 0, 1, 2, and 3.
[2] In a preferred embodiment, the present invention provides novel compounds of formula (I), wherein:

R4 is absent, taken with the nitrogen to which it is attached to form an N-oxide, or selected from C1_B
alkyl, (CH2)rC3-s cycloalkyl: and (CH2)r-phenyl substituted with 0-3 RQc;
R4c, at each occurrence, is selected from C1_6 alkyl, C2_g alkenyl, C2_g alkynyl, C3_6 cycloalkyl, C1, F, Br, I, CN, N02, (CFZ)rCF3. (CHZ)rOCl_5 alkyl, (CH2)rOH, (CHZ)rSCl_5 alkyl, (CH2)rNR4aR9a~, and (CH2)rphenyl;
alternatively, R4 joins with R~, R9, or R11 to form a 5, 6 or 7 membered piperidinium spirocycle or pyrrolidinium spirocycle substituted with 0-3 Ra;
R1 and RZ are independently selected from H and C1_4 alkyl;
R6, at each occurrence, is selected from C1_4 alkyl, C2_8 alkenyl, C2_8 alkynyl, (CH2)rC3-6 cycloalkyl, (CF2)rCF3, CN, ( CH2 ) rOH, ( CH2 ) rOR6b, ( CH2 ) rC ( O ) R6b, (CHZ)rC(0)NR6aR6a', (CH2)rNR6dC(O)R6a, and (CH2)tphenyl substituted with 0-3 R6c;
R6a and R6a', at each occurrence, are selected from H, C1_6 alkyl, C3_6 cycloalkyl, and phenyl substituted with 0-3 R6c;
R6b. at each occurrence, is selected from C1_6 alkyl, C3_6 cycloalkyl, and phenyl substituted with 0-3 R6c;
R6c, at each occurrence, is selected from C1_6 alkyl, C3-s cycloalkyl, C1, F, Br, I, CN, N02, (CF2)rCF3, (CH2)rOCi-5 alkyl , ( CH2 ) rOH, ( CHZ ) rSCl_5 alkyl , and ( CH2 ) rNR6dR6d;
R6d, at each occurrence, is selected from H, CZ_6 alkyl, and C3_6 cycloalkyl;
~. 5 WO 00!35451 PCT/US99l30332 R13, at each occurrence, is selected from C1_q alkyl, C3-s cycloalkyl, (CH2 ) NR13aR13a~ ~ (CH2 ) OH, (CH2 ) ORl3b (CH2),",C(0)Rl3b~ (CH2)wC(O)NR13aR13a'. (CHz)NRl3dC(0)Rl3a~
(CHZ)~",S (O) 2NR13aR13a'. (CHZ)NRl3dS (O) 2R13b, and (CH2)w-phenyl substituted with 0-3 Rl3c;
Rl3a and Rl3a'~ at each occurrence, are selected from H, C1_6 alkyl, C3_6 cycloalkyl, and phenyl substituted with 0-3 Rl3c.
Rl3b, at each occurrence, is selected from C1_6 alkyl, C3_6 cycloalkyl, and phenyl substituted with 0-3 Rl3c;
Rl3c~ at each occurrence, is selected from C1_6 alkyl, C3-s cycloalkyl, C1, F, Br, I, CN, N02, (CFZ)rCF3, (CH2)rOCl_ 5 alkyl, (CH2)=OH, and (CHz)rNR13dR13d~
Rl3d~ at each occurrence, is selected from H, C1_6 alkyl, and C3_6 cycloalkyl;
v is selected from 1 and 2;
q is selected from 1, 2, and 3; and r is selected from 0, 1, 2, and 3.
[3] In a more preferred embodiment, the present invention provides novel compounds of formula (I), wherein:
R3 is selected from a (CR3'H)r-carbocyclic residue substituted with 0-5 R15, wherein the carbocyclic residue is selected from phenyl, C3_6 cycloalkyl, naphthyl, and adamantyl; and a (CR3'H)r-heterocyclic system substituted with 0-3 R15, wherein the heterocyclic system is selected from pyridinyl, , thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, WO 00!35451 PCT/US99/30332 benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, indolinyl, isoindolyl, isothiadiazolyl, isoxazolyl, piperidinyl, pyrrazolyl, 1,2,4-triazolyl, 1,2,3-triazolyl, tetrazolyl, thiadiazolyl, thiazolyl, oxazolyl, pyrazinyl, and pyrimidinyl; and R5 is selected from (CR5'H)t-phenyl substituted with 0-5 R16; and a (CR5'H)t-heterocyclic system substituted with 0-3 R16, wherein the heterocyclic system is selected from pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, indolinyl, isoindolyl, isothiadiazolyl, isoxazolyl, piperidinyl, pyrrazolyl, 1,2,4-triazolyl, 1,2,3-triazolyl, tetrazolyl, thiadiazolyl, thiazolyl, oxazolyl, pyrazinyl, and pyrimidinyl.
[4] In an even more preferred embodiment, the present invention provides novel compounds of formula (I-i), wherein the compound of formula (I-i) is:
--E..~ -Rs H H
(I-i) R16, at each occurrence, is selected from C1_$ alkyl, (CH2)rC3-6 cycloalkyl, CF3, C1, Br, I, F, (CH2)rNR16aR16a~~ N02. CN, OH, (CH2)rORl6d~
(CH2)rC(O)Rl6b, (C:~2)rC(O)NR16aR16a~. (CH2)rNRl6fC(O)Rl6b~
(CH2)rS(O)pRl6b~ (CH2)rS(O)2NR16aR16a~
(CHZ)rNR~6fS(p)2R16b~ and (CH2)=phenyl substituted with 0-3 Rl6e WO 00!35451 PCT/US99/30332 Rl6a and Rl6a', at each occurrence, are selected from H, C1_6 alkyl, C3_6 cycloalkyl, and (CH2)rphenyl substituted with 0-3 Rl6e Rl6b~ at each occurrence, is selected from H, C1_6 alkyl, C3-6 cycloalkyl, and (CH2)rphenyl substituted with 0-3 Rl6e Rl6d~ at each occurrence, is selected from Cz_6 alkyl and phenyl;
Rl6e~ at each occurrence, is selected from C1_6 alkyl, C1, F, Br, I, CN, N02, (CF2)rCF3, OH, and (CH2)rOCl_5 alkyl;
and Rl6f~ at each occurrence, is selected from H, and C1-5 alkyl.
[5] In another even more preferred embodiment, the present invention provides novel compounds of formula (I-ii), wherein the compound formula (I-ii) is:
~_ L../
H H
(I-ii) R16, at each occurrence, is selected from C1_8 alkyl, (CH2)rC3-6 cYcloalkyl, CF3, C1, Br, I, F, (CH2)rNR16aR16a'~ N02. ~. OH, (CHZ)rORl6d~
( CH2 ) rC ( O ) Rl6b ~ ( CH2 ) rC ( O ) NR16aR16a' . ( CH2 ) rNRl 6 fC ( O ) Rl6b (CH2)rS(O)pRl6b~ (CH2)rS(O)z~16aR16a'~
(CH2)rNRl6fg(O)2R16b, ~d (CH2)rphenyl substituted with 0-3 nl6e~
Rl6a and Rl6a'~ at each occurrence, are selected from H, C1_6 alkyl, C3_6 cycloalkyl, and (CH2)rphenyl substituted with 0-3 Rl6e;

Rl6b~ at each occurrence, is selected from H, C1_6 alkyl, C3_6 cycloalkyl, and (CH2)rphenyl substituted with 0-3 Rl6e R~6d, at each occurrence, is selected from C1_6 alkyl and phenyl;
Rl6e~ at each occurrence, is selected from C1_6 alkyl, C1, F, Br, I, CN, N02, (CFz)rCF3, OH, and (CHZ)rOCl_5 alkyl;
and Rl6f~ at each occurrence, is selected from H, and C1-5 alkyl.
[6] In a preferred embodiment, the present invention provides novel compounds of formula (I-i) wherein:
R5 is CH2phenyl substituted with 0-3 R16 E is -CH2- (CH2 ) - (CH2 ) ;
r is selected from 0, 1, and 2.
[7]. In another preferred embodiment, the present invention provides novel compounds of formula (I-ii), wherein:
E is -CH2 - ( CHR9 ) -CHR11;
R5 is CH2phenyl substituted with 0-3 R16; and r is selected from 0, 1, and 2.
[8] In a more preferred embodiment, the present invention provides novel compounds of formula (I-i), wherein:

J is selected from CH2 and CHRS;
K is selected from CH2 and CHRS;
S L is selected from CH2 and CHRS;
R3 is a C3_lo carbocyclic residue substituted with 0-3 R15, wherein the carbocyclic residue is selected from cyclopropyl, cyclopentyl, cyclohexyl, phenyl, naphthyl and adamantyl, and a (CR3'H)r-heterocyclic system substituted with 0-3 R15, wherein the heterocyclic system is selected from pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, indolinyl, isoindolyl, isothiadiazolyl, isoxazolyl, piperidinyl, pyrrazolyl, 1,2,4-triazolyl, 1,2,3-triazolyl, tetrazolyl, thiadiazolyl, thiazolyl, oxazolyl, pyrazinyl, and pyrimidinyl; and R15, at each occurrence, is selected from C1_8 alkyl, (CH2)rC3-6 cycloalkyl, CF3, C1, Br, I, F, (CH2)rNR15aR15a'~ N02~ CN, OH, (CH2)rORl5d.
(CH2)rC(p)Rl5b. (CHZ)=C(p)NR15aR15a', (CH2)rNRlSfC(0)RlSb.
(CHz)rS(O)pRlSb. (CH2)rS(O)2NR15aR15a'.
(CH2)rNRlSfg(O)2R15b. (CH2)rphenyl Substituted with 0-3 Rl5e. and a (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 RlSe.
RlSa ~d RlSa~, at each occurrence, are selected from H, C
alkyl, C3_6 cycloalkyl, and (CH2)rphenyl substituted with 0-3 RlSe;
Rl.Sb. at each occurrence, is selected from H, Cl_6 alkyl, C3_6 cycloalkyl, and (CH2)rphenyl substituted with 0-3 Rl5e.

RlSd, at each occurrence, is selected from C1_6 alkyl and phenyl;
Rlse~ at each occurrence, .is selected from C1_6 alkyl, C1, F, Br, I, CN, NOZ, (CF2)rCF3, OH, and (CH2)rOCl_5 alkyl;
and RlSf~ at each occurrence, is selected from H, and C1-5 alkyl.
[9~ In another more preferred embodiment, the present invention provides novel compounds of formula (I-ii), wherein:
K is selected from CH2 and CHRS;
L is selected from CH2 and CHRS;
R3 is a C3_lo carbocyclic residue substituted with 0-3 R15, wherein the carbocyclic residue is selected from cyclopropyl, cyclopentyl, cyclohexyl, phenyl, naphthyl and adamantyl, and a (CR3'H)r-heterocyclic system substituted with 0-3 R15, wherein the heterocyclic system is selected from pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, indolinyl, isoindolyl, isothiadiazolyl, isoxazolyl, piperidinyl, pyrrazolyl, 1,2,4-triazolyl, 1,2,3-triazolyl, tetrazolyl, thiadiazolyl, thiazolyl, oxazolyl, pyrazinyl, and pyrimidinyl; and R15, at each occurrence, is selected from C1_8 alkyl, (CH2)rC3_6 cycloalkyl, CF3, C1, Br, I, F, (CH2)rNR15aR15a', N02, CN, OH, (CH2)rORlSd~
(CHZ)rC(O)RlSb, (CH2)rC(O)NR15aR15a'~ (CH2)rNRl5fC(O)Rl5b~

(CH2)rS(O)pRlSb~ (CH2)rS(0)2NR15aR15a'.
(CH2)rNRlSfS(O)2R15b~ (CH2)rphenyl substituted with 0-3 RlSe, and a (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2. RlSe RlSa and RlSa', at each occurrence, are selected from H, C1_6 alkyl, C3_6 cycloalkyl, and (CH2)rphenyl substituted with 0-3 RlSe;
R25b, at each occurrence, is selected from H, C1_6 alkyl, C3_6 cycloalkyl, and (CH2)rphenyl substituted with 0-3 RlSe RlSd, at each occurrence, is selected from C1_6 alkyl and phenyl;
RlSe, at each occurrence, is selected from C1_6 alkyl, C1, F, Br, I, CN, N02, (CF2)rCF3, OH, and (CH2)rOCl_5 alkyl;
and RlSf, at each occurrence, is selected from H, and C1_5 alkyl [10~ In a preferred embodiment, the present invention provides novel compounds of formula (I), wherein:
M is absent or selected from CHz;
Q is CHz;
J is CHI;
K and L are independently selected from CHI and CHRS;
Z is O;
Rl is H;

RZ is H;
R3 is a C3_1o carbocyclic residue substituted with 0-3 R15, wherein the carbocyclic residue is selected from cyclopropyl, cyclopentyl, cyclohexyl, phenyl, naphthyl and adamantyl, and a (CR3'H)r-heterocyclic system substituted with 0-3 R15, wherein the heterocyclic system is selected from pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, indolinyl, isoindolyl, isothiadiazolyl, isoxazolyl, piperidinyl, pyrrazolyl, 1,2,4-triazolyl, 2,2,3-triazolyl, tetrazolyl, thiadiazolyl, thiazolyl, oxazolyl, pyrazinyl, and pyrimidinyl; and RS is selected from a CHZ-C3_,a carbocyclic residue substituted with 1-5 R'6 and a heterocyclic system substituted with 0-3 R15, wherein the heterocyclic system is selected from pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, indolinyl, isoindolyl, isothiadiazolyl, isoxazolyl, piperidinyl, pyrrazolyl, 1,2,4-triazolyl, 1,2,3-triazolyl, tetrazolyl, thiadiazolyl, thiazolyl, oxazolyl, pyrazinyl, and pyrimidinyl [1-11] In a further even more preferred embodiment, the present invention provides novel compounds of formula (I) and pharmaceutically acceptable salt forms thereof, wherein the compound of formula I is selected from:
N-(2-hydroxymethylphenyl)-N'-[3-[4-(phenylmethyl)-1-piperidinyl]propyl]urea, N-(3-carboethoxyphenyl)-N'-[3-[4-(phenylmethyl)-1-piperidinyl]propyl]urea, N-(3-cyanophenyl)-N'-[3-[4-(phenylmethyl)-1-piperidinyl]
propyl]urea, N-[4-(benzyloxy)phenyl]-N'-[3-[4-(phenylmethyl)-1-piperidinyl]propyl]urea, N-(3-iodophenyl)-N'-[3-[4-(phenylmethyl)-1-piperidinyl) propyl]urea, N-(3-methoxyphenyl)-N'-[3-[4-(phenylmethyl)-1-piperidinyl]
propyl]urea, N-phenyl-N'-[3-[4-(phenylmethyl)-1-piperidinyl]propyl]urea, N-(4-carboethoxyphenyl)-N'-[3-[4-(phenylmethyl)-1-piperidinyl]propyl]urea, N-(4-fluorophenyl)-N'-[3-[4-(phenylmethyl)-1-piperidinyl]
propyl]urea, N-(2-methoxyphenyl)-N'-[3-[4-(phenylmethyl)-1-piperidinyl]propyl]urea, N-(4-methoxyphenyl)-N'-[3-[4-(phenylmethyl)-1-piperidinyl]propyl]urea, N-(3-cyanophenyl)-N'-j3-[4-(4-fluorophenylmethyl)-1-piperidinyl]propyl]urea, N-(4-fluorophenyl)-N'-[3-[4-(4-fluorophenylmethyl)-1-piperidinyl]propyl]urea, N-(4-carboethoxyphenyl)-N'-[3-[4-(4-fluorophenylmethyl)-1~
piperidinyl]propyl]urea, N-(3-cyanophenyl)-N'-[3-[4-((3,4-methylenedioxy)phenylmethyl)-1-piperidinyl]propyl]urea, N-(3-methoxyphenyl)-N'-[3-[4-(4-fluorophenylrnethyl)-1-piperidinyl]propyl]urea, N-(3-carboethoxyphenyl)-N'-[3-[4-((3,4-methylenedioxy) phenylmethyl)-1-piperidinyl]propyl]urea, N-(3-methoxyphenyl)-N'-[3-[4-((3,4-methylenedioxy) phenylmethyl)-1-piperidinyl]propyl]urea, N-(3-methoxyphenyl)-N'-[3-[4-((3-methoxy)phenylmethyl)-1-piperidinyljpropyl]urea, N-(3-cyanophenyl)-N'-[3-[4-(4-fluorophenylmethyl)-1-methyl-1-piperidinium]propyl]urea iodide, N-(4-cyanophenyl)-N'-[3-[4-(phenylmethyl)-1-piperidinyl]
propyl]urea, N-(4-fluorophenyl)-N'-[3-[4-((3,4-methylenedioxy) phenylmethyl)-1-piperidinyljpropyl]urea, N-(4-fluorophenyl)-N'-[3-[4-(2,4-bisfluorophenylmethyl)-1-piperidinyl]propyl)urea, N-(3-methoxyphenyl)-N'-[3-[4-(2,4-bisfluorophenylmethyl)-1-piperidinyl]propyl]urea, N-(3-cyanophenyl)-N'-[3-[4-(2,4-bisfluorophenylmethyl)-1-piperidinyl]propyl]urea, N-(phenylmethyl)-N'-[3-[4-(4-fluorophenylmethyl)-1-piperidinyl]propyljurea, N-[1-(2-phenylethyl)]-N'-[3-[4-(4-fluorophenylmethyl)-1-piperidinyl]propyl]urea, N-(2-fluorophenyl)-N'-[3-[4-(4-fluorophenylmethyl)-1-piperidinyl]propyl]urea, N-(3-fluorophenyl}-N'-[3-[4-(4-fluorophenylmethyl)-1-piperidinyl]propyl]urea, N-(cyclohexyl)-N'-[3-[4-(4-fluorophenylmethyl)-1-piperidinyl]propyl]urea, N-[1-[trans-2-phenylcyclopropyl)-N'-[3-[4-(4-fluorophenyl-methyl)-1-piperidinyl]propyl]urea, N-(3-methoxyphenyl)-N'-[3-[4-(4-methylphenylmethyl)-1-piperidinyl]propyl]urea, N-(3-cyanophenyl)-N'-[3-[4-(4-methylphenylmethyl)-1-piperidinyl]propyl]urea, N-(3-cyanophenyl)-N'-[3-[4-(4-chlorophenylmethyl)-1-piperidinyl]propyl]urea, N-(3-methoxyphenyl)-N'-[3-[4-(3-methoxyphenylmethyl)-1-piperidinyl]propyl]urea, N-(3-cyanophenyl)-N'-[3-[9-(3-methoxyphenylmethyl)-1-piperidinyl]propyl]urea, N-(4-fluorophenyl)-N'-[3-[4-(3-methoxyphenylmethyl)-1-piperidinyl]propyl]urea, N-(4-carboethoxyphenyl)-N'-[3-[4-(3-methoxyphenylmethyl}-1-piperidinyl]propyl]urea, N-(3-cyanophenyl)-N'-[3-[4-(2-fluorophenylmethyl)-1-piperidinyl]propyl]urea, N-(3-fluorophenyl)-N'-[3-[4-(3-methoxyphenylmethyl)-1-piperidinyl]propyl]urea, N-(3-carboethoxyphenyl)-N'-[3-[4-(3-methoxyphenylmethyl)-1-piperidinyl]propyl]urea, N-[3-acetylphenyl]-N'-[3-[4-(4-fluorophenylmethyl)-1-piperidinyl]propyl]urea, N-[3-(alpha-hydroxyethyl)phenyl]-N'-[3-[4-(4-fluorophenyl-methyl)-1-piperidinyl]propyl]urea, N-[4-acetylphenyl]-N'-[3-[4-(4-fluorophenylmethyl)-1-piperidinyl]propyl]urea, N-(3-methoxyphenyl)-N'-[3-[4-(phenylmethyl)-1-piperidinyl]
propyl]urea, cis-N-(3-methoxyphenyl)-N'-[3-[2,4-bis(phenylmethyl)-1-piperidinyl]propyl]urea, N-(3-acetylphenyl)-N'-[3-[4-(4-fluorophenylmethyl)-1-piperidinyl]propyl]urea, N-(3-methoxyphenyl)-N'-[3-[4-(4-fluorophenylmethylidenyl)-1-piperidinyl]propyl]urea, N-(4-acetylphenyl)-N'-[3-[4-(4-fluorophenylrnethyl)-1-piperidinyl]propyl]urea, N-(3-(1-hydroxyethyl)phenyl)-N'-[3-[4-(4-fluorophenylmethyl)-1-piperidinyl]propyl]urea hydrochloride, N-(3-acetylphenyl)-N'-[3-[4-(4-fluorophenylmethyl)-3-(phenylmethyl)-1-piperidinyl]propyl]urea, N-(4-fluorophenyl)-N'-[3-[4-(4-fluorophenylmethyl)-3-(phenylmethyl)-1-piperidinyl]propyl]urea, N-(3-methoxyphenyl)-N'-[3-[4-(4-fluorophenylmethyl)-3-(phenylmethyl)-1-piperidinyl]propyl]urea, N-(2-isopropylphenyl)-N'-[3-[4-(4-fluorophenylmethyl)-1-piperidinyl]propyl]urea, N-(2-trifluoromethylphenyl)-N'-[3-[4-(4-fluorophenylmethyl)-1-piperidinyl]propyl]urea, N-(3-chlorophenyl)-N'-[3-[4-(4-fluorophenylmethyl}-1-piperidinyl]propyl]urea, N-(3-trifluoromethylphenyl)-N'-[3-[4-(4-fluorophenylmethyl)-1-piperidinyl]propyl]urea, N-(2-chlorophenyl)-N'-[3-[4-(4-fluorophenylmethyl)-1-piperidinyl]propyl]urea, N-(2,4-difluororophenyl)-N'-(3-[4-(4-fluorophenylmethyl}-1-piperidinyl]propyl]urea, N- ( 3-cyanophenyl } -~N' - [ 3 - [ 4- ( 4-f luorophenylmethyl ) -1-piperidinyl]propyl]urea, hydrochloride, N-(3-cyanophenyl}-N'-[3-[4-(naphth-1-ylmethyl)-1-piperidinyl]propyl]urea, N-(4-fluorophenyl)-N'-[3-[4-(naphth-1-ylmethyl)-1-piperidinyl]propyl]urea, N- ( 3 -methoxyphenyl ) -N' - [ 3- [ 4-- (naphth-1-ylmethyl ) -1-piperidinyl]propyl]urea, N-(3-cyanophenyl)-N'-[3-[4-(3-methylphenylmethyl)-1-piperidinyl]propyl]urea, N-(3-methoxyphenyl)-N'-(3-[4-(3-methylphenylmethyl)-1-piperidinyl]propyl]urea, N-(4-cyanophenyl)-N'-[3-(4-(4-fluorophenylmethyl)-1-piperidinyl)propyl]urea, N-(4-fluorophenyl)-N'-[3-[4-(4-chlorophenyl)methyl-1-piperidinyl]propyl]urea, N-(3-methoxyphenyl)-N'-[3-[4-(4-chlorophenyl)methyl-1-piperidinyl]propyl]urea, N-(3-cyanophenyl)-N'-[3-[4-(3,4-bisfluorophenyl)methyl-1-piperidinyl]propyl]urea, N-(3-methoxyphenyl)-N'-[3-[4-(3,4-bisfluorophenyl)methyl-1-piperidinyl]propyl]urea, N-(4-fluorophenyl)-N'-[3-[4-(3,4-bisfluorophenyl)methyl-1-piperidinyl]propyl]urea, N-(3-methoxyphenyl)-N'-[3-[4-(3-fluorophenyl) methyl-1-piperidinyl]propyl]urea, N-(3-cyanophenyl)-N'-[3-[4-(3-chlorophenyl)methyl-1-piperidinyl]propyl]urea, N-(3-methoxyphenyl)-N'-(3-[4-(3-carbomethoxyphenyl)a~ethyl-1-piperidinyl]propyl]urea, N-(3-cyanophenyl)-N'-[3-[4-(3-carbomethoxyphenyl)methyl-1-piperidinyl]propyl]urea, N-(3-acetylphenyl)-N'-[3-[4-(4-fluorophenyl)methyl-1-piperidinyl]propyl]urea, N-(3,5-diacetylphenyl)-N'-[3-[3-(4-fluorophenyl)methyl-1-piperidinyl]propyl]urea, N-(3-acetylphenyl)-N'-[3-[3-(4-fluorophenyl)methyl-1-piperidinyl]propyl]urea;
N-(3,5-diacetylphenyl)-N'-[3-[4-(4-fluorophenyl)methyl-1-piperidinyl]propyl]urea, N-(3-cyanophenyl)-N'-[1-phenyl-3-[4-(4-fluorophenylrnethyl)-1-piperidinyl]propyl]urea, N-(3-methoxyphenyl)-N'-[1-phenyl-3-[4-(phenylmethyl)-1-piperidinyl]propyl]urea, N-(3-cyanophenyl)-N'-[1-phenyl-3-[4-(phenylmethyl)-1-piperidinyl]propyl]urea, N-(1-adamantyl)-N'-[1-phenyl-3-[4-(phenylmethyl)-1-piperidinyl]propyl]urea, N-(4-fluorophenyl)-N'-[1-phenyl-3-[4-(phenylmethyl)-1-piperidinyl]propyl]urea N-(3-carboethoxyphenyl)-N'-[3-[3-(phenylmethyl)-1-piperidinyl]propyl]urea, N-(3-cyanophenyl)-N'-(3-[3-(phenylmethyl)-1-piperidinyl]propyl]urea, N-(4-fluorophenyi)-N'-[3-(3-(phenylmethyl)-1-piperidinyl]propyl]urea, N-phenyl-N'-[3-[3-(phenylmethyl)-1-piperidinyl]propyl)urea, N-(1-adamantyl)-N'-[3-[3-(phenylmethyl)-1-piperidinyl]propyl]urea, N-(3-methoxyphenyl)-N'-[3-[3-(phenylmethyl)-1-piperidinyl)propyl]urea, N-(4-carboethoxyphenyl)-N'-[3-[3-(phenylmethyl)-1-piperidinyl]propyl]urea, N-phenyl-N'-[3-[3-(4-fluorophenyl)methyl-1-piperidinyl]propyl]urea, N-(3-cyanophenyl)-N'-[3-[3-(4-fluorophenyl)methyl-1-piperidinyl]propyl]urea, N-(1-adamantyl)-N'-[3-[3-(4-fluorophenyl)methyl-1-piperidinyl]propyl]urea, N-(3-methoxyphenyl)-N'-[3-[3-(4-fluorophenyl)methyl-1-piperidinyl]propyl]urea, N-(3-carboethoxyphenyl)-N'-[3-[3-(4-fluorophenyl)methyl-1-piperidinyl]propyl]urea, N-(4-fluorophenyl)-N'-[3-[3-(4-fluorophenyl)methyl-1-piperidinyl]propyl]urea, N-(3-cyanophenyl)-N'-[3-[3-[2-(phenyl)ethyl]-1-piperidinyl]propyl]urea, N-(3-carboethoxyphenyl)-N'-[3-[3-[2-(phenyl)ethyl]-1-piperidinyl]propyl]urea, N-(4-carboethoxyphenyl)-N'-[3-[3-[2-(phenyl)ethyl]-1-piperidinyl)propyl]urea, N-(4-fluorophenyl)-N'-[3-[3-[2-(phenyl)ethyl]-1-piperidinyl]propyl]urea, N-phenyl-N'-[3-[3-[2-(phenyl)ethyl]-1-piperidinyl]propyl]urea, N-(1-adamantyl)-N'-[3-[3-[2-(phenyl)ethyl]-1-piperidinyl]propyl]urea, N- ( 3 -me thoxyphenyl ) -N' - [ 3 - [ 3 - [ 2 - ( phenyl ) ethyl ] -1-piperidinyl]propyl]urea, N-phenyl-N'-[3-[3-(4-fluorophenyl)methyl]-1-pyrrolinyl]propyl]urea, N-(3-cyanophenyl)-N'-[3-[3-(4-fluorophenyl)methyl-1-pyrrolinyl]propyl]urea, N-(3-methoxyphenyl)-N'-[3-[3-(4-fluorophenyl)methyl-1-pyrrolinyl]propyl]urea, N- (4-fluorophenyl) -N' - [3- [3- (4-fluorophenyl)methyl-1-pyrrolinyl]propyl]urea, N-(3-carboethoxyphenyl)-N'-[3-[3-(4-fluorophenyl)methyl-1-pyrrolinyl]propyl]urea, N-(4-carboethoxyphenyl)-N'-(3-[3-(4-fluorophenyl)methyl-1-pyrrolinyl]propyl]urea, N-(1-adamantyl)-N'-[3-[3-(4-fluorophenyl)methyl-1-pyrrolinyl]propyl]urea, N-phenyl-N'-[3-[3-(2-fluorophenyl)methyl-1-piperidinyl]propyl]urea, N-(3-cyanophenyl)-N'-[3-[3-(2-fluorophenyl)methyl-1-piperidinyl]propyl]urea, N-(3-methoxyphenyl)-N'-[3-[3-(2-fluorophenyl)methyl-1-piperidinyl]propyl]urea, N-(4-fluorophenyl)-N'-[3-[3-(2-fluorophenyl)methyl-1-piperidinyl]propyl]urea, N-(3-methoxyphenyl)-N'-(3-[3-(3-fluorophenyl)methyl-1-piperidinyl]propyl]urea, N-(3-cyanophenyl)-N'-[3-[3-(3-fluorophenyl)methyl-1-piperidinyl]propyl]urea, N-(4-fluorophenyl)-N'-[3-[3-(3-fluorophenyl)methyl-1-piperidinyl]propyl]urea N-[3-(1-methyltetrazol-5-yl)phenyl]-N'-[3-[4-(4-fluorophenylmethyl)-1-piperidinyl]propyl]urea, N-(3-(1-methyltetrazol-5-yl)phenyl]-N'-[3-[3-(4-fluorophenylmethyl)-1-piperidinyl]propyl]urea, N-[3,5-bis(1-methyltetrazol-5-yl)phenyl]-N'-[3-[4-(4-fluorophenylmethyl)-1-piperidinyl]propyl]urea, N-[3,5-bis(1-methyltetrazol-5-yl)phenyl]-N'-[3-[3-(4-fluorophenylmethyl)-1-piperidinyl]propyl]urea, N-(4-(1-methyltetrazol-5-yl)phenyl]-N'-[3-[4-(4-fluorophenylmethyl)-1-piperidinyl]propyl]urea, and N-[4-(1-methyltetrazol-5-yl)phenyl]-N'-[3-[3-(4-fluorophenylmethyl)-1-piperidinyl]propyl]urea.
[1-12] In a further even more preferred embodiment, the present invention provides novel compounds of formula (I) and pharmaceutically acceptable salts form thereof, wherein the compound of formula I is selected from:
N-(1-adamantyl)-N'-[3-[4-(phenylmethyl)-1-piperidinyl]
propyl]urea, and N-[1-(trans-2-phenylcyclopropyl)]-N'-[3-[4-(phenylmethyl)-1-piperidinyl]propyl]urea.
[1-13] In a further even more preferred embodiment, the present invention provides novel compounds of formula (I) and pharmaceutically acceptable salts form thereof, wherein the compound of formula I is selected from:
N-(3-methoxyphenyl)-N'-[3-[1,4-bis(phenylmethyl)-1-piperidinium]propyl]urea bromide, N-(3-cyanophenyl}-N'-(3-(1,4-bis(phenylmethyl)-1-piperidinium]propyl]urea bromide, N-(3-methoxyphenyl)-N'-[3-[1-methyl-4-(phenylmethyl)-1-piperidinium]propyl]urea bromide, N-(3-cyanophenyl)-N'-[3-[1-methyl-4-(phenylmethyl)-1-piperidinium]propyl]urea bromide, N-(3-cyanophenyl)-N'-[3-[1-(carbomethoxymethyl)-4-(phenylmethyl)-1-piperidinium]propyl]urea bromide, N-(4-fluorophenyl)-N'-[3-[1-methyl-4-(phenylmethyl)-1-piperidinium]propyl]urea bromide, N-(4-fluorophenyl)-N'-[3-[1,4-bis(phenylmethyl)-1-piperidinium]propyl]urea bromide, N-(4-fluorophenyl)-N'-(3-[1-(carbomethoxyrnethyl)-4-(phenylmethyl)-1-piperidinium]propyl3urea bromide, N-(3-cyanophenyl)-N'-[3-[1-(cyanomethyl)-4-(phenylmethyl)-1-piperidinium]propyl]urea bromide, N-(3-cyanophenyl)-N'-[3-[1-(phenylcarbonylmethyl)-4 (phenylmethyl)-1-piperidinium]propyl]urea bromide, N-(2-methoxyphenyl)-N'-[3-[1-methyl-4-(phenylmethyl)-1-piperidinium]propyl]urea bromide, N-(4-methoxyphenyl)-N'-[3-[1-methyl-4-(phenylmethyl)-1-piperidinium]propyl]urea bromide, N-(3-methoxyphenyl)-N'-[3-[1-oxo-4-(phenylmethyl)-1-piperidinium]propyl]urea, and N-(3-methoxyphenyl)-N'-[3-[1-methyl-4-(phenylmethyl)-1-piperidinium]propyl]urea iodide.
[1-14) In a further even more preferred embodiment, the present invention provides novel compounds of formula (I) and pharmaceutically acceptable salts form thereof, wherein the compound of formula I is selected from:
N-(3-cyanophenyl)-N'-[4-[4-(phenylmethyl)-1-piperidinyl]
butyl]urea, N-(3-acetylphenyl)-N'-[4-[4-(4-fluorophenylmethyl)-1-piperidinyl]butyl]urea, N-(3,5-diacetylphenyl)-N'-[4-[4-(4-fluorophenylmethyl)-1-piperidinyl]butyl]urea, N-(3-cyanophenyl)-N'-[4-[4-(4-fluorophenylmethyl)-1-piperidinyl]butyl]urea, N-(3-acetylphenyl)-N'-[4-[3-(4-fluorophenylmethyl)-1-piperidinyl]butyl]urea, N-(3,5-diacetylphenyl)-N'-[4-[3-(4-fluorophenylmethyl)-1-piperidinyl]butyl]urea, N-(3-cyanophenyl)-N'-[4-[3-(4-fluorophenylmethyl)-1-piperidinyl]butyl]urea, N-(3-methoxyphenyl)-N'-[4-[3-(4-fluorophenylmethyl)-1-piperidinyl]butyl]urea, N-(4-fluorophenyl)-N'-[4-[3-(4-fluorophenylmethyl)-1-piperidinyl]butyl]urea, N-phenyl-N'-[4-[3-(4-fluorophenylmethyl)-1-piperidinyl]butyl]urea,N-[3-(1-methyltetrazol-5-yl)phenyl]-N'-[4-[4-(4-fluorophenylmethyl)-1-piperidinyl]butyl]urea, N-[3-(1-methyltetrazol-5-yl)phenyl]-N'-[4-[3-(4-fluorophenylmethyl)-1-piperidinyl]butyl]urea, N-[3,5-bis(1-methyltetrazol-5-yl)phenyl]-N'-[4-[4-(4-fluorophenylmethyl)-1-piperidinyl]butyl]urea, N-[3,5-bis(1-methyltetrazol-5-yl)phenyl]-N'-[4-[3-(4-fluorophenylmethyl)-Z-piperidinyl]butyl]urea, N-(3-carbomethoxyphenyl)-N'-[4-[4-(phenylmethyl)-1-piperidinyl]butyl]urea, N-(3-iodophenyl)-N'-[4-[4-(phenylmethyl)-1-piperidinyl]butyl] urea, N-[1-(4-benzyloxyphenyl)]-N'-[4-[4-(phenylmethyl)-1-piperidinyl]butyl]urea, N-(1-adamantyl)-N'-[4-[4-(phenylmethyl)-1-piperidinyl]butyl]urea, N-(3-methoxyphenyi)-N'-[4-[4-(phenylmethyl)-1-piperidinyl]butyl]urea, N-phenyl-N'-[4-[4-(phenylmethyl)-1-piperidinyl]butyl]urea, N-(3-methoxyphenyl)-N'-[4-[4-(phenylmethyl)-1-piperidinyl]butyl]urea, N-(4-carbomethoxyphenyl)-N'-[4-[4-(phenylmethyl)-1-piperidinyl]butyl]urea, N-(4-cyanophenyl)-N'-[4-[4-(phenylmethyl)-1-piperidinyl]
butyl]urea, N-(3-acetylphenyl)-N'-{(2Z)-4-[3-(4-fluorobenzyl)-1-piperidinyl]-2-butenyl}urea, N-(3-acetylphenyl)-N'-{(2E)-4-[3-(4-fluorobenzyl)-1-piperidinyl]-2-butenyl}urea, N-(3-cyanophenyl)-N'-{(2Z)-4-[3-(4-fluorobenzyl)-1-piperidinyl]-2-butenyl}urea, N-(4-fluorophenyl)-N'-{(2Z)-4-[3-(4-fluorobenzyl)-1-piperidinyl]-2-butenyl}urea, and N-(3-acetylphenyl)-N'-{4-[3-(4-fluorobenzyl)-1-piperidinyl]-2-butynyl}urea [15] In another embodiment, the present invention provides a pharmaceutical composition, comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of the present invention.
[16] In another embodiment, the present invention provides a method for modulation of chemokine receptor activity comprising administering to a patient in need thereof a therapeutically effective amount of the compounds of the present invention.
[17] In another embodiment, the present invention provides a method for treating or preventing inflammatory diseases, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of the present invention.
[18] In another embodiment, the present invention provides a method for treating or preventing asthma, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of the present invention.
[19) Thus, in another embodiment, the present invention provides novel compounds of formula (I):

-R
L-D ~~ R2 (I) or stereoisomers or pharmaceutically acceptable salts thereof, wherein:
M is absent or selected from CH2 , CHRS , CHR13 , CR13R13 , and CR5RI3 ;
Q is selected from CH2, CHRS, CHR13, CR13R13, and CR5R13;
J, K, and L are independently selected from CH2, CHRS, CHR6, CR6R6 and CRSR6;
with the provisos:
1) at least one of M, J, K, L, or Q contains an R5;
and 2) when M is absent, J is selected from CH2, CHRS, CHR13, and CR5R13;
Z is selected from NRla, CHCN, CHN02, and C(CN)2;
_ Rla is selected from H, C1_6 alkyl, C3_6 cycloalkyl, CONRIbRib ~ ORib ~ CN, N02 , and ( CH2 ) Wphenyl ;
~1b is independently selected from H, C1_3 alkyl, C3_6 cycloalkyl, and phenyl;
E i s - ( CR~Rg ) - ( CR9R10 ) ~- ( CR11R12 ) _ R1 and R2 are independently selected from H, C1_g alkyl, C2_g alkenyl, C2_8 alkynyl, (CH2)rC3_s cycloalkyl, and a (CH2)r-C3_lp carbocyclic residue substituted with 0-5 Rah Ra, at each occurrence, is selected from C1_4 alkyl, C2_g alkenyl, C2_8 alkynyl, (CH2)rC3_6 cycloalkyl, C1, Br, I, F. (CF2)rCF3, N02. CN, (CH2)rNRbRb. (CH2)rOH, {CH2)rOR~, (CH2)rSH, {CH2)rSR~, (CH2)rC(O)Rb. (CH2)rC{O)NRbRZ', ( CH2 ) rNRZ'C ( O ) Rb, ( CH2 ) rC { O ) ORb, ( CH2 ) rOC ( O ) R~ , (CH2)rCH(=NRb)NRbRb. (CH2)rNHC(=NRb)NRbRb. (CH2)rS{O)pR~, (CH2)rS(O)2NRbRb. (CH2)rNRbS(O)2R~, and (CH2)rphenyl;
Rb, at each occurrence, is selected from H, C1_6 alkyl, C3-6 cycloalkyl, and phenyl;
R~, at each occurrence, is selected from C1-6 alkyl, C3-6 cycloalkyl, and phenyl;
alternatively, R2 and R3 join to form a 5, 6, or 7-membered ring substituted with 0-3 Ra;
R3 is selected from a (CR3'R3")r-C3_io carbocyclic residue substituted with 0-5 R15 and a (CR3'R3')r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R15;
R3' and R3", at each occurrence, are selected from H, C1_s alkyl, (CH2)rC3_s cycloalkyl, and phenyl;
R4 is absent, taken with the nitrogen to which it is attached to form an N-oxide, or selected from C1_8 alkyl, C2_g alkenyl, C2_g alkynyl, (CH2)rC3-6 cycloalkyl, (CH2)qC(O)R4b, (CH2)qC(O)NR4aR4a'~
(CH2 ) qC (O) OR4b, and a (CHZ ) r-C3-1o carbocyclic residue substituted with 0-3 R4c;
R4a and R4a', at each occurrence, are selected from H, C1_s alkyl, (CHZ)rC3-6 cycloalkyl, and phenyl;
R4b, at each occurrence, is selected from C1_6 alkyl, C2_g alkenyl, (CH2)rC3_6 cycloalkyl, C2_8 alkynyl, and phenyl;
R4c, at each occurrence, is selected from C1_6 alkyl, C2_g alkenyl, C2_g alkynyl, C3_6 cycloalkyl, C1, F, Br, I, CN, N02, (CF2)rCF3, (CH2)rOCl_5 alkyl, (CH2)rOH, (CH2)rSCl_5 alkyl, (CH2)rNR4aR4a~, and (CHz)rphenyl;
alternatively, R4 joins with R~, R9, or R11 to form a 5, 6 or 7 membered piperidinium spirocycle or pyrrolidinium spirocycle substituted with 0-3 Ra;
3 0 R5 is selected from a (CRS'RS" ) t-C3_lo carbocyclic residue substituted with 0-5 R16 and a (CR5'R5")t-5-10 mernbered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R16;
R5' and R5", at each occurrence, are selected from H, C1_s alkyl, (CH2)rC3-6 cycloalkyl, and phenyl;

Rs, at each occurrence, is selected from C1_6 alkyl, C2_g alkenyl, Cz_g alkynyl, (cH2)rc3-6 cycloalkyl, (CF2)rCF3, CN, (CH2)rNR6aR6a'. (CH2)rOH, (CH2)rOR6b, (CH2)rSH, (CH2)rSR6b, (CH2)rC(O)OH, (CH2)rC(O)R6b, (CHZ)rC(O)NR6aR6a', (CH2)rNR6dC(O)R6a. (CH2)rC(O)OR6b, (CH2 ) rOC (0) R6b, (CH2 ) rS (O) pR6b. (CHz ) rS (O) 2NR6aR6a' (CH2)rNR6dS(0)ZR6b, and (CH2)tphenyl substituted with 0-3 Rsc;
R6a and R6a', at each occurrence, are selected from H, C1_6 alkyl, C3_6 cycloalkyl, and phenyl substituted with 0-3 R6c R6b, at each occurrence, is selected from C1_6 alkyl, C3_6 cycloalkyl, and phenyl substituted with 0-3 R6c.
R6c, at each occurrence, is selected from C1_6 alkyl, C3-6 cycloalkyl, C1, F, Br, I, CN, N02, (CF2)rCF3, (CH2)rOCl_ 5 alkyl, (CH2)rOH, (CH2)rSCl_5 alkyl, and (CH2)rNR6dR6d~
R6d, at each occurrence, is selected from H, C1_6 alkyl, and C3-6 cycloalkyl;
R~, is selected from H, C1_6 alkyl, C2_g alkenyl, C2_g alkynyl, (CH2)qOH, (CH2)qSH, (CH2)qOR~d, (CH2)qSR~d, (CH2)qNR~aR7a'. (CHZ)rC(O)OH, (CH2)rC(O)R~b, (CH2)rC(O)NR~aR7a', (CH2)qNR~aC(O)R7a, (CH2)qNR~aC(O)H, (CH2)rC(O)OR~b, (CH2)qOC(O)R~b, (CH2)qS(O)pR7b.
(CH2)qS(O)2NR7aR7a'. (CH2)qNR~aS(O)2R7b, Ci-6 haloalkyl, a (CH2)r-C3-1o carbocyclic residue substituted with 0-3 Roc, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R~~;
Rya and Rya', at each occurrence, are selected from H, Ci alkyl, C2_g alkenyl, C2_g alkynyl, a (CH2)r-C3_lo carbocyclic residue substituted with 0-5 R7e, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 Rye;
Rib, at each occurrence, is selected from C1_6 alkyl, C2_ alkenyl, C2_8 alkynyl, a (CH2)r-C3-6 carbocyclic residue substituted with 0-2 Rye, and a (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 Rye;
R~~, at each occurrence, is selected from C1_6 alkyl, Cz_a alkenyl, C2_g alkynyl, (CH2)rC3-6 cycloalkyl, Cl, Br, I, F, (CF2}rCF3, N02, CN, (CH2)rNR~fR7f, (CH2)rOH, (CH2)rOCl_q alkyl, (CH2)rSCl_4 alkyl, (CH2)rC(0)OH, (CH2)rC(O)R~b, (CH2)rC(O)NR~fR7f, (CHZ)rNR7fC(0)R7a.
(CHz ) rC (O) OC1_4 alkyl, (CH2 ) rOC (0) R~~', ( CH2 ) rC ( =NR~ f ) NR~ f R7 f ~ ( CH2 ) rS ( O ) pR7b, CH2 ) rNHC ( =NR~ f ) NR~ f R7 f , ( CH2 ) rS ( O ) 2NR7 fR7 f (CH2)rNR~fS(O)2R~b, and (CH2)rphenyl substituted with 0-3 Rye;
Rid, at each occurrence, is selected from C1_6 alkyl substituted with 0-3 Rye, alkenyl, alkynyl, and a C3_lo carbocyclic residue substituted with 0-3 R7~;

Rye, at each occurrence, is selected from C1_6 alkyl, C2_8 alkenyl, C2_a alkynyl, C3_6 cycloalkyl, C1, F, Br, I, CN, N02, (CF2)rCF3, (CH2}rOCl_5 alkyl, OH, SH, (CH2)rSCl_ s alkyl . ( CH2 ) rNR~ fR7 f , and ( CH2 ) rPhenyl ;
Ref, at each occurrence, is selected from H, CZ-6 alkyl, and C3-6 cycloalkyl;
R8 is selected from H, C1_6 alkyl, C3~6 cycloalkyl, and (CH2)rphenyl substituted with 0-3 Rya;

R8a, at each occurrence, is selected from C1_6 alkyl, C2_8 alkenyl, C2_8 alkynyl, C3-6 cycloalkyl, Cl, F, Br, I, CN, N02, (CF2)rCF3, (CH2)rOCl_5 alkyl, OH, SH, {CH2)rSCl_ alkyl, (CH2)rNR~fR~f, and (CH2)rphenyl;

alternatively, R~ and R8 join to form C3_~ cycloalkyl, or =~8b;
R8b is selected from H, C1-6 alkyl, C3_6 cycloalkyl, OH, CN, and (CH2)r-phenyl;
R9, is selected from H, C1_6 alkyl, C2_g alkenyl, C2_$
alkynyl, F, C1, Br, I, N02, CN, {CH2)rOH, (CH2)rSH, (CH2)rOR9d, (CH2)rSR9d, (CH2)rNR9aR9a'. (CH2)zC(O)OH, ( CH2 ) rC ( O ) R9t', ( CH2 ) rC ( O ) NR9aR9a' . ( CH2 ) rNR9aC ( 0 ) R9a, (CH2)rNR9aC(O)H. (CH2)rNR9aC(0)NHR9a, (CH2)rC{O)OR9b, ( CH2 ) rOC ( 0 ) R9b, ( CHZ ) rOC ( 0 ) NHR9°, ( CH2 ) rS ( 0 ) pR9b.
{CH2)=S(O)2NR9aR9a'. (CH2)rNR9aS(O)2R9b, C1-6 haloalkyl, a (CH2)r-C3-1o carbocyclic residue substituted with 0-5 Rg~, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R9c;
R9a and R9a', at each occurrence, are selected from H, C1_6 alkyl, C2_g alkenyl, C2_g alkynyl, a (CH2)r-C3-1o carbocyclic residue substituted with 0-5 R9e, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, 0, and S, substituted with 0-3 R9e;
R9b, at each occurrence, is selected from C1_6 alkyl, CZ_8 alkenyl, C2_g alkynyl, a (CHZ)r-C3-6 carbocyclic residue substituted with 0-2 R9e, and a (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R9e;

WO 00/35451 PCT/US99/30332, R9c, at each occurrence, is selected from C1_6 alkyl, C2_$
alkenyl, C2_8 alkynyl, (CH2)rC3-6 cycloalkyl, C1, Br, I, F. (CF2)rCF3. NO2. CN, (CH2)rNR9fR9f, (CHZ)rOH, (CH2)rOCl_4 alkyl, (CHZ)rSCl_q alkyl, (CH2)rC(O)OH, (CH2)rC(0)R9b, (CH2)rC(O)NR9fR9f~ (CH2)rNR9fC(0)R9a.
(CH2)rC(0)OC1_4 alkyl, (CH2)rOC(O)R9b, (CH2)rC(=NR9f)NR9fR9f~ (CH2)rS(OjpR9b~
(CH2)rNHC(=NR9f)NR9fR9f~ (CH2)rg(0)2NR9fR9f~
(CH2)rNR9fS(O)2R9b, and (CH2)rphenyl substituted with 0-3 R9e R9d, at each occurrence, is selected from C1_6 alkyl, C2-6 alkenyl, C2_6 alkynyl, a C3_lo carbocyclic residue substituted with 0-3 R9c, and a 5-6 membered heterocyclic system containing 1-4 heteroatoms selected from the group consisting of N, O, and S
substituted with 0-3 R9c;
R9e, at each occurrence, is selected from C1_6 alkyl, CZ_g alkenyl, Cz_g alkynyl, (CH2)rC3_6 cycloalkyl, C1, F, Br, I, CN, N02, (CF2)rCF3, (CH2)rOCl_5 alkyl, OH, SH, (CH2)rSCl_5 alkyl, (CH2)rNR9fR9f~ and (CH2)=phenyl;
R9f, at each occurrence, is selected from H, C1-6 alkyl, and C3-6 cycloalkyl;
R10, is selected from H, Cl_6 alkyl, C2_8 alkenyl, C2_8 alkynyl, F, C1, Br, I, N02, CN, (CH2)rOH, (CH2)rORlOd~
(CH2 ) rSRZOd, (CH2 ) r~l0aR10a' . (CH2 ) rC (O) OH, 3 0 ( CH2 ) rC ( 0 ) Rl Ob, ( CH2 ) rC ( O ) NR10aR10a' , ( CH2 ) rNRlOaC ( O
) RlOa ( CH2 ) rNRlOaC ( O ) H , ( CH2 ) rC ( O ) OR 1 Ob ~ ( CH2 ) rOC ( O ) RlOb (CH2) rS (0) pRlOb, (CH2 ) rS (O) zNR10aR10a' , (CH2)rNRlOaS(O)2R10b~ C1-6 haloalkyl, a (CH2)r.-C3_10 carbocyclic residue substituted with 0-5 RlOc, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, 0, and S, substituted with 0--3 Rloc ' WO OOI35451 PCT/US99/30332 Rloa and Rloa~, at each occurrence, are selected from H, alkyl, C2_e alkenyl, C2_8 alkynyl, a (CHz)r-C3-1o carbocyclic residue substituted with 0-5 Rloe, and a (CH2)r-5-10 membered,.heterocyclic system containing 1-4 heteroatoms selected from N, 0, and S, substituted with 0-3 Rloe;
Rlob~ at each occurrence, is selected from Cl_6 alkyl, C
alkenyl, C2_8 alkynyl, a (CH2)r-C3-5 carbocyclic residue substituted with 0-2 Rloe, and a (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 Rloe Rloc, at each occurrence, is selected from C1_6 alkyl, C2_8 alkenyl, C2_a alkynyl, (CH2)rC3-6 cycloalkyl, C1, Br, I, F. (CF2)rCF3, N02. CN, (CH2)rNR10fR10f~ (CH2)rOH, (CH2)rOCl_q alkyl, (CH2)rSCl_4 alkyl, (CH2)rC(O)OH, (CH2)rC(O)RlOb, (CH2)rC(O)NR10fR10f~ (CH2)rNRlOfC(O)RlOa~
(CH2) rC (O) OC1_q alkyl, (CHZ ) rOC (O) RlOb, (CH2)rC(=NRlOf)~lOfRlOf~ {CH2)=S(O)pRlob, (CH2)rNHC(=NRlOf)~lOfRlOf~ (CH2)rS(O)2NRlOfRlOf~
(CH2)rNRlofS(0)2Rlob, and (CH2)rphenyl substituted with 0-3 RlOe;
Rlod~ at each occurrence, is selected from Cl_6 alkyl, CZ-s alkenyl, CZ_6 alkynyl, a C3_1o carbocyclic residue substituted with 0-3 Rloc, and a 5-6 membered heterocyclic system containing 1-4 heteroatoms selected from the group consisting of N, 0, and S
substituted with 0-3 Rloc;
Rloe~ at each occurrence, is selected from Cl_6 alkyl, C2 alkenyl, C2_8 alkynyl, (CH2)rC3-6 cYcloalkyl, C1, F, Br, I, CN, N02, (CF2)rCF3, (CH2)rOCl_5 alkyl, OH, SH, (CHZ)rSCl_5 alkyl, (CH2)r.NRlofRlOf~ and (CH2)rphenyl;

Rlof~ at each occurrence, is selected from H, C1-6 alkyl, and C3-6 cycloalkyl;
alternatively, R9 and Rl~ join to form C3_~ cycloalkyl, 5-6-membered cyclic ketal, or =0;
with the proviso that when R1~ is -OH, R9 is not halogen, cyano, or bonded to the carbon to which it is attached through a heteroatom;
R11, is selected from H, C1_6 alkyl, C2_g alkenyl, C2_8 alkynyl, (CH2 ) qOH, (CH2 ) qSH, (CH2 ) qORlld~ (CH2 ) qSRlld~
(CH2)qNRIIaRIla~~ (CH2)rC(O)OH, (CHZ)rC(O)Rllb~
( CH2 ) rC ( O ) NRllaRlla' , ( CH2 ) qNRllaC ( O ) Rlla (CHZ)qNRllaC(O)NHRlla~ (CHZ)rC(O)ORllb (CH2)qOC(0)Rllb~
(CH2)qS(O)pRllb~ (CH2)qS(O)2NR11aRlla'~
(CH2) qNRllaS (O) 2R11b~ C1-6 haloalkyl, a (CH2) r-C3-10 carbocyclic residue substituted with 0-5 Rllc, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 Rllc Rlla ~d Rlla' , at each occurrence, are selected from H, C1_s alkyl, C2_g alkenyl, C2_g alkynyl, a (CH2)r-C3-10 carbocyclic residue substituted with 0-5 Rlle, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, 0, and S, substituted with 0-3 Rlle Rllb, at each occurrence, is selected from C1_6 alkyl, C2_g alkenyl, C2_g alkynyl, a (CH2)r-C3_6 carbocyclic residue substituted with 0-2 Rlle~ and a (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 Rlle Rllc ~ at each occurrence, is selected from Cl_6 alkyl, C2_g alkenyl, CZ_g alkynyl, (CH2)rC3-s cycloalkyl, C1, Br, I, F, (CF2 ) rCF3 , N02 , CN, ( CH2 ) rNRllfRllf ~ (CH2 ) =OH, (CH2)rOCl_q alkyl, (CH2}rSCl_4 alkyl, (CH?)rC(0)OH, (CH2)rC(O)Rilb~ (CH2)rC(O)NRilfRllf~ (CHZ)rNRilfC(O)Rila~
(CH2)rC(0}OCl_4 alkyl, (CH2)rOC(O}Rllb~
(CHZ)rC(=NRilf)~llfRllf~ (CH2)r~C(-NRllf)~11fR11f~
(CH2)rS(p}pRllb~ (CH2)rS(O)2NRilfRllf~
(CH2}rNRllfS(O)2Rllb~ and (CH2)rphenyl substituted with 0-3 Rlle Rild, at each occurrence, is selected from C1_6 alkyl substituted with 0-3 Riie, C2-6 alkenyl, C2_6 alkynyl, and a C3_lo carbocyclic residue substituted with 0-3 Rllc Riie, at each occurrence, is selected from C1_6 alkyl, C2_8 alkenyl, C2_8 alkynyl, C3_6 cycloalkyl, C1, F, Br, I, CN, N02, (CF2)rCF3, (CH2)rOCl_5 alkyl, OH, SH, (CH2)rSCl_ 5 alkyl, (CH2)rNR11fR11f~ and (CH2)rphenyl;
Riif, at each occurrence, is selected from H, C1_6 alkyl, and C3_6 cycloalkyl;
R12 is selected from H, C1_6 alkyl, (CH2)qOH, (CH2)rC3_6 cycloalkyl, and (CH2)tphenyl substituted with 0-3 Rl2a;
Ri2a~ at each occurrence, is selected from C1_6 alkyl, C2_g alkenyl, C2_8 alkynyl, C3_6 cycloalkyl, C1, F, Br, I, CN, N02, (CF2)rCF3, (CH2)rOCl_5 alkyl, OH, SH, (CH2)rSCl_ 5 alkyl, (CH2)rNR9fR9f, and (CH2)rphenyl;
alternatively, Rii and R12 join to form C3_~ cycloalkyl;
Ri3, at each occurrence, is selected from C1_6 alkyl, C2_8 alkenyl, C2_8 alkynyl, C3_6 cycloalkyl, (CF2),",CF3, (CH2 ) ~13aR13a' ~ (CH,2 ) OH, (CH2 ) ORi3b, (CH2 ) SH, (CH2)SRl3b, (CHZ)wC(O)OH, (CH2),,,,C(O)Rl3b~
(CH2),",C(O)NR13aR13a'. (CH2)NRl3dC(O)Ri3a~ (CH2)wC(O)ORl3b~

WO 00/35451 PCT/US9913033~' (CH2)OC(0)Rl3b, (CH2)wS(O)pRl3b, (CHZ)wS(O)2NR13aR13a'.
(CH2)NRl3dS(O)2RI3b~ and (CH2)w-phenyl Substituted With 0-3 Rl3c;
Rl3a and Rl3a' , at each occurrence, are selected from H, C1_6 alkyl, C3_6 cycloalkyl, and phenyl substituted with 0-3 Rl3c;
Rl3b~ at each occurrence, is selected from C1_6 alkyl, C3_s cycloalkyl, and phenyl substituted with 0-3 Rl3c;
Rl3c, at each occurrence, is selected from C1_6 alkyl, C3-5 cycloalkyl, C1, F, Br, I, CN, N02, (CF2)rCF3, (CH2)rOCl_ alkyl, (CH2)rOH, (CH2)rSCl_5 alkyl, and (CH2 ) rj~jR13dR13d~
Rl3d, at each occurrence, is selected from H, C1_6 alkyl, and C3_6 cycloalkyl;
R15, at each occurrence, is selected from C1_a alkyl, (CH2)rC3-6 cycloalkyl, C1, Br, I, F, N02, CN, Cue' ) rNg15aR15a' ~ ( CHR' ) rOH , ( CHR' ) r0 ( CHR' ) rRl 5d (CHR' ) rSH, (CHR' ) rC (O) H, (CHR' ) rS (CHR~ ) rRlSd, ( CHR' ) rC ( O ) OH, ( CHR' ) rC ( O ) ( CHR' ) rRlSb (CHR' ) rC (O)NR15aR15a' . (CHR' ) rNRlSfC (O) (CHR' ) =RlSb, (C~')r~lSfC(O)~15fR15f~ (CHR')rC(O)O(CHR')=RlSd~
( CHR' ) rOC ( 0 ) ( CHR' ) rRlSb ~ ( CHR' ) rC ( =NR15 f ) ~15aR15a' (CHR')z.NHC(=NRlSf)~l5fRl5f~ (C~')rS(O)p(CHR')rRlSb~
(CHR' ) rS (O) ZNRI5aRl5a'. (CHR' ) rNRl5fS (O) 2 (CHR' ) rRlSb~ C1-5 haloalkyl, C2_8 alkenyl substituted with 0-3 R' , C2_e alkynyl substituted with 0-3 R', (CHR')rphenyl substituted with 0-3 Rlse~ and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 RlSe;

R', at each occurrence, is selected from H, C1_6 alkyl, C2_g alkenyl, C2_g alkynyl, (CH2)rC3-6 cycloalkyl, and (CH2)rphenyl substituted with RlSe;
RlSa ~d RlSa' ~ at each occurrence, are selected from H, C1_6 alkyl, C2_B alkenyl, C2_e alkynyl, a (CH2)r-C3-10 carbocyclic residue substituted with 0-5 RlSe, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, 0, and S, substituted with 0-2 RlSe RlSb~ at each occurrence, is selected from C1_6 alkyl, C2_8 alkenyl, C2_8 alkynyl, a (CH2)r-C3-6 carbocyclic residue substituted with 0-3 RlSe, and (CH2)r-5-s membered heterocyclic system containing Z-4 heteroatoms selected from N, O, and S, substituted with 0-2 RZ5e RlSd~ at each occurrence, is selected from C2_8 alkenyl, alkynyl, C1_6 alkyl substituted with 0-3 Rise, a (CH2)r-C3-1o carbocyclic residue substituted with 0-3 RlSe, and a (CH2)r5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 Rl5e RlSe~ at each occurrence, is selected from C1_6 alkyl, CZ_s alkenyl, C2_8 alkynyl, (CH2)rC3-s cYcloalkyl, C1, F, Br, I. CN, NO2, (CF2)rCF3, (CH2)rOCl-5 alkyl, OH, SH, (CH2)rSCl_5 alkyl, (CH2)rNR15fR15f~ and (CH2)rphenyl;
RlSf, at each occurrence, is selected from H, C1_6 alkyl, Cs-6 cycloalkyl, and phenyl;
R16, at each occurrence, is selected from C1_8 alkyl, C2_g alkenyl, C2_8 alkynyl, (CHZ)rC3-s cYcloalkyl, C1, Br, I, F, N02, CN, (CHR')rNR16aR16a', (C~')rOH, (CHR')=O(CHR')rRi6d, (CHR')rSH, (CHR')rC(O)H, (CHR' ) rS (CHR' ) rRl6d~ (C~' ) rC (0) OH, (CHR')rC(O)(CHR')rRl6b, (CHR')rC(O)NR16aR16a'~
(CHR' ) rNRl6fC (O) (CHR' ) rRl6b, (CHR' ) rC (O) O (CHR' ) rRl6d~
( CHR' ) rOC ( 0 ) ( CHR' ) rRl6b ~ ( CHR' ) rC ( =NR16 f ) NR16aR16a' ( CHR' ) rNHC ( =NR16 f ) NR16 fRl6 f ~ ( CHR' ) rS ( O ) p ( CHR' ) rRl6b (CHR')rS(O)2NR16aR16a'. (CHR')rNRl6fS(O)2(CHR')rRl6b~ C1-6 haloalkyl, C2_8 alkenyl substituted with 0-3 R', C2_8 alkynyl substituted with 0-3 R', and (CHR')rphenyl substituted with 0-3 Rl6e;
Rl6a and Rl6a', at each occurrence, are selected from H, C1-6 alkyl, C2_g alkenyl, C2_g alkynyl, a (CH2)r-C3-l0 carbocyclic residue substituted with 0-5 Rlse~ and a (CH2)r-5-.IO membered heterocyclic system containing 1--4 heteroatoms selected from N, O, and S, substituted with 0-2 Rl6e;
Rl6b~ at each occurrence, is selected from C1_6 alkyl, C2_e alkenyl, C2_g alkynyl, a (CH2)rC3-6 carbocyclic residue substituted with 0-3 Rl6e, and a (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 Rl6e;
Rl6d~ at each occurrence, is selected from C2_B alkenyl, CZ_8 alkynyl, C1_6 alkyl substituted with 0-3 Rlse~ a (CH2)r-C3-to carbocyclic residue substituted with 0-3 Rl6e~ ~d a (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 Rl6e.
Rl6e, at each occurrence, is selected from Cl_6 alkyl, C2_8 alkenyl, C2_8 alkynyl, (CH2)rC3-6 cYcloalkyl, C1, F, Br, I, CN, N02, (CFZ)rCF3, (CH2)rOCl_5 alkyl, OH, SH, (CHZ)rSCl-5 alkyl, (CH2)rNR16fR16f~ and (CH2)rphenyl;
Rl6f, at each occurrence, is selected from H, C1-5 alkyl, and C3_6 cycloalkyl, and phenyl;

v is selected from 0, 1, and 2;
t is selected from 1 and 2;
w is selected from 0 and~.l;
r is selected from 0, 1, 2, 3, 4, and 5;
q is selected from 1, 2, 3, 4, and 5; and p is selected from 1, 2, and 3.
[20l In a preferred embodiment, the present invention provides novel compounds of formula (I), wherein:
R4 is absent, taken with the nitrogen to which it is attached to form an N-oxide, or selected from C1_e alkyl, (CHZ)rC3-5 cycloalkyl, and (CH2)r-phenyl substituted with 0-3 R4c;
R4c, at each occurrence, is selected from C1_6 alkyl, C2_8 alkenyl, C2_8 alkynyl, C3-6 cycloalkyl, Cl, F, Br, I, CN, N02, (CF2)rCF3, (CH2)rOCl_5 alkyl, (CH2)rOH, (CH2)rSCl_5 alkyl, (CH2)=NR4aR4a'~ and (CH2)=phenyl;
alternatively, R4 joins with R~, R9, or R11 to form a 5, 6 or 7 membered piperidinium spirocycle or pyrrolidinium spirocycle substituted with 0-3 Ra;
R1 and R2 are independently selected from H and C1_q alkyl;
R6, at each occurrence, is selected from Cl_4 alkyl, C2_8 alkenyl, C2_g alkynyl, (CH2)rC3-6 cycloalkyl, (CF2)rCF3, CN, (CH2)rOH, (CH2)rOR6b, (CH2)rC(O)R6b~
(CH2 ) rC (O) NR6aR6a' . (CH2 ) rNR6dC (O) R6a, and (CH2) tphenyl substituted with 0-3 Rsc;

R6a and R6a', at each occurrence, are selected from H, C1-6 alkyl, C3_6 cycloalkyl, and phenyl substituted with 0-3 R6c;
R6b, at each occurrence, ~is selected from C1_6 alkyl, C3_6 cycloalkyl, and phenyl substituted with 0-3 R6c;
R6c, at each occurrence, is selected from C1_6 alkyl, C3-6 cycloalkyl, C1, F, Br, I, CN, N02, (CF2)rCF3, (CH2)rOCl-5 alkyl, (CH2)rOH, (CH2)rSCl_5 alkyl, and (CH2)rNR6dR6d~
R6a, at each occurrence, is selected from H, C1_6 alkyl, and C3-6 cycloalkyl;
R~, is selected from H, C1_3 alkyl, (CH2)rC3-s cycloalkyl, (CH2)qOH, (CH2)qOR~d, (CH2)qNR?aR7a', (CH2)rC(0)R~b, (CH2)rC(O)NR~aR7a', (CH2)qNR~aC(O)R~a, C1_6 haloalkyl, (CHZ)rphenyl with 0-2 Roc;
Rya and Rya', at each occurrence, are selected from H, C1 alkyl, (CH2)rC3-6 cYcloalkyl, a (CH2)rphenyl substituted with 0-3 Rye;
Rib, at each occurrence, is selected from C1_6 alkyl, CZ_g alkenyl, C2_g alkynyl, (CH2)rC3-5 cycloalkyl, (CH2)rPhenyl substituted with 0-3 Rye;
Roc, at each occurrence, is selected from C1_4 alkyl, C2_g alkenyl, C2_8 alkynyl, (CH2)rC3-6 cycloalkyl, C1, Br, I, F, (CF2)rCF3, N02, CN, (CHz)rNR~fR7f, (CH2)rOH, (CHZ)rOCl_4 alkyl, (CH2)rC(O)R~b, (CH2)rC{O)NR~fR7f~
(CH2)rNR~fC(O)R~a, (CH2)rS(O)pR7b~ (CH2)rS(O)2NR7fR7f~
(CH2)rNR~fS(0)2R~b, and (CHZ)rphenyl substituted with 0-2 Rye;

Rid, at each occurrence, is selected from C1_6 alkyl, (CH2)rC3-6 cYcloalkyl, (CH2)rphenyl substituted with 0-3 Rye;
Rye, at each occurrence, is selected from C1_6 alkyl, C
alkenyl, C2_8 alkynyl, C3_6 cycloalkyl, Cl, F, Br, I, CN, N02. (CF2)rCF3. (CH2)rOCl_5 alkyl, OH, SH, (CH2)rSCl_ 5 alkyl , ( CH2 ) rNR~ fR~ f , and ( CH2 ) =phenyl ;
Ref, at each occurrence, is selected from H, C1_5 alkyl, and C3-6 cycloalkyl;
RB is H or joins with R~ to form C3_~ cycloalkyl or =NReb;
R11, is selected from H, C1_6 alkyl, (CH2)rC3-6 cYcloalkyl, (CH2)qOH, (CH2)qORlld, (CH2)qNRllaRlla'~ (CH2)rC(0)Rllb~
(CH2 ) rC (O) NRllaRlla~ ~ (CH2 ) qNRllaC (O) Rlla~ C1-6 haloalkyl, (CH2)rphenyl with 0-2 Rllc~ (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R15;
Rlla and Rlla~, at each occurrence, are selected from H, C1_s alkyl, (CH2)rC3-6 cYcloalkyl, a (CH2)rphenyl substituted with 0-3 Rlle.
Rllb~ at each occurrence, is selected from C1_6 alkyl, C
alkenyl, C2_g alkynyl, (CH2)rC3-s cYcloalkyl, (CH2)rphenyl substituted with 0-3 Rlle Rllc, at each occurrence, is selected from C1_4 alkyl, C2_8 alkenyl, C2_8 alkynyl, (CH2)rC3-6 cycloalkyl, C1, Br, I, F. (CFZ)rCF3, N02, CN, (CH2)rNRllfRllf~ (CH2)=OH, (CHZ)rOCl_q alkyl, (CH2)=C(O)Rllb, (CH2)rC(O)NRllfRllf~
(CH2)rNRllfC(O)Rlla~ (CH2)rS(0)pRllb~
(CHZ ) rS (0) 2NR11fRllf ~ (CH2 ) rNRllfS (O) 2Rllb~ arid (CH2)rphenyl substituted with 0-2 Rlle;

Rlld, at each occurrence, is selected from C1_6 alkyl, (CH2)rC3-5 cYcloalkyl, (CH2)rphenyl substituted with 0-3 Rlle Rlle, at each occurrence,~is selected from C1_6 alkyl, C
alkenyl, C2_8 alkynyl, C3_6 cycloalkyl, C1, F, Br, I, CN, N02, (CF2)rCF3, (CHZ)rOC1_5 alkyl, OH, SH, (CH2)rSC1_ 5 alkyl, (CH2)rNR11fR11f~ and (CH2)rphenyl;
Rllf, at each occurrence, is selected from H, C1_5 alkyl and C3_6 cycloalkyl;
R12 is H or joins with R11 to form C3_~ cycloalkyl;
R13, at each occurrence, is selected from C1_4 alkyl, C3-s cycloalkyl, (CH2 ) NR13aR13a' , (CH2 ) pH, (CH2 ) ORl3b~
(CH2)~,,C(0)Rl3b~ (CH2)'",C(O)NR13aR13a'. (CH2)NRl3dC(O)Rl3a~
(CH2 ) wS (0) 2NR13aR13a' ~ (CH2 ) NRl3dS (O) ZRl3b~ and (CH2)W-phenyl substituted with 0-3 Rl3c;
Rl3a and Rl3a' , at each occurrence, are selected from H, C1-6 alkyl, C3_6 cycloalkyl, and phenyl substituted with 0-3 Rl3c Rl3b~ at each occurrence, is selected from C1_6 alkyl, C3-6 cycloalkyl, and phenyl substituted with 0-3 Rl3c;
Rl3c~ at each occurrence, is selected from C1_6 alkyl, C3-s cycloalkyl, C1, F, Br, I, CN, N02, (CF2)rCF3, (CH2)rOC1_ 5 alkyl, (CH2)rOH, arid (CH2)rNR13dR13d~
Rl3d~ at each occurrence, is selected from H, C1_6 alkyl, and C3_6 cycloalkyl;
v is selected from 1 and 2;
q is selected from 1, 2, and 3; and ..

r is selected from 0, l, 2, and 3.
[21] In a more preferred embodiment, the present invention provides novel compounds of formula (I), wherein:
R3 is selected from a (CR3'H)r-carbocyclic residue substituted with 0-5 R15, wherein the carbocyclic residue is selected from phenyl, C3_6 cycloalkyl, naphthyl, and adamantyl; and a (CR3'H)r-heterocyclic system substituted with 0-3 R15, wherein the heterocyclic system is selected from pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, 25 benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, indolinyl, isoindolyl, isothiadiazolyl, isoxazolyl, piperidinyl, pyrrazolyl, 1,2,4-triazolyl, 1,2,3-triazolyl, tetrazolyl, thiadiazolyl, thiazolyl, oxazolyl, pyrazinyl, and pyrimidinyl; and R5 is selected from (CR5'H)t-phenyl substituted with 0-5 R16; and a (CRS'H)t-heterocyclic system substituted with 0-3 R16, wherein the heterocyclic system is selected from pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, isoindolyl, piperidinyl, pyrrazolyl, 1,2,4-triazolyl, 1,2,3-triazolyl, tetrazolyl, thiazolyl, oxazolyl, pyrazinyl, and pyrirnidinyl.
[22] In an even more preferred embodiment, the present invention provides novel compounds of formula (I-i), wherein the compound of formula (I-i) is:

Z
J II
K ~N-E-N~N-R3 H H
(I-i) R16, at each occurrence, is selected from C1_g alkyl, (CH2)rC3-6 cycloalkyl, CF3, C1, Br, I, F, (CHZ)rNR16aR16a' N02~ CN, OH, (CH2)rORl6d~
(CH2)rC(O)Rl6br (CH2)rC(O)NR16aR16a'. (CH2)rNRl6fC(O)Rl6b~
(CH2)rS(O)pRl6b~ (CH2)rS(O)2NR16aR16a'.
(CH2)rNRl6fs(O)2R16b~ and (CH2)rphenyl substituted with 0-3 Rl6e Rl6a and Rl6a', at each occurrence, are selected from H, C1-6 alkyl, C3_6 cycloalkyl, and (CHZ)rphenyl substituted with 0-3 Rl6e Rl6b, at each occurrence, is selected from H, C1_6 alkyl, C3_6 cycloalkyl, and (CH2)rphenyl substituted with 0-3 Rl6e.
Rl6d, at each occurrence, is selected from C1_6 alkyl and phenyl;
Rl6e~ at each occurrence, is selected from C1_6 alkyl, C1, F, Br, I, CN, N02, (CF2)rCF3, OH, and (CH2)rOCl_5 alkyl;
and Rl6f~ at each occurrence, is selected from H, and C1_~
alkyl.
[23] In another even more preferred embodiment, the present invention provides novel compounds of formula (I-ii), wherein the compound formula (I-ii) is:
Z
K~ -E-N~NvRs H H

(I-ii) R16, at each occurrence, is selected from C1_$ alkyl, (CH2)rC3-6 cYcloalkyl, CF3, C1, Br, I, F, (CH2 ) rNR16aR16a' ~ N02 ~ CN, OH, (CH2 ) rORl6d~
( CH2 ) rC ( O ) Rl6b, ( CH2 ) rC ( O ) NR16aR16a' . ( CH2 ) rNRl6 f C ( 0 ) Rl6b (CH2 ) rS (O)pRl6b~ (CH2 ) rS (O) 2NR16aR16a'.
(CHZ)rNRl6fS(O)2R16b~ and (CH2)rphenyl substituted with 0-3 Rl6e;
Rl6a and Rlsa~, at each occurrence, are selected from H, C1_6 alkyl, C3_6 cycloalkyl, and (CH2)rphenyl substituted with 0-3 Rl6e;
Rlsb~ at each occurrence, is selected from H, C1_6 alkyl, C3_6 cycloalkyl, and (CH2)rphenyl substituted with 0-3 Rl6e Rl6d~ at each occurrence, is selected from C1_6 alkyl and phenyl;
Rl6e~ at each occurrence, is selected from C1_6 alkyl, C1, F, Br, I, CN, N02, (CF2)rCF3, OH, and (CH2)rOCl_5 alkyl;
and Rl6f, at each occurrence, is selected from H, and C1-5 alkyl.
[24] In a preferred embodiment, the present invention provides novel compounds of formula (I-i) wherein:
R5 is CH2phenyl substituted with 0-3 R16;
E is -CH2- (CR9R1~) - (CR11R12 ) R9, is selected from H, C1_6 alkyl, (CH2)rC3-6 cYcloalkyl, F, C1, CN, (CH2)rOH, (CH2)rO.R9d, (CH2)rNR9aR9a'~

PCT/US99/3033?
(CH~)rOC(O)NHR9°, (CH2)rphenyl substituted with 0-5 R9e, and a heterocyclic system substituted with 0-2 R9e, wherein the heterocyclic system is selected from pyridyl, thiophenyl, furanyl, oxazolyl, and thiazolyl;
R9a and R9a', at each occurrence, are selected from H, C1-6 alkyl, C3_6 cycloalkyl, and (CH2)rphenyl substituted with 0-3 R9e;
R9d, at each occurrence, is selected from C1_6 alkyl and phenyl;
R9e, at each occurrence, is selected from C1_6 alkyl, C1, F, Br, I, CN, N02, (CFZ)rCF3, OH, and (CH2)rOCl_5 alkyl;
R1~ is selected from H, C1_5 alkyl, OH, and CH20H;
alternatively, R9 and R1~ join to form C3_~ cycloalkyl, 5-6-membered cyclic ketal or =O;
with the proviso that when Rlo is -OH, R9 is not halogen, cyano, or bonded to the carbon to which it is attached through a heteroatom;
R11 is selected from H, C1_8 alkyl, (CH2)rphenyl substituted with 0-5 Rlle, and a (CH2)r-heterocyclic system substituted with 0-2 Rlie~ wherein the heterocyclic system is selected from pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, isoindolyl, piperidinyl, pyrrazolyl, 1,2,4-triazolyl, 1,2,3-triazolyl, tetrazolyl, thiazolyl, oxazolyl, pyrazinyl, and pyrimidinyl; and Rlle~ at each occurrence, is selected from CI_6 alkyl, Cl, F, Br, I, CN, N02, (CF2)rCF3, OH, and (CH2)~OC~_5 alkyl;

R12 is H;
alternatively, R11 and R12 join to form C3_~ cycloalkyl; and r is selected from 0, 1, and 2.
[25]. In another preferred embodiment, the present invention provides novel compounds of formula (I-ii), wherein:
R5 is CH2phenyl substituted with 0-3 R16;
E is -CH2- (CR9R1~) - (CR11R12 ) R9, is selected from H, C1_6 alkyl, (CH2)rC3-6 cycloalkyl, F, C1, CN, (CH2)rOH, (CH2)rOR9d, (CH2)=NR9aR9a', (CHz) rOC (0)NHR'°, (CH2) rphenyl substituted with 0-5 R9e, and a heterocyclic system substituted with 0-2 R9e, wherein the heterocyclic system is selected from pyridyl, thiophenyl, furanyl, oxazolyl, and thiazolyl;
R9a and R9a', at each occurrence, are selected from H, C1_6 alkyl, C3_6 cycloalkyl, and :.'.HZ)rphenyl substituted with 0-3 R9e;
R9d, at each occurrence, is selected from C1_6 alkyl and phenyl;
R9e, at each occurrence, is selected from C1_6 alkyl, C1, F, Br, I, CN, N02, (CF2)rCF" OH, and (CH2)rOCl_5 alkyl;
R1~ is selected from H, C1_g alkyl, OH, and CH20H;
alternatively, R9 and R1~ join to form C3_~ cycloalkyl, 5-6-membered cyclic ketal or =O;

with the proviso that when Rlo is -OH, R9 is not halogen, cyano, or bonded to the carbon to which it is attached through a heteroatom;
R11 is selected from H, Ci_g alkyl, (CH2)rphenyl substituted with 0-5 Rlle~ and a (CH2)r-heterocyclic system substituted with 0-2 Rlle, wherein the heterocyclic system is selected from pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, isoindolyl, piperidinyl, pyrrazolyl, 1,2,4-triazolyl, 1,2,3-triazolyl, tetrazolyl, thiazolyl, oxazolyl, pyrazinyl, and pyrimidinyl; and Rlle~ at each occurrence, is selected from C1_6 alkyl, C1, F, Br, I, CN, N02, (CF2)rCF3, OH, and (CH2)rOCl_5 alkyl;
R12 is H;
alternatively, R11 and R12 join to form C3_~ cycloalkyl; and r is selected from 0, 1, and 2.
[26] In a more preferred embodiment, the present invention provides novel compounds of formula (I-i), wherein:
J is selected from CH2 and CHRS;
K is selected from CHZ and CHRS;
L is selected from CH2 and CHRS;
R3 is a C3_lo carbocyclic residue substituted with 0-3 R15, wherein the carbocyclic residue is selected from cyclopropyl, cyclopentyl, cyclohexyl, phenyl, naphthyl and adamantyl, and a (CR3'H)r-heterocyclic system substituted with 0-3 R15, wherein the heterocyclic system is selected from pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, indolinyl, isoindolyl, isothiadiazolyl, isoxazolyl, piperidinyl, pyrrazolyl, 1,2,4-triazolyi, 1,2,3-triazolyl, tetrazolyl, thiadiazolyl, thiazolyl, oxazolyl, pyrazinyi, and pyrimidinyl; and R15, at each occurrence, is selected from C1_8 alkyl, (CH2)rC3_6 cycloalkyl, CF3, C1, Br, I, F, (CH2)rNR15aR15a'~ Np2~ CN, OH, (CHZ)rORl5d~
(CH2)rC(O)RlSb~ (CH2)rC(O)NR15aR15a', (CH2)rNRlSfC(O)RlSb~
(CH2)rS(O)pRlSb~ (CH2)rS(O)2NR15aR15a'.
(CH2)rNRl5fS(O)2R15b~ (CH2)rphenyl substituted with 0-3 RlSe~ and a (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 RlSe.
RlSa ~d RlSa' ~ at each occurrence, are selected from H, C1_6 alkyl, C3_6 cycloalkyl, and (CH2)rphenyl substituted with 0-3 RlSe RISb~ at each occurrence, is selected from H, C1_6 alkyl, C3_6 cycloalkyl, and (CH2)rphenyl substituted with 0-3 RlSe RlSd, at each occurrence, is selected from C1_6 alkyl and phenyl;
RlSe~ at each occurrence, is selected from C1_6 alkyl, C1~
F, Br, I, CN, N02, (CF2)rCF3, OH, and (CH2)rOCl_5 alkyl;
and RlSf~ at each oecurrence, is selected from H, and C1-5 alkyl.

[27] In another more preferred embodiment, the present invention provides novel compounds of formula (I-ii), wherein:
K is selected from CHz and CHRS;
L is selected from CH2 and CHRS;
R3 is a C3_lo carbocyclic residue substituted with 0-3 R15, wherein the carbocyclic residue is selected from cyclopropyl, cyclopentyl, cyclohexyl, phenyl, naphthyl and adamantyl, and a (CR3'H)r-heterocyclic system substituted with 0-3 R15, wherein the heterocyclic system is selected from pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyi, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, indolinyl, isoindolyl, isothiadiazolyl, isoxazolyl, piperidinyl, pyrrazolyl, 1,2,4-triazolyl, 1,2,3-triazolyl, tetrazolyl, thiadiazolyl, thiazolyl, oxazolyl, pyrazinyl, and pyrimidinyl; and R15, at each occurrence, is selected from C1_8 alkyl, (CH2)rC3-6 cYcloalkyl, CF3, C1, Br, I, F, ( CH2 ) rNR15aR15a' ~ N02 , CN, OH, ( CH2 ) rORlSd ( CHz ) rC ( 0 ) RlSb ~ ( CH2 ) rC ( O ) NR15aR15a' ~ ( CH2 ) rNRlS fC ( O ) RlSb (CHZ)rS(O)pRlSb~ (CH2)rS(0)2NR15aR15a'.
(CH2)r~lSfS(O)2R15b~ (CH2)rphenyl substituted with 0-3 RlSe~ ~d a (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 RlSe RlSa and RlSa'~ at each occurrence, are selected from H, C1-6 alkyl, C3_6 cycloalkyl, and (CH2)rphenyl substituted with 0-3 RlSe;

RlSb~ at each occurrence, is selected from H, C1_6 alkyl, C3_6 cycloalkyl, and (CH2)rphenyl substituted with 0-3 RlSe RlSd, at each occurrence, is selected from C1_6 alkyl and phenyl;
RlSe~ at each occurrence, is selected from C1_6 alkyl, C1, F, Br, I, CN, N02, (CF2)rCF3, OH, and (CH2)rOCl-5 alkyl;
and RlSf~ at each occurrence, is selected from H, and C1-5 alkyl.
(28] In a further even more preferred embodiment, the present invention provides,novel compounds of formula (I) and pharmaceutically acceptable salt forms thereof, wherein the compound of formula I is selected from:
N"-cyano-N-(3-methoxyphenyl)-N'-[3-[4-(phenylmethyl)-1-piperidinyl]propyl]guanidine, N"-cyano-N-(3-methoxyphenyl)-N~-[3-[4-(4-fluorophenylmethyl)-1-piperidinyl]propyl]guanidine.
N-(3-acetylphenyl)- N"-cyano-N'-[3-[4-(4-fluorophenylmethyl)-1-piperidinyl]propyl]guanidine, N-(3-acetylphenyl)-N"-cyano-N'-(3-[(3S)-3-(4-fluorobenzyl)piperidinyl]propyl}guanidine, N" -cyano-N- ( 3 , 5-diacetylphenyl ) -N' - { 3 - [ ( 3 S) -3 - ( 4-fluorobenzyl)piperidinyl]propyl}guanidine, N"-cyano-N-{3-((3S)-3-(4-fluorobenzyl)piperidinyl]propyl}-N'-[3-(1-methyl-1H-tetraazol-5-yl)phenyl]guanidine, N"-cyano-N- (2, 4-dimethoxyphenyl) -N'-(3- [ (3S) -3- (4-fluorobenzyl)piperidinyl]propyl}guanidine, N-(5-acetyl-2-methoxyphenyl)-N"-cyano-N'-{3-[(3S)-3-(4-fluorobenzyl)piperidinyl]propyl}guanidine, N-(3-acetylphenyl)-N"-cya~o-N'-{(3R, 4R)-5-[4-(4-fluorobenzyl)piperidinyl]-4-hydroxy-1-methyl-3-pentyl}guanidine, N"-cyano-N-{3- [ (3S) -3- (4-fluorobenzyl)piperidinyl] -2- (2E) -propenyl}-N'-[3-(1-methyl-1H-tetraazol-5-yl)phenyl]guanidine, 2-[(3-acetylanilino)((3-[(4-(4-fluorobenzyl)piperidinyl]propyl}amino)methylene]malono nitrile, 2-[ (3-acetylanilino) ({3-[ (3S)-3-(4-fluorobenzyl)piperidinyl]propyl}amino)methylene]malono nitrile, 2- [ [3- (1-methyl-1H-tetrazol-5-yl) anilino] ( {3- [ (3S) -3- (4-fluorobenzyl)piperidinyl]propyl}amino)methylene]malono nitrile, N- [ (E) - (3-acetylanilino) ( {3- [ (3S) -3- (4-fluorobenzyl)piperidinyl]propyl}amino)methylidene]urea N- [ (E) - (3, 5-diacetylanilino) ( (3- j (3S) -3- (4-fluorobenzyl)piperidinyl]propyl}amino)methylidene]urea N-[(E)-[3-(1-methyl-1H-tetrazol-5-yl)anilino]{{3-[(3S)-3-(4-fluorobenzyl)piperidinyl]propyl}amino)methylidene]urea Methyl (E) - (3, 5-diacetylanilino) ( (3- [ (3S) -3- (4-fluorobenzyl)piperidinyl]propyl}amino)methylidenecarba mate, 1-(3-([(E)-1-({3-[4-(4-fluorobenzyl)piperidinyl]propyl}amino)-2-nitroethenyl)amino}phenyl)ethanone, and 1-(3-{ [ (E)-1-({3-[ (3S)-3-(4-fluorobenzyl)piperidinyl]propyl}amino)-2-nitroethenyl]amino}phenyl)ethanone.
(29] In another embodiment, the present invention provides novel compounds of formula (I):
_R3 (I) or stereoisomers or pharmaceutically acceptable salts thereof, wherein:
M is absent or selected from CH2, CHRS, CHR13, CR13R13, and CRSR13~
Q is selected from CH2, CHR5, CHR13, CR13R13, and CR5R13;
J, K, and L are independently selected from CH2, CHRS, CHR6, CR6R6 and CR5R6;
with the provisos:
1) at least one of M, J, K, L, or Q contains an R5;
and 2) when M is absent, J is selected from CH2, CHRS, CHR13 , and CRSRI3 Z is selected from NRla, CHCN, CHNOz, and C(CN)2;
Rla is selected from H, C1_6 alkyl, C3_6 cycloalkyl, CONRIbRI,b ~ pRib , CN, NOZ , and ( CH2 ) Wphenyl ;
Rlb is independently selected from H, C1_3 alkyl, C3_s cycloalkyl, and phenyl;
E is selected from:

R~ a ~ s A A A
(R14)s (R14)g R9 ~R1° (R14)g Rs ~io (R14)g 11 12 s 10 ~ Rg 9 10 A ~ A Rii R12 A 11 R12 (R 14)g (R 14)9 (R 14)9 a 11 R12 ~ s R s Rs Rio R R9~Rio '~
~R 14)g ' R R 1 ° ~R 14~g , (R 14)g r and R~ g s 10 11812 R ~1° A _ ~-'~ 14) ring A is a C3_6 carbocyclic residue;
R1 and RZ are independently selected from H, C~~6 alkyl, alkenyl, C2_g alkynyl, (CH2)rC3_6 cycloalkyl, and a (CH2)r-C3-1o carbocyclic residue substituted with 0-5 Ra;
Ra, at each occurrence, is selected from C1_6 alkyl, C2_g alkenyl, C2_g alkynyl, (CH2)rC3-6 cYcloalkyl, C1, Br, I, F, (CF2)rCF3. NO2, CN, (CH2)rNRbRb. (CH2)rOH, (CH2)rOR~, (CH2)rSH, (CH2)rSR~, (CH2)rC(O)Rb, (CH2)rC(O)NRbRb, ( CH2 ) rNRbC ( O ) R~', ( CH2 ) rC ( O ) ORb, ( CH2 ) rOC ( O ) R~ , ( CH2 ) rCH ( =NR~' ) NRr'Rb , ( CH2 ) rNHC ( =NRb ) NRbRb , ( CH2 ) r S ( 0 ) pR~ , (CH2)rS(O)2NRbRb, (CH2)rNRbS(O)2R~, and (CH2)rphenyl;
Rb, at each occurrence, is selected from H, C1-6 alkyl, C3-6 cycloalkyl, and phenyl;
Rte, at each occurrence, is selected from C1_6 alkyl, C3-6 cycloalkyl, and phenyl;
alternatively, R2 and R3 join to form a 5, 6, or 7-membered ring substituted with 0-3 Ra;
R3 is selected from a (CR3'R3")r-C3-so carbocyclic residue substituted with 0-5 R15 and a (CR3'R3")r-5-10 mernbered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R15;
R3' and R3", at each occurrence, are selected from H, C1_6 alkyl, (CH2)rC3-6 cycloalkyl, and phenyl;
R4 is absent, taken with the nitrogen to which it is attached to form an N-oxide, or selected from C1_6 alkyl, C2_8 alkenyl, C2_8 alkynyl, (CH2)rC3-s cycloalkyl, (CH2)qC(O)R4b, (CH2)qC(0)NR4aR4a'~
(CH2 ) qC (O) OR4b, and a (CH2 ) r-C3-io carbocyclic residue substituted with 0-3 Rq~;
R4a and R4a', at each occurrence, are selected from H, C1_6 alkyl, (CH2)rC3-6 cYcloalkyl, and phenyl;
6~

R4b, at each occurrence, is selected from C1_6 alkyl, CZ_8 ,alkenyl, (CH2)rC3-6 cYcloalkyl, C2_g alkynyl, and phenyl;
R4c, at each occurrence, is selected from C1_6 alkyl, C2_g alkenyl, C2_e alkynyl, C3_6 cycloalkyl, C1, F, Br, I, CN, N02, (CFZ)rCF3, (CH2)rOCl_5 alkyl, (CHZ)=OH, (CH2)rSCl_5 alkyl, (CH2)rNR4aR4a', and (CH2)rphenyl;
alternatively, R4 joins with R~, R9, or R11 to form a 5, 6 or 7 membered piperidinium spirocycle or pyrrolidinium spirocycle substituted with 0-3 Ra;
15 R5 is selected from a (CRS'R5")t-C3_1o carbocyclic residue substituted with 0-5 R16 and a (CRS'R5")t-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 Rls;
20 R5' and RS", at each occurrence, are selected from H, C1_s alkyl, (CH2)rC3-5 cycloalkyl, and phenyl;
R6, at each occurrence, is selected from C1_6 alkyl, C2_g alkenul, CZ_8 alkynyl, (CH2)rC3-6 cYcloalkyl, (CF2)rCF3, CN, (CHz)rNR6aR6a', (CH2)rOH, (CH2)rOR6b, (CH2)rSH, (CH2)rSR6b, (CH2)rC(O)OH, (CH2)=C{O)R6b, (CH2)rC(O)NR6aR6a'. (CH2)rNR6dC(O)R6a, {CH2)rC(O)OR6b, {CH2)zOC{O)R6b, (CHZ)rS(O)pR6b, {CH2)rS(O)2NR6aR6a'.
(CH2)rNR6aS(O)2R6b, and (CH2)tphenyl substituted with 0-3 R6c;
R6a and R6a', at each occurrence, are selected from H, C1 alkyl, C3_6 cycloalkyl, and phenyl substituted with 0-3 R6c;
R6b, at each occurrence, is selected from C1_6 alkyl, C3_s cycloalkyl, a.nd phenyl substituted with 0-3 R6c;

R6~, at each occurrence, is selected from C1_6 alkyl, C3-6 cycloalkyl, C1, F, Br, I, CN, N02, (CF2)rCF3, (CH2)rOCl_ alkyl, (CH2)rOH, (CH2)rSCl_5 alkyl, and (CH2)rNR6dR6d;

R6d, at each occurrence, is selected from H, C1_6 alkyl, and C3-6 cycloalkyl;
R~, is selected from H, C1-6 alkyl, Cz_8 alkenyl, C2_g alkynyl, (CH2)qOH, (CH2)qSH, (CH2)qOR~d, (CHZ)qSR~d, ( CH2 ) qNR~aR7a' , ( CH2 ) rC ( O ) OH, ( CH2 ) rC ( O ) R~1', (CH2)rC(O)NR~aR7a', (CH2)qNR~aC(O)R~a, (CH2)qNR~aC(O)H.
(CH2)rC(O)OR~b, (CH2)qOC{O)R~b, (CH2)qS(O)pR~b, (CH2)qS(O)2NR~aR7a'. (CH2)qNR~aS(O)ZR7b, C1_6 haloalkyl, a (CH2)r-C3-1o carbocyclic residue substituted with 0-3 R~~, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R~~;
Rya and Rya' , at each occurrence, are selected from H, C~_6 alkyl, C2_g alkenyl, C2_8 alkynyl, (CH2)rC3-6 cycloalkyl, a (CH2)r-C3-1o carbocyclic residue substituted with 0-5 Rye, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 Rye;
Rib, at each occurrence, is selected from C1_6 alkyl, C2_8 alkenyl, C2_a alkynyl, a (CH2)r-C3-6 carbocyclic residue substituted with 0-2 Rye, and a (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 Rye;
R~~, at each occurrence, is selected from C1-6 alkyl, C2_e alkenyl, C2_8 alkynyl, (CfI~) rC3_6 cycloalkyl, C1, Br, I, F, (CF2)rCF3. N02, CN, (CH2)rNR~fR7f, (CH2)rOH, (CH2)~OC1_4 alkyl, (CHz)rSC1-4 alkyl, (CH2)rC{O)OH, (CH2)rC(O)R~b, (CH2)=C(O)NR~fR7f, (CH2)rNR~fC(O)R7a~

(CH2)rC(O)OC1_4 alkyl, (CH2)rOC(O)R~b, (CH2)rC(=NR7f)NR~fR7f~ (CH2}rS(O)pR7b~
(CH2)rNHC(-NR7f)NR7fR7f~ (CH2)rS(O)2NR7fR7f~
(CH2)rNR~fS(0}2R~b, and (CH2)rphenyl substituted with 0-3 Rye;
Rid, at each occurrence, is selected from C1_6 alkyl substituted with 0-3 Rye, alkenyl, alkynyl, and a C3_1Q
carbocyclic residue substituted with 0-3 R~~;
Rye, at each occurrence, is selected from C1_6 alkyl, C2_8 alkenyl, C2_g alkynyl, C3_6 cycloalkyl, C1, F, Br, I, CN, N02, (CF2)rCF3, (CH2)rOCl_5 alkyl, OH, SH, (CHZ)rSC2_ .
alkyl, (CHz)rNR~fR~f, and (CH2)rphenyl;
Ref, at each occurrence, is selected from H, Cz_6 alkyl, and C3-6 cycloalkyl;
R8 is selected from H, C~_6 alkyl, C3_6 cycloalkyl, and (CH2)tphenyl substituted with 0-3 Rea Rsa, at each occurrence, is selected from C1_6 alkyl, C2_8 alkenyl, C2_g alkynyl, C3_6 cycloalkyl, C1, F, Br, I, CN, N02, (CF2)rCF3, (CH2)rOCl_S alkyl, OH, SH, (CH2)rSCl_ 5 alkyl, (CHZ)rNR~fR~f, and (CH2)rphenyl;
alternatively, R~ and R8 join to form C3_~ cycloalkyl, or =j~8b;
Rab is selected from H, C1_6 alkyl, C3_6 cycloalkyl, OH, CN, and (CH2)r-phenyl;
R9 , is selected from H, C1_6 alkyl, C2_8 alkenyl , C2_g alkynyl, F, C1, Br, I, NOz, CN, (CH2)rOH, (CH2)rSH, (CH2)rOR9d, (CH2)rSR9d, (CHz)rNR9aR9a', (CH2)rC(O}OH, (CH2)rC(O)R9b, (CH2)rC(p)NR9aR9a', (CHZ}rNR9aC(0)R9a, (CH2)rNR9aC(O}H, (CH2)rNR9aC(O)NHR9a, (CH2)z.C(0)OR9b, (CHZ)rOC(0)R9b, (CHz)rOC(0)NHR'°, (CH2)rS(O)pR9b~
(CH2)rS(O)2NR9aR9a'~ (CH2)rNR9aS(0)ZR9b, C1_6 haloalkyl, a (CH2)r-C3_lo carbocyclic residue substituted with 0-5 R9~, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, 0, and S, substituted with 0-3 R9~;
R9a and R9a', at each occurrence, are selected from H. C1_6 alkyl, C2_e alkenyl, C2_g alkynyl, a (CH2)r-C3-10 carbocyclic residue substituted with 0-5 R9e, and a (CHZ)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R9e;
R9b, at each occurrence, is selected from C1_6 alkyl, C2_g alkenyl, C2_g alkynyl, a (CH2)r-C3_6 carbocyclic residue substituted with 0-2 R9e, and a (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R9e;
R9~, at each occurrence, is selected from C1_6 alkyl, C2_8 alkenyl, C2_g alkynyl, (CH2)rC3-6 cYcloalkyl, C1, Br, I, F, (CF2)rCF3, N02, CN, (CH2)rNR9fR9f, (CH2)rOH, (CH2)rOCl_q alkyl, (CH2)rSCl_q alkyl, (CH2)rC(O)OH, (CH2)rC(O)R9b, (CH2)rC(O)NR9fR9f, (CH2)rNR9fC(O)R9a~
(CH2 ) rC (O) OCl_q alkyl, (CH2 ) rOC (0) R9b.
(CH2)rC(=NR9f)NR9fR9f~ (CH2)rS(O)pR9b~
(CH2)rNHC(=NR9f)NR9fR9f~ (CH2)rS(O)2NR9fR9f~
(CH2)rNR9fS(0)2R9b~ and (CH2)rphenyl substituted with 0-3 R9e;
R9d, at each occurrence, is selected from C1_s alkyl. C2-s alkenyl, C2-6 alkynyl, a C3_io carbocyclic residue substituted with 0-3 R9~, and a 5-6 membered heterocyclic system containing 1-4 heteroatoms selected from the group consisting of N, O, and S
substituted with 0-3 R9~;

R9e, at each occurrence, is selected from C1_6 alkyl, C2_8 alkenyl, C2_g alkynyl, (CH2)rC3-6 cYcloalkyl, Cl, F, Br, I, CN, N02, (CF2)rCF3, (CH2)rOC1_5 alkyl, OH, SH, (CH2)rSC1_5 alkyl, (CH2)rNR9fR9f, and (CH2)rphenyl;
R9f, at each occurrence, is selected from H, C1_6 alkyl, and C3_6 cycloalkyl;
Rlo, is selected from H, C1_6 alkyl, CZ_g alkenyl, C2_8 alkynyl, F, C1, Br, I, N02, CN, (CH2)rOH, (CH2)rORlOd~
(CH2)rSRlOd~ (CH2)rNR10aR10a'. (CH2)rC(O)OH, ( CH2 ) rC ( O ) RlOb ~ ( CH2 ) rC ( O ) NR10aR10a' . ( CH2 ) rNRlOaC ( O ) RlOa ( CH2 ) rNRlOaC ( O ) H , ( CH2 ) rC ( O ) ORlOb ~ ( CH2 ) rOC ( O ) Rl Ob ( CH2 ) rS ( O ) pRl Ob, ( CH2 ) rS ( O ) 2NR10aR10a' .
(CH2)rNRlOaS(O)2R10b~ C1-6 halOalkyl, a (CH2)r-C3-1C
carbocyclic residue substituted with 0-5 Rloc, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 Rloc Rloa and Rloa' , at each occurrence, are selected from H, C1_6 alkyl, C2_8 alkenyl, C2_8 alkynyl, a (CH2)r-C3-to carbocyclic residue substituted with 0-5 Rloe, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 Rloe;
Rlob~ at each occurrence, is selected from Cl_6 alkyl, C2_8 alkenyl, C2_8 alkynyl, a (CH2)r-C3-6 carbocyclic residue substituted with 0-2 Rloe, and a (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 Rloe Rloc, at each occurrence, is selected from C1_6 alkyl, C2_8 alkenyl, CZ_8 alkynyl, (CHZ)rC3-s cYcloalkyl, C1, Br, I, F, (CF2)rCF3. NO2, CN, (CH2)rNR10fR10f (CHZ)rOH, (CH2)rOCl_q alkyl, (CH2)rSCl_q alkyl, (CH2)rC(O)OH, (CH2)rC(O)RlOb, (CH2)rC(0)NR10fR10f~ (CH2)rNRlOfC(0)RlOa~
(CH2 ) rC (0) OC1_4 alkyl, (CHZ ) rOC (O) RlOb (CH2)rC(=NRlOf)~lOfRlOf~ (CH2)rS(O)pRlOb~
(CH2)rNHC(=NRlOf)NR10fR10f~ (CH2)rS(O)2NRlOfRlOf~
(CH2)rNRlofS(O)2R10b~ and (CHZ)rphenyl substituted with 0-3 Rloe Rlod, at each occurrence, is selected from Cl_6 alkyl, C2_6 alkenyl, C2-6 alkynyl, a C3_io carbocyclic residue substituted with 0-3 Rloc~ and a 5-6 membered heterocyclic system containing 1-4 heteroatoms selected from the group consisting of N, O, and S
substituted with 0-3 Rloc.
Rloe~ at each occurrence, is selected from C1_6 alkyl, C2_8 alkenyl, C2_a alkynyl, (CH2)rC3_6 cycloalkyl, C1, F, Br, I, CN, NO2, (CF2)rCF3, (CH2)rOCl_5 alkyl, OH, SH, (CH2)rSCl_5 alkyl, (CH2)rNRlofRlOf~ and (CH2)=phenyl;
Rlof~ at each occurrence, is selected from H, C1_5 alkyl, and C3_6 cycloalkyl;
alternatively, R9 and R10 join to form C3_~ cycloalkyl, 5-6-membered cyclic ketal or =O;
with the proviso that when R10 is -OH, R9 is not halogen, cyano, or bonded to the carbon to which it is attached through a heteroatom;
R11, is selected from H, Cl_6 alkyl, C2_8 alkenyl, C2_8 alkynyl, (CH2)qOH, (CH2)qSH, (CH2)qORlid, (CH2)qSRlld~
(CH2)qNRllaRlla'~ (CH2)rC(O)OH, (CH2)rC(O)Rllb~
(CH2)rC(O)NRllaRlla', (CH2)qNRllaC(O)Rlla~
(CH2)qNRllaC(O)NHRlla~ (CH2)rC(O)ORllb~ (CH2)qOC(O)Rllb~
(CH2)qS(O)pRllb, (CH2)qS(O)ZNRIIaRlla~~
(CH2)qNRllaS(o)2R11b~ C1-6 haloalkyl, a (CH2)r-C3-10 carbocyclic residue substituted with 0-5 Rllc, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, 0, and S, substituted with 0-3 Rllc Rlla and Rlla' , at each occurrence, are selected from H, C1_6 alkyl, CZ_8 alkenyl, C2_g alkynyl, a (CH2)r-C3-to carbocyclic residue substituted with 0-5 Rlle~ and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 Rlle Rllb~ at each occurrence, is selected from C1_6 alkyl, C2_g alkenyl, C2_8 alkynyl, a (CH2)r-C3-6 carbocyclic residue substituted with 0-2 Rlle, and a (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 Rlle Rllc~ at each occurrence, is selected from C1_6 alkyl, C2_8 alkenyl, C2-8 alkynyl, (CHz)rC3_6 cycloalkyl, Cl, Br, I, F, (CF2)rCF3, N02, CN, (CH2)rNRllfRllf~ (CH2)rOH, (CH2)rOCl_4 alkyl, (CH2)rSCl_4 alkyl, (CH2)rC(O)OH, (CH2)rC(O)Rllb~ (CH2)rC(O)NRllfRllf~ (CH2)rNRllfC(O)Rlla~
(CH2)rC(O)OC1_4 alkyl, (CH2)rOC(O)Rllb~
(CH2)r['(=~llf)~llfRllf~ (CH2)r~f~(-NRllf)~llfRllf~
(CH2)rS(O)pRllb, (CH2)rS(O)2NR11fR11f~
(CH2)rNRllfs(O)2Rllb~ and (CH2)rphenyl substituted with 0-3 Rlle Rlld, at each occurrence, is selected from C1_6 alkyl substituted with 0-3 Rlle, C2-5 alkenyl, C2_6 alkynyl, and a C3-1o carbocyclic residue substituted with 0-3 Rllc Rlle, at each occurrence, is selected from Cl_6 alkyl, C2_8 , alkenyl, CZ_8 alkynyl, C3-6 cyeloalkyl, C1, F, Br, I, .. ...

CN, N02, (CF2)rCF3, (CH2)rOC1_5 alkyl, OH, SH, (CH2)rSC1_ alkyl, (CH2)rNR11fR11f~ and (CH2)rphenyl;
Rllf~ at each occurrence, is selected from H, C1_6 alkyl, 5 and C3_6 cycloalkyl;
R12 is selected from H, C1_6 alkyl, (CH2)qOH, (CH2)rC3-6 cycloalkyl, and (CH2)tphenyl substituted with 0-3 Rl2a Rl2a~ at each occurrence, is selected from C1_6 alkyl, C2_8 alkenyl, C2_8 alkynyl, C3_6 cycloalkyl, C1, F, Br, I, CN, N02, (CF2)rCF3, (CH2)rOC1_5 alkyl, OH, SH, (CH2)rSC1_ S alkyl , ( CH2 ) rNR9 fR9 f , and ( CH2 ) =phenyl ;
alternatively, R11 and R12 join to form C3_~ cycloalkyl;
R13, at each occurrence, is selected from C1_6 alkyl, C2_g alkenyl, C2_g alkynyl, C3_6 cycloalkyl, (CF2)WCF3, (CH2)NR13aR13a'~ (CH2)OH, (CH2)ORl3b~ (CH2)SH, (CH2)SRl3b, (CH2),"~C(O)OH, {CH2)~",C(O)Rl3b~
(CH2)~,~C(O)NR13aR13a'~ (CH2)NRl3dC(O)Rl3a~ (CH2)""C(O)ORl3b~
(CH2)OC(O)Rl3b~ (CH2)~"iS(O)pRl3b, (CH2)v,,S(O)2NR13aR13a'~
(CH2)NRl3dS(0)2R13b~ and (CH2)W-phenyl substituted with 0-3 Rl3c Rl3a and Rl3a', at each occurrence, are selected from H, C1_s alkyl, C3_6 cycloalkyl, and phenyl substituted with 0-3 Rl3c Rl3b, at each occurrence, is selected from C1_6 alkyl, C3_6 cycloalkyl, and phenyl substituted with 0-3 Rl3c;
Rl3c~ at each occurrence, is selected from C1_6 alkyl, C3-6 cycloalkyl, C1, F, Br, I, CN, N02, (CF2)rCF3, (CH2)rOC1_ 3 5 5 alkyl , ( CH2 ) rOH , ( CH2 ) ZSC1_.5 alkyl , and (CH2)rNR13dR13d~

Rl3d~ at each occurrence, is selected from H, C1_6 alkyl, and C3-6 cycloalkyl;
R14, at each occurrence, is selected from C1_6 alkyl, C2_g alkenyl, C2_g alkynyl, (CH2)rC3-6 cYcloalkyl, C1, Br, I, F, N02, CN, (CHR')rNR14aR14a'~ (CHR')rOH, (CHR')r0(CHR')rRl4d, (CHR')rSH, (CHR')rC(O)H, (CHR')rS(CHR~)rRl4d~ (CHR')rC(0)OH, (CHR')rC(O)(CHR')rRl4b, (CHR')rC(O)NR14aR14a'~
(CHR' ) rNRl4fC (0) (CHR' ) rRl4b, (CHR' ) rC (0) 0 (CHR' ) rRl4d~
( CHR' ) rOC ( O ) ( CHR' ) rRl4b , ( CHR' ) rC ( =NR14 f ) ~14aR14a' (CHR' ) rNHC (=NRl4f) NR14fR14f ~ (CHR' ) rS (O) p (CHR' ) rRl4b~
(CHR')rS(O)2NR14aR14a'~ (CHR')=NRl4fS(O)2(CHR')rRl4b, C1-6 haloalkyl, C2_8 alkenyl substituted with 0-3 R', Cz_8 alkynyl substituted with 0-3 R', (CHR')rphenyl substituted with 0-3 Rl4e, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 RlSe;
R', at each occurrence, is selected from H, C1_6 alkyl, C2-g alkenyl, CZ_g alkynyl, (CH2)rC3-6 cycloalkyl, and (CH2)rphenyl substituted with Rl4e;
Rl4a and Rl4a', at each occurrence, are selected from H, C1_6 alkyl, C2_8 alkenyl, C2_8 alkynyl, a (CHZ)r-C3-io carbocyclic residue substituted with 0-5 Rl4e, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 Rl4e;
Rl4b~ at each occurrence, is selected from C1_6 alkyl, C2_8 alkenyl, C2_g alkynyl, a (CH2)r-C3_6 carbocyclic residue substituted with 0-3 Rl4e, and (CH2)=-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 Rl4e Rl4d~ at each occurrence, is selected from C2_8 alkenyl, alkynyl, C1_6 alkyl substituted with 0-3 Rl4e, a (CH2)r-C3-1o carbocyclic residue substituted with 0-3 Rl4e~ and a (CH2)r5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 Rl4e;
Rl4e~ at each occurrence, is selected from C1_s alkyl, C
alkenyl, Cz_8 alkynyl, (CH2)rC3_6 cycloalkyl, C1, F, Br, I, CN, N02, (CFZ)rCF3, (CH2)rOC1_5 alkyl, OH, SH, (CH2)rSC1_5 alkyl, (CH2)rNR14fR14f~ and (CH2)rphenyl;
Rl4f~ at each occurrence, is selected from H, C1_6 alkyl, C3-6 cycloalkyl, and phenyl;
alternatively, R14 joins with R4 to form a 5, 6 or 7 membered piperidinium spirocycle or pyrrolidinium spirocycle fused to ring A, the spirocycle substituted with 0-3 Ra;
R15, at each occurrence, is selected from C1_6 alkyl, C2_8 alkenyl, CZ_8 alkynyl, (CH2)=C3-6 cycloalkyl, C1, Br, I, F, N02, CN, (CHR')rNR15aR15a'~ (CHR')rOH, (CHR')r0(CHR')rRlSd, (CHR')rSH, (CHR')rC(O)H, (CHR')rS(CHR~)rRlSd, (CHR')rC(O)OH, (CHR')rC(O)(CHR')rRl5b~ (CHR')=C(0)NRl5aRl5a~~
( CHR' ) rNRlS f C ( O ) ( CHR' ) rRlSb ~ ( CHR' ) rC ( O ) 0 ( CHR' ) rRlS d ( CHR' ) rOC ( O ) ( CHR' ) rRlSb, ( CHR' ) rC ( 0 ) NR15aR15a' (CHR' ) rC (-NRlSf ) ~l5aRl5a' ~ (CHR' ) rNHC (=NRlSf ) NR15fR15f (CHR')rS(O)p(CHR')rRlSb~ (CHR')rS(0)2NR15aR15a~~
{CHR')rNRlSfS(O)2(CHR')rRlSb, C1-6 haloalkyl, C2_g alkenyl substituted with 0-3 R', C2_e alkynyl substituted with 0-3 R', (CHR')rphenyl substituted with 0-3 RlSe, and a (CH2)=-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 RlSe;

RlSa and RlSa' , at each occurrence, are selected from H, C1-6 alkyl, C2_8 alkenyl, C2_e alkynyl, a (CH2) r-C3-to carbocyclic residue substituted with 0-5 RlSe, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 RlSe;
RlSb, at each occurrence, is selected from C1_6 alkyl, CZ_8 alkenyl, C2_8 alkynyl, a (CH2)r-C3-6 carbocyclic residue substituted with 0-3 RlSe, and (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 RlSe;
RlSd, at each occurrence, is selected from C2_8 alkenyl, C2-a alkynyl, C1_6 alkyl substituted with 0-3 RlSe~ a (CH2)r-C3_1o carbocyclic residue substituted with 0-3 RlSe, and a (CH2)r5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 Rlse;
RlSe~ at each occurrence, is selected from C1_6 alkyl, C2_8 alkenyl, C2_g alkynyl, (CH2)rC3-6 cYcloalkyl, C1, F, Br, I, CN, N02, (CF2)rCF3, (CH2)rOCl_5 alkyl, OH, SH, (CH2)rSCl_5 alkyl, (CH2)rNR15fR15f, and (CH2)rphenyl;
RlSf~ at each occurrence, is selected from H, C1_6 alkyl, C3-6 cycloalkyl, and phenyl;
R16, at each occurrence, is selected from C1_6 alkyl, C2_g alkenyl, C2_8 alkynyl, (CHZ)rC3-6 cYcloalkyl, C1, Br, I, F, N02, CN, (CHR')rNR16aR16a'~ (CHR')rOH, (CHR')r0(CHR')rRl6d, (CHR')rSH, (CHR')rC(O)H, (CHR')rS(CHR')rRl6d, (CHR')rC(O)OH, (CHR' ) rC (O) (CHR' ) rRl6b, (CHR' ) rC (O) NR16aR16a' (CHR' ) rNRl6fC (O) (CHR' ) rRl6b~ (CHR' ) rC (O) O (CHR' ) ~.Rl6d, ( CHR' ) rOC ( O ) ( CHR' ) rRl6b, ( CHR' ) rC ( =NR16 f ) ~l6aRl6a' (CHR' ) rNHC (=NRl6f ) NR16fR16f ~ (CHR' ) rS (O) p (CHR' ) rRl6b~

(CHR' ) rS (0) 2NR16aR16a' , (CHR' ) rNRl6fS (p) 2 (CHR' ) rRl6b, C1-6 haloalkyl, C2_g alkenyl substituted with 0-3 R', C2_g alkynyl substituted with 0-3 R', and (CHR')rphenyl substituted with 0-3 Rl6e;
Rl6a and Rl6a~ , at each occurrence, are selected from H, C1-6 alkyl, CZ_g alkenyl, C2_g alkynyl, a (CH2)r-C3-10 carbocyclic residue substituted with 0-5 Rl6e, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 Rl6e Rl6b~ at each occurrence, is selected from C1_6 alkyl, Cz_e alkenyl, C2_g alkynyl, a (CH2)rC3-6 carbocyclic residue substituted with 0-3 Rl6e, and a (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 Rl6e;
Rlsd~ at each occurrence, is selected from C2_g alkenyl, C2_g alkynyl, C1_6 alkyl substituted with 0-3 Rlse~ a (CH2)r-C3-1o carbocyclic residue substituted with 0-3 Rl6e, and a (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 Rl6e.
Rl6e~ at each occurrence, is selected from C1_6 alkyl, CZ_g alkenyl, C2_g alkynyl, (CH2)rC3-6 cycloalkyl, C1, F, Br, I, CN, N02, (CF2)rCF3, (CH2)rOCl_5 alkyl, OH, SH, (CH2 ) rSCl_5 alkyl, (CH2 ) rNR16fR16f ~ and (CH2 ) rphenyl;
Rl6f~ at each occurrence, is selected from H, C1_6 alkyl, and C3_6 cycloalkyl, and phenyl;
g is selected from 0, 1, 2, 3, and 4;
v is selected from 0, 1, and 2;

t is selected from 1 and 2;
w is selected from 0 and 1;
r is selected from 0, 1, 2, 3, 4, and 5;
q is selected from 2, 2, 3, 4, and 5; and p is selected from 1, 2, and 3.
[30] In a preferred embodiment, the present invention provides novel compounds of formula (I), wherein:
E is selected from:
7 Rg 11 12 7 8 7 g A A A ' (R1a)9 Rs Rio (R14)9 Rs R1o (R14)s 11 12 ' , A
(R 14)9 Rs 10 ~ g s 10 g 11 R12 (R 14) (R 14) 14 9 , and ~ ) ;
R4 is absent, taken with the nitrogen to which it is attached to form an N-oxide, or selected from C1_g alkyl, (CH2)rC3-s cYcloalkyl, and (CHZ)r-phenyl substituted with 0-3 R4c;
R4c, at each occurrence, is selected from CI._fi alkyl, C2_g alkenyl, C2_8 alkynyl, C3_6 cycloalkyl, C1, F, Br, I, CN, N02, (CF2)rCF~, (CH2)rOCl_5 alkyl, (CH2)rOH, (CH2)rSCl_5 alkyl, (CH2)rNR4aR4a~, and (CH2)rphenyl;

alternatively, R4 joins with R~ or R9 to form a 5, 6 or 7 membered piperidinium spirocycle substituted with 0-3 Ra;
R1 and R2 are independently selected from H and C1_4 alkyl;
R6, at each occurrence, is selected from C1_4 alkyl, CZ_8 alkenyl, C2_g alkynyl, (CH2)rC3_6 cycloalkyl, (CF2)rCF3, CN, ( CH2 ) rOH, ( CH2 ) rOR6b, ( CHz ) rC ( 0 ) R6b, ( CH2 ) rC ( O ) NR6aR6a' , ( CH2 ) rNR6dC ( O ) R6a ~ and ( CH2 ) tPhenyl substituted with 0-3 R6c;
R6a and R6a~, at each occurrence, are selected from H, C1-s alkyl, C3_6 cycloalkyl, and phenyl substituted with 0-3 R6c R6b, at each occurrence, is selected from C1_6 alkyl, C3_6 cycloalkyl, and phenyl substituted with 0-3 R6c;
R6c, at each occurrence, is selected from C1_6 alkyl, C3-6 cycloalkyl, C1, F, Br, I, CN, N02, (CFZ)rCF3, (CH2)rOCl_ 5 alkyl, (CH2)rOH, (CHZ)rSCl_5 alkyl, and (CHZ)rNR6dR6d~
R6d, at each occurrence, is selected from H, C1_6 alkyl, and C3-6 cycloalkyl;
R~, is selected from H, C1_3 alkyl, (CH2)rC3-6 cycloalkyl, (CH2)qOH, (CH2)qOR?d, (CH2)qNR7aR~a'~ (CH2)rC(O)R7b, (CHZ) rC (O)NR~aR~a' , (CH2) qNR~aC (O)R~a, C1_6 haloalkyl, (CH2)rphenyl with 0-2 RFC;
Rya and Rya' , at each occurrence, are selected from H, C1-s alkyl, (CH2)rC3-6 cycloalkyl, a (CH2)rphenyl substituted with 0-3 Rye;

Rib, at each occurrence, is selected from C1_6 alkyl, C2_8 alkenyl, C2_8 alkynyl, (CH2)rC3-6 cYcloalkyl, (CHZ)rphenyl substituted with 0-3 Rye;
R~~, at each occurrence, is selected from C1_g alkyl, C2_g alkenyl, C2_g alkynyl, (CH2)rC3-6 cycloalkyl, C1, Br, I, F, (CF2)rCF3, N02, CN, (CH2)rNR~fR7f~ (CH2)rOH, (CH2)rOCl_g alkyl. (CH2)rC(0)R7b, (CH2)rC(O)NR~fR7f~
(CHz)rNR~fC(O)R7a~ (CH2)rS(O)pR~b, (CH2)rS(O)ZNR~fR7f~
(CHz)rNR~fS(O)2R~b, and (CH2)rphenyl substituted with 0-2 Rye;
Rid, at each occurrence, is selected from C1_6 alkyl, (CH2)rC3-6 cYcloalkyl, (CH2)rphenyl substituted with 0-3 Rye;
Rye, at each occurrence, is selected from C1_6 alkyl, C2_8 alkenyl, C2_g alkynyl, C3-6 cycloalkyl, C1, F, Br, I, CN, N02, (CF2 ) rCF3 , (CH2 ) rOCl_5 alkyl, OH, SH, (CH2 ) rSCl_ 5 alkyl, (CH2)rNR~fR~f, and (CH2)rphenyl;
Ref, at each occurrence, is selected from H, C1_5 alkyl, and C3-6 cycloalkyl;
Rg is H or joins with R~ to form C3_~ cycloalkyl or =NRBb;
R11, is selected from H, C1_6 alkyl, (CH2)rC3-6 cYcloalkyl, (CH2)qOH, (CH2)qORlld, (CH2)qNRllaRlla'. (CHZ)rC(O)Rllb~
(CH2) rC (O)NRllaRlla' ~ (CH2) qNRllaC (O) Rlla~ C1-6 haloalkyl, (CH2)rphenyl with 0-2 Rllc, (CH2)r_5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R15;
Rlla ~d Rlla' ~ at each occurrence, are selected from H, C1-6 alkyl, (CH2)rC3-s cYcloalkyl, a (CH2)rphenyl substituted with 0-3 Rlle;

Rllb~ at each occurrence, is selected from C1_6 alkyl, C
alkenyl, C2_g alkynyl, (CH2)rC3-6 cycloalkyl, (CH2)rphenyl substituted with 0-3 Rlle;
Rllc, at each occurrence, -is selected from C1_4 alkyl, C2_g alkenyl, C2_8 alkynyl, (CH2)rC3-6 cycloalkyl, C1, Br, I, F, (CF2 ) rCF3 , N02 , CN, (CH2 ) rNRllfRllf ~ (CH2 ) rOH, (CH2) rOCl_4 alkyl, (CH2 ) rC (O) Rllb, (CH2 ) rC (O)NRllfRllf (CH2)r~llfC(O)Rlla~ (CH2)rS(0)pRllb~
(CH2) rS (O) 2NR11fRllf ~ (CH2 ) rNRllfS (0) 2R11b~ and (CH2)rphenyl substituted with 0-2 Rlle;
Rlld, at each occurrence, is selected from C1_6 alkyl, (CH2)rC3-6 cYcloalkyl, (CH2)rphenyl substituted with 0-3 Rlle Rlle~ at each occurrence, is selected from C1_6 alkyl, C2 alkenyl, Cz_8 alkynyl, C3_6 cycloalkyl, C1, F, Br, I, CN, N02, (CF2)rCF3, (CH2)rOCl_5 alkyl, OH, SH, (CH2)rSCl_ 5 alkyl, (CHZ)rNRllfRllf~ and (CH2)rphenyl;
Rllf~ at each occurrence, is selected from H, C1-5 alkyl and C3-6 cycloalkyl;
R12 is H or joins with R11 to form C3_~ cycloalkyl;
R13, at each occurrence, is selected from C1_4 alkyl, C3-6 cycloalkyl, (CH2)NRl3aRl3a'~ (CH2)OH, (CH2)ORl3b~
(CH2)WC(O)Rl3b, (CH2)~",C(O)NRl3aRl3a', (CH2)NRl3dC(0)Rl3a~
(CH2)WS(O)2NR13aR13a'~ (CH2)NRl3dS(O)2R13b~ and (CHZ)W-phenyl substituted with 0-3 Rl3c;
Rl3a and Rl3a' ~ at each occurrence, are selected from H, C1_s alkyl, C3_6 cycloalkyl, and phenyl substituted with 0-3 Rl3c Rl3b~ at each occurrence, is selected from C1_6 alkyl, C3_s WO 00/35451 PCT/US99/30332, cycloalkyl, and phenyl substituted with 0-3 Rl3c R23c~ at each occurrence, is selected from C1_6 alkyl, C3-s cycloalkyl, C1, F, Br, I, CN, NO2, (CF2)rCF3, (CH2)rOC1_ 5 alkyl, (CH2)rOH, arid (CH2)rNR13dR13d;
Rl3d, at each occurrence, is selected from H, C1_6 alkyl, and C3_6 cycloalkyl;
v is selected from 1 and 2;
q is selected from 1, 2, and 3; and r is selected from 0, 1, 2, and 3.
[31] In a more preferred embodiment, the present invention provides novel compounds of formula (I), wherein:
ring A is selected from:

(R )9 ([~ X4)9 ' (R 14)9 ~"' (R~4)9 (R~4) R' ( ~s , and (R X4)9 ;
R3 is selected from a (CR3'H)r-carbocyclic residue substituted with 0-5 R15, wherein the carbocyclic residue is selected from phenyl, C3_6 cycloalkyl, naphthyl, and adamantyl; and a (CR3'H)=-heterocyclic system substituted with 0-3 R25, wherein the heterocyclic system is selected from pyridiriyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, indolinyl, isoindolyl, isothiadiazolyl, isoxazolyl, piperidinyl, pyrrazolyl, 1,2,4-triazolyl, 1,2,3-triazolyl, tetrazolyl, thiadiazolyl, thiazolyl, oxazolyl, pyrazinyl, and pyrimidinyl; and R5 is selected from (CR5'H)t-phenyl substituted with 0-5 R16; and a (CR5'H)t-heterocyclic system substituted with 0-3 R16, wherein the heterocyclic system is selected from pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, isoindolyl, piperidinyl, pyrrazolyl, 1,2,4-triazolyl, 1,2,3-triazolyl, tetrazolyl, thiazolyl, oxazolyl, pyrazinyl, and pyrimidinyl.
[32]. In an even more preferred embodiment, the present invention provides novel compounds of formula (I-i), wherein the compound of formula (I-i) is:
Z
J
K ~N-E-N~N-R3 ~ H H
(I-i) R16, at each occurrence, is selected from C1_8 alkyl, (CH2)=C3_6 cycloalkyl, CF3, C1, Br, I, F, {CH2)rNR16aR16a'~ Np2, CN, OH, (CH2)rORl6d 16b 16a 16a' , 16f 16b (CH2)rC(O)R , (CH2)rC(0)NR R , (CH2)rNR C(O)R , (CH2)rS(O)pRl6b~ (CH2)rS(O)2NR16aR16a'.
(CH2)rNRl6fS(O)2R16b~ and (CH2)=phenyl. substituted with 0-3 Rl6e Rl6a and Rl6a' ~ at each occurrence, are selected from H, C1_6 alkyl, C3_6 cycloalkyl, and (CH2)rphenyl substituted with 0-3 Rl6e;
Rl6b, at each occurrence, is selected from H, C1_6 alkyl, C3_6 cycloalkyl, and (CH2)rphenyl substituted with 0-3 Rl6e Rl6d~ at each occurrence, is selected from C1_6 alkyl and phenyl;
Rl6e, at each occurrence, is selected from C1_6 alkyl, C1, F, Br, I, CN, N02, (CF2)rCF3, OH, and (CH2)rOCl_5 alkyl;
and Rl6f, at each occurrence, is selected from H, and C1-5 alkyl.
j33) In an another even more preferred embodiment, the present invention provides novel compounds of formula (I-ii), wherein (I-ii) is:
Z
N-E_N~N-Ra L-~/ ' ' H H
(I-ii) R16, at each occurrence, is selected from C1_e alkyl, (CH2)=C3_6 cycloalkyl, CF3, C1, Br, I, F, (CH2) rNR16aR16a' ~ NOZ. CN, OH, (CH2) rORl6d~
(CH2)rC(01R16b (CH2)rC(p)NR16aR16a'. (CH2)rNRl6fC(O)Rl6b~
(CH2)rS(0)pRl6b, (CH2)rS(O)2NR16aR16a'~
(CH2) rNRl6fS (O) 2R16b~ ~d (CH2) rphenyl substituted with 0-3 Rl6e;
Rl6a and Rlsa~, at each occurrence, are selected from H, C1_6 alkyl, C3_6 cycloalkyl, and (CH2)rphenyl substituted with 0-3 Rl6e;

Rl6b~ at each occurrence, is selected from H, C1_6 alkyl, C3_6 cycloalkyl, and (CHZ)rphenyl substituted with 0-3 RlSe.
Rl6d~ at each occurrence, is selected from C1_6 alkyl and phenyl;
Rl6e~ at each occurrence, is selected from C1_6 alkyl, C1, F, Br, I, CN, N02, (CFZ)rCF3, OH, and (CH2)rOCl_5 alkyl;
and Rl6f~ at each occurrence, is selected from H, and C1-5 alkyl.
[34] In a preferred embodiment, the present invention provides novel compounds of formula (I-i), wherein:
RS is CH2phenyl substituted with 0-3 R16;
R9, is selected from H, C1_6 alkyl, (CH2)rC3-6 cYcloalkyl, F, C1, CN, (CHZ)rOH, (CH2)rOR9d, (CH2)rNR9$R9a'~
(CHZ)rOC(O)NHR9°, (CH2)rphenyl substituted with 0-5 R9e, and a heterocyclic system substituted with 0-2 R9e, wherein the heterocyclic system is selected from pyridyl, thiophenyl, furanyl, oxazolyl, and thiazolyl;
R9a and R9a', at each occurrence, are selected from H, C1_6 alkyl, C3_6 cycloalkyl, and (CH2)rphenyl substituted with 0-3 R9e;
Rya, at each occurrence, is selected from C1_6 alkyl and phenyl;
R9e, at each occurrence, is selected from C1_6 alkyl, C1, F, Br, I, CN, N02, (CF2)rCF3, OH, and (CH2)rOCl_5 alkyl;

R1~ is selected from H, C1_5 alkyl, OH, and CH20H;
alternatively, R9 and R10 join to form C3_~ cycloalkyl, 5-6-membered cyclic ketal or =0;
with the proviso that when R1~ is -OH, R9 is not halogen, cyano, or bonded to the carbon to which it is attached through a heteroatom;
R11 is selected from H, C1_g alkyl, (CH2)rphenyl substituted with 0-5 Rlle, and a (CH2)r-heterocyclic system substituted with 0-2 Rlle, wherein the heterocyclic system is selected from pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, isoindolyl, piperidinyl, pyrrazolyl, 1,2,4-triazolyl, 1,2,3-triazolyl, tetrazolyl, thiazolyl, oxazolyl, pyrazinyl, and pyrimidinyl; and Rlle. at each occurrence, is selected from C1-6 alkyl, C1, F, Br, I, CN, N02, (CF2)rCF3, OH, and (CH2)rOCl_5 alkyl;
R12 is H;
alternatively, R11 and R12 join to form C3_~ cycloalkyl;
R14, at each occurrence, is selected from C1_8 alkyl, (CHZ)rC3-6 cYcloalkyl, CF3, C1, Br, I, F, (CH2)rNR14aR14a'. N02~ CN, OH, (CH2)rORl4d.
(CH2)rC(O)Rl4b. (CH2)rC(O)NR14aR14a'~ (CH2)rNRl4fC(0)Rl4b~
(CH2)rS(O)pRl4b. (CH2)rS(O)2NR14aR14a'.
(CHZ)rNRl4fS(O)2R14b. (CH2)rPhenyl substituted with 0-3 Rl4e;
Rl4a and Rl4a', at each occurrence, are selected from H, alkyl, C3_6 cycloalkyl, and (CHZ)rphenyl substituted with 0-3 Rl4e~ and a (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 RlSe;
Rl4b, at each occurrence, is selected from H, C1_6 alkyl, C3_6 cycloalkyl, and (CH2)rphenyl substituted with 0-3 Rl4e;
Rl4d, at each occurrence, is selected from C1_6 alkyl and phenyl;

Rl4e, at each occurrence, is selected from C1_6 alkyl, Cl, F, Br, I, CN, N02, (CF2)rCF3, OH, and (CH2)rOCl_5 alkyl;
and Rl4f~ at each occurrence, is selected from H, and C1-5 alkyl; and r is selected from 0, 1, and 2.
[35] In a preferred embodiment, the present invention provides novel compounds of formula (I-ii), wherein:
R5 is CH2phenyl substituted with 0-3 R16;
R9, is selected from H, C1_6 alkyl, (CH2)rC3-6 cycloalkyl, F, C1, CN, (CH2)rOH~ (CH2)rOR9d, (CH2)rNR9aR9a'~
(CHz) rOC (0) NHR'°, (CH2 ) rphenyl substituted with 0-5 R9e, and a heterocyclic system substituted with 0-2 R9e, wherein the heterocyclic system is selected from pyridyl, thiophenyl, furanyl, oxazolyl, and thiazolyl;
R9a and R9a', at each occurrence, are selected from H, C1_6 alkyl, C3_6 cycloalkyl, and (CH2)rphenyl substituted with 0-3 R9e;

R9d, at each occurrence, is selected from C1_6 alkyl and phenyl;
R9e, at each occurrence, is selected from C1_6 alkyl, C1, F, Br, I, CN, N02, (CFZ)rCF3, OH, and (CH2)rOCl_5 alkyl;
R1~ is selected from H, C1_e alkyl, OH, and CH20H;
alternatively, R9 and R1~ join to form C3_~ cycloalkyl, 5-6-membered cyclic ketal or =O;
with the proviso that when R1~ is -OH, R9 is not halogen, cyano, or bonded to the carbon to which it is attached through a heteroatom;
R11 is selected from H, C1_g alkyl, (CH2)rphenyl substituted with 0-5 Rlle, and a (CH2)r-heterocyclic system substituted with 0-2 Rlle, wherein the heterocyclic system is selected from pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, isoindolyl, piperidinyl, pyrrazolyl, 1,2,4-triazolyl, 1,2,3-triazolyl, tetrazolyl, thiazolyl, oxazolyl, pyrazinyl, and pyrimidinyl; and Rlle~ at each occurrence, is selected from C1_6 alkyl, C1, F, Br, I, CN, N02, (CF2)=CF3, OH, and (CH2)rOCl_5 alkyl;
R12 is H;
alternatively, R11 and R12 join to form C3__~ cycloalkyl;
R14, at each occurrence, is selected from C1_a alkyl, (CH2)rC3-6 cYcloalkyl, CF3, C1, Br, I, F, (CH2)rNR14aR14a'~ N02, CN, OH, (CHZ)rORl4d~
(CH2)rC(0)Rl4b, (CH2)rC(O)NR14aR14a°, (CH2)rNRl4fC(O)Rl4b ( CH2 ) rS ( 0 ) pRl4b, ( CH2 ) rS ( O ) 2NR14aRl4a' (CH2)rNRl4fS{0)2R14b~ (CH2)rphenyl substituted with 0-:l Rl4e~ and a (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatorns selected from N, O, and S, substituted with 0-2 Ri~e;
Rl4a and Rl4a', at each occurrence, are selected from H, Ci_s alkyl, C3_6 cycloalkyl, and (CH2)rphenyl substituted with 0-3 Rl4e Rl4b~ at each occurrence, is selected from H, Ci_6 alkyl, C3_6 cycloalkyl, and (CHz)rphenyl substituted with 0-3 Rl4e Rl4d, at each occurrence, is selected from Ci_6 alkyl and phenyl;
Rl4e~ at each occurrence, is selected from Ci_6 alkyl, C1, F, Br, I, CN, N02, (CF2 ) rCF3, OH, and (CH2 ) rOCi_5 alkyl;
Rl4f~ at each occurrence, is selected from H, and C1-5 alkyl; and r is selected from 0, 1,, and 2.
[36] In a more preferred embodiment, the present invention provides novel compounds of formula (I-i), wherein:
J is selected from CH2 and CHRS;
K is selected from CHZ and CHRS;
L is selected from CH2 and CHRS;
R3 is a C3_io carbocyclic residue substituted with 0-3 R15, wherein the carbocyclic residue is selected from cyclopropyl, cyclopentyl, cyclohexyl, phenyl, naphthyl and adamantyl, and a (CR3'H)r-heterocyclic system substituted with 0-3 R15, wherein the heterocyclic system is selected from pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, indolinyl, isoindolyl, isothiadiazolyl, isoxazolyl, piperidinyl, pyrrazolyl, 1,2,4-triazolyl, 1,2,3-triazolyl, tetrazolyl, thiadiazolyl, thiazolyl, oxazolyl, pyrazinyl, and pyrimidinyl; and R15, at each occurrence, is selected from C1_8 alkyl, (CH2)rC3_6 cycloalkyl, CF3, C1, Br, I, F, (CH2)rNR15aR15a'. N02. CN, OH, (CHZ)rORlSd.
(CH2) rC (0) RlSb. (CH2) rC (O)NR15aR15a' . (CHZ ) rNRlSfC (O) Rl5b.
(CH2)rS(O)pRlSb. (CH2)rS(O)2NR15aRi5a'.
(CH2) rNRlSfS (p) 2R15b. (CH2 ) rphenyl substituted with 0-3 RlSe. and a (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 RlSe;
RlSa and RlSa'. at each occurrence, are selected from H, C1_6 alkyl, C3_6 cycloalkyl, and (CH2)rphenyl substituted with 0-3 RlSe;
RlSb. at each occurrence, is selected from H, C1_6 alkyl, C3_6 cycloalkyl, and (CH2)rphenyl substituted with 0-3 RlSe;
RlSd. at each occurrence, is selected from C1_6 alkyl and phenyl;
RlSe. at each occurrence, is selected from C1_6 alkyl, C1, F, Br, I, CN, NO2, (CF2)rCF3, OH, and (CH2)rOCl_5 alkyl;
and RlSf, at each occurrence, is selected from H, and C1-5 alkyl.
[37] In a more preferred embodiment, the present invention provides novel compounds of formula (I-ii), wherein:
K is selected from CHZ and CHRS;
L is selected from CH2 and CHRS;
R3 is a C3_lo carbocyclic residue substituted with 0-3 R15, wherein the carbocyclic residue is selected from cyclopropyl, cyclopentyl, cyclohexyl, phenyl, naphthyl and adamantyl, and a (CR3'H)r-heterocyclic system substituted with 0-3 R15, wherein the heterocyclic system is selected from pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, indolinyl, isoindolyl, isothiadiazolyl, isoxazolyl, piperidinyl, pyrrazolyl, 1,2,4-triazolyl, 1,2,3-triazolyl, tetrazolyl, thiadiazolyl, thiazolyl, oxazolyl, pyrazinyl, and pyrimidinyl; and R15, at each occurrence, is selected from C1_8 alkyl, (CH2)rC3_~ cycloalkyl, CF3, C1, Br, I, F, (CH2)=NR15dR15a', Np2. CN, OH, (CH2)rORlSd~
(CH2)rC(O)RlSb, (CH2)rC(O)NRl5aRl5a'. (CH2)rNRl5fC(O)RlSb~
(CH2)rS(O)pRlSb~ (CH2)rS(O)2NR15aRlSa'.
(CH2)rNRlSfs(O)2R15b~ and (CH2)rphenyl substituted with 0-3 RlSe, and a (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 RlSe.
Rl5a and RlSa' ~ at each occurrence, are selected from H, C1_s alkyl, C3_6 cycloalkyl, and (CH2)rphenyl substituted with 0-3 RlSe Rlsb~ at each occurrence, is selected from H, CI_6 alkyl, C3_6 cycloalkyl, and (CHz)rphenyl substituted with 0-3 RlSe;
Rl5d~ at each occurrence, is selected from C1_6 alkyl and phenyl;
Rlse~ at each occurrence, is selected from C1-6 alkyl, C1, F, Br, I, CN, NO2, (CF2)=CF3, OH, and (CH2)rOCl_s alkyl;
and Rlsf~ at each occurrence, is selected from H and C1-s alkyl.
[38] In a further even more preferred embodiment, the present invention provides novel compounds of formula (I) and pharmaceutically acceptable salt forms thereof, wherein the compound of formula (I) is selected from N"-cyano-N-(3-acetylphenyl)-N'-[(1R,2S)-2-[[(3S)-3-(4-fluorobenzyl)piperidinyl]methyl]cyclohexyl]guanidine, N"-cyano-N-(4-((1H)-1-methyl-tetrazol-5-yl)phenyl)-N'-[ (1R,2S)-2-[ [ (3S)-3-(4-fluorobenzyl)piperidinyl]methyl]cyclohexyl]guanidine, N"-cyano-N-(3-acetylphenyl)-N'-[(1R,2S)-2-[[4-(4-fluorobenzyl)piperidinyl]methyl]cyclohexyl]guanidine, N"-cyano-N-(phenyl)-N'-[(1R,2S)-2-[[4-(4-fluorobenzyl)piperidinyl]methyl]cyclohexyl]guanidine, N"-cyano-N-(phenyl)-N'-[(1R,2S)-2-[[(3S)~-3-(4-fluorobenzyl)piperidinyl]methyl]cyclohexyl]guanidine, N"-cyano-N-(3-cyanophenyl)-N'-[(1R,2S)-2--[[(3S)-3-(4-fluorobenzyl)piperidinyl]methyl]cyclohexyl]guanidine, N"-cyano-N-(3-cyanophenyl)-N'-[(1R,2S)-2-[[4-(4-fluorobenzyl)piperidinyl]methyl]cyclohexyl]guanidine, N"-cyano-N-(2,4-dimethoxyphenyl)-N'-[(1R,2S)-2-[[(3S)-3-(4-fluorobenzyl)piperidinyl]methyl]cyclohexyl]guanidine, N"-cyano-N-(2,5-dimethoxyphenyl)-N'-[(1R,2S)-2-[[(3S)-3-(4-fluorobenzyl)piperidinyl]methyl]cyclohexyl]guanidine, N"-cyano-N-(4-((1H)-1-propyl-tetrazol-5-yl)phenyl)-N'-[(1R,2S)-2-[[(3S)-3-(4-fluorobenzyl)piperidinyl]methyl]cyclohexyl]guanidine, N"-cyano-N-(1-adamantyl)-N'-[(1R,2S)-2-[[(3S)-3--(4-fluorobenzyl)piperidinyl]methyl]cyclohexyl]guanidine, N"-cyano-N-(2-adamantyl)-N'-[(1R,2S)-2-[[(3S)-3-(4-fluorobenzyl)piperidinyl]methyl]cyclohexyl]guanidine, N"-cyano-N-(ethoxycarbonylmethyl)-N'-[(1R,2S)-2-[[(3S)-3-(4-fluorobenzyl)piperidinyl]methyl]cyclohexyl]guanidine, N"-cyano-N-(5,6,7,8-tetrahydronaphth-1-yl)-N'-[(1R,2S)-2-[ [ (3S) -3- (4-fluorobenzyl)piperidinyl]methyl]cyclohexyl]guanidine, N"-cyano-N-(2,4-dimethylphenyl)-N'-[(1R,2S)-2-[[(3S)-3-(4-fluorobenzyl)piperidinyl]methyl]cyclohexyl]guanidine, N"-cyano-N-(2-methoxyphenyl)-N'-[(1R,2S)-2-[[(3S)-3-(4-fluorobenzyl)piperidinyl]methyl]cyclohexyl]guanidine, N"-cyano-N-(2-methyl-4-hydroxyphenyl)-N'-[(1R,2S)-2-[[(3S)-3- (4-fluorobenzyl)piperidinyl]methyl]cyclohexyl]guanidine, N"-cyano-N-(2,5-dimethylphenyl)-N'-[(1R,2S)-2-[[(3S)-3-(4-fluorobenzyl)piperidinyl]methyl]cyclohexyl]guanidine, N"-cyano-N-(2-phenylethyl~)-N'-[(1R,2S)-2-[[(3S)-3-(4-fluorobenzyl)piperidinyl]methyl]cyclohexyl]guanidine, N"-cyano-N-(5-acetyl-2-methoxyphenyl)-N'-[(1R,2S)-2-[[(3S)-3-(4-fluorobenzyl)piperidinyl]methyl]cyclohexyl]guanidine, N"-cyano-N-[4-(4-morpholinyl)phenyl]-N'-[(2R,2S)-2-[[(3S)-3-(4-fluorobenzyl)piperidinyl]methyl]cyclohexyl]guanidine, 2-{(3-acetylanilino)[((1R,2S)-2-{[(3S)-3-(4-fluorobenzyl)piperidinyl]methyl}cyclohexyl]amino}methy lene}malonitrile, 2-{(5-acetyl-2-methoxyanilino)[((1R,2S)-2-{[(3S)-3-(4-fluorobenzyl)piperidinyl]methyl}cyclohexyl]amino}methy lene}malonitrile, 1-[3-({1-[({(1R,2S)-2-[{3(S)-3-(4-fluorobenzyl)piperidinyl]methyl}cyclohexyl)amino]-2-nitroethenyl}amino)phenyl]ethanone, 1-{3-([1-{ (2-[{4-(4-fluorobenzyl)piperidinyl}methyl]phenyl)amino}-2-nitroethenyl]amino)phenyl}ethanone, N"-cyano-N-(3,5-diacetylphenyl)-1-N'-[2-[[4-(4-fluoYobenzyl)piperidinyl]methyl]3-(N-methylcarbamoyl)phenyl]guanidine, N"-cyano-N-(3-diacetylphenyl)-1-N'-[2-[[4-(4-fluorobenzyl)piperidinyl]methyl]3-(N-methylcarbamoyl)phenyl]guanidine, and N"-cyano-N-[3-[(1H)-1-methyltetrazol-5-yl]phenyl]-1-N'-[2-[[4-(4-fluorobenzyl)piperidinyl]methyl]3-(N-methylcarbamoyl)phenyl]guanidine.
In another embodiment, the present invention provides a pharmaceutical composition, comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of the present invention.
In another embodiment, the present invention provides a method for modulation of chemokine receptor activity comprising administering to a patient in need thereof a therapeutically effective amount of a compound of the present invention.
In another embodiment, the present invention provides a method for treating inflammatory disorders comprising administering to a patient in need thereof a therapeutically effective amount of a compound of the present invention In another embodiment, the present invention provides a method for treating or preventing disorders selected from asthma, allergic rhinitis, atopic dermatitis, inflammatory bowel diseases, idiopathic pulmonary fibrosis, bullous pemphigoid, helminthic parasitic infections, allergic colitis, eczema, conjunctivitis, transplantation, familial eosinophilia, eosinophilic cellulitis, eosinophilic pneumonias, eosinophilic fasciitis, eosinophilic gastroenteritis, drug induced eosinophilia, HIV infection, cystic fibrosis, Churg-Strauss syndrome, lymphoma, Hodgkin's disease, and colonic carcinoma.

DEFINITIONS
The compounds herein described may have asymmetric centers. Compounds of the present invention containing an asymmetrically substituted atom may be isolated in optically active or racem~ic forms. It is well known in the art how to prepare optically active forms, such as by resolution of racemic forms or by synthesis from optically active starting materials. Many geometric isomers of olefins, C=N double bonds, and the like can also be present in the compounds described herein, and all such stable isomers are contemplated in the present invention. Cis and traps geometric isomers of the compounds of the present invention are described and may be isolated as a mixture of isomers or as separated isomeric forms. All chiral, diastereomeric, racemic forms and all geometric isomeric forms of a structure are intended, unless the specific stereochemistry or isomeric form is specifically indicated.
The term "substituted,~ as used herein, means that any one or more hydrogens on the designated atom is replaced with a selection from the indicated group, provided that the designated atom's normal valency is not exceeded, and that the substitution results in a stable compound. When a substitent is keto (i.e., =O), then 2 hydrogens on the atom are replaced.
When any variable (e. g., Ra) occurs more than one time in any constituent or formula for a compound, its definition at each occurrence is independent of its definition at every other occurrence. Thus, for example, if a group is shown to be substituted with 0-2 Ra, then said group may optionally be substituted with up to two Ra groups and Ra at each occurrence is selected independently from the definition of Ra. Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
when a bond to a substituent is shown to cross a bond connecting two atoms in a ring, then such substituent may be bonded to any atom on the ring. When a substituent is listed without indicating the atom via which such substituent is bonded to the rest of the compound of a given formula, then such substituent may be bonded via any atom in such substituent. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
As used herein, "C1_8 alkyl" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms, examples of which include, but are not limited to, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl, t-butyl, pentyl, and hexyl. C1_g alkyl, is intended to include Cl, C2, C3, Cq, C5, C6, C~, and Cg alkyl groups.
~Alkenyl" is intended to include hydrocarbon chains of either a straight or branched configuration and one or more unsaturated carbon-carbon bonds which may occur in any stable point along the chain, such as ethenyl, propenyl, and the like. "Alkynyl" is intended to include hydrocarbon chains of either a straight or branched configuration and one or more unsaturated triple carbon-carbon bonds which may occur in any stable point along the chain, such as ethynyl, propynyl, and the like. "C3_6 cycloalkyl" is intended to include saturated ring groups having the specified number of carbon atoms in the ring, including mono-, bi-, or poly-cyclic ring systems, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl in the case of C~ cycloalkyl. C3_6 cycloalkyl, is intended to include C3, C4, C5, and C6 cycloalkyl groups "Halo" or "halogen" as used herein refers to fluoro, chloro, bromo, and iodo; and "haloalkyl" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups, for example CF3, having the specified number of carbon atoms, substituted with 1 or more halogen (for example -C"FW where v = 1 to 3 and w = 1 to (2v+1)).
The compounds of Formula I can also be quaternized by standard techniques such as alkylation of the piperidine or pyrrolidine with an alkyl halide to yield quaternary piperidinium salt products of Formula I. Such quaternary piperidinium salts would include a counterion. As used herein, "counterion" is used to represent a small, negatively charged species such as chloride, bromide, hydroxide, acetate, sulfate, and the like.
As used herein, the term "piperidinium spirocycle or pyrrolidinium spirocycle" is intented to mean a stable spirocycle ring system, in which the two rings form a quarternary nitrogene at the ring junction.
As used herein, the term "5-6-membered cyclic ketal"
is intended to mean 2,2-disubstituted 1,3-dioxolane or 2,2-disubstituted 1,3-dioxane and their derivatives.
As used herein, "carbocycle" or "carbocyclic residue"
is intended to mean any stable 3, 4, 5, 6, or 7-membered monocyclic or bicyclic or 7, 8, 9, 10, 11, 12, or 13-membered bicyclic or tricyclic, any of which may be saturated, partially unsaturated, or aromatic. Examples of such carbocycles include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, cyclooctyl,; [3.3.0]bicyclooctane, [4.3.0]bicyclononane, [4.4.0]bicyclodecane (decalin), [2.2.2]bicyclooctane, fluorenyl, phenyl, naphthyl, indanyl, adamantyl, or tetrahydronaphthyl (tetralin).
As used herein, the term "heterocycle" or "heterocyclic system~ is intended to mean a stable 5, 6, or 7-membered monocyclic or bicyclic or 7, 8, 9, or 10-membered bicyclic heterocyclic ring which is saturated, partially unsaturated or unsaturated (aromatic), and which consists of carbon atoms and 1, 2, 3, or 4 heteroatoms independently selected from the group consisting of N, NH, O and S and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring. The nitrogen and sulfur heteroatoms may optionally be oxidized. The heterocyclic ring may be attached to its pendant group at any heteroatom or carbon atom which results in a stable structure. The heterocyclic rings described herein may be substituted on carbon or on a nitrogen atom if the resulting compound is stable. If specifically noted, a nitrogen in the heterocycle may optionally be quaternized. It is preferred that when the total number of S and O atoms in the heterocycle exceeds 1, then these heteroatoms are not adjacent to one another. As used herein, the term "aromatic heterocyclic system" is intended to mean a stable 5- to 7- membered monocyclic or bicyclic or 7- to 10-membered bicyclic heterocyclic aromatic ring which consists of carbon atoms and from 1 to 4 heterotams independently selected from the group consisting of N, O and S.
Examples of heterocycles include, but are not limited to, 1H-indazole, 2-pyrrolidonyl, 2H,6H-1,5,2-dithiazinyl, 2H-pyrrolyl, 3H-indolyl, 4-piperidonyl, 4aH-carbazole, 4H-quinolizinyl, 6H-1,2,5-thiadiazinyl, acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazalonyl, carbazolyl, 4aH-carbazolyl, ~-carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 2H,6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b]tetrahydrofuran, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 1H-indazolyl, indolenyl, indolinyl, indolizinyl, indolyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl (benzimidazolyl), isothiazolyl, isoxazolyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl., oxazolyl, oxazolidinylperimidinyl, phenanthridinyl, phenanthrolinyl, phenarsazinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, pteridinyl, piperidonyl, 4-piperidonyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazole, pyridoimidazole, WO 00/35451 PCT/US99/3033'_ pyridothiazole, pyridinyl, pyridyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, pyrrolyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, carbolinyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, 6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiophenyl, triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, tetrazolyl, and xanthenyl. Preferred heterocycles include, but are not limited to, pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazalyl, benzimidazolyl, benzothiaphenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, isoidolyl, piperidinyl, piperidonyl, 4-piperidonyl, piperonyl, pyrrazolyl, 1,2,4-triazolyl, 1,2,3-triazolyl, tetrazolyl, thiazolyl, oxazolyl, pyrazinyl, and pyrimidinyl. Also included are fused ring and spiro compounds containing, for example, the above heterocycles.
The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
As used herein, "pharmaceutically acceptable salts"
refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium ' WO 00/35451 PCT/US99/30332 salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobrornic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, malefic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, and the like.
The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two;
generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, PA, 1985, p. 1418, the disclosure of which is hereby incorporated by reference.
Since prodrugs are known to enhance numerous desirable qualities of pharmaceuticals (e. g., solubility, bioavailability, manufacturing, etc...) the compounds of the present invention may be delivered in prodrug form.
Thus, the present invention is intended to cover prodrugs of the presently claimed compounds, methods of delivering the same and compositions containing the same. "Prodrugs"
are intended to include any covalently bonded carriers which release an active parent drug of the present invention in vivo when such prodrug is administered to a mammalian subject. Prodrugs the present invention are prepared by modifying functional groups present in the compound in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compound. Prodrugs include compounds of the present invention wherein a hydroxy, amino, or sulfhydryl group is bonded to any group that, when the prodrug of the present invention is administered to a mammalian subject, it cleaves to form a free hydroxyl, free amino, or free sulfhydryl group, respectively. Examples of prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of alcohol and amine functional groups in the compounds of the present invention.
"Stable compound" and "stable structure" are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.
SYNTHESIS
The compounds of Formula I can be prepared using the reactions and techniques described below. The reactions are performed in a solvent appropriate to the reagents and materials employed and suitable for the transformations being effected. It will be understood by those skilled in the art of organic synthesis that the functionality present on the molecule should be consistent with the transformations proposed. This will sometimes require a judgment to modify the order of the synthetic steps or to select one particular process scheme over another in order to obtain a desired compound of the invention. It will also be recognized that another major consideration in the planning of any synthetic route in this field is the judicious choice of the protecting group used for protection of the reactive functional groups present in the compounds described in this invention. An authoritative account describing the many alternatives to the trained practitioner is Greene and Wuts (Protective Groups In .
Organic Synthesis, Wiley and Sons, 1991).

WO 00/35451 PCTlUS99/30332 Generally, compounds described in the scope of this patent application can be synthesized by the route described in Scheme 1. The appropriately substituted pyrrolidine (n=0) or piperidine (n=1) 1_ is alkylated by a N-protected alkylhalide (halide = C1, Br, I), mesylate, tosylate or triflate, 2_, (where E represents a linkage described within the scope of this application in its fully elaborated form with the appropriate protecting groups as understood by one skilled in the art or in a precursor form which can be later elaborated into its final form by methods familiar to one skilled in the art) with or without base or an acid scavenger to yield the piperidinyl- or pyrrolidinylalkyl protected amine 3. If the halide is not I, then KI can also be added to facilitate the displacement, provided the solvent is suitable, such as an alcohol, 2-butanone, DMF or DMSO, amongst others. The displacement can be performed at room temperature to the reflux temperature of the solvent. The protecting group is subsequently removed to yield amine ~. Protecting groups include phthalimide which can be removed by hydrazine, a reaction familiar to one skilled in the art; bis-BOC which can be removed by either TFA or HC1 dissolved in a suitable solvent, both procedures being familiar to one skilled in the art; a nitro group instead of an amine which can be reduced to yield an amine by conditions familiar to one skilled in the art; 2,4-dimethyl pyrrole (S. P. Breukelman, et al. J. Chem. Soc. Perkin Trans. I, 1984, 2801); N-1,1,4,4-Tetramethyl-disilylazacyclopentane (STABASE) (S.
Djuric, J. Venit, and P. Magnus Tet. Lett 1981, 22, 1787) and other protecting groups. Reaction with an isocyanate or isothiocyanate _5 (Z = O,S) yields urea or thiourea 6.
Reaction with a chloroformate or chlorothioformate 7 (Z=O,S) such as o-, p-nitrophenyl-chloroformate or phenylchloroformate (or their thiocarbonyl equivalents), followed by diplacement with an amine 9_, also yields the corresponding urea or thiourea 6. Likewise, reaction of carbamate _8 (X = H, or 2- or 4-N02) with disubstituted WO 00/35451 PCT/US99/303~2 amine 10 yields trisubstituted urea or thiourea _12.
Reaction of the amine 4 with an N,N-disubstituted carbamoyl chloride 11 (or its thiocarbonyl equivalent) yields the corresponding N,N-disubstituted urea or thiourea _12.
Amine 4 can also be reductively- aminated to yield 13 by conditions familiar to one skilled in the art and by the following conditions: Abdel-Magid, A. F., et al. Tet. Lett.
1990, 31, (39) 5595-5598. This secondary amine can subsequently be reacted with isocyanates or isothiocyanates to yield trisubstituted ureas 14 or with carbamoyl chlorides to yield tetrasubstituted ureas 15.
1.06 ' WO 00135451 PCT/US99/30332 H
~- P
+ ~~_P -RS 1 n P=protecting,group 5 'n X=leaving group: Cl,Br,I, ri=0 , 1 OTs , OMs , OTf , etc E=linker F-NH- ( C=Z ) -NR2R 3 ~2 ~ C1- (C=Z ) -NR2R3 11 5 'n R5 n 12 R 4 C1-(C=Z)-OPh R3N=C=Z
R2R3~ 7 5 F~-NH- ( C=Z ) -OPh- Y ~~- ( C=Z ) -NH-R 3 Jn 6 RS n g 9 RS

Y = H, o- or p-N02 Na(Ac0)3BH /
F~-NRz - ( C=Z ) -NHR 3 R3N=C=Z ~Rz i RS n 14 ~ n 13 ~--~Rz- (C=Z ) -NR2R3 Cl- (C=Z) -NR2R3 Z=O or S 11 RS n 15 One can also convert amine ~, into an isocyanate, isothiocyanate, carbamoyl chloride or its thiocarbonyl 5 equivalent (isocyanate: Nowakowski, J. J Prakt. Chem/Chem-Ztg 1996, 338 (7), 667-671; Knoelker, H.-J. et al., Angew.
Chem. 1995, 107 (22), 2746-2749; Nowick, J. S.et al., J.
Org. Chem. 1996, 61 (11), 3929-3934; Staab, H. A.; Benz, W.; Angew Chem 1961, 73; isothiocyanate: Strekowski L.et al., J. Heterocycl. Chem. 1996, 33 (6), 1685-1688;
Kutschy, Pet al., Synlett. 1997, (3), 289-290) carbamoyl chloride: Hintze, F.; Hoppe, D.; Synthesis (1992) 12, 1216-~5 1218; thiocarbamoyl chloride: Ried, W.; Hillenbrand, H.;
Oertel, G.; Justus Liebigs Ann Chem 1954, 590) (these reactions are not shown in Scheme 1). These isocyanates, isothiocyantes, carbamoyl chlorides or thiocarbamoyl chlorides can then be reacted with R2R3NH to yield di- or trisubstituted ureas or thioureas 12. An additional urea forming reaction involves the reaction of carbonyldiimidazole (CDI) (Romine, J. L.; Martin, S. W.;
Meanwell, N. A.; Epperson, J. R.; Synthesis 1994 (8), 846-850) with 4 followed by reaction of the intermediate imidazolide with 9 or in the reversed sequence (9 + CDI, followed by 4). Activation of imidazolide intermediates also facilitates urea formation (Bailey, R. A., et al., Tet. Lett. 1998, 39, 6267-6270). One can also use 13 and 10 with CDI. The urea forming reactions are done in a non-hydroxylic inert solvent such as THF, toluene, DMF, etc., at room temperature to the reflux temperature of the solvent and can employ the use of an acid scavenger or base when necessary such as carbonate and bicarbonate salts, triethylamine, DBU, Hunigs base, DMAP, etc.
Substituted pyrrolidines and piperidines _2 can either be obtained commercially or be prepared as shown in Scheme 2. Commercially available N-benzylpiperid-3-one ~ can be debenzylated and protected with a BOC group employing reactions familiar to one skilled in the art. Subsequent Wittig reaction followed by reduction and deprotection yields piperidine 20 employing reactions familiar to one skilled in the art. Substituted pyrrolidines may be made by a similar reaction sequence. Other isomers and analogs around the piperidine ring can also be made by a similar reaction sequence. Chiral pyrrolidines/piperidines can be synthesized via asymmetric hydrogenation of 18 using chiral catalysts (see Parshall, G.W. Homogeneous Catalysis, John Wiley and Sons, New York: 1980, pp. 43-45; Collman, J.P., Hegedus, L.S. Principles and Applications of Organotransition Metal Chemistry, University Science Books, Mill Valley, CA, 1980, pp. 341-348).

H2/Pd Wittig H2/Pd --s BOCZ O g B~ BOC

H+

H
The cyanoguanidines (Z = N-CN) can be synthesized by the method of K. S. Atwal, et al. and references contained therein (J. Med. Chem. (1998) 41, 217-275). The nitroethylene analog (Z = C-N02) can be synthesized by the method of F. Moimas, et al. (Synthesis 1985, 509-510) and references contained therein. The malononitrile analog (Z
- C(CN)2) may be synthesized by the method of S. Sasho, et al. (J. Med. Chem. 1993, 36, 572-579).
Guanidines (Z=NRla) can be synthesized by the methods outlined in Scheme 3. Compound 21 where Z=S can be methylated to yield the methylisothiourea ~. Displacement of the SMe group with amines yields substituted guanidines 23 (see H. King and I. M. Tonkin J. Chem. Soc. 1946, 1063 and references therein). Alternatively, reaction of thiourea ~ with amines in the presence of triethanolamine and "lac sulfur" which facilitates the removal of H2S
yields substituted guanidines 23 (K. Ramadas, Tet. Lett.
1996, 37, 5161 and referenees therein). Finally, the use of carbonimidoyldichloride 2~, or 25 followed by sequential displacements by amines yields the corresponding substituted guanidine 23 (S. Nagarajan, et al., Syn. Comm.
1992, 22, 1191-8 and references therein). In a similar manner, carbonimidoyldichlorides, R2-N=C(C1)2 (not shown in Scheme 3) and R3-N=C(C1)2 (not shown) can also be reacted sequentially with amines to yield di- and trisubstituted guanidine 23.

~1 _ ( C=S ) _~ la ~1 _ ( C=NHRla ) -SMe R5 n 21 R5 n 22 n= 0 , 1 ~zR3 N(CH20H)3, "lac sulfur~, ~~-(C=NHRla)-lVRzR3 R2R 3NH w l/
l.HzNR", Et3N RS n 23 2 . HNR2R3 or 1 . HNR2R3 , Et3N 1 . HNR2R3 , Et3N
2 . HzNR" 2 . 13 or 1 . 13 , Et3N
N=C ( C 1 ) z 2 . HNRZR3 l Rla-N=C ( C1 ) 2 /n 2 4 A method for introducing substituents in linkage E is that of A. Chesney et al. (Syn. Comm. 1990, 20 (20), 3167-3180) as shown in Scheme 4. Michael reaction of pyrrolidine or piperidine _1 with Michael acceptor 26 yields intermediate 27 which can undergo subsequent reactions in the same pot. For example, reduction yields alcohol _2_8 which can be elaborated to the amine ~9 by standard procedures familiar to one skilled in the art. Some of these include mesylation or tosylation followed by displacement with NaN3 followed by reduction to yield amine 29. Another route as depicted in Scheme 4 involves reaction with diphenylphosphoryl azide followed by reduction of the azide to~ yield amine 29.

g 9 7 / O Michael R5 n -----1 g _m ~ Rs n Rl i n=0, 1 Ri2Li or Rl2MgBr g 9 NaBH4 31 OH
R5 n R11 ~--OH
2 8 R5 - v ~n Rl l R12 (Ph0)2(p=O)N3 32 (Ph0)2(p=O)N3 H2. pd/C
H2, Pd/C
7 g 9 7 g 9 ~2 R5 n Rli 2 9 R5 n R11 Rlz 3 3 as described as described previously _ previously 1- ( C=Z ) -NR2 R3 - ( C=Z ) -~2 R3 WO 00/35451 PCT/US99/303?2 The mesylate or tosylate can also be displaced by other nucleophiles such as NH3, BOC2N-, potassium phthalimide, etc., with subsequent deprotection where necessary to yield amines 29. Finally, 29 can be converted to urea or thiourea 30 by procedures discussed for Scheme 1 or to the compounds of this invention by procedures previously discussed. Similarly, aldehyde 27 may be reacted with a lithium or a Grignard reagent 31 to yield alcohol adduct 32. This in turn can be converted to urea or thiourea 34 in the same way as discussed for the conversion of 28 to 30.
Scheme 5 shows that intermediate 36 can be extended via a Wittig reaction (A. Chesney, et al. Syn. Comm. 1990, (20), 3167-3180) to yield 37. This adduct can be 15 reduced catalytically to yield 38 or by other procedures familiar to one skilled in the art. Alkylation yields 39, followed by saponification and Curtius rearrangement (T. L.
Capson and C. D. Poulter, Tet. Lett., (1984) 25, 3515-3518) followed by reduction of vhe benzyl protecting group yields 20 amine 40 which can be elaborated further as was described earlier in Scheme 1 and elsewhere in this application to make the compounds of this invention. Dialkyllithium cuprate, organocopper, or copper-catalyzed Grignard addition (for a review, see G. H. Posner, "An Introduction to Synthesis Using Organocopper Reagents", J. Wiley, New York, 1980; Organic Reactions, 19, 1 (1972)) to alpha, beta-unsaturated ester 37 yields 41 which can undergo subsequent transformations just discussed to yield amine 43 which can be elaborated further to the compounds of this invention as was described earlier. The intermediate enolate ion obtained upon cuprate addition to 37 can also be trapped by an electrophile to yield 42 (for a review, see R. J. K.
Taylor, Synthesis 1985, 364). Likewise, another 2-carbon homologation is reported by A. Chesney et al. (ibid.) on intermediate 36 which involves reacting 36 with an enolate anion to yield aldol condensation product 42 where R12-OH.
The OH group can undergo synthetic transformations which ,.

are familiar to one skilled in the art and which will be discussed in much detail later on in the application.
Chiral auxilliaries can also be used to introduce stereo-and enantioselectivity in these aldol condensations, procedures which are familiar to one skilled in the art.

WO 00/35451 PCT/US99/3(3332 g 9 H
RS 1n R ~ 0 Michael Rxn ~0 1 Ra R9 ' R5 n R9 n=0, 1 35 11 Wittig ~ pph - ~ ~OMe H2 Pd / C
OMe OMe 1 . LllA
2 . R 12X .i /

1 . -OH 11 12 2 . ( Ph0 ) 2 ( P O ) N3 R9i R5 n ,~~ ~2 3.BnOH
39 4.H2 Pd/C 40 to compounds by methods g previously discussed 11 as above 11 n R 9~2 OMe R R R5 ~n R9 Rio 44 41 p (Rlo)2CuLi 1.LDA
to compounds by methods 2 . Rl2x previously ~ ~ a ' a 9 2 . R12X
discussed ~ 11 R
12 as ' li above 12 _.
R5 'n R9 Rio NH2 R5 n R9 R1° OMe Examples of such methods are taught in D. A. Evans, et al., J. Am. Chem. Soc. 1981, 103, 2127; D. A. Evans, J. Am.
5 Chem.Soc. 1982, 104, 1737; D. A. Evans, J. Am. Chem. Soc.

' WO 00/35451 PC'f/US99/30332 1986, 108, 2476; D. A. Evans. et al., J. Am. Chem. Soc.
1986, 108, 6757; D. A. Evans, J. Am. Chem. Soc. 1986, 108, 6395; D. A. Evans, J. Am. Chem. Soc. 1985, 107, 4346; A.
G. Myers, et al., J. Am. Chem. Soc. 1997, 119, 6496. One can also perform an enantioselective alkylation on esters 38 or 41 with R12X where X is a leaving group as described in Scheme 1, provided the ester is first attached to a chiral auxiliary (see above references of Evans, Myers and Mauricio de L. Vanderlei, J. et al., Synth. Commum. 1998, 28, 3047).
One can also react alpha,beta-unsaturated ester (Scheme 6) with Corey's dimethyloxosulfonium methylide (E.J. Corey and M. Chaykovsky, J. Am. Chem. Soc. 1965, 87, 1345) to form a cyclopropane which can undergo eventual Curtius rearrangement and subsequent elaboration to the compounds of this invention wherein the carbon containing R9R1~ is tied up in a cyclopropane ring with the carbon containing R11R12_ In addition, compound 48 can also undergo the analogous reactions just described to form cyclopropylamine 50 which can be further elaborated into the compounds of this invention as described previously.
Compound 48 may be synthesized by an alkylation reaction of pyrrolidine/piperidine ~ with bromide 47 in an inert solvent employing the conditions as described for the alkylation of 2 onto _1 in Scheme 1.
Another way to synthesize the compounds in the scope of this application is shown in Scheme 7. Michael reaction of amine ~ with an acrylonitrile 51 (as described by I.
Roufos in J. Med. Chem. 1996, 39, 1514-1520) followed by Raney-Nickel hydrogenation yields amine ~3 which can be elaborated to the compounds of this invention as previously described.

I-NaH, THF

1 . -OH
2 . ( Ph0 ) 2 ( P=O ) N3 3.BnOH
4.H2 Pd/C
g 9 to compounds 11 by methods -.
previously , discussed R5 'n R9 NH2 I_ COZ Me -----Me R5 n R11 NaH, s 1.'OH
1 + 2 . ( Ph0 ) 2 ( P=O ) N3 Br ~ 3.BnOH
47 C02Me 4. H2 Pd/C

to compounds by methods previously discussed RS n R11 In Schemes 4,5, and 6, we see that there is no gem-substitution on the alpha-carbon to the electron-s withdrawing group of what used to be the Michael acceptor.
In other words, in Scheme 4, there is no R10 gem to R9; in Scheme 5, there is no R10 gem to one of the Rss and in Scheme 7 there is no R10 gem to R9. Gem-substitution can be introduced by reacting pyrrolidine or p:~.peridine 1 with the epoxide of Michael acceptors 26, 35, and 51 to yield the corresponding alcohols (for amines reacting with epoxides of Michael acceptors, see Charvillon, F. B.;
Amouroux, R.; Tet. Lett. 1996, 37, 5103-5106; Chong, J.
M.; Sharpless, K. B.; J Org Chem 1985, 50, 1560). These alcohols eventually can be further elaborated into R10 by one skilled in the art, as, for example, by tosylation of the alcohol and cuprate displacement (Hanessian, S.;
Thavonekham, B.; DeHoff, B.; J Org. Chem. 1989, 54, 5831), etc., and by other displacement reactions which will be discussed in great detail later on in this application.
SCH~ 7 R~
H CN
Ra-Ni /Hz + R _ R ~ CN -r 9 R5 n 1 Re R5 n n=0,1 51 R~
CHz -NHz to compounds R9 by methods previously discussed RS n Further use of epoxides to synthesize compounds of this invention are shown in Scheme 8. Reaction of pyrrole or piperidine ,~ with epoxide 54 yields protected amino-alcohol 55. This reaction works exceptionaly well when R~
and Re are H hut is not limited thereto. The reaction is performed in an inert solvent at room temperature to the reflex temperature of the solvent. Protecting groups on the nitrogen atom of 54 include BOC and CBZ but are not limited thereto. The hydroxyl group can be optionally i protected by a variety of protecting groups familiar to one skilled in the art.

H R~ 9or10 ~ 8 9or10 + Rs NH- p OH
R5 n R1 -~-~

1 ~ p R5 n R11 R12 n=0,1 55 [0]
~ -P
( R9or1 o-H ) D7 ,R8 p9orlQ
_P
57 ~
R9or10-M R~~n R1- 1 Rlz where M=Li,MgBr, 56 MgCl, ZnCl, etc.
_P
7 8 9or10 to compounds OH
by methods ~- P previously discussed Rs ~ ~n R11 R12 Deprotection of the nitrogen by methods familiar to one skilled in the art yields 56 which can be elaborated to the compounds of this invention by the procedures previously discussed. If R9=H, then oxidation, for example, by using PCC (Corey E.J. and Suggs, J.W., Tet, Lett. 1975, 31, 2647-2650) or with the Dess-Martin periodinane (Dess, D.B. and Martin, J.C., J. Org. Chem. 1983, 48, 4155-4156) yields ketone 57 which may undergo nucleophilic 1,2-addition with organometallic reagents such as alkyl- or aryllithiums, Grignards, or zinc reagents, with or without CeCl3 (T.
Imamoto, et al., Tet. Lett. 1985, 26, 4763-4766; T.
Imamoto, et al., Tet. Lett. 1984, 25, 4233-4236) in aprotic solvents such as ether, dioxane, or THF to yield alcohol 58. The hydroxyl group can be optionally protected by a variety of protecting groups familiar to one skilled in the art. Deprotection of the nitrogen yields 56 which can be finally elaborated to the compounds of this invention as previously discussed. Epoxides disclosed by structure 54 may be synthesized enantio-selectively from amino acid starting materials by the methods of Dellaria, et al. J Med Chem 1987, 30 (11), 2137, and Luly, et aI. J Org Chem 1987, 52 (8), 1487.
The carbonyl group of ketone 57 in Scheme 8 may undergo Wittig reactions followed by reduction of the double bond to yield alkyl, arylalkyl, heterocyclic-alkyl, cycloalkyl, cycloalkylalkyl, etc. substitution at that position, reactions that are familiar to one skilled in the art. Wittig reagents can also contain functional groups which after reduction of the double bond yield the following functionality: esters (Buddrus, J. Angew Chem., 1968, 80), nitriles (Cativiela, C.et al., Tetrahedron 1996, 52 (16), 5881-5888.), ketone (Stork, G.et al., J Arn Chem Soc 1996, 118 (43), 10660-10661), aldehyde and methoxymethyl (Bertram, G.et al., Tetrahedron Lett 1996, 37 (44), 7955-7958.), gamma-butyrolactone Vidari, G.et al.,Tetrahedron: Asymmetry 1996, 7 (10), 3009-3020.), carboxylic acids (Svoboda, J.et al., Collect Czech Chem Cornmun 1996, 61 (10), 1509-1519), ethers (Hamada, Y.et al., Tetrahedron Lett 1984, 25 (47), 5413), alcohols (after hydrogenation and deprotection--Schonauer, K.; Zbiral, E.;
Tetrahedron Lett 1983, 24 (6), 573), amines (Marxer, A.;
Leutert, T. Helv Chim Acta, 1978, 61) etc., all of which may further undergo transformations familiar to one skilled in the art to form a wide variety of functionality at this position.

Scheme 9 summarizes the displacement chemistry and subsequent elaborations that can be used to synthesize the R9 groups. In Scheme 9 we see that alcohol 55 or 58 may be tosylated, mesylated, triflated, or converted to a halogen by methods familiar to one skilled in the art to produce compound 59. (Note that all of the following reactions in this paragraph can be also performed on the compounds, henceforth called carbon homologs of 55 or 58 where OH can be (CH2)rOH - -and it is also understood that these carbon homologs may have substituents on the methylene groups as well). For example, a hydroxyl group may be converted to a bromide by CBr4 and Ph3P (Takano, S. Heterocycles 1991, 32, 1587). For other methods of converting an alcohol to a bromide or to a chloride or to an iodide see R.C. Larock, Comprehensive Organic Transformations, VCH Publishers, New York, 1989, pp. 354-360. Compound 59 in turn may be displaced by a wide variety of nucleophiles as shown in Scheme 9 including but not limited to azide, cyano, malonate, cuprates, potassium thioacetate, thiols, amines, etc., all nucleophilic displacement reactions being familiar to one skilled in the art. Displacement by nitrite yields a one-carbon homologation product. Nitrite 60 can be reduced with DIBAL to yield aldehyde 61. This aldehyde can undergo reduction to alcohol 62 with, for example, NaBH4 which in turn can undergo all of the SN2 displacement reactions mentioned for alcohol 55 or 58.
Alcohol 62 is a one carbon homolog of alcohol 55 or 58.
Thus one can envision taking alcohol 62, converting it to a leaving group X as discussed above for compound 55 or 58, and reacting it with NaCN or KCN to form a nitrite, subsequent DIBAL reduction to the aldehyde and subsequent NaBH4 reduction to the alcohol resulting in a two carbon homologation product. This alcohol can undergo activation followed by the same SN2 displacement reactions discussed previously, ad infinitum, to result in 3,4,5...etc. carbon homologation products. Aldehyde 61 can also be reacted with a lithium or Grignard reagent to form an alcohol 61a which can also undergo the above displacement reactions.
Oxidation by methods familiar to one skilled in the art yields ketone 6~b. Displacement by malonate yields malonic ester 63 which can be saponified and decarboxylated to yield carboxylic acid 64, a two carbon homologation product. Conversion to ester f5 (A. Hassner and V.
Alexanian, Tet. Lett, 1978, 46, 4475-8) and reduction with LAH yields alcohol ~8 which can undergo all of the displacement reactions discussed for alcohol 55 or ~.
Alcohols may be converted to the corresponding fluoride _70 by DAST (diethylaminosulfur trifluoride) (Middleton, W. J.;
Bingham, E. M.; Org. Synth. 1988, VI, pg. 835). Sulfides 7~ can be converted to the corresponding sulfoxides _72 (p=1) by sodium metaperiodate oxidation (N. J. Leonard, C.
R. Johnson J. Org. Chem. 1962, 27, 282-4) and to sulfones 72 (p=2) by Oxone~ (A. Castro, T.A. Spencer J. Org. Chem.
1992, 57, 3496-9). Sulfones 72 can be converted to the corresponding sulfonamides 73 by the method of H.-C. Huang, E. et al., Tet. Lett. (1994) 35, 7201-7204 which involves first, treatment with base followed by reaction with a trialkylborane yielding a sulfinic acid salt which can be reacted with hydroxylamine-O-sulfonic acid to yield a sulfonamide. Another route to sulfonamides involves reaction of amines with a sulfonyl chloride (G. Hilgetag and A. Martini, Preparative Organic Chemistry, New York:
John Wiley and Sons, 1972, p.679). This sulfonyl chloride (not shown in Scheme 9) can be obtained from the corresponding sulfide (71 where R9d=H in Scheme 9, the hydrolysis product after thioacetate displacement), disulfide, or isothiouronium salt by simply reacting with chlorine in water. The isothiouronium salt may be synthesized from the corresponding halide, mesylate or tosylate 59 via reaction with thiourea (for a discussion on the synthesis of sulfonyl chlorides see G. Hilgetag and A.
Martini, ibid., p. 670). Carboxylic acid 64 can be converted to amides 6~f by standard coupling procedures or via an acid chloride by Schotten-Baumann chemistry or to a Weinreb amide (66: R9a=OMe, R9a'= Me in Scheme 9) (S. Nahm and S. M. Weinreb, Tet. Lett., 1981, 22, 3815-3818) which can undergo reduction to an aldehyde 67 (R9b=H in Scheme 9) with LAH (S. Nahm and S. M. Weinreb, ibid.) or reactions with Grignard reagents to~form ketones 67 (S. Nahm and S.
M. Weinreb, ibid.). The aldehyde 67 obtained from the Weinreb amide reduction can be reduced to the alcohol with NaBH4. The aldehyde or ketone 67 (or 61 or 61b for that matter) can undergo Wittig reactions as discussed previously followed by optional catalytic hydrogenation of the olefin. This Wittig sequence is one method for synthesizing the carbocyclic and heterocyclic substituted systems at R9 employing the appropriate carbocyclic or heterocyclic Wittig (or Horner-Emmons) reagents. Of course, the Wittig reaction may also be used to synthesize alkenes at R9 and other functionality as well. Ester 65 can also form amides 66 by the method of Weinreb (A. Basha, M.
Lipton, and S.M. Weinreb, Tet. Lett. 1977, 48, 4171-74) (J.
I. Levin, E. Turos, S. M. Weinreb, Syn. Comm. 1982, 12, 989-993). Alcohol 68 can be converted to ether 69 by procedures familiar to one skilled in the art, for example, NaH, followed by an alkyliodide or by Mitsunobu chemistry (Mitsunobu, O. Synthesis, 1981, I-28). Alcohol 55 or 58, 62, or 68, can be acylated by procedures familiar to one skilled in the art, for example, by Schotten-Baumann conditions with an acid chloride or by an anhydride with a base such as pyridine to yield 78. Halide, mesylate, tosylate or triflate 59 can undergo displacement with azide followed by reduction to yield amine 74 a procedure familiar to one skilled in the art. This amine can undergo optional reductive amination and acylation to yield 75 or reaction with ethyl formate (usually refluxing ethyl formate) to yield formamide 75. Amine 74 can again undergo optional reductive amination followed by reaction with a sulfonyl chloride to yield 76, for example under Schotten-Baumann conditions as discussed previously. This same sequence may be employed for amine 60a, the reduction product of nitrile 60. Tosylate 59 can undergo displacement with cuprates to yield 77 (Hanessian, S.;
Thavonekham, B.; DeHoff, B.; J Org. Chem. 1989, 54, 5831).
Aldehyde 61 or its homologous extensions can be reacted with a carbon anion of an aryl (phenyl, naphthalene, etc.) or heterocyclic group to yield an aryl alcohol or a heterocyclic alcohol. If necessary, CeCl3 may be added (T.
Imamoto, et al., Tet. Lett. 1985, 26, 4763-4766; T.
Imamoto, et al., Tet. Lett. 1984, 25, 4233-4236). This alcohol may be reduced with Et3SiH and TFA (J. Org. Chem.
1969, 34, 4; J. Org. Chem. 1987, 52, 2226) (see discussion of aryl and heterocyclic anions for Schemes 20-22). These aryl and heterocyclic anions may also be alkylated by 59.
(or its carbon homology to yield compounds where R9 contains an aryl or heterocyclic group. Compound 59 or its carbon homologs may be alkylated by an alkyne anion to produce alkynes at R9 (see R.C. Larock, Comprehensive Organic Transformations, New York, 1989, VCH Publishers, p 297). In addition, carboxaldehyde 61 or its carbon homologs can undergo 1,2-addition by an alkyne anion (Johnson, A.W. The Chemistry of Acetylenic Compounds. V.
1. "Acetylenic Alcohols," Edward Arnold and Co., London (1946)). Nitro groups can be introduced by displacing bromide 59 (or its carbon homologs) with sodium nitrite in DMF (J.K. Stille and E.D. Vessel J. Org. Chem. 1960, 25, 478-490) or by the action of silver nitrite on iodide 59 or its carbon homologs (Org. Syntheses ~, 37-39).

to 8 10 ~ 8 10 10 7 ~ ~ R9d ( O ) 9d 'O ( CO) R9b (0~
\ ~. --78 ' 70 ~' ' 71 72 1.
KSAc 10 2 . -OH ~ ' ( O ) 2~9a DAST
3 . R9'jX R9a' or KSR9d /~ ~ 73 to OH ~ 8 10 -p w R5 n R11 Rla 5 9 - p 55 or 58 R5 n Rll R12 If an anion is made of the pyrrolidine/piperidine _1 with LDA or n-BuLi, etc., then that anion in a suitable nonhydroxylic solvent such as THF, ether, dioxane, etc., can react in a Michael-type fashion (2,4-addition) with an alpha, beta-unsaturated ester to yield an intermediate enolate which can be quenched with an electrophile (R9X) (where X is as described in Scheme 1) (Uyehara, T.; Asao, N.; Yamamoto, Y.; J Chem Soc, Chem Commun 1987, 1410) as shown in Scheme 10.

' WO 00/35451 PCT/US99/30332 SCHEME 9 (con't) _ P _--s _ P
1, 1, 55 or 58 , 59 X=OTs ; ( R9 ) 2CuLi KCN' Et OEt - Na to R1o ~ OE
1 . N 7 B i0 \ 2. [H 60 ~ 0 r'~C OEt R1o l0 63 y ~z ~ - CHZ OH io CHO

1 . R98'CHO
Na (Ac0) 3HH 1 .R9aCH0, 61 1 - OH
2 . R9bS02C1 Na (Ac0) 3BH 2 -H+.
2 . R9aCOC1 or -C02 ~OH to Et0 ( C=O ) H , D

' NRa SO2Rb 61 a 'N;"
76 l0 60a NHR 9a'C ( O ) R9a H
(or -NHCHO) 7 a to to 7 B 10 reductive b _ OR9d ~ ~ 0 amination +
acylation 64 if desired 61b OH Rg R9aR9a' R9b LAH

68 ~ \ ~ 65 L H

It is to be understood that R9 is either in its final form or in a suitable protected precursor form. This electrophile can be a carbon-based electrophile, some examples being formaldehyde to introduce a CH20H group, an aldehyde or a ketone which also introduces a one-carbon homologated alcohol, ethylene oxide (or other epoxides) which introduces a -CH2CH20H group (a two-carbon homologated alcohol), an alkyl halide, etc., all of which can be later elaborated into R9. It can also be an oxygen-based electrophile such as MCPBA, Davis~ reagent (Davis, F. A.;
Haque, M. S.; J Org Chem 1986, 51 (21),4083; Davis, F. A.;
Vishwaskarma, L. C.; Billmers, J. M.; Finn, J.; J Org Chem 1984, 49, 3241) or Mo05 (Martin, T. et al., J Org Chem 1996, 61 (18), 6450-6453) which introduces an OH group.
These OH groups can undergo the displacement reactions discussed previously in Scheme 9 or protected by suitable protecting groups and deprotected at a later stage when the displacement reactions decribed in Scheme 9 can be performed. In addition, these OH groups can also undergo displacement reactions with heterocycles as described for Schemes 19-22 to introduce N- or C-substituted heterocycles at this position. Ester 80 can be converted into its Weinreb amide 82 (S. Nahm and S. M. Weinreb, Tet. Lett., 1981, 22, 3815-3818) or Weinreb amide 82 can be synthesized via Michael-type addition of _1 to alpha, beta-unsaturated Weinreb amide 83. Subsequent reaction with a Grignard reagent forms ketone 85. This ketone can also be synthesized in one step directly from _1 and alpha,beta-unsaturated ketone 84 using the same procedure. This ketone may be reduced with LAH, NaBH4 or other reducing agents to form alcohol 86. Or else, ketone 85 can be reacted with an organolithium or Grignard reagents to form tertiary alcohol 87 . Or else, ester 80 can be directly reduced with LiBH4 or LAH to yield primary alcohol 88.

,.. q _.....

, WO 00/35451 PCT/US99/30332 R~
H ~ 10 R ~ l.BuLi ~OMe Re 0 --9 ~Rlo Rs n 2 . R X
7 9 OMe Rs Jn n 0,1 1.
R ~ R1o R~ 8 R~ io 84 O 1/~\ ~OH
R8 O R'9 'Rio Rllorl2 l.BuLi N(CH3)OMe 2.R9X Rs n 2 . R9X ~ 83 R'7 s R~
~ ~N(CH3)OMe ~ Rllorl2 R9 'R1D Rll 9 io MgBr or ~ R ~R
Rs Jn 82 Ri2MgBr Rs n R~ a _p Rllorl2 R11or12MgBr Rs 'Rio R7 s H
R5 ~n 8 9 ~ a H
Rllorl2 R12 Rllor l2MgBr ~9'R1D ~ ~ 'Rll Rs n 9 Rio Rs 'n -p 86 ~ 87 R~2 ~ r 9 .Rio ~ 7 B
OH ~ NH 2 to co OOH
9 0 mpounds ~ ~ to by methods ~ R R
previoiusly R5 n described Alcohols 86, 87 , and 88 can all be tosylated, mesylated, triflated, or converted to a halogen by methods discussed 5 previously and displaced with an amine nucleophile such as azide, diphenylphosphoryl azide (with or without DEAD and WO 00/35451 PCTNS99/3~332 Ph3P), phthalimide, etc. as discussed previously (and which are familiar to one skilled in the art) and after reduction (azide) or deprotection with hydrazine (phthalimide), for example, yield the corresponding amines. These can then be elaborated into the compounds of this invention as discussed previously. Ketone 85 can also be converted into imine 89 which can be reacted with a Grignard reagent or lithium reagent, etc., to form a protected amine 90 which can be deprotected and elaborated into the compounds of this invention as discussed previously. Some protecting groups include benzyl and substituted benzyl which can be removed by hydrogenation, and cyanoethyl, which can be removed with aqueous base, etc. It is to be understood that R~-12 in Scheme 10 can be in their final form or in precursor form which can be elaborated into final form by procedures familiar to one skilled in the art.
Magnesium amides of amines have been used to add in a Michael-type manner to alpha, beta-unsaturated esters where the substituents at the beta position of the unsaturated ester are tied together to form a cyclopentane ring (for example, compound 79 where R~ and R8 are taken together to be -(CH2)4-) (Kobayashi, K. et al., Bull Chem Soc Jpn, 1997, 70 (7), 1697-1699). Thus reaction of pyrrolidine or piperidine _1 with cycloalkylidine esters 79 as in Scheme 10 yields esters 80 where R~ and R8 are taken together to form a cycloalkyl ring. Subsequent elaboration yields compounds of this invention where R~ and R8 are taken together to form a cycloalkyl ring.
Compounds of structure 95a may also be synthesized from epoxyalcohols which are shown in Scheme 11. Allylic alcohol 91 can be epoxidized either stereoselectively using VO(acac)2 catalyst (for a review, see Evans: Chem.
Rev. 1993, 93, 1307) or enantioselectively (Sharpless: J.
Am. Chem. Soc. 1987, 109, 5765) to epoxyalcohol 92. SN2 displacement of the alcohol using zinc azide and triphenylphosphine (Yoshida, A. J. Org. Chem. 57, 1992, 1321-1322) or diphenylphosphoryl azide, L7EAD, and ,.

triphenylphosphine (Saito, A. et al., Tet. Lett. 1997, 38 (22), 3955-3958) yields azidoalcohol 93. Hydrogenation over a Pd catalyst yields aminoalcohol ~4_. This can be protected in situ or in a subsequent step with BOC20 to put on a BOC protecting group, or with CBZ-Cl and base to put on a CBZ-group or other protecting groups. Alternatively, the amino group can be reacted with an isocyanate, an isothiocyanate, a carbamoyl chloride, or any reagent depicted in Scheme 1 to form 95 which can be alkylated with _1 to form the compounds of this invention.

R ' R
Re OH RB OH
-s R ~ R~ 9 B 2 s R~ 9 R
R8 P Re - ( C=Z ) NR2R3 R R12 Rl 12 R

H
as in Scheme 8 R5 'n n=0,1 _ ( C=Z ) NR2R3 n 95a Sometimes amine 1 might have to be activated with Lewis acids in order to open the epoxide ring (Fujiwara, M.; Imada, M.; Baba, A.; Matsuda, H.;Tetrahedron Lett 1989, 30, 739; Caron, M.; Sharpless, K. B.; J Org Chem 1985, 50, 1557) or 1 has to be deprotonated and used as a metal amide, for example the lithium amide (Gorzynsk.i-Smith, J.;
Synthesis 1984 (8), 629) or MgBr amide (Carre, M. C.;

WO 00/35451 PC'~'/US99/30332 Houmounou, J. P.; Caubere, P.; Tetrahedron Lett 1985, 26, 3107) or aluminum amide (Overman, L. E.; Flippin, L. A.;
Tetrahedron Lett 1981, 22, 195).
The quaternary salts (where R4 is present as a substituent) of pyrrolidines and piperidines can be synthesized by simply reacting the amine with an alkylating agent, such as methyl iodide, methyl bromide, ethyl iodide, ethyl bromide, ethyl or methyl bromoacetate, bromoacetonitrile, allyl iodide, allylbromide, benzyl bromide, etc. in a suitable solvent such as THF, DMF, DMSO, etc. at room temperature to the reflux temperature of the solvent. Spiroquaternary salts can be synthesized in a similar manner, the only difference being that the alkylating agent is located intramolecularly as shown iri Scheme 12. It is understood by one skilled in the art that functional groups might not be in their final form to permit cyclization to the quaternary ammonium salt and might have to be in precursor form or in protected form to be elaborated to their final form at a later stage. For example, the NR1(C=Z)NR2R3 group on the rightmost phenyl ring of compound 1Q4 might exist as a nitro group precursor for ease of manipulation during quaternary salt formation.
Subsequent reduction and NR1(C=Z)NR2R3 group formation yields product ~. The leaving groups represented by X in Scheme 12 may equal those represented in Scheme 1, but are not limited thereto. N-oxides of pyrrolidines and piperidines can be made by the procedure of L_ W. Deady (Syn. Comm. 1977, 7, 509-514). This simply entails reacting the pyrrolidine or piperidine with MCPBA, for example, in an inert solvent such as methylene chloride.

11812 7 g 11812 1 (C=Z ) NR2R3 X ~ NRl ( C=Z ) NR2R3 R Rlo X=leaving Rs~lo Rs n group R5 ~n n=0,1 96 X- R
1 (C Z) NR2R3 1 (C=Z) NR2R3 /9 ~Rlo ~ + ~Rlo Rs n ~ Q_X ~~R9 Rs n n=0,1 R a ~11 12 811 NR1 ( C-Z ) NR2R3 X_ R
NR1 (C=Z) NR2R3 ~ Rlo R9 Rlo --a s n R 100 RS~nR R 101 9 10 ~ 11 1 (C=Z) NR2R3 R
RI to 1 ( C=Z ) NR2R3 X R
w + ~R9 R9 Rlo p l l 812 ~ 810 RS ~n ~' 5 n R9 R4_X R R R8 ~1 ( C=Z ) NR2R 3 X_84_814\ , (C=Z) NR2R3 s .
y~ Ry Rlo Rs - , Jn 104 105 h ' Multisubstituted pyrrolidines and piperidines may be synthesized by the methods outlined in Scheme 13.
Monoalkylation of 106 via an enolate using LDA or potassium hexamethyldisilazane, or converting 106 first to an enamine, or by using other bases, all of which can be done in THF, ether, dioxane, benzene, or an appropriate non-hydroxylic solvent at -78 oC to room temperature with an alkylating agent such asvmethyl iodide, benzyl bromide, etc. where X is as defined in Scheme 1, yields product 107.
This product can subsequently undergo alkylation again under thermodynamic or kinetic conditions and afterwards, if need be, can undergo two more alkylations to produce tri- and tetrasubstituted analogs of X07. The thermodynamic or kinetic conditions yield regioselectively alkylated products (for a discussion on thermodynamic vs.
kinetic alkylations see H. House Modern Synthetic Reactions, W. A. Benjamin, Inc. (Menlo Park, CA: 1972) chapter 9).

R R
~Ph 1. Base Ph Ph n 2. R5-X
106 107n Sp n n=0,1 X = leaving group R5p=precursor to RS
H2 / Pd or Pd(OH)2 R H
to compounds.by methods previously described RS n cis and trans C02 Et C02 Et C02 Et BoC2o l.Base Rs ---~
2 . R 6X
H B~ X=leaving OC

group as defined in 1. [H]
Scheme 1 2.Swern 5*
CH2R CH ( OH) RS* RS*MgBr or CHO
~Rs .~ ~Rs s Rs R5*Li B~ BOC BOC 113 lI9 118 Wittig CHZ R5 * CH2 CHZR 5 * CH= CHR5 R6 R6 H2 Pd/C
.~ ~Rs 120 ~ 114 H+1 CH2 CHzR 5* CH= CHRS *
~Rs ~R6 H 117 ~ H 115 RS*=R5 or a precursor thereof to products by methods previously described Subsequent Wittig olef ination yields compound X08.
Hydrogenation (asymmetric hydrogenation is an option here:
Parshall, G.W. Homogeneous Catalysis, John Wiley and Sons, ' New York: 1980, pp. 43-45; Collman, J.P., Hegedus, L.S.
Principles and Applications of Organotransition Metal Chemistry, University Science Books, Mill Valley, CA, 1980, pp. 341-348) yields pyrrolidine or piperidine 109 which can W O 00/3545 i be resolved into its relative and/or absolute isomers at this stage or later on in the synthesis either by crystallization, chromatographic techniques, or other methods familiar to one skilled in the art. The amine 109 an then be elaborated into the compounds of this invention by methods discussed previously (Scheme 1). The carbonyl-containing intermediate 107 in Scheme 13 can also be reduced to the methylene analog via a Wolff-Kishner reduction and modifications thereof, or by other methods familiar to one skilled in the art. The carbonyl group can also be reduced to an OH group, which can undergo all of the reactions described in Scheme 9 to synthesize the R6 groups. This piperidine or pyrrolidine can be deprotected and elaborated to the compounds of this invention by methods discussed earlier. Thus, mono-, di-, tri-, or tetraalkylated carbonyl-containing pyrrolidines or piperidines can be synthesized, which in turn can be reduced to the corresponding -CH2- analogs employing the Wolff-Kishner reduction or other methods.
Another method for synthesizing gem-substituted pyrrolidines and piperidines is shown in Scheme 14. It is understood by one skilled in the art that some of the steps in this scheme can be rearranged. It is also understood that gem-disubstitution is only shown at only one position on the piperidine ring and that similar transformations may be performed on other carbon atoms as well, both for piperidine and pyrrolidine. Thus, 3-carboethoxypiPeridine ~0 may be BOC-protected and alkylated employing a base such as LDA, KHMDS, LHDMS, etc., in THF, ether, dioxane, etc. at -78 °C to room temperature, and an alkylating agent R6X where X is a halide (halide = C1, Br, I1, mesylate, tosylate or triflate, to yield . Reduction using DIBAL, for example, and if necessary followed by oxidation such as a Swern oxidation (S. L. Huang, K. Omura, D. Swern J. Org.
Chem. 1976, 41, 3329-32) yields aldehyde ~3_. Wittig olefination (~.~4_) followed by deprotection yields ~ which may be elaborated as described previously into the compounds of this invention. Reduction of the Wittig adduct 114 yields 116 which may be deprotected to yield 1 which may be in turn elaborated as described previousl Y
into the compounds of this invention. Reaction of aldehyde 113 with an alkyllithium or Grignard rea gent yields alcohol 118 which may be reduced catalyticall o Y r with Et3SiH/TFA (J. Org. Chem. 1969, 34~ 4; J. Or C
9. hem.
1987, 52, 2226) if RS* (R5* _ R5 or a precursor thereof is aromatic to yield 119. If R5* is not aromatic, then the OH
may be reduced by the method of Barton (Barton, D.
H. R., Jaszberenyi, J. C. Tet. Lett. 1989, 30, 2619 and other references therein). Once tosylated, the alcohol can a lso be displaced with dialkyllithium cuprates (not shown (Hanessian, S.; Thavonekham, B.; DeHoff, B . J Or C
'' 3. hem.
1989, 54, 5831). Deprotection if necessary field Y s 120 which may be elaborated as described previously into the compounds of this invention.

r R R
n 1. s-BuLi )n R 5orR13 TMEDA
BOC
OC 2 , R5- or R13-X 122 X=as defined n=0,1 in Scheme 1 1, s-BuLi TN~DA
2. R5- or R13-X
R~ . / n R
1. s-BuLi 13~ RSO rRl3 s ~ n R orR R5orR13 TMEDA
OC 5 _ 5~ 5 13 B 2 . R R ~R orR
124 or R13-X or Rl3 BOC

1. s-BuLi TMEDA
2. R5- or R13-X
R
R13r5o~ R50r'R13 R5orR13~ ~R5orR13 BOC

A method for the alkylation of alkyl groups, arylalkyl groups, allylic groups, propargylic groups, etc., and a 5 variety of other electrophiles onto the pyrrolidinyl and/or piperidinyl alpha-carbons (alpha to the ring nitrogen atom) is represented by the work of Peter Beak, et al. as shown in Scheme 15. It is understood by one skilled in the art that the R5 and R13 groups are either in their precursor, protected, or final form. Only one R5 group is shown to be substituted on piperidine/pyrrolidine ~. However it is understood by one skilled in the art that additional functionality may be present on the ring in either precursor, protected, or final form. Thus lithiation with an alkyllithium reagent such as n-BuLi or s-BuLi as shown, followed by quenching with an electrophilic species such as R5X or R13X where X is as defined in Scheme 1 and R5 and R13 are in their precursor, protected, or final form, yields monoalkylated piperidine/pyrrolidine 122. This alkylation may occur either stereoselectively (P. Beak and W.K. Lee J. Org. Chem. 1990, 55, 2578-2580) or enantioselectively if sparteine is included as a source of chirality (P. Beak, et al., J. Am. Chem. Soc. 1994, 116, 3231-3239). The alkylation process may be repeated up to three more times as shown in Scheme 15 to result in di-, tri-, and tetrasubstitution at the alpha-positions.
Compounds where R9 and R1~ form a cyclic 3,4,5,6, or 7-membered ring can be synthesized by the methods disclosed in Scheme 16. These same methods may also be used to synthesize gem-disubstituted compounds in which R9 can be different from R1~ by step-wise alkylation of the malonate derivative. Of course, this scheme may be used to synthesize compounds where R1~=H also. For example, a cyclohexyl-fused malonate may be synthesized by Michael addition and alkylation of I(CH2)qCH=CCOZMe with dimethyl malonate employing NaH/DMF (Desmaele, D.; Louvet, J.-M.;
Tet Lett 1994, 35 (16), 2549-2552) or by a double Michael addition (Reddy, D. B., et al., Org. Prep. Proced. Int. 24 (1992) 1, 21 -26) (Downes, A. M.; Gill, N. S.; Lions, F.; J
Am Chem or by an alkylation followed by a second intromolecular alkylation employing an iodoaldehyde (Suami, T.; Tadano, K.; Kameda, Y.; Iimura, Y.; Chem Lett 1984, 1919), or by an alkylation followed by a second intramolecular alkylation employing an alkyl dihalide (Kohnz, H.; Dull, B.; Mullen, K.; Angew Chem 1989, 101 (10), 1375), etc.

~ ,..

R9 Rlo R9 Rio diethyl ~ pEt OEt s H
malonate -' ~OEt H
R5 n r n=0,1 t (H) 1.

1 j U 1~
to compounds by methods previously described Subsequent monosaponification (Pallai, P.V., Richman, S., Struthers, R.S., Goodman, M. Int. J. Peptide Protein Res. 1983, 21, 84-92; M. Goodman Int. J. Peptide Protein Res. 19831, 17, 72-88), standard coupling with pyrrolidine/
piperidine 1 yields 128. Reduction with borane yielus 129 followed by reduction with LAH yields X30 which can be then converted to amine 131 and then to the compounds of this invention by procedures as discussed previously. Ester 12~
can also be converted to a Weinreb amide and elaborated to the compounds of this invention as described in Scheme 10 for ester 80 which would introduce substituents R11 and R12.

Scheme 17 describes another method for the synthesis of compounds where R9 and R1~ are taken together to form cycloalkyl groups. Aminoalcohols 132 are found in the literature (CAS Registry Nos. for n = 0,2,2,3, respectively: 45434-02-4; 2041-56-7, 2239-31-8, 2041-57-8).
They can easily be protected, as with a BOC group (or CBZ, or any other compatible protecting group) by known procedures familiar to one skilled in the art to yield alcohols 133. The alcohols can then be activated either by conversion to a halide or to a mesylate, tosylate or triflate by methods familiar to one skilled in the art and as discussed previously, and then alkylated with pyrrolidine/piperidine 1 by the conditions described in Scheme 1 to yield I35. Subsequent deprotection yields amine 136 which can be elaborated to the compounds of this invention as described previously. Of course, alcohol 133 can be oxidized to the aldehyde and then reacted with R~°rBMgBr or R~~raLi with or without CeCl3 to yield the corresponding alcohol 133 where instead of -CH20H, we would have -CHR~~r80H. This oxidation-I,2-addition sequence may be repeated to yield a tertiary alcohol. The alcohol may then be tosylated, mesylated, triflated, or converted to C1, Br, or I by procedures familiar to one skilled in the art to yield 134 and then displaced with pyrrolidine/piperidine 1 to yield I35. Subsequent deprotection yields 136 which may undergo elaboration to the compounds of this invention as discussed previously.

~ .,.,~

(CH2)n (CH2)n (CHZ)n H2N-CH2 '~ BOC-NH-CH2 --~gOC-NH-CH2 BOCZO
OH OH g n=0,1,2,3 133 132 "
R5 'n n=0,1 .... , n_ (H+) ,.,., , to compounds by previously described - BOC
A method to introduce cycloalkyl groups at RllRlz is shown in Scheme 18. Protection of the nitrogen of compounds 137 which are commercially available yields 138 (the protecting group may be BOC, CBZ, or any other compatible protecting group) by procedures familiar to one skilled in the art. Esterification by any one of a number procedures familiar to one skilled in the art (for example A. Hassner and V. Alexanian, Tet. Lett, 1978, 46, 4475-8) followed by reduction with DIBAL (or alternatively reduction to the alcohol with, for example, LiBH4, followed by Swern oxidation (op. cit.)) yields aldehyde ~. One carbon homologation via the Wittig reaction followed by hydrolysis of the, vinyl ether yields aldehyde 141.
Reductive amination (Abdel-Magid, A. F., et al. Tet. Lett.
1990, 31, (39) 5595-5598) yields 142 followed by deprotection yields amine 143 which can be elaborated to the compounds of this invention by the methods previously discussed. Of course, aldehyde 139 can be reacted with R9orloMgBr or R9orloLi with or without CeCl3 to yield an alcohol which can be oxidized to a ketone. Wittig one-carbon homologation on this ketone as described above followed by hydrolysis yields 141 where the -CH2CH0 is substituted with one R9orio group (-CHR9orlo CHO) .

(CH2)n BOCzO (CH2)n (CH2)r, H2 ~ BOC ---~ BOC
2.ROH

n=0, l, 2, 3 DAP 138 139 (CH2)n H+ (CH2)n ~-- BOC
B OC CH2 CHO CH= CHOMe 1, Na(Ac0)3BH 141 140 t r-~u_ v - BOC
~H+~ to compounds -~ by methods described previously R, ..

Aldehyde 141 (-CH2CH0) or its monosubstituted analog synthesized above (-CHR9or1oCH0) can undergo alkylation with R9orloX where X is as defined in Scheme 1 to yield compound X41 containing one or both of the R9 and Rlo substituents alpha to the aldehyde group. Alkylati.on can be performed using LDA or lithium bistrimethylsilyl amide amongst other bases in an inert solvent such as ether, THF, etc., at -78 °C to room temperature. Aldehyde ~ (-CH2CH0)or its substit~.~ted analogs synthesized above (i.e., -CHR9R1~CH0) can undergo reductive amination with _1 and subsequent elaboration to the compounds of this invention. Aldehyde 141 (-CH2CH0)or its substituted analogs synthesized above (i.e., -CHR9R1~CH0) can also undergo 1,2-addition with R~°rBMgBr or R~°rBLi to yield the corresponding alcohol -CH2CHR~°reOH or -CHR9R1~CHR~°r80H. The alcohol may then be tosylated, mesylated, triflated, or converted to C1, Br, or I by procedures familiar to one skilled in the art and displaced with pyrrolidine/piperidine _1 to yield, after subsequent deprotection and elaboration, the compounds of this invention. Or else alcohol -CH2CHR~°r80H or -CR9R1~CHR~°r80H can be oxidized (i.e., Swern, op. cit.) to the ketone and reductively arninated with 1 and subsequently elaborated to the compounds of this invention. Or else alcohol -CH2CHR~°r80H or -CR9R1~CHR~°=gOH can be oxidized (i.e., Swern, op. cit.) to the ketone and reacted once more with R~°r8MgBr or R~°rBLi to yield the corresponding alcohol -CH2CR~R80H or -CR9R1~CR~ReOH. If the ketone enolizes easily, CeCl3 may be used together with the Grignard or lithium reagent. The alcohol can again be tosylated, mesylated, triflated, or converted to Cl, Br, or I by procedures familiar to one skilled in the art and displaced with pyrrolidine/ piperidine _1 to yield, after subsequent deprotection and elaboration, the compounds of this invention. Thus each one of the R~, R8, R9, and R1~ groups may be introduced into compounds ~, and 143 and and, of course, in the compounds of this invention, by the methods discussed above.
A method for the synthesis of N-substituted heterocycles at RS is shown in Scheme 19. The heterocycle can be deprotonated with NaH or by other bases familiar to one skilled in the art, in a solvent such as DMF, THF, or another appropriate non-hydroxylic solvent and reacted with piperidine or pyrrolidine 143 at room temperature to the reflux temperature of the solvent. Deprotection and elaboration as described before yields compounds where R5 contains an N-substituted heterocycle. If the nitrogen atom of the heterocycle is sufficiently nucleophilic, then an acid scavenger, such as K2C03, KHC03, Na2C03, NaHC03, amongst others, can be used in place of NaH, employing THF, DMF, or methyl ethyl ketone as solvents. In this case hydroxylic solvents may be used as well, such as methanol, ethanol, etc. from room temperature to the reflux temperature of the solvent. Compound 143 as well as its other positional isomers are available, for example, from commercially available 4-hydroxymethylpiperidine, 2-, 3-, and 4-carboethoxypiperidine, L- or D-proline ethyl ester, or from methyl 1-benzyl-5-oxo-3-pyrrolidinecarboxylate by methods familiar to one skilled in the art and as discussed previously in this application.

he' rocycle heterocycle BOC
H
NaH or KZC03 X

n=0,1 deprotect X = leaving group to compounds by methods described previously A method for the synthesis of C-substituted heterocycles at R5 is shown in Scheme 20. Many heterocycles such as the ones shown in Scheme 20, but not limited thereto, can be metallated with strong bases such as LDA, n-BuLi, sec-BuLi, t-BuLi, etc. t.o yield the corresponding anionic species. These anions may also be generated via halogen-metal. exchange employing n-BuLi, or other alkyllithium reagents. These reactions may be performed in THF, ether, dioxane, DME, benzene, etc. at -78 °C to room temperature.

..~ ~ (_) (_) x (_) (-) ~ (_) heterocycle HOC ~ t '' ( CH ) m X
'n ~ (_) (-) (-) Boc 143 ~ 145 n=0,1 X = leaving m=1,2 w group ~ (_) described in Scheme 1 C02Li to compounds by methods described i (_) ~ (-) previously R=suitable protecting (_) I (-) group or functional group etc.
For reviews of these metallations and halogen-metal exchange reactions see Organometallics in Organic Synthesis, FMC Corp., Lithium Division, 1993, pp. 17-39;
Lithium Link, FMC Corp., Spring 1993, pp. 2-17; n-Butyllithium in Organic Synthesis, Lithium Corp. of America, 1982, pp. 8-16; G. Heinisch, T. Langer, P.
Lukavsky, J. Het. Chem. 1997, 34, 17-19. The anions can then be quenched with electrophile 143 or its positional isomers to yield the corresponding C-alkylated heterocyclic pyrrolidine or piperidine ~4~5.

1 (-) ~ (-) i R
he'.
BOC ~ ~(-) (-) (-) >.
H n ~ (-) 146 ~ ~ ( ) n=G , 1 (H]
~ (-) 02Li (') C02 Li etc . hetE -R=suitable protecting group or functional group to compounds by methods described previously "
Another method for the synthesis of C-substituted heterocyclic-methylpyrrolidines or piperidines is shown in Scheme 21. The protected aldehyde 146 is reacted with the anion of the heterocycle (its generation as described previously) at -78 °C to room temperature with or without CeCl3 in an inert solvent such as THF, ether, dioxane, DME, benzene, etc. to yield carbinol 147. Catalytic hydrogenation of the alcohol yields the corresponding methylene compound 145. Other reduction methods include Et3SiH/TFA (J. Org. Chem. 1969, 34, 4; J. Org. Chem. 1987, 52, 2226) amongst others familiar to one skilled in the art. It is understood by one skilled in the art that the aldehyde group can be located in other positions instead of, for example, the 4-position of piperidine in compound ~.

as depicted in Scheme 21. It is to be understood that other heterocycles may also be used besides the ones shown in Scheme 20 and 21.
The anions of the methyl-substituted heterocycles may also be reacted with a BOC-protected piperidone or pyrrolidone (148) to yield alcohols 149 as shown in Scheme 22 (see above reviews on metallations for references).
These alcohols may be reduced using Pt02 and TFA (P. E.
Peterson and C. Casey, J. Org. Chem. 1964, 29, 2325-9) to yield piperidines and pyrrolidines 150. These can subsequently be taken on to the compounds of this invention as described previously. It is understood by one skilled in the art that the carbonyl group can be located in other positions instead of, for example, the 4-position of piperidine in compound 148 as depicted in Scheme 22. It is to be understood that other heterocycles may also be used besides the ones shown in Scheme 22.

heterocycle BOC ~ (_) (-) ~ /
/n H
~'BOC
(-) 149 n 148 (_) n=0, 1 etc. TFA, Et3SiH
R=suitable protecting group or functional heterocycle group to compounds of by methods described previously as One may also react aryl (phenyl, naphthyl, etc.) anions, generated either by halogen-metal exchange or by ortho-directed metallation (Snieckus, V. Chem. Rev. 1990, 90, 879-933) using n- or s- or t-BuLi in a non-hydroxylic solvent such as THF, ether, etc., with or without TMEDA and allow them to react with compounds 143, 146, and 148 with subsequent elaboration to yield the compounds of this invention by the methods~depicted in Schemes 19-22.
Another method for the preparation of C-substituted heterocycles is shown in Scheme 23. Protected piperidone 148 undergoes a Wittig reaction with heterocyclic phosphorous ylides to yield 151. Hydrogenation over a noble metal catalyst such as Pd in an alcoholic solvent or with an optically active transition metal catalyst (see asymmetric hydrogenation references of Parshall and Coleman, op. cit.) yields 152 which can be further elaborated into the compounds of this invention by the procedures described previously. It will be appreciated by one skilled in the art that the carbonyl group can be located in other positions instead of, for example, the 4-position of piperidine in compound 148 as depicted in Scheme 23. It is to be understood that other heterocycles may also be used besides the ones shown in Scheme 23.

r .. ._ Scheme 23 Ph3 heteroc cle BOC ~ / Ph3 Y
n 148 PPh3 n=0,1 PPh3 etc.
R=suitable protecting group or functional group hetE ' to compounds by methods described '' previously ..
Syntheses of amines ~, 10, and the amines which are precursors to isocyanates or isothiocyanates 5 will now be discussed. For example, 3-nitrobenzeneboronic acid (1~:
Scheme 24) is commerically available and can undergo Suzuki couplings (Suzuki, A. Pure Appl. Chem. 1991, 63, 419) with a wide variety of substituted iodo- or bromo aryls (aryls such as phenyl, naphthalene, etc.), heterocycles, alkyls, akenyls (Moreno-manas, M., et al., J. Org. Chem., 1995, 60, 2396), or alkynes. It can also undergo coupling with triflates of aryls, heterocycles, etc. (Fu, J.-m, Snieckus, V. Tet. Lett. 1990, 31, 1665-1668). Both of the above reactions can also undergo carbonyl insertion in the presence of an atmosphere of carbon monoxide (Ishiyama, et al., Tet. Lett. 1993, 34, 7595). These nitro-containing compounds (155 and X57) can then be reduced to the corresponding amines either via catalytic hydrogenation, or via a number of chemical methods such as Zn/CaCl2 (Sawicki, E. J Org Chem 1956, 21). The carbonyl insertion compounds WO 00/35451 PCT/US99/3033.2 (158) can also undergo reduction of the carbonyl group to either the CHOH or CH2 linkages by methods already discussed (NaBH4 or Et3SiH, TFA, etc.). These amines can then be converted to isocyanate 5 via the following methods (Nowakowski, J. J Prakt Chem/Chem-Ztg 1996, 338 (7), 667-671; Knoelker, H.-J. et al., Angew Chem 1995, 107 (22), 2746-2749; Nowick, J. S.et al., J Org Chem 1996, 61 (11), 3929-3934; Staab, H. A.; Benz, W.; Angew Chem 1961, 73); to isothiocyanate 5 via the following methods (Strekowski L.et al., J Heterocycl Chem 1996, 33 (6), 1685-1688; Kutschy, Pet al., Synlett 1997, (3), 289-290); to carbamoyl chloride 11 (after 156 or 158 is reductively aminated with an R2 group) (Hintze, F.; Hoppe, D.;
Synthesis (1992) 12, 1216-1218); to thiocarbamoyl chloride 11 (after 156 or 158 is reductively- aminated with an R2 group) (Ried, W.; Hillenbrand, H.; Oertel, G.; Justus Liebigs Ann Chem 1954, 590); or just used as 9, or 10 (after 156 or 158 is reductively aminated with an R2 group), in synthesizing the compounds of this invention by the methods depicted in Scheme 1.

Suzuki-type 02 X-~ coupling B (OH) 2 X=Br, I, OTf Suzuki-type coupling, CO (g) ~H~

n2 make isocyanate or isothiocyanate ~, or carbamoyl chlorides or used as ~ or ~ to make the compounds of this invention as described for the compounds of Scheme 1 Likewise, protected aminobromobenzenes or triflates or protected aminobromoheterocycles or triflates 159 (Scheme 25) may undergo Suzuki-type couplings with arylboronic acids or heterocyclic boronic acids (160) These same bromides or triflates _15~ may also undergo Stille-type coupling (Echavarren, A. M., Stille, J.K. J. Am. Chem.
Soc., 1987, 109, 5478-5486) with aryl, vinyl, or heterocyclic stannanes X63. Bromides or triflates 159 may also undergo Negishi-type coupling with other aryl or heterocyclic bromides 1~4 (Negishi E. Accts. Chem. Res.
1982, 15, 340; M. Sletzinger, et al., Tet. Lett. 1985, 26, 2951). Deprotection of the amino group yields an amine with can be coupled to make a urea and other linkers containing Z as described above and for Scheme 1. Amino protecting groups include phthalimide, 2,4-dimethyl pyrrole (S. P. Breukelman, et al. J. Chem. Soc. Perkin Trans. I, 1984, 2801); N-1,1,4,4-Tetramethyldisilyl-azacyclopentane (STABASE) (S. Djuric, J.~Venit, and P. Magnus Tet. Lett 1981, 22, 1787) and others familiar to one skilled in the art.

P Suzuki-type -P
coupling + (HO) 2 Br,I,OTf 160 Stille-type 161 coupliing 9 + Bu3 Srr-Negishi-type coupling 159 + Br or vn2 make isocyanate or isothiocyanate _5, s or carbamoyl chlorides 11, or used as 9 or 10 to make 1 62 the compounds of this invention as described for the compounds of Scheme 1 Compounds where R7 and R8 are taken together to form =NRBb can be synthesized by the methods in Scheme 25a.
Reacting 1 with nitrile a with CuCl catalysis forms amidine b where R8b is H (Rousselet, G.; Capdevielle, P.; Maumy, M.; Tetrahedron Lett. 1993, 34 (40), 6395-6398). Note that the urea portion may be in final form or in precursor form (for example, a protected nitrogen atom; P = protecting group such as STABASE, bis-BOC, etc., as was discussed previously) which may be subsequently elaborated into the compounds of this invention. Compounds b may be also synthesized by reacting iminoyl chloride c with pyrrolidine/piperidine 1 to yield b where R8b is not H
(Povazanec, F., et al., J. J. Heterocycl. Chem., 1992, 29, 6, 1507-1512). Iminoyl chlorides are readily available from the corresponding amide via PC15 or CC14/PPh3 (Duncia, J.V. ~t al., J. Org. Chem., 1991, 56, 2395-2400). Again, the urea portion may be in final form or in precursor form.
Scheme 25a H R9 Rio R' NRl(C=Z)NR2R3 or N-P
R~ n ~Ri2 --1 n=0,1 a R 1 (C=Z) NR2R3 .2 R9 Rio + R~ NR1(C=Z)NR2R3 or N-P
R5 n C B Rl~'R12 -~ b NR8 b n=0,1 c Many amines are commercially available and can be used as _9, 10, or used as precursors to isocyanates or isothiocyanates _5. There are numerous methods for the synthesis of non-commercially available amines familiar to one skilled in the art. For example, aldehydes and ketones may be converted to their O-benzyl oximes and then reduced with LAH to form an amine (Yamazaki, S.; Ukaji, Y.;

Navasaka, K.; Bull Chem Soc Jpn 1986, 59, 525). Ketones and trifluoromethylketones undergo reductive amination in the presence of TiCl4 followed by NaCNBH4 to yield amines (Barney, C.L., Huber, E.W., McCarthy, J.R. Tet. Lett. 1990, 31, 5547-5550). Aldehydes and ketones undergo reductive amination with Na(Ac0)3BH as mentioned previously to yield amines (Abdel-Magid, A. F., et al. Tet. Lett. 1990, 31, (39) 5595-5598). Amines may also be synthesized from aromatic and heterocyclic OH groups (for example, phenols) via the Smiles rearrangement (Weidner, J.J., Peet, N.P. J.
Het. Chem., 1997, 34, 1857-1860). Azide and nitrile displacements of halides, tosylates, mesylates, triflates, etc. followed by LAH or other types or reduction methods yield amines. Sodium diformyl amide (Yinglin, H., Hongwen, H. Synthesis 1989 122), potassium phthalimide, and bis-BOC-amine anion can all displace halides, tosylates, mesylates, etc., followed by standard deprotection methods to yield amines, procedures which are familiar to one skilled in the art. Other methods to synthesize more elaborate amines involve the Pictet-Spengler reaction, imine/immonium ion Diels-Alder reaction (Larsen, S.D.; Grieco, P.A. J: Am.
Chem. Soc. 1985, 107, 1768-69; Grieco, P.A., et al., J.
Org. Chem. 1988, 53, 3658-3662; Cabral, J. Laszlo, P. Tet.
Lett. 1989, 30, 7237-7238; amide reduction (with LAH or diborane, for example), organometallic addition to imines (Bocoum, A. et al., J. Chem. Soc. Chem. Comm. 2993, 1542-4) and others all of which are familiar to one skilled in the art.
Compounds containing an alcohol side-chain alpha to the nitrogen of the piperidine/pyrrolidine ring can be synthesized as shown in Scheme 25b. Only the piperidine case is exemplified, and it is to be understood by one skilled in the art that the alpha-substituted pyrrolidines may be synthesized by a similar route. It is also understood that appropriate substituents may be present on the piperidine/pyrrolidine ring. A 4-benzylpiperidine 196 is protected with a BOC group. The BOC-piperidine 197 is then metallated under conditions similar to those Beak, et al. (P. Beak and W.-K. Lee, J. Org. Chem. 1990, 55, 2578-2580, and references therein) and quenched with an aldehyde to yield alcohol 298. The metallation may also be done enantioselectively using sparteine (P. Beak, S.T. Kerrick, S. Wu, J. Chu J. Am. Chem. Soc. 1994, 116, 3231-3239).
This alcohol can be deprotonated with NaH and cyclized to carbamate 198a which permits structural assignments of the erythro and threo isomers. Deprotection with base yields aminoalcohol 199. Subsequent N-alkylation yields phthalimidoalkylpiperidine 201. It is to be understood that the alkyl chain does not necessarily have to be n-propyl, but that n-propyl was chosen for demonstration purposes only. Deprotection of the phthalimido group with hydrazine yields amine 202. Finally, reaction with an isocyanate or via any of the previously described conditions described in Scheme 1 yields urea 203. If an isocyanate is used, the isocyanate can add twice to yield urea-carbamate 204.

Schane 25b O
N.H N~p v -Di-t-butyl Bicarbonate 'IxF' , 0 C to 2 5 C

196 p 1) EtZo, ~, -70 °c ~ 2) sec-BuLi, N p'_ ° °
-70 C to -30 C &
OH
O again to -70 °C
R ~ N ~ 3) RCHO, 1 g g O -70 °C to -30 °C then v=
R quench with water NaOH, EtOH, reflex, 3h ~ 195a + threo erythro OH K2~. KI, 2-butanone NON
OH
i R
t o I o il R
199 Br~N ~ ~ ~ 20I

2 0 0 N2H4 , EtOH
O
N ~N ~NHR3 i R 203 + O THF, 25 °c _ N OH ~z N ~N~NHR3 O H
R O ~R3 202 Compounds where Z = N-CN, CHN02, and C(CN)2 can be synthesized by the methods shown in Scheme 25c. Thus amine 208 reacts with malononitrile 207 neat or in an inert solvent at room temperature to the reflex temperature of the solvent, or at the melting point of the solid/solid mixture, to yield malononitrile 206. This in turn can undergo reaction with amine 205 under similar conditions stated just above to yield molononitrile 209. Likewise, a similar reaction sequence may be used to make 212 and 215 [for Z = C(CN) 2J, see for example P. Traxler, et al., J.
Med. Chem. (1997), 40, 3601-3616; for Z = N-CN, see K. S.
Atwal, J. Med. Chem. (1998) 41, 271; for Z = CHN02, see J.
M. Hoffman, et al., J. Med. Chem. (1983) 26, 140-144).
Scheme 25c.
+ R2R3NH
S

NC CN
\S /
NC CN
NC CN
5 ~N/E\~ I 2 5 ~N/E\N N/R
R ~ R1 + \S N/R ~ R ~ Rl R2 NOz /E~ /E~ I iR3 ~N ~ ~N N N
R5 ~ R1 + \S I N'/R3 .-~ R5 Rl R2 i2 + R2R3NH
\ /
S S

,,.rCN
N
~N/E\~ ~ NfCN E
R ~ + N/ ~ ~ /R3 Ri ~ ~ R3 ~ R5 ~ N N

0 N ~ R R
205 214 Rz N/CN /
+ RZR3NH
O

E
The compounds of this invention and their preparation can be understood further by the following working examples. These examples are meant to be illustrative of the present invention, and are not to be taken as limiting thereof.

Part A: Preparation of 4-benzyl-1-(3-N-phthalimido-n-prop-1-yl)piperidine V

4-benzylpiperidine (8.0 g , 45.6 mmol, 1eq), N-(3-bromopropyl)-phthalimide (I3.5 g, 50.2 mmol, 1.1 eq), potassium iodide (7.6 g, 45.6 mmol, 1 eq) and potassium carbonate (2.6 g, 91.3 mmol, 2 eq) were refluxed in 125 mL
of 2-butanone. The reaction was worked up after 5 hours by filtering off the inorganic solids then adding EtOAc and rinsing the organic layer 2X with water. The organic layer was dried over magnesium sulfate then the solvent removed in vacuo to obtain an amber oil. The oil was purified by flash chromatography in 100 EtOAc to remove impurities then 8:2 chloroform/methanol to isolate 3.67 g of the product as a light amber oil. NMR(300 MHz, CDC13) 8 8.00-7 . 80 (m, 2H) ; 7 . 80-7 . 60 (3n, 2H) ; 7 .35-7 . 10 (m, 3H) ; 7 . 08 (d, 2H, J=7 Hz); 3.76 (t, 2H, J = 7 Hz); 2.83 (d, 2H, J=10 Hz);
2.45-2.30 (m, 4H); 1.95-1.30 (m, 7H); 1.20-0.90 (m, 2H).
Part B: Preparaton of 4-benzyl-1-(3-amino-n-prop-1-yl)piperidine ~~z 4-benzyl-1-(3-N-phthalimido-n-prop-1-yl)piperidine (13.72 g, 37.9 mmol, 1 eq.) was dissoved in 200 mL of EtOH
at 25 oC under N2, the anhydrous hydrazine (2.38 mL, 75.7 mmol, 2 eq.) was added. The solution was then refluxed during which time a white precipitate formed. The reaction was worked up after refluxing 4 hours by filtering off the solids. The solvent was removed in vacuo to obtain an oil which was re-rotovapped from toluene to remove excess hydrazine. Obtained an oil which was stirred in Et20.
Insoluble material was filtered then the solvent removed in vacuo to obtain 5.558 of an amber oil as product. NMR
(300 MHz, CDC13) b 7.40-7.21 (m, 2H); 7.21-7.05 (m, 3H);
2.92 (d, 2H, J=10 Hz) ; 2.73 (t, 2H, J=7 Hz) ; 2 .53 (d, 2H, J=7 Hz); 2.40-2.20 (m, 2H); 1.84 (t of t, 2H, J=7,7 Hz);
1.75-1.10 (m, 9H).
Part C: N-(3-cyanophenyl)-N'-[3-[4-(phenylmethyl)-1-piperidinyl]propyl]urea r H H ~N

4-benzyl-1-(3-amino-n-prop-1-yl)piperidine (300 mg, 1.29 mmol, 1 eq} was dissoved in THF at 25 oC under N2 then 3-cyanophenyl isocyanate (186 mg, 1.29 mmol, 1 eq) was added. TLC after 30 minutes shows the reaction complete.
The solvent was removed in vacuo then the residue was purified over silica gel in 100 EtOAc to 8:2 chloroform/MeOHto yield 437 mg of an amber oil as product.
NMR (300 MHz, DMSO-d6) 8 9.90-9.50 (m, 1H); 9.32 (s, 1H);
7.93 (s, 1H); 7.59 (d, 1H, J= 7Hz); 7.43 (t, 1H, J= 7Hz);
7.40-7.24 (m, 3H); 7.24-7.10 (m, 3H); 6.68 (t, 1H, J=7 Hz);
3.50-3.25 (m, 2H); 3.25-3.07 (m, 2H); 3.07-2_90 (m, 2H);
2.90-2.60 (m, 2H); 2.60-2.40 (m, 2H); 2.00-1.60 (m, 5H);
1.60-1.30 (m, 2H).

Part A: Preparation of 4-benzyl-1-carbomethoxymethyl-1-[3-(3-cyanophenylaminocarbonylamino)prop-1-yl]piperidinium bromide Br-H H
4-benzyl-1-[3-(3-cyanophenylaminocarbonylamino)prop-1-yljpiperidine (50mg, 0_133 mmol, ~ eq}, was dissoved in acetone at 25 oC under N2 then methyl bromoacetate (l3uL, 0.133 mmol, 1 eq),was added. After 16 hours, the solvent was removed in vacuo and the residue was purified over silica gel in 100 EtOAc to 8:2 chloroform/MeOH to yield 50 mg of white solids as product. NMR (30GMHz, CD30D) 8 8.00-7.80 (m, 1H) ; 7.65-7_45 (m, 1H); 7.45-7.33 (m, IH); 7.33-7.05 (m, 6H); 4.50-4.25 (m, 2H); 4.00-3.60 (m, 5H); 3.50-3.20 (m, 6H); 2.70-2.50 (m, 2H); 2.10-1.60 (m, 7H).

Part A: Preparation of 1-(t-Butoxycarbonyl)-3-piperidone i . H2, Pd/C, CH30H, 23 °C

ii. (Boc)20, NaHC03, THF, 23 °C
86~
To a deep yellow solution of 1-benzyl-3-piperidone hydrochloride (3.00 g, 1.33 mmol, 1 equiv) in methanol (100 mL) was added 10 wt. ~ (dry basis) palladium on activated carbon (600 mg) under a stream of nitrogen. The resulting black suspension was deoxygenated by alternate evacuation and flushing with nitrogen (3x) followed by alternate evacuation and flushing with hydrogen (3x). The reaction suspension was then shaken vigorously under a hydrogen atmosphere of 55 psi. After 12 hours, gravity filtration of the supsension and concentration of the resulting filtrate in vacuo yielded crude 3-piperidone as a viscous light green oil. The oil was immediately treated with tetrahydrofuran (150 m.L) and di-t-butyldicarbonate (4.73 g, 21.7 mmol, 0.98 equiv). Upon addition of saturated aqueous sodium bicarbonate (25 mL), the oil completely dissolved to give a light yellow suspension. After stirring the suspension vigorously for 2 hours, the now white suspension was poured into aqueous hydrogen chloride (1N, 100 mL), and the layers were separated. The aqueous layer was extracted with ethyl acetate (3 x 70 mL), and the combined organic layers were washed with saturated aqueous sodium chloride (50 mL), dried over sodium sulfate, and filtered.
Concentration of the resulting filtrate in vacuo yielded 1-(t-butoxyarbonyl)-3-piperidone (3.79 g, 86~) as a white oily solid. 1~H Nl~t (300 l~iz, CDC13), 8:3.94 (s, 2H), 3.53 (t, 2H, J = 6 Hz), 2.41 (t, 2H, J = 7 Hz), 1.92 (m, 2H), 1.41 (s, 9H) Part B: Preparation of 1',3-(2H)-Dehydro-3-benzyl-1-(t-butoxycarbonyl)piperidine NaH, Bn(0)P(OEt)2 DME, 23-80 °C

23~
To a flame-dried 100-mL flask charged with sodium hydride (60~ wt. dispersion in mineral oil; 601 mg, 15.0 mmol, 2.3 equiv)) and 1,2-dimethoxyethane (20 mL) was added benzyl diethylphosphite (3.42 g, 3.13 mL, 15.0 mmol, 2.3 equiv) dropwise over a period of 5 min. After 20 min, 1-(t-butoxycarbonyl)-3-piperidone was added in one portion to the pale yellow suspension. The flask was fitted with a relfux condensor, and the resulting yellow-gray suspension at heated under reflux conditions for 2 hrs. Upon cooling to 23 °C, the reaction was poured into aqueous hydrogen chloride (0.20 N, 100 mL) and diethyl ether (75 mL). The I5 layers were separated and the aqueous layer was basified with saturated aqueous sodium bicarbonate to pH 9. The aqueous layer was extracted with diethyl ether (4 x 75 mL), and the combined organic layers were dried over sodium sulfate. Filtration, concentration in vacuo, and purification of the resulting residue by flash column chromatography (5~ ethyl acetate in hexanes) afforded a mixture of the desired olefin (410 mg, 23~) and the corresponding ethoxycarbamate (550 mg, 34~) as a clear oil.
The ethoxycarbamate was removed in the subsequent step by flash column chromatography. 1H NMR (300 MHz, CDC13), $:
7.30 (m, 2H), 7.18 (m, 3H), 6.42 (s, 1H), 4.02 (s, 2H), 3.50 (t, 2H, J = 6 Hz), 2.51 (t, 2H, J = 5 Hz), 1.61 (m, 2H), 1.49 (s, 9H)_ MS (CI), m+/z: (M+H)+ = 274, [(M+H)+ -(-C(O)OC(CH3)3)) 174.
Part C: Preparation of 1-(t-Butoxycarbonyl)s3-benzylpiperidine Hz. Pd/C
CH30H, 23 °C
99~
To a solution of impure product (410 mg, 1.50 mmol) obtained in the previous step in methanol (100 mL) was added 10 wt. ~ (dry basis) palladium on activated carbon (200 mg) under a stream of nitrogen. The resulting black suspension was deoxygenated by alternate evacuation and flushing with nitrogen (3x) followed by alternate evacuation and flushing with hydrogen (3x). The reaction suspension was then shaken vigorously under a hydrogen atmosphere of 55 psi. After 12 hours, gravity filtration of the supsension and concentration of the resulting filtrate in vacuo resulted in a pale yellow residue.
Purification of this residue by flash column chromatography afforded 1-(t-butoxycarbonyl)-3-benzyl-piperidine~(407 mg, 99~) as a clear oil. 1H NMR (300 MHz, CDC13), $: 7.23 (m, 2H), 7.14 (m, 3H), 3.86 (m, ZH), 2.75 (br m, 1H), 2.51 (m, 3H), 1.70 (br. m, 2H), 1.64 (br, m, 1H), 1.41 (s, 9H), 1.34 (br. m, 1H), 1.09 (br. m, 1H). MS (CI), m+/z: (M+ + 1) 276, [(M+H)+ - (-C(O)OC(CH3)3)l - 176.
Part D: 3-Benzylpiperidine hydrochloride ~ HC1 To a solution of 1-(t-butoxycarbonyl)-3-benzylpiperidine (400 mg, 1.45 mmol) in methanol (5 mL) was added hydrogen chloride in dioxane (4M, 15 mL). The resulting yellow solution was stirred for 1 hr, at which time the reaction was concentrated in vacuo to provide 3-benzylpiperidine hydrochloride (308 mg, 1000) as an amorphous solid. 1H NMR (300 MHz, CD30D), 8: 7.27 (m, 2H, ) , 7.19 (m, 3H) , 3 .29 (br. d, 1H, J = l2Hz) , 3 .20 (br.
d, 1H, J = 12 Hz), 2.87 (br. t, 1H, J = 12 Hz), 2.67 (m, ~.H), 2.60 (d, 2H, J = 7Hz), 2.08 (m, 1H) 1.70-1.87 (m, 3H), 1.26 (m, 1H). MS (CI), m+/z: (M+H)+ = 176.
Part E: Preparation of N-(3-methoxyphenyl)-N'-[3-[3-[(phenyl)methyl]-1-piperidinyl]propyl]urea The above compound was prepared by the methods similar to the ones employed in Example 1, part C.
1H NMR (300 MHz, CD30D), 8:7.29-7.23 (m, 4H); 7/07 (d, 1H, J=9 Hz); 7.02 (m, 1H); 6.78 (d, 1H, J = 9 Hz); 6.60 (d, 1H, J = 9 Hz); 3.77 (s, 3H); 3.30 (m, 2H); 2.80 (m, 2H);
2.53-2.32 (m, 4H); 1.85-1.55 (m, 7H); 1.44-0.78 (m, 2H).
MS (ESI), m+/z: (M+H)+ = 382.

Part A: Preparation of a,a'-Dibromo-3-nitro-o-xylene B _ ~+
~O
3-Nitro-o-xylene (lO.Og, 66.14 mmol, 1.00 eq), N-bromosuccinimide (24.14 g, 135.6 mmol, 2.05 eq), and ' WO 00/35451 PCT/US99/30332 benzoyl peroxide (0.8 g, 3.30 mmol, 0.5 eq) were refluxed under N2 in 200 ml of carbon tetrachloride. The reaction was worked up after two days by washing with 3 x 100 ml of water. The organic phase was dried over sodium sulfate, then the solvent was removed in vacuo to obtain an amber oil. The oil was purified by flash chromatography on a 8 cm x 20 cm quartz column, eluting with 7.5$ EtOAc/Hexanes to yield 4.46 g of product as a sticky solid. NMR (300 MHz, CDC13) $ 7.88 (d, 2H, J=7 Hz), 7.64 (d, 1H, J=7 Hz), 7 .48 dd, 1H, J=8 Hz) , 4.86 (s, 2H) , 4.69 (s, 2H) .
Part B: Preparation of 1,3-Dihydro-4'-[4-fluorophenylmethyl)-4-vitro-spiro[2H-isoindole-2,1'-piperidinium) bromide ~+ 0 F
Br-' 4-Fluorobenzylpiperidine (0.94 g, 4.86 mmol, 1.0 eq), a,a'-dibromo-3-vitro-o-xylene (1.50 g, 4.86 mmol, 1.0 eq), and sodium carbonate (2.57 g, 24.3 mmol, 5.0 eq) were combined in 20 ml THF and stirred at 25~ C under N2, during which time a white solid precipitated from the reaction mixture. The reaction was worked up after 22 hours by filtering the solids and rinsing with THF. The solids were dissolved in methanol and applied to a 3.5 cm x 5 cm quartz column via silica plug. The product was eluted with 20~
MeOH/CHC13 to yield 1.04 g of a white foam. NMR (300 MHz, CD30D) 8 8.27 (d, 1~~, J=8 Hz), 7.84 -7.80 (m, 1H), ?.75-7.69 (m, 1H), 7.23 (m, 2H), 7.01 (dd, 2H, J=8 Hz, 8 Hz), 5.38-5.37 (m, 2H), 5.09 (s, 1H), 5.04 (s, 1H), 3.80-3.72 (m, 2H), 3.65-3.54 (m, 2H), 2.71-2.68 (m, 2H), 2.05-1.75 (m, 5H).

' Part C: Preparation of 4-Amino-1, 3-dihydro-4'-[4-fluorophenylmethyl)-spiro[2H-isoindole-2,1'-piperidinium]
bromide I+ 2 1,3-Dihydro-4'-[4-fluorophenylmethyl]-4-nitro-spiro[2H-isoindole-2,1'-piperidinium] bromide (1.03 g, 2.46 mmol, 1.0 eq), zinc (5.32 g, 81.5 mmol, 33.0 eq), and calcium chloride (0.18 g, 1.60 mmol, 0.65 eq) were refluxed under N2 in 25 ml of a 78~ ethanol/water solution. The reaction was worked up after 5 hours by filtering through Celite~ and rinsing the cake with methanol. The filtrate was concentrated in vacuo to a mixture of water and an amber oil. The mixture was dissolved in 50 ml of 2-propanol, and concentrated in vacuo to remove excess water.
The resulting yellow foam was dissolved in methanol and applied to a 3.5 cm x 5 cm quartz column via silica plug.
The product was eluted with 20$ MeOH/CHC13 to yield 0.81g of a yellow foam. NMR (300 ~z, DMSO) $ 7.27-7.05 (m, 5H), 6.61-6.53 (m, 2H), 5.43-5.41 (m, 2H), 4.80 (bs, 1H), 4.74 (bs, 2H), 4.63 (bs, 1H), 3.62-3.43 (m, 4H), 2.60 (bd, 2H, J=7 Hz), 1.98-1.59 (m, 5H).
Part D: Preparation of N-[1,3-Dihydro-4'-[4-fluorophen 1-Y
methyl]spiro[2H isoindole-2,1'-piperdinium-4-yl)-N'-4-fluorophenylurea bromide 4-Amino-1, 3-dihydro-4'-[4-fluorophenylmethyl]-spiro[2H-isoindole-2, 1'-piperidinium] bromide (0.33 g, 0.84 mmol, 1.0 eq), and 4-fluorophenyl isocyanate (0.23 g, 1.69 mmol, 2.0 eq) were combined in 3 ml DMF and stirred at 25~ C under N2 . The reaction was worked up after 22 hours by removing the solvent in vacuo, dissolving the residue in methanol, and applying the mixture to a 3.5 cm x cm quartz column via silica plug. The product was eluted with 10~ MeOH/CHC13 to yield 65 mg of a yellow foam.
10 NMR (300 MHz, DMSO) 8 9.18 (s, 1H), 9.00 (s, 1H), 7.49-7.43 (m, 2H), 7.41-7.34 (m, 2H), 7.26-7.21 (m, 2H), 7.17-7.10 (m, 5H), 4.94 (s, 2H), 4.80 (s, 2H), 3.63-3.45 (m, 4H), 2.61 (bd, j=7 Hz), 1.91-I.62 (m, 5H) Part A. Preparation of 4-benzyl-1-(3-hydroxy-3-phenylprop-1-yl)piperidine To a flame-dried 3-neck flask under a N2 atmosphere with a magnetic stirring bar, 4-benzylpiperidine (5.00 mL, 28 mmol, 1 eq), DBU (42 uL, 0.28 mmol, 0.01 eq), and THF
(100 mL) were added, mixed, and cooled to -15 °C using a CC14/C02(s) bath_ Acrolein (1.87 mL, 28 mmol, 1 eq) was then syringed in slowly during 10 minutes maintaining the temp. at -15 °C. After 0.5 hours at -15 °C, phenylmagnesium chloride (2.0 M, 14.0 mL, 28 mmol, 1 eq) was syringed in slowly and the contents allowed to slowly warm to room temperature and then stirred for 48 h. The reaction was worked up by adding 0.1 N NaOH and EtOAc (200 mL each).
The viscous magnesium salts were suction filtered through fiberglass filter paper'. The layers were separated and the aqueous layer was extracted again with ethyl acetate (2 x 200 mL). The organic layers were combined, washed with brine (1 x 200 mL), dried (MgS04) and the solvent removed in vacuo to yield 7.39 g of an amber oil. Flash chromatography in 100 ethyl actetate yielded 2.48 g of an orange oil. NMR (CDC13) $ 7.40-7.10 (m, lOH); 4.93 (d of d, 1H, J=3,7 Hz); 3.12-2.96 (m, 2H); 2.68-2.46 (m, 4H);
2. 01 (t of d, 1H, J=2, 10 Hz) ; 1.86-1.26 (m, 8H) . ESI MS
detects (M+H)+ = 310.
Part B: Preparation of 4-benzyl-1-(3-azido-3-phenylprop-1-yl)piperidine The product from part A (209 mg, 0.675 mmol, 1 eq), DBU (123 mg, 0.810 mmol, 1.2 eq), diphenylphosphoryl azide (0.175 mL, 0.810 mmol, 2.2 eq), and toluene (1.0 mL) were mixed and stirred overnight at room temperature under a NZ
atmosphere. The reaction was then worked up by adding ethyl acetate (50 mL), washing with water (3 x 25 mL), followed by washing with brine (1 x 25 mL), drying (MgS04) and removing the solvent in vacuo to yield 277 mg of an amber oil. Flash chromatography in 1:I hexane/ethyl acetate yielded 84 mg of product as an oil. NMR (CDC13) $
7.41-7.09 (m, 10 H); 4.56 (t, 1H, J=7 Hz); 3.83 (m, 2H);
2.52 (d, 2H, J=7 Hz); 2.32 (t, 2H, J=7 Hz); 2.30-1.77 (m, 5H); 2.59 (m, 2H); 1.98 (m, 1H); 1.39-1.26 (m, 4H). IR
(neat) 2095 cm-1.
Part C: Preparation of 4-benzyl-1-(3-amino-3-phenylprop-1-yl)piperidine ' WO 00/35451 PCT/US99/30332 The compound from part B (100 mg), 10~ Pd on carbon (120 mg), and methanol (100 mL) were carefully combined in a flask under a N2 atmosphere. The contents were then submitted to 1 atm of H2 being delivered via a sparge tube for 0.5 h at room temperature. Filtration of the contents through Celite~ and removal of the solvent in vacuo yielded_ 70 mg of product. NMR (CDC13) (key peak only) 83.94 (t, 1, J = 7 Hz). NH4-CI MS detects (M+H)+ = 309.
Part D: N-(3-cyanophenyl)-N'-[3-[4-(phenylmethyl)-1-piperidinyl]-1-phenylpropyl]urea n ~N
The compound from Part C (57 mg, 0.185 mmol, 1 eq) was mixed and stirred with 3-cyanophenylisocyanate 26.6 mg, 0.185 mmol, 1 eq) in THF (1 mL) overnight at room temperature under a N2 atmosphere. The solvent was removed in vacuo and the residue flash chromatographed on silica gel in 3:1 to 1:1 hexane/ethyl acetate to 100 ethyl acetate to yield 44.3 mg of a yellow oil. NMR (CDC13) 8 7.58 (s, 1H); 7.52 (d, 1H, J = 9 Hz); 7.42 (s, 1H);
7.30-7.17 9m, 8H); 7.12 (m, 3H); 4.82 (m, 1H); 2.97-2.80 (m, 3H); 2.52 (d, 2H, J=7 Hz); 2.35 (m, 2H); 2.05-1.85 (m, 4H); 1.81-1.60 (m, 2H); 1.54 (m, 1H); 1.25 (m, 1H).
ESI MS detects (M+H)+ = 453.

Part A: Preparation of 2-benzyloxycarbonylamino-1-phenyl-3-butene.
To a stirred suspension of methyltriphenylphosphonium bromide (10.72 g, 0.03 moles) in 200 mL of dry tetrahydofuran at -78°C was added dropwise 1.6M n-butyl lithium (17.5 mL, 0.028 moles), and the mixture was stirred for 0.5 hrs at -78 - -20°C. Then was added a solution of N-Cbz-phenylalaninal (5.67 g, 0.02 moles) in 50 mL of dry tetrahydrofuran, and the mixture was stirred for 16 hrs at room temperature. After addition of saturated NH4C1 (50 mL) the mixture was extracted with EtOAc, and the extract was washed with water and brine. It was dried over Na2S04 and evaporated to give an oily residue. The crude product was purified by column chromatograpy on silica gel with elution by 5:95 EtOAc-hexane to give pure 2-benzyloxycarbonylamino-1-phenyl-3-butene.
Part B: Preparation of 2-benzyloxycarbonylamino-1-phenyl-3,4-epoxy-butane.
To a stirred solution of 2-benzyloxycarbonylamino-1-phenyl-3-butene (1.43 g, 5.08 mmoles) in 20 mL of CH2C12 was added 3-chloroperoxybenzoic acid (2.19 g, 60~, 7.62 mmoles) in several portions, and the mixture was stirred at ~ WO 00/35451 PCT/U~99/30332 room temperature for 30 hrs. After addition of EtOAc (60 mL), the mixture was washed with saturated NaHC03 and brine, and the organic layer was dried over Na2S04.
Evaporation of the solvent afforded an oily residue. The crude product was purified by column chromatography on silica gel with elution by 2:8 EtOAc-hexane to give pure 2-benzyloxycarbonylamino-1-phenyl-3,4-epoxy-butane.
Part C: Preparation of 2-benzyloxycarbonylamino-4-[4-(4-fluorophenyl)methyl-1-piperidinyl]-1-phenyl-butan-3-ol.
A solution of 4-(4-fluorophenyl)methyl-piperidine (0.515 g, 2.314 mmoles) and 2-benzyloxycarbonylamino-1-phenyl-3,4-epoxy-butane (0.688 g, 2.314 mmoles) in 5 mL of DMF was stirred for 4 hours at 100°C and cooled to room temperature. After addition of EtOAc (30 mL), the mixture was washed with water (2x) and brine. The oranic solution was dried over Na2S04, and evaporated to give an oily residue. It was then purified by passing through a plug of silica gel with elution by EtOAc to give pure product.
Part D: Preparation of 2-amino-4-[4-(4-fluorophenyl)methyl-1-piperidinyl]-1-phenyl-butan-3-ol.

The above product was dissolved in 10 mL of ethanol, and was added 0.1 g of 10~ Pd on carbon. The mixture was stirred under hydrogen (1 atm) for 8 hours, and filtered through Celite. Evaporation of the solvent gave the titled product as solid (0.662 g}.
Part E: Preparation of N-(3-cyanophenyl)-N'-[1-benzyl-2-hydroxy-3-[4-(4-fluorophenylmethyl}-1-piperidinyl]propyl]urea H H ~N
H
To a solution of 2-amino-4-[4-(4-fluorophenyl)methyl-1-piperidinyl]-1-phenyl-butan-3-of (50 mg, 0.14 mmoles) in 2.5 mL of dry THF was added 3-cyanophenyl isocyanate (20.2 mg, 0.14 mmoles) and the mixture was stirred for 15 minutes at room temperature. Then the solvent was evaporated off to give an oily residue. It was purified by column chromatography on silica gel with elution by EtOAc to give pure titled compound as an amorphous solid.
MS (ES+) for C3pH33FN402 - 501.
The following examples were prepared by the procedures previously described in Schemes 1-25 , Examples 1-6 and/or by procedures familiar to one skilled in the art.
TAB

' WO 00/35451 PCT/US99/30332 N~~ ~ R3 Cr~l~H ~ ~ H H
H H ~ R3 0 ~ R3 a b 0 c N~ ~ R3 /~ H ~ G H H H
N N' G ~/~r R3 /~N~ 1R
H H ~' R3 f G~N~H~ G HHH HHH
R3 ~ TI G'~ IS

0 Ph 0 p h i G~N H N N.R ~N H N N. G H H
3 Y R3 '~N N N.
~ T R
P 0 Prf O
~ k 1 Ex # Core G R3 M+1 7 _a Ph ~ 3-C02Et 410 -Ph 8 a Ph _ 464 _ 3-I-Ph a Ph 1-adamant 1 396 a Ph 3-OCH3-Ph 368 11 a Ph Ph 338 12 a Ph 4-F-Ph 356 13 a Ph 4-C02Et-Ph 420 24 a Ph 4-CN-Ph 363 b Ph 1-adamant 1 410 16 b Ph 2-F-5-CF3-Ph 438 17 b Ph 2-na hth 1 402 18 b Ph 2-F-5-N02-Ph 415 19 b Ph 4-N(CH3)2-Ph 395 b Ph 2-N02-Ph 397 21 b Ph 2-C2H5-Ph 380 22 b Ph 4-CF4-Ph 420 23 b Ph 3,5-diCF3-Ph 488 24 b Ph 3-C02Et-Ph 424 b Ph 3-CN-Ph 377 26 b Ph 4-OBn-Ph 458 27 b Ph 2-Ph-Ph 428 28 b Ph 2-BrPh 431 29 b Ph 4-I-Ph 478 b Ph 3-I-Ph 478 31 b Ph 4-OEt-Ph 396 32 b Ph 4-nBu-Ph 408 33 b Ph 4-nBuO-Ph 424 34 b Ph CH(Bn)C02Et 452 35 b Ph CH(iPr)C02Et ~ 404 36 b Ph nC8H17 3gg 37 b Ph 3-OCH3-Ph 382 38 b Ph Ph 352 39 b Ph 4-C02Et-Ph 424 40 b Ph 4-F-Ph 370 41 b Ph 2-Phenyl- 392 cyclopro 1 42 b Ph 2-OCH3-Ph 382 43 b Ph 4-OCH3-Ph 382 44 b 4-F-Ph 3-CN-Ph 395 45 b 4-F-Ph 4-F-Ph 388 46 b 4-F-Ph 4-C02Et-Ph 442 47 b 3,4-OCH20-Ph 3-CN-Ph 421 48 b 4-F-Ph 3-OCH3-Ph 400 49 b 3,4-OCH20-Ph 3-C02Et-Ph 468 50 b 3,4-OCH20-Ph 3-OCH3-Ph 426 51 b 4-OCH3-Ph 3-OCH3-Ph 412 52 b 4-OCH3-Ph 4-F-ph 400 53 b Ph 4-CN-Ph 377 54 b 3,4-OCH20-Ph 4-F-Ph 414 55 b 4-OCH3-Ph 4-CN-Ph 407 56 b 2,4-diF-Ph 4-F-Ph 406 57 b 2,4-diF-Ph 3-OCH3-Ph 418 58 b 2,4-diF-Ph 3-CN-Ph 413 59 b 3-CF3-Ph 4-F-Ph 438 60 b 3-CF3-Ph 3-OCH3-Ph 450 61 b 4-F-Ph CH2Ph 384 62 b 4-F-Ph CH2CH2Ph 39g 63 b 4-F-Ph 2-F-Ph 388 64 b 4-F-Ph 3-F-Ph 388 65 b 4-F-Ph cYclohexyl 376 66 b 4-F-Ph iPr 336 67 b 4-F-Ph 2-phenyl- 410 c clo ropyl b 4-CF3-Ph 3-CN-Ph 445 69 b 3-CF3-Ph 3-CN-Ph 445 70 b 4-CH3-Ph 3-OCH3-Ph 396 71 b 4-CH3-Ph 3-CN-Ph 391 72 b 4-C1-Ph 3-CN-Ph 411 73 b 4-CF3-Ph 4-C02Et-Ph 492 74 b 3-OCH3-Ph 3-OCH3-Ph 412 75 b 3-OCH3-Ph 3-CN-Ph 407 76 b 4-C02CH3-Ph 3-OCH3-Ph 440 77 b 4-C02CH3-Ph 3-CN-Ph 435 78 b 4-C02CH3-Ph 4-F-Ph 428 79 b 4-C02CH3-Ph 4-C02CH3-Ph 482 80 b 4-CF3-Ph 4-F-Ph 438 81 b 4-CF3-Ph 3-OCH3-Ph 450 82 b 3-OCH3-Ph 4-F-Ph 400 83 b 3-OCH3-Ph 4-C02Et-Ph 454 84 b 2-F-Ph 3-CN-Ph 395 85 b 3-OCH3-Ph 3-F-Ph - 400 86 b 2-F-Ph 3-OCH3-Ph 400 ~ '--~

8 b 7 3-C0~2E Ph 454 -88 b 2-F-Ph 3-F-Ph 388 89 b 2-F-Ph 4-F-Ph 388 90 b 2-F-Ph 3-C02Et-Ph 442 91 b 3-F-Ph 3-CN-Ph 395 92 b 3,4-diF-ph 3-CN-Ph 93 b 3,4-diF-Ph 3-OCH3-Ph 94 b 4-C1-Ph 4-F-Ph 95 b 4-C1-Ph 3-OCH3-Ph 96 b 2-F-Ph 4-C02Et-Ph b 3-F-Ph 3-OCH3-Ph .

_98 b 3-F-Ph 4-F-Ph 3 99 b 3-F-Ph 4-C02Et-Ph 442 100 b 3;4-diF-Ph 4-F-ph 101 b 3-C1-Ph 3-CN-Ph 102 b 4-F-Ph 3-COCH3-Ph 103 b 3,5-diF-Ph 3-CN-Ph 104 b 3,5-diF-Ph 3-OCH3-Ph 105 b 4-F-Ph 4-COCH3-Ph 106 b 1-na hth 1 3-CN-Ph 107 b 1-na hth 1 4-F-Ph 108 b 1-na hth 1 3-OCH3-Ph 109 b 3-CH3-Ph 3-CN-Ph 110 b 3-CH3-Ph 4-F-Ph 111 b 3-CH3-ph 3-OCH3-ph 112 b 4-F-Ph 2-iPr-Ph 113 b 4-F-Ph 2-CF3-Ph 114 b 4-F-Ph 3-C1-ph 115 b 4-F-Ph 3-CF3-ph 116 b 4-F-Ph 4-Ph-Ph 117 b 4-F-Ph 2-C1-Ph 118 b 4-F-Ph 2,4-diF-Ph 406 119 c Ph 3-C02Et-Ph 424 120 c Ph 3-CN-Ph 377 121 c Ph 4-F-Ph 370 122 c Ph Ph 352 123 c Ph 1-adamant 1 410 124 c Ph 4-C02Et-Ph 424 125 c 4-F-Ph Ph 126 c 4-F-Ph 3-CN-Ph 127 c 4-F-Ph 1-adamant 1 128 c 4-F-Ph 3-OCH3-Ph 129 c 4-F-Ph 3-C02Et-Ph 442 130 c 4-F-Ph 4-F-Ph 3gg 130a c 4-F-Ph 3-COCH3-Ph 412 131 c 2-F-Ph Ph 132 c 2-F-Ph ~ 3-CN-Ph 133 c 2-F-Ph 3-OCH3-Ph 134 c 2-F-ph 4-F-Ph 135 c 3-F-Ph 3-OCH3-Ph 136 c 3-F-Ph 3-CN-Ph 137 c 2,4-diF-Ph 3-CN-Ph WO 00/35451 PCTlUS99/30332 138 c 2,4-diF-Ph 3-OCH3-Ph 418 139 c 2,4-diF-Ph Ph 388 140 c 2,4-diF-Ph 4-F-Ph 406 141 c 2,4-diF-Ph 3-COCH3-Ph 430 142 d Ph 3-CN-Ph 392 143 d Ph 3-C02Et-Ph 438 144 d Ph 3-I-Ph 492 145 d Ph 4-OCH2Ph-Ph 472 146 d Ph 1-adamantyl 424 147 d Ph 3-OCH3-Ph 396 148 d Ph Ph 366 149 d Ph 4-F-Ph 384 150 d Ph 4-C02Et-Ph 438 151 d Ph 4-CN-Ph 391 152 a 4-F-Ph Ph 356 153 a 4-F-Ph 3-CN-Ph 381 154 a 4-F-Ph 3-OCH3-Ph 386 155 a 4-F-Ph 4-F-Ph 374 156 a 4-F-Ph 3-C02Et-Ph 428 157 a 4-F-Ph 4-C02Et-Ph 428 158 a 4-F-Ph 1-adamant 1 414 159 f 4-F-Ph 3-CN-Ph 411 160 f 4-F-Ph 3-OCH3-Ph 416 161 j Ph Ph 458 162 Ph 3-CN-Ph 483 163 j Ph 3-OCH3-Ph 488 164 j 4-F-Ph 3-OCH3-Ph 506 165 4-F-Ph 4-F-Ph 494 166 j 4-F-Ph 1-adamantyl 534 167 I Ph 3-OCH3-Ph 458 168 1 Ph 1-adamantyl 486 169 c imidazol-1- 1 3-OCH3-Ph 372 All stereocenters are (+/-) unless otherwise indicated TABLE 2**
R5 a R5b R5C il ~2 YI +
I ~N~ n~~ Z

X -m Ex Y Z R4 X R5a R5b R5c R1 R2 #

170 H H - - H H H H ph 172 H 3-OCH3 CH2Ph Br H H H H H

t 176 H 3-CN CH2Ph Br H H H

H H

h H H Et H

H H H H
180 H 4-F CH2Ph Br H H

H H H
181 H 4-F CH2C02CH Br H H

H H H

182 H 3-CN CH2CN Br H H H H

H
183 H 3-CN CH2COPh Br H H H

H H

H H H

H H H H

H H H H

- H H H

H H H H

h H H H

COCH3 h 192 F 4-F-Ph - - H CH2P H

H H

h H H H

h h h **All compounds are amorphous unless otherwise indicted.
TABLE 3**
X_ ~~:~~-~~Z Y X_ F~~~ Z
Y~ + N O ~,~~N

Ex # Core Z X

19 6 n H 3 -CN Br 197 n H 3-CN Br 198 n H 4-F Br 199 n H 4-F Br 200 n F 3- CN Br 201 n F 3-CN Br 202 n F 3-OCH3 Br 203 n F 3-OCH3 Br 204 o F 4-F Br 205 o F 4-F Br 206 o F 3-OCH3 gr 207 o F 3-OCH3 Br WO 00/35451 PCTlUS99/30332 209 o F 3=cN Br Br **All compounds are amorphous unless otherwise indicted.
The compounds of the present invention in which E
contains ring A can be prepared in a number of ways well known to one skilled in the art of organic synthesis. As shown in Scheme 26, 4-benzyl piperidine is N-alkylated with an alkylating agent, such as 165 (2-vitro-benzyl bromide (X
= Br, R14 = H), Scheme 26) to give the N-benzyl compound 166. The vitro group of 166 is then reduced using catalytic hydrogenation to give the corresponding aniline 167. The aniline can be converted to the carbamate 168 using chloro-phenyl formate. The carbamate 168 can then be reacted with various amines to give the urea 169.
Alternatively, the aniline 167 can be reacted with the appropriate isocyanates to give the urea 169 directly. The saturated ring analogs can also be used. For ex~ple, 4-benzyl piperidine can be alkylated with the urea mesylate 185 (Scheme 30) to give corresponding cyclohexyl derivative 186.
As shown in Scheme 27, 4-benzyl piperidine can also be N-alkylated with the phenacyl bromide 170 to give the vitro ketone 171. The vitro group of 171 is then reduced using catalytic hydrogenation to give the corresponding aniline 172. The aniline 172 can be reacted with the appropriate isocyanates to give the ketone urea _173. The ketone of 173 can be reduced with NaBH4 to give the alcohol 174.
Alternatively, the epoxide I75 (R14 - H) can be opened with the 4-benzyl piperidine to give the corres o p nding vitro benzyl alcohol which is hydrogenated to give the aniline alcohol 176. The aniline 276 may be treated with various isocyanates to give the urea alcohols 174.
The 4-benzyl piperidine can also be N-al.kylated with 3-cyanobenzyl bromide (177, Scheme 28 ) to give true cyano analog 178. The cyano group is reduced using Raney nickel to give the corresponding benzyl amine 179. Treatment of 179 with isocyanates gives the urea 180.
As shown in Scheme 29, treatment of 3-cyano aniline with phenylisocyanate gives the urea 82. The cyano group of 182 is converted to the imidate 183 by HC1/ethanol.
Reaction with 4-benzyl piperidine in ethanol then gives the amidine 184.
The saturated ring analogs can also be synthesized using analogous procedures as outlined in Schemes 30 and 31. For example, 4-benzyl piperidine can be alkylated with the urea mesylate 185 (Scheme 29) to give corresponding cyclohexyl derivative 186. Alternatively, starting with the enantiomerically pure amino alcohol 187 [J. Am. Chem. Soc.
1996, 118, 5502-5503 and references therein] one can protect the nitrogen to give the N-Cbz alcohol 188. Swern oxidation of the alcohol gives the aldehyde 89. Reductive amination with piperidine analogs gives the cyclohexyl methyl-1-piperidinyl analogue ~. The Cbz group is removed by catalytic hydrogenation to give the free amine 191, which is treated with a phenylisocyanate to give the desired urea analogue ~ Several examples using these synthetic methods are listed in Table 3a and Table 3.1.

x \ 1 R14 ~ ~ +
A
NOz ~ RW-~ -\

z X = C1, Br, MsO, etc.

' ' 1B
R14~! \
/ C
1a i R /

168 \ D E

A: DMF/KZC03/RT or THF/RT. B:lO~Pd/C, H 2 50 psi.
C: THF/Et 3N/chlorophenylformate. D:NHR/DMF/50°C.
E: R-N=C=O/THF

' WO 00/35451 PCTNS99/30332 r \
\
Rla i + - ~ \ v A
NOz 171 B
r v \ ~ ( / \
R1~ / C \ /
~R ~ R1~/
p ~z 172 D D
H \ H \
\ ~/
R1~ R1~ \
/ C
~~R ~'-- / ~z 17 6 A, B

\ v R14 ( +
NO
z r A: DMF/K2C03/RT or DMF/50°C. B:10%Pd/C, ji50 psi. C: R-N=C=O/THF. D:NaBI~/MeOH/RT

SCHF2~ 2 8 Br \ / A N w N

CN CN
177 ~ g ,_, N
C N
O
N--~ ~ 17 9 N-R
180 N~
A: DMF/KZC03/RT B:Raney nickel, HZ 50 psi. C: R-N=C=O/THF.

NH
CN
A' ~ ~ CN B' ~ ~ pEt C ~ ~
/ / / ~ / V w O / O ~ / O
/

A: R-N=C=O/THF. B:EtOH/HCl/RT
C: 4-benzylpiperidine/EtOH/RT

OH OMs A,B
C
~~ N~ ~ OMe ' N~ ( ~ OMe ~0 A: R-N=C=O/DMF. B:Ms-Cl/THF
C:4-benzylpiperidine/DMF/RT

OH
g OH
b ---~- --1~
,~~z .~NH-CBZ

F F
O
H N
N
d .~NH-CBZ
.~~~'N-CBZ

F F
N N
a .,~~~NH2 --~~~~'N~ N ~ OMe ~0 ~ /

a:Benzyl chloroformate/NazC03/CHZClZ. b.Swern Ox.
c:NaBH(OAc)3 d:H2/10~ Pd/C e:R-N=C=O/THF.

SCHEME 31a OH
a OH
b .~NH2 I~NH-CBZ

O
H
N
// N
-.~ ~/ d NH-CBZ -----c '~~~~N-CBZ

N
// N
Va '~~.~2 ~ O
N N \

a:Benzyl chloroformate/NazC03/CH2Clz. b.Swern Ox.
c:NaBHtOAc;3 d:H~/10~ Pd/C e:R-N=C=O/THF.
The following examples were synthesized using the methods outlined in Schemes 26-31a. These examples are meant to be illustrative of the present invention, and are not to be limiting thereof.

N-[1-(phenylmethyl)4-piperidinyl)-N~-[2-[[4-(phenylmethyl)-1-piperidinyl]-methyl)phenyl)urea.
A solution of 4-benzylpiperidine (1.75 g, 10 mmol) in 25 mL of DMF was treated with 2-nitrobenzyl bromide (2.16 g, 10 mmol) and K~C03 (1.38 g, 10 mmol) and the reaction ' WO 00/35451 PCT/US99/30332 mixture stirred at room temperature for 2 h. The mixture was diluted with water and. extracted into ethyl acetate.
The organic extracts were washed successively with water and brine, and the organic solvent removed under vacuum on a rotary evaporator to give 166 (Scheme 26, R~4 - H) as a yellow oil.
The oil was re-dissolved in ethyl acetate (50 ml) and treated with 10~ Pd/C and hydrogenated at 50 psi hydrogen at room temperature for 40 min. The solution was then filtered and the solvent removed under vacuum to give the aniline 167 as a white solid. The aniline was purified by chromatography (MPLC, 40o ethyl acetate/ hexane; silica gel) to give 2:0 g of aniline 167 as a white solid.
A solution of aniline 167 (1.2 g, 4.3 mmol) in THF was treated with Et3N (1.0 g, 10 mmol) and cooled in an ice bath to °0 C. Chlorophenyl formate (0.71 g, 4.5 mmol) was added to the mixture and stirred for 1 h. The mixture was diluted with water and extracted into ethyl acetate. The extracts were washed with water and brine, and the solvent removed under vacuum to give the phenyl carbamate 168 as an off-white solid. The crude product was used without further purification.
A solution of phenylcarbamate 168 (0.2 g, 0.5 mmol) in DMF is treated with 4-amino-1-benzylpiperidine (95 mg, 0.5 mmol) and K2C03 (138 mg, 1 mmol) and the mixture was heated at 50 °C for 2 h. The mixture was diluted with water and extracted into ethyl acetate. The extracts were washed with water and brine; and the solvent removed under vacuum.
The residue was purified by chromatography (MPLC, 0-25 MeOH/ethyl acetate; silica gel) to give 200 mg of the target compound as a white solid. esi ms: (M+H)' - 497.

N-(2,5-difluorophenyl)-N'-[2-[[4-(phenylmethyl)-1 piperidinyl]-methyl]phenyl]urea.
A solution of aniline 167 (Scheme 26; (R - H)) (140 mg, 0.5 mmol) in THF is treated with 2,5-difluoro-isocyanate (80 mg, 0.5 mmol) at room temperature for 1 h.
The solvent is removed under vacuum and the residue was purified, by chromatography (MPLC, 20~ EtOAc/Hexane, silica gel) to give the desired urea as a white solid. esi ms:
(M+H)+ - 436.

N-(2,5-difluorophenyl)-N'-[[3-[[4-(phenylmethyl)-1-piperidinyl)methyl]phenyl]methyl)urea.
A solution of 4-benzylpiperidine (1.75 g, 10 mmol) in 25 mL of DMF was treated with 3-cyanobenzyl bromide 177 (1.96 g, 10 mmol) and KzC03 (2.76 g, 20 mmol) and the reaction mixture stirred at room temperature for 2 h. The mixture was diluted with water and extracted into ethyl acetate. The organic extracts were washed successively with water and brine, and the organic solvent removed under vacuum on a rotary evaporator to give 178 (Scheme 28) as a yellow oil.
To a suspension of Raney nickel (2.0 g) in EtOH
(saturated with NH3~gas>) was added crude 178 (Scheme 28) (1.45 g, 5 mmol) and hydrogenated at 50 psi for 3 days.
The solution was then filtered and the solvent removed under vacuum to give the amine 179 as a yellow oil. A
solution of amine 179 (200 mg, 0.68 mmol) in THF is treated with 2,5-difluoroisocyanate (115 mg, 0.74 mmol) at room temperature for 1 hour. The solvent is removed under vacuum and the residue is washed with 1 NaOH and water to give the desired urea as a white solid. esi ms: (M+H)' _ 450.

N-(2,5-difluorophenyl)-N'-[2-[[4-(phenylmethyl)-1 piperidinyl]acetyl]phenyl]urea To an ice cold solution of 2-bromo-2'-nitro-acetophenone 170 (2.4 g, 10 mmol) in DMF is added 4-benzylpiperidine (1.75 g, 10 mmol) and stirred for 30 min.
The solution was poured into a mixture of K2C03 (1.38 g, 10 mmol) in water/ice and extracted into ethyl acetate. The ethyl acetate extract was washed several times with water.
The resultant ethyl acetate solution of crude nitroketone 171 is treated with 10~ Pd/C and hydrogenated at 50 psi hydrogen at room temperature for 40 min. The solution was then filter, the solvent removed under vacuum, and the residue purified by chromatography (MPLC, 30~ ethyl acetate/hexane; silica gel) t.o give 1.8 g of aniline 172 as a tan/brown solid.
A solution of aniline 172 (Scheme 27) (310 mg, 1.0 mmol) in THF is treated with 2,5-difluoroisocyanate (160 mg, 1.0 mmol) at room temperature for 1 h. The solvent is removed under vacuum and the residue is purified by chromatography (MPLC, 20o EtOAc/Hexane, silica gel) to give 420 mg of the desired urea-ketone 173 as a white solid. esi ms: (M+H)+ - 464.

N-(2,5-difluorophenyl)-N'-[2-[2-[4-(phenylmethyl)-1-piperidinyl]-1-hydroxyethyl]phenyl]urea A solution of the urea-ketone 173 (260 mg, 0.56 mmol) in MeOH is treated with NaBH9 (400 mg, 11 mmol) at room temp for 1 hour. The solvent is removed under vacuum and the residue is treated with 1 N NaOH and extracted into EtOAc.
The extracts are washed with water, brine and the solvent removed under vacuum to give the desired alcohol 174 as a white solid. esi ms: (M+H)f - 466.

N-[3-[imino-[4-(phenylmethyl)-1-piperidinyl]methyl]
phenyl]-N'-phenylurea A solution of 3-cyanoaniline (3.54 g, 30 mmol) in THF
is treated with phenylisocyanate (3.58 g, 30 mmol) at room temperature for 1 h. The solvent is removed under vacuum and the residue is titurated with hexane to give 7 grams of urea 182 (Scheme 29) as a white solid. Urea 182 (1.0 g, 4.2 mmol) is dissolved in EtOH, cooled in an ice bath while HC1 is bubbled-in for 20 min. The solution is left standing at room temperature for 24 h. The solvent is removed under vacuum to give 1.1 g of the imidate 183 as a white solid. The crude imidate (0.5 g, 1.8 mmol) was dissolved in EtOH and treated with 4-benzyl-piperidine (1.8 g, 10 mmol) at room temperature for 2 days. The solvent was removed under vacuum and the residue was purified by chromatography (MPLC, 0 to 30~ MeOH/EtOAc, silica gel) to give 200 mg of the desired amidine 184 (Scheme 29) as a white solid. esi ms: (M+H); - 413.

N-(3-methoxyphenyl)-N'-[(1R,2S)-2-[[(4-phenylmethyl) piperidinyl]methyl]cyclohexyl]urea.
Step a: To a solution of (R,R) amino alcohol 187 [J. Am.
Chem. Soc. 1996, 118, 5502-5503 and references therein]
(1.9 g, 14.7 mmol) in CHZCl~ (50 mL) is added SO ml of an aqueous solution of Na~C03 (2.4 g, 28.9 mmol). While stirring, benzyl chloroformate (2.51 g, 14.7 mmol) is added and the mixture is stirred at room temperature for 1 h. The organic layer is separated and washed with water and brine.
The solution is concentrated on a rotary evaporator and the residue is chromatographed on silica gel (30~ ethyl acetate/hexane) to give 3.1 g (12 mmol) of 188 as a white solid. 1H NMR (300 MHz, CDC1~) 8 7.40-7 .29 (m, S H) , 5.11 (s, 2 H) , 4 . 71 (bd, 1 H) , 3 .76-3 .71 (m, 1 H) , 3 .53--3 .28 (m, 3 H), 2.00-1.9S (m, 1 H}, 1.90-1.09 (m, 8 H}. MS AP' (M+H)' - 264.3 (100 Step b: A solution of DMSO (2.52 g, 30 mmol) in CH~C12 (50 mL) is cooled to -78°C. To this solution is added drop-wise oxalyl chloride (1.81 g, 14 mmol) and the resulting solution is stirred for an additional 10 min. Then a solution of alcohol 188 (2.5 g, 9.5 mmol) in CH2C12 (70 ml) is added via an addition funnel and stirred for 10 min.
Then Et3N (5.0 g, 50 mmol) is added and the solution is allowed to warm to room temperature. The solution is diluted with water and the organic layer washed with water, 1 N HC1, and brine. The organic layer is dried over Na2S0q, filtered, and concentrated to give 2.5 g (9.5 mmol) of the aldehyde 189 as a white solid. 1H NMR (300 MHz, CDC13) $
9.59 (d, 3.6 Hz, 1 H), 7.38-7.28 (m, 5 H), 5.07 (m, 2 H), 4.69 (m, 1 H), 3.84 (m, 21 H), 2.19-2.11 (m,l H), 2.09-2.01 ( m, 1 H), 1.86-1.75 (m, 3 H), 1.54-1.17 (m, 4 H).
Step c: A solution of aldehyde ,~89 (2.0 g, 7.7 mmol) , 4-(4-fluorophenylmethyl)piperidine hydrochloride (1.8 g, 7.8 mmoI) in dichloroethane (80 ml) was treated with Na(OAc)3BH (3.23 g, 15 mmol) and 1 ml AcOH and stirred overnight at room temperature. The resulting solution was diluted with methylene chloride and washed with 1 n NaOH, water, and brine. The organic solvents were removed under vacuum and the residue chromatographed on silica gel (50%
EtOAc/hex - 100% EtOAc) to give 3.0 g (6_8 mmol) of 190 as an oil.
Step d: A solution of 190 (3.0 g, 6.8 mmol) in MeOH
was treated with 1.5 g of 10% Pd/C and hydrogenated at 50 psi overnight in a Parr apparatus. The mixture was filtered and the filtrate concentrated on a rotary evaporator to give 1.8 g (5.9 mmol) of the amine 191 as an oil.
Step e: A solution of amine 191 (200 mg, 0.67 mmol) in THF is treated with 3-methoxyphenyl isocyanate (110 mg, 0.75 mmol) and the mixture is stirred for 30 min. The solvent is removed on a rotary evaporator and the residue is chromatographed on silica gel (50% EtOAc/hex - 100%

EtOAc) to give 250 mg of urea 192 as a solid. MS esi:
(M+H)' - 454 . 4 (1000 , HRMS (M+H)' - 454 .2875.

N-(3-acetvlphenyl)~-N'-((1R 2S)-2-(f(3S) 3 (4 fluorophenyl)methyllpiperidinyllmeth~rllcyclohexyllurea Step a: To a solution of (R, R) amino alcohol 187 [J.Org.
Ch em. 1996, 61, 5557-5563; J. Am. Cherri. Soc. 1996, 118, 5502-5503] (9.5 g, 73.8 mmol) in CHzCl2 (200 mL) is added 200 ml of an aqueous solution of Na2C03 (15 g, 141 mmol).
While stirring, benzyl chloroformate (12.6 g, 73.8 mmol) is added slowly and the mixture is stirred at room temperature for 1 h. The organic layer is separated and washed with water and brine. The organic solvent is removed on a rotary evaporator to give a white solid. The solid is recrystallized from hexane to give 16.3 g (62 mmol) of the alcohol 188 (Scheme 31a)as a white solid. 1H NMR (300 MHz, CDC13) $ 7.40-7.29 (m, S H), 5.11 (s, 2 H), 4.71 (bd, 1 H), 3.76-3.71 (m, 1 H), 3.53-3.28 (m, 3 H), 2.00-1.95 (m, 1 H), 1 . 90-1. 09 (m, 8 H) . MS AP' (M+H) ~ - 264 . 3 ( 100 0) Step b: A solution of DMSO (36 g, 430 mmol) in CH~C12 (200 mL) is cooled to -78°C. To this solution is added drop-wise oxalyl chloride (27.41 g, 216 mmol) and the resulting solution is stirred for an additional 10 min. A solution of alcohol 188 (38 g, 144 mmol) in CHzCl2 (150 ml) is added via an addition funnel and stirred for 10 min. Then, Et3N (58 g, 570 mmol) is added and the solution is stirred for 20 min and the ice bath removed and stirred for an additional 30 min. The solution is diluted with water and the organic layer separated and washed with water, 1 N HCl, and brine.
The organic layer is dried over Na2SOQ, filtered, and concentrated to give 38 g of aldehyde 189 as a white solid.
The solid is recrystallized from hexane to give 19.7 grams of a first crop of aldehyde 189 as white needles. A second crop gave an additional 11 grams. lei NMR (300 MHz, CDC13) $

.. .

' WO 00/35451 PCT/US99/30332 9.59 (d, 3.6 Hz, 1 H), 7.38-7.28 (m, 5 H), 5.07 (m, 2 H), 4.69 (m, 1 H), 3.84 (m, 21 H), 2.19-2.11 (m,l H), 2.09-2.01 ( m, 1 H), 1.86-1.75 (m, 3 H), 1.54-1.17 (m, 4 H).
Step c: A solution of aldehyde 189 (19.6 g, 75 mmol) and (3S)-3-(4-fluorophenylmethyl)piperidine (14.5 g, 75 mmol) in dichloroethane (400 ml) was treated with Na(OAc)~BH (32 g, 152 mmol) and stirred overnight at room temperature. The resulting solution was poured slowly into a stirred mixture of ice/water/1 N NaOH and stirred for 20 min. The organic layer was separated and washed water, and brine. The solution was dried over MgSOa and the organic solvent was removed under vacuum and the residue chromatographed on basic alumina (50$ EtOAc/hexane) to give 32.1 g (73 mmol) of amine 193 as mixture of (15~)cis and trans isomers. 1H
NMR (300 MHz, CDC13) b 7.79 (bs, 1 H), 7.38-7.29 (m, 5 H), 6.95-6.84 (m, 4 H), 5.08 (m, 2 H), 3.71 (m, 1 H, cis isomer ), 3.06 (m, 1 H, trans isomer), 2.80 (m, 1 H), 2.55-2.36 (m, 2 H), 2.30 (dd, J = 9 Hz, J = 13 Hz, 1 H, trans isomer), 2.05 (dd, J = 2 Hz, J = 13 Hz , 1 H, trans isomer), 1.81-0.90 (m, 16 H).
Step d: A solution of 193 (32 g, 73 mmol) in MeOH was treated with 8 g of loo Pd/C and hydrogenated at 50 psi overnight in a Parr apparatus. The mixture was filtered and the filtrate concentrated on a rotary evaporator to give 20 g (65 mmol) of the amine 194, which was used without further purification.
Step e: A solution of amine 194 (10 g, 32.8 mmol) in THF is treated with 3-acetylyphenyl isocyanate (5.3 g, 32.8 mmol) and the mixture is stirred for 30 min. The solvent is removed on a rotary evaporator and the residue is chromatographed on silica gel (0.5:4.5:95 NHaOH/MeOH/CHzCl~) to give 11 g of urea 195 (Example 415) as a solid. Also obtained 2 g of cis isomer (Example 416a). The urea Example 415 was further purified by a second chromatography on silica gel (40:60:1 EtAc/Hex/TEA) and final recrystallization from ether to give crystalline solid. mp 115-117 °C, [a] °~5 - +16 . 8° (CH30H, c = 0 . 23 g/dL) .
'H NMR
(300 MHz, CDC13) 87.86 (m, 1 H), 7.78 (bs, 1 H), 7.68-7.64 (m, 1 H), 7.62-7.59(m, 1 H), 7.38 (t, J = 8 Hz, 1 H), 6.95-6.90 (m, 2 H), 6.79-6.72 (m, 2 H), 6.25 (s, 1 H), 3.21 (dt, J = 3 Hz, 11 Hz, 1 H), 3.00-2.97 (m, 1 H), 2.66-2.56 (m, 1 H), 2.61 (s, 3 H), 2.44-2.32 (m, 4 H), 2.06 (dd, J = 2 Hz, J = 13 Hz, 1 H) , 1 . 80-0 . 86 (m, 15 H) . MS esi : (M+H)' - 466. 3 (1000 . Anal. Calcd for CzBH36N30zF: C, 72.23; H 7.70; N, 9.02. Found: C, 72.33; H, 7.91; N, 9.00.
EXAMPLE 415a N-(3-acetyl~henvl)-N'-f(1R 2S)-2-ff(3S)-3-(4 fluorophenvl)methvllpiperidinyllmethyllc~rclohexyllurea Hvdrochloride A solution of example 415 (15 g, 32 mmol) in 300 ml of THF
was cooled in an ice bath and treated drop-wise with 36 ml of a 1 M HC1/ether solution. The resulting solution was stirred for 30 min and concentrated in vacuo. The resulting solid was titurated with ether and the resulting white solid dried under high vacuum overnight to give 16 g of the hydrochloride salt. mp 58-60 °C. [a]pz5 - +20.0 ° (CH30H, c =
0.23 g/dL). 'H NMR (400 MHz, DMSO-D6) 8 9.61 (s, 1 H), 9.15 (s, 1 H), 8_00 (m, 1 H), 7.63-7.61 (m, 1 H), 7.51-7.49(m, 1 H), 7.39-7.34 (m, 1 H), 7.22-7.17 (m, 2 H), 7.09-7.04 (m, 2 H), 6.86 (d, J = 8 Hz, 1 H), 3.47-3.3i (m, 4 H), 3.11 (m, 1 H), 2.98-2.82 (m, 2 H), 2.67-2.62 (dd, J = 5 Hz, J = 13 Hz, 1 H), 2.58-2.50 (m, 2 H), 2.52 (s, 3 H), 2.39 (dd, J = 8 Hz, J = 13 Hz, 1 H), 2.16-2.06 (m, 2 H), 1.84-1.556 (m, 7 H), 1.30-1.00 (m, 4 H). Anal. Calcd for C2BH3,N30~FC1 ~Hz0 ~THFo_zs : C, 64 . 73 ; H 7 . 68 ; N, 7 . 81 . Found : C, 64.89; H, 7.41; N, 7.81.
EXAMPLE 415b ,.

' WO 00/35451 PCT/US99/30332 N-(3-acetylphenyl)-N'-f(1R.2S)-2-f~(3S)-3-(4 fluorophenyl)methyllpiaeridinyl3methyllcyclohexyllurea Benzenesulfonate.
Bezenesulfonic acid monohydrate (1.06 g, 6 mmol) was dried by azeotroping off the water of a benzene solution (twice) and adding the dried acid solution to a solution of example 415 (2.81 g, 6 mmol) in toluene (40 ml). The solvents were removed in vacuo (twice) and the resulting residue recrystallized twice from toluene and dried under high vacuum overnight give 2.77 g of benzenesulfonic acid salt as a white solid. mp 157-159 °C. [oc]DZ5 - +16.9 ° (CH30H, c -0.23 g/dL) . Anal. Calcd for C3aH4zN~O5FS: C, 65.47; H 6.80;
N, 6.75; S, 5.14. Found: C, 65.48; H, 6.80; N, 6.70; S, 5.35.
The compounds of Table 3a and Table 3.1 were prepared by procedures described in Schemes 26-31A, other examples and methods taught herein, and procedures familiar to one skilled in the art.
TABLE 3a ' / N,E R
N,E
14 ~ 3 R ,~ ~~ N-R Rla / ,R3 4~ 2 H 4~ 2 H
P q N, R ~ / + NiCH3 E E
5!' '1J
Rla \ ~ 2 N_R3 Rla ~~Z N_R3 H q ' H

r s Ex Core R1 E Z R14 R3 MS
#

M+Hi p H CHZ (1) (phenylmethyl) 497 NH H _4_ pi eridinyl]

2,5-219 p H CHZ (1) difluorophenyl 436 NH H

2,5-220 p H CH2 (2) difluorophenyl 450 CHZNH H

2,5-221 p H _~ (1) difluorophenyl 464 ~, ~ NH H

O

2,5-222 p H ;~ (1) difluorophenyl 466 ~

~ NH H

OH

223 phenyl p H C=~ (2) 413 NH H

p H CHz (2) (phenylmethyl) 497 piperidinyl ]

2-(4-225 p H CHZ (1) fluorophenyl)-- 446 H ethyl 226 p H CHZ (1) H hydroxypropyl 382 NH

2-(1-227 p H CHz (1) H piperidinyl)- 435 NH ethyl ~, 228 p H CHZ (1) H (dimethylamino 395 NH )ethyl 4_ 229 p H CHZ (1) H (phenylrnethyl) 483 NH -1-piperazine 230 p H CHz (1) H (phenylmethyl) 482 NH -1-piperidine (1~ 3-231 p H CHZ (1) H benzodioxol-5- 458 NH ylmethyl) 2, 2-232 p H CHz (1) H (diphenyl)ethy 504 NH

4- ( 4-233 p H CHz (1) H chlorophenyl)- 518 NH 4-hydroxy-1-piperidine 4-phenyl-4-234 p H CHZ (1) H hydroxy-1- 484 NH piperidine 4-phenyl-1-235 p H CH2 (1) H piperidine 468 NH

(1H)-indazol-236 p H CHz (1) H 5-yl 440 NH

(1H)-indazol-237 p H CHz (1) H 6-yl 440 NH

phenylmethyl 238 p H CH2 (1) H 414 1,3-239 p H CHZ (1) H benzodioxol-5- 444 yl (3-4) 240 p H CH2 (1) 1_ (phenylmethyl) 541 NH ~ _4_ piperidinyl]

O

(3-4) 2-(4_ 241 p H CHz (1) fluorophenyl)- 490 NH ~ ethyl 'O

(3-4) 4-((2-242 p H CHI (1) phenyl)ethyl) 541 O

-1-piperazine 'O

243 (3-4) (1H)-indazol-P H CH ( 1 Z ) 5 NH

'O

244 (3-4) (1H)-indazol-P H CH (1 2 ) 6-yl 484 NH

'O

(3-4) benzothiazol-245 p H CH 1 2 ( ) 6-Y1 501 O
'O

[2- (4-246 p H CHI (1) (4) fluorophenyl)- 462 OH eth 1 247 P H CHz (1) (4) (phenylmethyl) 513 NH OH _4_ i eridin 1]

(3-4) 3-phenylpropyl 248 p H

CHz (1) O
'O

249 (1H)-indazol-P H CH (2 ) 2 H 5-yl 440 NH

250 p H CHz (2) H

fluorophenyl)- 446 ethyl 2~5-251 p H bond (1) H difiuorophenyl 422 NH

Phenyl 252 p H CH2 (1) H 400 NH

253 p H CHz (1) H methoxyphenyl 430 NH

3_ 254 p H CHz (1) H methoxyphenyl 430 NH

3 _ 255 q 4-F CHZ (2) H methoxyphenyl 454 NH

3-acetylphenyl 256 q 4-F CHZ (2) H 466 NH

257 r H CH2 (1) H methoxyphenyl 430 NH

3-cyanophenyl 258 p H CH2 (2) H 425 NH

3-cyanophenyl 259 p H CH2 (3) H 425 NH

260 p H CHZ (3) H methoxyphenyl 430 NH

2-phenylethyl 261 p H CHZ (3) H 428 NH

3-carboethoxy-262 p H CHZ (1) H phenyl 472 NH

3-cyanophenyl 263 p H CHz (1) H 425 NH

phenyl ' 264 p 4-F CH2 (1) H 418 NH

phenyl 265 p H CHz (1) H 490 N-Benzyl 3-cyanophenyl 266 p H CH2 (1) H 515 N-Benzyl 2-Phenylethyl 267 p H CHZ (1) H 428 NH

(3-4) 3-cyanophenyl 268 p H CHz (1) 469 'O

(3-4) 3-carboethoxy-269 p H CHZ (1) phenyl 516 NH O

'O

(3-4) 4-carboethoxy-270 p H CHz (1) phenyl 516 NH o 'O

phenyl 271 p H CH2 (1) (4) 416 NH OH

3-cyanophenyl 272 p H CHZ (1) (4) 441 NH OH

(4) 3-273 p H CHz (1) methoxyphenyl 524 NH O~~
fJ

S

(4) Trans-2-274 p H CH2 (1) phenyl- 534 cyclopropyl w0 CH3 (3) 3-cyanophenyl 275 P H CHz (1) 483 NH CO~Me (3 ) 3-276 p H CHz (1) methoxyphenyl 488 NH CO_Me r.. ..

(4) 3-cyanophenyl 277 p H CHZ (1) 519 NH O' (3) 3-278 p H CH2 (1) methoxyphenyl 460 NH OOH

(3) 3-cyanophenyl 279 p H CHZ (1) 455 NH ~JH

(4) 3-cyanophenyl 280 p 4-F CHz (1) 501 NH COZMe (5) 3-cyanophenyl 280a p 4-F CHZ (1) 501 NH CO~Me (5) 3-cyanophenyl 280b p 4-F CH2 (1) 500 NH CONMe (5) 3-cyanophenyl 280c p 4-F CHz (1) 486 NH CONHz (5) 3-(1-280d P 4-F CHZ (1) hydroxyethyl)- 520 NH COzMe phenyl (5) phenyl 280e r H CHZ (1) 458 NH C02Me (5) phenyl 280f P 4-F CHz (1) 462 NH COzH

(5) 3-cyanophenyl 2808 r H CH2 (1) 483 NH CO~Me (5) 3-280h r H CH2 (1) methoxyphenyl 488 NH COzMe 3-acetylphenyl 2801 r H CH 1 z ( 500 ) NH COZMe (5) 3-acetylphenyl 280j p 4-F CH 1 z ( ) HC1 ( sa NH CO,Me lt) ' (5) 3-cyanophenyl 280k p 4-F CH 1 Z ( ) HC1 ( sa NH COzMe lt) 28I p 4-F CHz (1) (4) Phenyl NH CO.Me 281a p 4-F CH2 (1) (5) I phenyl CO,Me 281b p 4-F CH~ (1) (5) phenyl ~TH CONMe 281c p 4-F CH2 (1) (5) phenyl 282 p 4-F CH2 (1) (4) methoxyphenyl 506 NH

CO.Me 282a p 4-F CH, (1) 5) ( methoxyphenyl 506 NH

CO,Me ?82b p 4-F CHI (1) (5) methoxyphenyl 505 NH CONMe (5) 3-acetylphenyl !82c p 4-F CH 1 z ) ( COzMe (5) 3-acetylphenyl 82d p 4-F CH 1 Z ( ) NH CONMe (5) 3-acetylphenyl 82e p 4-F

CHI (1) NH COl~H

z (4) 3-cyanophenyl 283 p 4-F CHz (1) 473 NH OOH

3-cyanophenyl 284 p 4-F CH2 (1) (3-4) 493 fused Phenyl 285 p 4-F CHZ (1) (3-4) methoxyphenyl 498 fused Phenyl 3-cyanophenyl 286 p 4-F CH2 (1) (4) 562 NH

-CONPh 3-cyanophenyl 286a p 4-F CHZ (1) (5) NH

-CONPh 3-acetylphenyl 286b p 4-F CHZ (1) (5) 579 NH

-CONPh (4) 3-287 p 4-F CH2 (1) methoxyphenyl 478 NH OOH

(4) 3-cyanophenyl 288 p 4-F CHZ (1) 500 NH CONMe (4) 3-cyanophenyl 288a p 4-F CH2 (1) 500 HC1(sa NH CONMe lt) (5) 3-acetylphenyl 288b p 4 CH2 ( 1 517 -F ) HC1(sa NH CONMe lt) (5) 3-acetylphenyl 288c p 4-F CHz (1) 574 NH CON

( CHa ) 2 NMe 2 (5) 3-acetylphenyl 288d p 4-F CHZ (1) 557 NH CON

( CHZ
) z NMe2 (5) 3-acetylphenyl 288e p 4-F CH2 (1) NH CON

C3Hs (5) 3-acetylphenyl 288f p 4-F CH (1 z ) 531 CON

(5) 3_ 2889 p 4-F CHZ (1}

methoxyphenyl 519 NH CONMez (5) 3-acetylphenyl 288h p 4-F CH 1 z ( 531 ) NH CONMe2 (5) 3-acetylphenyl 288i p 4-F CHz (1) NH CON(2-pyridi nyl) _ (5) 3_ 288 p 4 CHz (1) F

methoxyphenyl 568 NH CONMez 2,5-289 P H CH2 (1) H difluorophen 45 l y 0 CH~NH

290 3-cyanophenyl P H CH2 ( 1 ) 3-carboethoxy-2 91 p H CH ( 1 z ) H
Phenyl 4 8 CHzNH

292 3_ p H CHI (1) H

methoxyphenyl 444 CHzNH

293 p H CH2 (1) methoxyphenyl 444 CHZNH H

294 p H ,~ ~ (1) H methoxyphenyl 460 NH

OH

295 r H .~ ~ (1) H methoxyphenyl 460 NH

OH

3-cyanophenyl 296 p H ,~ (1) H 455 ~

~ NH

OH

3-carboethoxy-297 p H ,~ (1) H phenyl 502 OH

phenyl 298 p H ,~ (1) H 430 ~

~ NH

OH

(5) phenyl 299 p 4-F CHz ( 1 ) 448 ~ ~H

phenyl H _~
~

300 p ~ ( 1 443 ) NOH NH H

phenyl 3 O p H .~ ( 2 H 42 1 ~, ) 8 ~ NH

O

phenyl 302 p H ,~ (2) H 430 ~

~ NH

OH

phenyl 303 p 4-F ,~ (1) H 448 ~

~ NH

OH

-_3_ 304 p 4-F ,~ (1) H methoxyphenyl 478 ~

~ NH

OH

3-cyanophenyl 305 p 4-F ,~ (1) H 473 ~

~ NH

OH

( 3-4 3 -cyanophenyl ) 306 p H _~ (1) 499 ~

~ NH

O

3-cyanophenyl 307 p H CH2- (1) H 439 3-cyanaphenyl 308 p 4-F CH2- ,( 1 H 457 ) 309 p H CHz- (1) H methoxyphenyl 444 310 p 4-F CHZCH2 (1) H metho xyphenyl 462 NH

311 r H CH2- (1) H methoxyphenyl 444 CHz NH

3-acetylphenyl 312 p 4-F CH2- (1) H

CHI NH

4-fluorophenyl 313 p 4-F CHZ- (1) H 450 CHZ NH

1-adamantyl 314 p 4-F CHZ- (1) H 490 ( 3-4 3 -cyanophenyl ~

315 s H CH2 (1) 483 NH O
(M+) 'O

3-cyanophenyl 316 s H CHZ (1) (4) 455 NH OH ( M+
) 3-cyanophenyl 317 s H CH2 (1) (4) 539 NH o- (M+
) f2-THP) TABLE 3.1 ~Ris R~s Z NV

HN~NHR3 !'O
a b R~s HN~NHR3 O
C
Ex Core R16 Stereo- Salt MS
#

3 M+H+
chemistry Form R

400 a H 1,2 traps - 3-methoxylphenyl 436 racemic 401 a 4-F 1,2 traps - 3-methoxylphenyl 454 racemic 402 a H 1,2 cis - 3-methoxylphenyl 436 racemic 403 a 4-F 1,2 traps - 3-cyanophenyl 449 racemic 403a a 4-F 1,2 traps - 3-acetylphenyl 466 racemic 403b a 4-F 1,2 traps - 3-nitrophenyl 469 racemic 403c a 4-F 1,2 traps - 4-nitrophenyl 469 racemic 403d a 4-F 1,2 traps - 4-pyridinyl 425 racemic 403e a 4-F 1,2 traps HC1 3-acetylphenyl 466 racemic 403f a 4-F 1,2 traps - (1H)-indazol-5-yl 464 racemic 404 a 4-F 1S,2R - 3-acetylphenyl 466 405 a 4-F 1S,2R - 3-cyanophenyl 449 406 a 4-F 1S,2R - 3-methoxylphenyl 454 L I I I I

WO 00!35451 PCT/US99/30332 407 a 4-F 1S,2R - phenyl 424 408 a 4-F 1R,2S - 3-acetylphenyl 466 409 a 4-F 1R,2S - 3-cyanophenyl 449 410 a 4-F 1R,2S - 3-methoxyphenyl 454 411 a 4-F 1R,2S - phenyl 424 412 a 4-F 1R,2S - phenylmethyl 438 413 a 4-F 1R,2S - (1H)-indazol-5-yl 464 414 a 4-F 1R,2S - (1H)-indol-5-yl 463 414a b H 1,2 traps - 3-methoxyphenyl 464 (3RS) racemic 414b b H 1,2 traps - 3-cyanophenyl 431 (3RS) racemic 414c b H 1,2 traps - 3-acetylphenyl 448 (3RS) racemic 414d b 4-F 1,2 traps - 3-acetylphenyl 466 (3RS) racemic 414e b 4-F 1,2 traps - 3-cyanophenyl 449 (3RS) racemic 414f b 4-F 1,2 traps - 3-methoxyphenyl 454 (3RS) racemic 4148 b 4-F 1,2 traps - 3-nitrophenyl 469 (3RS) racemic 415 b 4-F 1R,2S,3S - 3-acetylphenyl 466 415a b 4-F 1R,2S,3S HCl 3-acetylphenyl 466 415b b 4-F 1R,2S,3S Besyl 3-acetylphenyl 466 416 b 4-F 1R,2S,3R - 3-acetylphenyl 466 416a b 4-F 1R,2R,3S - 3-acetylphenyl 466 416b b 4-F 1R,2S,3R HCl 3-acetylphenyl 466 417 b 4-F 1R,2S,3S - 3-cyanophenyl 449 418 b ~ 4-F 1R, 2S, ~ - 3-cyanophenyl i 449 ~ ~ 3R

419 b 4-F 1R,2S,3S - 3-methoxylphenyl 454 420 b 4-F 1R,2S,3R - 3-methoxylphenyl 454 421 b 4-F 1R,2S,3S - 4-fluorohenyl 442 422 b 4-F 1R,2S,3R, - 4-fluorohenyl 442 423 b 4-F 1R,2S,3S - phenyl 424 424 b 4-F 1R,2S,3S - (1H)-indazol-5-yl 464 425 b 4-F 1R,2S,3S - (1H)-indazol-6-yl 464 426 b 4-F 1R,2S,3S - benzthiazol-6-yl 481 427 b 4-F 1R,2S,3S - (1H)-indol-5-yl 463 428 b 4-F 1R,2S,3S - (1H)-indoi-6-yl 463 429 b 4-F 1R,2S,3S - (IH)-2,3- 491 dimethylindol-5-430 b 4-F 1R,2S,3S - benzimidazol-5-yl 464 431 b 4-F 1R,2S,3S - indolin-5-yl 465 432 b 4-F 1R,2S,3S - 3-cyano-4- 467 fluoro henyl 433 b 4-F 1R,2S,3S - 3-acetyl-4- 484 fluoro henyl 434 b 4-F 1R,2S,3S - 3,5-diacetylphenyl 508 435 b 4-F 1R,2S,3S - 3-(1- 468 hydroxyethyl)-henyl 436 b 4-F 1R,2S,3S - 4-methyl-thiazol- 445 437 b 4-F 1R,2S,3S - 4-methyl-5-acetyl- 487 thiazol-2-yl 438 b 4-F 1R,2S,3S - 1,3,4-thiadiazol- 432 439 b 4-F 1R,2S,3S - 4-chlorol- 515 benzthiazol-2-yl 440 b 4-F 1R,2S,3S - thiazol-2-yl 431 441 b 4-F 1R,2S,3S - 5-methyl-isoxazol- 429 _ 3-yl 442 b 4-F 1R,2S,3S - 1-methyl-pyrazol- 428 443 b 4-F 1R,2S,3S - 4-(1,2,4-triazol- 491 1- 1 ) hen 1 443a b 4-F 1R,2R,3S - 4-(1,2,4-triazol- 491 1- 1 ) henyl 444 b 4-F 1R,2S,3S - (1H)-3-chloro- 499 indazol-5- 1 445 b 4-F 1R,2S,3S - 4-fluorophenyl 492 446 b 4-F 1R,2S,3S - 4-chlorophenyl 458 447 b 4-F 1R,2S,3S - 4-bromophenyl 502 448 b 4-F 1R,2S,3S. - 3-bromophenyl 502 449 b 4-F 1R,2S,3S - 3-fluorophenyl 442 450 b 4-F 1R,2S,3S - 3,4-difluorophenyl 460 451 b 4-F 1R,2S,3S - 3-chloro-4- 476 fluorophenyl 452 b 4-F 1R,2S,3S - 3,5-dichlorophenyl 492 453 c 4-F 1R,2S,3S - 3-acetylphenyl 452 454 c 4-F 1R,2S,3R - 3-acetylphenyl 452 455 c 4-F 1R,2R,3S - 3-acetylphenyl 452 456 c 4-F 1R,2S,3S - 3-cyanophenyl 435 457 c 4-F 1R,2S,3R - 3-cyanophenyl 435 458 c 4-F 1R,2R,3S - 3-cyanophenyl 435 458a c 4-F 1R,2R,3R - 3-cyanophenyl 435 459 c 4-F 1R,2S,3S - phenyl 410 460 c 4-F 1R,2S,3R - phenyl 410 461 c 4-F 1R,2R,3S - phenyl 410 462 b 4-F 1R,2S,3S - (1H)-5-amino- 464 indazol-1-yl 463 b 4-F 1R,2S,3S - 3-chlorophenyl 458 464 b 4-F 1R,2S,3S - 3-fluoro-4- 456 methyl henyl 465 b 4-F 1R,2S,3S - 3-cyano-4-(1- 515 yrazolyl) hen 1 466 b 4-F 1R,2S,3S - 2-methylphenyl 454 467 b 4-F 1R,2S,3S - 2-methylphenyl 438 468 b 4-F 1R,2S,3S - 2,4-dimethylphenyl 452 469 b 4-F 1R,2S,3S - 2,4- 484 dimetho hen 1 470 b 4-F IR,2S,3S - 2,5- 484 dimethoxyphenyl i 471 b 4-F 1R,2S,3S - 2-methoxy-5- 468 meth 1 henyl 472 b 4-F 1R,2S,3S - 2-methyl-5- 456 i ~ f luoro her. 1 473 b 4-F 1R,2S,3S - 3,5-bis((1H)-1- 588 methyltetrazol-5-1) hen 1 ' 474 b 4-F 1R,2S,3S - (3-((1H)-1- 506 methyltetrazol-5-yl)phen 1 475 b 4-F 1R,2S,3S - (4- 517 (carboethoxymethyl )thiazol-2- 1 476 b 4-F 1R,2S,3S - 5-bromothiazol-2- 509 477 b 4-F 1R,2S,3S - 4,5-di(4- 619 fluorophenyl)thiaz ol-2-yl 478 b 4-F 1R,2S,3S - 2-fluorophenyl 442 479 b 4-F 1R,2S,3S - 2-chlorophenyl 458 480 b 4-F 1R,2S,3S CF,CO,H indanon-6-yl 478 481 b 4-F~1R, 2S, 3S CF,CO,H indanon-4-yl 478 482 b 4-F 1R, 2S, 3S CF,CO,H 4- 466 (iso ro 1) hen 1 483 b 4-F 1R, 2S, 3S CF,CO,H 3-nitro-4- 483 meth 1 hen 1 484 b 4-F 1R,2S,3S CF,CO,H trans-2- 464 phenylcycloprop-1-485 b 4-F 1R,2S,3S CF,CO,H 2,4-difluorophenyl 460 486 b 4-F 1R,2S,3S CF,CO,H 2,5-difluorophenyl 460 487 b 4-F 1R,2S,3S CF,CO,H 2,4-dichlorophenyl 492 488 b 4-F 1R,2S,3S CF,CO,H 2,5-dichlorophenyl 492 489 b 4-F 1R,2S,3S CF,CO,H 2-methoxyphenyl 454 490 b 4-F 1R,2S,3S CF,CO,H 2,4-dimethoxy- 484 hen 1 491 b 4-F 1R, 2S, 3S CF,CO,H 2, 5- 484 dimetho hen 1 492 b 4-F 1R, 2S, 3S CF,CO,H 2- 492 trifluoromethylyph en 1 493 b 4-F 1R,2S,3S CF,CO,H 2-methylphenyl 438 494 b 4-F 1R, 2S, 3S CF,CO,H 3- 492 trifluoromethyly-henyl 495 b 4-F 1R, 2S, CF,CO,H 3-methylphenyl 438 496 b 4-F 1R,2S,3S CF~CO,H 4-methoxyphenyl 454 497 b 4-F 1R,2S,3S CF,CO,H 4-carboethoxy- 496 phenyl 498 b 4-F 1R, 2S, CF,CO,H 4- 492 3S trifluoromethyly-henyl 499 b 4-F 1R, 2S, CF,CO,H 4-methylphenyl 438 500 b 4-F 1R,2S,3S CF,CO,H 2-fluorophenyl 442 501 b 4-F 1R,2S,3S CF,CO,H 2-chloropheny 458 502 b 4-F 1R,2S,3S CF,CO,H 2-nitrophenyl 469 503 b 4-F 1R,2S,3S CF,CO,H 2,4-dichlorophenyl 563 504 b 4-F 1R,2S,3S CF,CO,H 3-nitrophenyl 469 505 b 4-F 1R, 2S, CF,CO,H 3, 5-di 560 3S (trif luoromethyly) -phenyl 506 b 4-F 1R, 2S, CF,CO,H 2, 4- 452 3S dimeth 1 henyl 507 b 4-F 1R,2S,3S CF,CO,H 2,4-dimethoxy-5- 518 chloro henyl 508 b 4-F 1R, 2S, CF~CO,H 3 , 4, 5- 514 3S trimetho hen 1 509 b 4-F 1R,2S,3S CF,CO,H 3,5-dimethylphenyl 452 510 b 4-F 1R,2S,3S CF,CO,H 3-trifluorornethyl- 526 4-chloro henyl 511 b 4-F 1R,2S,3S CF~CO,H 4-phenoxyphenyl 516 512 b 4-F 1R,2S,3S CF,CO,H 4-ethoxyphenyl 468 513 b 4-F 1R,2S,3S CF,CO,H 4-thiomethylphenyl 470 514 b 4-F 1R, 2S, CF,CO,H 2-naphthyl 474 515 b 4-F 1R,2S,3S CF,CO,H 4-acetylphenyl 466 516 b 4-F 1R,2S,3S CF,CO,H 2,6-dichloro- 493 pyridin-4- 1 517 b 4-F 1R, 2S, CF,CO,H 5-indan-~4-yl 464 518 b 4-F 1R,2S,3S CF,CO,H 4-chloronaphth-1- 508 yl 519 b 4-F 1R, 2S, CF,CO,H 3-fluoro-4- 472 3S metho henyl 520 b 4-F 1R, 2S, CF~CO,H 4- 502 3S (methylsulfonyl)-phenyl) q 521 b 4-F 1R, 2S, CF,CO,H 3- 502 (methylsulfonyl)-hen 1 522 b 4-F 1R, 2S, CFzCO,H 2- ( (1H) -pyrrol-1-489 ) 523 b 4-F 1R, 2S, CF,CO,H 1, 3-ben 468 3S zodioxol-5-yI
~

524 b 4-F 1R,2S,3S CF,CO,H 1-acetylindolin-6- 507 525 b 4-F 1R, 2S, CF~CO,H 4- ( 6- 571 methylbenzothiazol -2- 1) hen 1 526 b 4-F 1R, 2S, CF,CO,H 4- ( (2 , 2- 523 dimethylpropanoyl) amino) hen 1 527 b 4-F 1R, 2S, CF,CO,H 4- (1- 506 methyltetrazol-5-1 ) phen 1 528 b 4-F 1R, 2S, CF,CO,H 4- ( 1- 509 mo holino) hen 1 529 b 4-F 1R,2S,3S CF,CO,H quinolin-8-yl 475 530 b 4-F 1R,2S,3S CF;CO,H 3-hydroxyphenyl 440 531 b 4-F 1R,2S,3S CF,CO,H 4-(acetylamino)- 481 hen 1 532 b 4-F 1R,2S,3S CF,CO,H 4-hydroxyphenyl 440 533 b 4-F 1R,2S,3S CF,CO,H 3-hydroxy-4- 470 metho henyl 534 b 4-F 1R,2S,3S CFzCO,H 3-(acetylamino)- 481 hen 1 535 b 4-F 1R,2S,3S CF,CO,H 4-fluoro-3- 456 meth lphenyl 536 b 4-F 1R,2S,3S CF~CO,H 3-methoxy-4- 468 meth lphen 1 537 b 4-F 1R,2S,3S CF,CO,H 4-chloro-3- 472 meth 1 hen 1 538 b 4-F 1R, 2S, CF~CO,H 4- (N- 481 methylcarboxamide) hen 1 539 b 4-F 1R,2S,3S CF,CO,H 1-adamantyl 482 540 b 4-F 1R,2S,3S CF,CO,H quinolin-5-yl 475 541 b 4-F 1R,2S,3S CF,CO,H quinolin-6-yl 475 542 b 4-F 1R,2S,3S CF,CO,H 1,4-benzodioxan-6- 482 543 b 4-F 1R,2S,3S CF,CO,H isoquinolin-5-yl 475 544 b 4-F 1R, 2S, CF,CO~H 4- (sulfonamide) 503 hen 1 545 b 4-F 1R,2S,3S CF,CO,H benzotriazol-5-yl 465 546 b 4-F 1R,2S,3S CF~CO~H 2-hydroxy-4- 454 meth 1 henyl 547 b 4-F 1R, 2S, CF.~CO~H3-hydroxy-4- 454 methylphenyl 548 b 4-F 1R, 2S, CF.~CO~H2-methyl- 495 benzothiazol-5-yl 549 b 4-F 1R, 2S, CF.~CO~H(4- 468 3S .

methoxylphenyl)-methyl 550 b 4-F 1R,2S,3S CF~CO~H (4-fluorophenyl)- 456 meth 1 551 b 4-F 1R,2S,3S CF.~CO~H(4-methylphenyl)- 452 methyl 552 b 4-F 1R, 2S, CF.~CO~H(1R) -1- 452 (phenyl)ethyl 553 b 4-F 1R,2S,3S CF~CO~H 1-acetylindolin-5- 507 yl 554 b 4-F 1R,2S,3S CF~CO~H 5,6,7,8- 478 tetrahydronaphth-1-yl 555 b 4-F 1R,2S,3S CF~CO~H 3-acetyl-4- 482 h dro hen 1 556 b 4-F 1R,2S,3S CF~CO~H 4-(Piperidin-1- 507 yl) henyl 557 b 4-F 1R, 2S, CF.~CO~HcYclohexyl 430 558 b 4-F 1R,2S,3S CF~CO~H 2-methoxyphenyl 468 559 b 4-F 1R,2S,3S 2,6-dimethylphenyl 452 CF~CO~H

560 b 4-F 1R, 2S, CF.~CO~H2-ethylphenyl 452 561 b 4-F 1R,2S,3S CF~CO~H 2,4,6- 466 trimeth lphen 1 562 b 4-F 1R, 2S, CF.~CO~H2, 5- 484 dimethox henyl 563 b 4-F 1R,2S,3S CF~CO~H t-butyl 404 564 b 4-F 1R, 2S, CF.~CO~Hi-Propyl 390 565 b 4-F 1R,2S,3S Ethoxycarbonyl- 434 CF~CO~H

meth 1) 566 b 4-F 1R, 2S, CF.~CO~H2- 508 trifluoromethoxy-hen 1 567 b 4-F 1R,2S,3S CF~CO~H (1R,S)-1-- 462 (methoxycarbonyl)-2-meth 1-pro 1 568 b 4-F 1R,2S,3S CF~CO~H ~(1S)-1- 510 (methoxycarbonyl)-2-phenylethyl 569 b 4-F 1R,2S,3S CF~CO'H 24,4-trimethyl-2- 460 ent 1 570 ~ ~ ~ 1R, 2S, ~ CF.~CO~H~ 2-Phenylethyl 452 b 4-F 3S

571 b 4-F 1R,2S,3S CF CO 3-acetylphenyl 466 H

572 b 4-F 1R,2S,3S CF~CO~H 2-carbomethoxy- 482 hen 1 573 b 4-F 1R,2S,3S (1S)-1- 452 CF~CO~H

(phenyl)ethyl 574 b 4-F 1R, 2S, 3S CF.~CO~H4- (Phenyl ) phenyl 500 .

575 b 4-F 1R,2S,3S CF.~CO~H1-naphthyl 474 576 b 4-F 1R,2S,3S CF~CO~H 2-(Phenyl)phenyl 500 577 b 4-F 1R,2S,3S CF~CO~H phenylmethoxy 454 578 b 4-F 1R,2S,3S CF~CO~H 3,4- 484 dimetho hen 1 579 b 4-F 1R, 2S, 3S CF.~CO~H_ 520 (3H) -2-ethylquinazolin-4-on-3- 1 580 b 4-F 1R,2S,3S _ 425 CF~CO~H 3-pyridinyl 581 b 4-F 1R,2S,3S &-methoxy-3- 455 CF.~CO~H

p ridinyl 582 b 4-F 1R,2S,3S -2-methylquinolin- 489 CF.~CO~H

583 b 4-F 1R,2S,3S CF.~CO~H2-methylnaphth-1- 488 584 b 4-F 1R,2S,3S CF~CO~H 4-((1H)-1-propyl- 534 tetrazol-5-1) hen 1 585 b 4-F 1R,2S,3S CF~CO~H 3-aminophenyl 439 586 b 4-F 1R,2S,3S - 3-(acetylamino)- 481 hen 1 587 b 4-F 1R, 2S, 3S CF.~CO~H3- (N- 481 methylcarbamoyl)-hen 1 588 b 4-F 1R, 2S, 3S CF.~CO~H2-nitro-4- 499 metho henyl 589 b 4-F 1R,2S,3S CF~CO~H 8-hydroxyquinolin- 491 5-yl 590 b 4-F 1R,2S,3S 3-methylpyridin-2- 439 CF~CO~H

591 b 4-F 1R,2S,3S CF.~CO~Hisoquinolin-1-yl 475 Example 318 WO 00/3545t PCT/US99/30332 O
N ~0~
Part A: Preparation of 1-t-butyloxvcarbonyl 4 benzylpiperidine 4-benzylpiperidine (10.0 g, 57.1 mmol, 1.0 eq.) was dissolved in 100 mL of THF under N2 and subsequently cooled to 0 °C. Di-tert-butyl dicarbonate (11.21 g, 51.3 mmol, 0.9 eq.) dissolved in 50 mL of THF, was added dropwise. Gas, evolution was observed. Once gas evolution ceased, the ice bath was removed. After 20 hours, the THF was removed in vacuo then the residue was dissolved in EtOAc and rinsed 3X
with 1N citric acid, 1X with brine. The organic was dried over magnesium sulfate and stripped to yield 15.4 g of colorless oil as product. Yield = 97.90. IJMR (300 MHz, CDC13)S 7.35-7.17 (m,3H); 7.14 (d, 2H, J = 7 Hz); 4.20-3.90 (m, 2H); 2.75-2.55 (m, 2H); 2.54 (d, 2H, J = 7 Hz); 1.70-1.50 (m, 3H);
1.46 (s, 9H); 1.20-1.00 (m, 2H).

a I' N~O
)H + ~~ , OH
erythro threo Part B: Preparation of erythro-and threo-cis-4-benzyl-1-t-butoxycarbonyl-~-ethylpiperidinemethanol 1-t-butyloxycarbonyl-4-benzylpiperidine (5.0 g, 18.2 mmol, 1.0 eq. ) was dissolved in EtzO at 25 °C under Nz and cooled to -78 °C. N,N,N',N'-Tetramethylethylenediamine (TMEDA) (3.29 mL, 21.8 mmol, 1.2 eq.) was added followed by the dropwise addition of sec-butyllithium (16.76 mL, 21.8 mmol, 1.2 eq.). The reaction was allowed to warm and stir at -30 °C for 30 minutes then again cooled to -78 °C. Once cool, propionaldehyde (1.31 mL, 20.0 mmol, 1.1 eq.) was added neat. The reaction was allowed warmed to warm to -30 °C then immediately quenched with 10 mL of water and the organic layer was separated. The aqueous layer was extracted 2X more with EtzO. The organic layers were combined, dried over magnesium sulfate and the solvent removed in vacuo to yield a colorless oil which was purified by flash chromatography in 4 . 1 to 1 _ 1 hexane/
EtOAc. Obtained 0.68 g of a colorless oil as isomer A, yield = 11.2 and 0.91 g of a colorless oil as isomer B, yield = 15Ø
Isomer A NMR (300 MHz, CDC1~)87.40-7.25 (m, 2H); 7.21 (d, 1H, J = 7 Hz); 7.16 (d, 2H, J = 7 Hz); 3.60-3.30 (m, 2H);
2.56 (d, 2H J = 7 Hz); 1.90-1.00 (m, 7H); 1.46 (s, 9H);
1.00-0.70 (m, 5H).
Isomer B NMR (300 MHz, CDC13)S 7.30-7.23 (m, 2H); 7.20 (d, 1H, J = 7 Hz); 7.14 (d, 2H, J = 7 Hz.); 3.60-3.20 (m, 2H);

2.60-2.40 (m, 2H); 1.90-1.00 (m, 9H); 1.44 (s, 9H); 0.96 ( t, 3H, J = 7 Hz ) .
O
S
erythro Part C: Structure determination of Isomer B via cyclization to 4a,6a,7a-4-benzyl-7-ethyl-8-oxa-1-azabicyclo[4.3.0]nonane-9-one Isomer B (60 mg, 0.18 mmol, 1 eq.) was dissolved in DMF at °C under N2 then NaH (7.9 mg, 0.198 mmol, 1 eq.) was added. After 20 hours, 2 mL of water was added followed by EtOAc. The layers were separated. The aqueous layer was 20 extracted 2X more with EtOAc. The organic layers were combined, dried over magnesium sulfate, and the solvent removed in vacuo to yield an oil which was purified over silica gel in 9:1 to 1:1 hexane/EtOAc_ Obtained 30 mg.
Yield = 64~. Product structure confirmed by N.O.E. NMR
25 (300 MHz, CDC13) 8 7.40-7.20 (m, 3H) ; 7.16 (d, 2H, J = 7 Hz); 4.45-4.25 (m, 1H); 4.00-3.80 (m, 1H); 3.65-3.45 (m, 1H); 2.95-2.70 (m, 1H); 2.65-2.45 (m, 2H); 1.85-1.40 (m, 4H); 1.40-1.00 (m, 6H).

,.., )H
Part D: Preparation of erythro-cis-4-benzyl-oc-ethylpiperidinemethanol Erythro-cis-4-benzyl-1-t-butoxycarbonyl-~-ethylpiperidinemethanol(isomer B from part B)(815 mg, 2.44 mmol, 1 eq.) was dissolved in 8 mL of ethanol at 25 °C under Nz . NaOH ( 3 91 mg , 9 . 7 8 mmo 1, 4 eq . ) was added and the mixture refluxed for 4 hours. The solvent was removed in vacuo to yield an oil. Water was added followed by EtOAc.
The layers were separated. The aqueous layer was extracted 2X more with EtOAc. The organic layers were combined dried over magnesium sulfate, and the solvent removed in vacuo to yield 390 mg of an oil. Yield = 68~. NMR (300 MHz, CDC13) ~ 7.35-7.20 (m, 2H); 7.23-7.00 (m, 3H); 3.75-3.65 (m, 1H);
3.20-3.00 (m, 1H); 2.90-2.40 (m, 4H); 1.70-1.50 (m, 2H);
1.50-1.30 (m, 1H); 1.20-0.80 (m, 5H).
O
a )H 0 Part E: Preparation of erythro-cis-4-benzyl-a-ethyl-1-(3-N-phthalimido-n-prop-1-yl)piperidinemethanol Erythro-cis-4-benzyl-a-ethylpiperidinemethanol (195 mg, 0.84 mmol, 1 eq.), N-(3-bromopropyl)phthalimide (224 mg, 0.84 mmol, 1 eq.), potassium iodide (139 mg, 0.84 mmol, 1 eq.), and potassium carbonate (231 mg, 0.84 mmol, 1 eq.) were refluxed in 10 mL of 2-butanone for 3 hours. The reaction was worked up by__filtering off the inorganic solids. The filtrate solvent was removed in vacuo to yield an oil. Purified by flash chromatography in 100$ EtOAc then 4:1 chloroform/MeOH. Obtained 200 mg. Yield = 57~.
NMR (300 MHz, CDC1,) 8 7.95-7.80 (m, 2H); 7.80-7.65 (m, 2H); 7.35-7.00 (m, 5H); 3.90-3.60 (m, 3H); 3.20-2.90 (m, 2H); 2.65-2.30 (m, 3H); 2.20-2.00 (m, 2H); 2.00-1.75 (m, 2H); 1.70-1.40 (m, 4H); 1.35-0.90 (m, 3H); 0.96 (t, 3H, J =
7 Hz ) .
._ /''NHZ
)H
Part F: Preparation of erythro-cis-1-(3-amino-n-prop-1-yl)-4-benzyl-a-ethylpiperidinemethanol Erythro-cis-4-benzyl-a-ethyl-1-(3-N-phthalimido-n-prop-1-yl)piperidinemethanol(200 mg, 0.48 mmol, 1 eq.) was dissolved in 5 mL of ethanol at 25 °C under Nz. Anhydrous hydrazine (0.03mL, 0.95 mmol, 2 eq.) was added and the reaction refluxed for 3 hours during which time a white precipitate (phthalhydrazide) formed. Once cool, The solids were filtered. The filtrate solvent was removed in vacuo to yield an oil which was stirred in EtzO. The triturated solids were filtered and the filtrate solvent was removed in vacuo to yield 120 mg of an oi.l. Yield =
87~. NMR (300 MHz, CDC13) b 7.27(t, 2H, J = 7 Hz); 7.17 (d, 1H, J Hz); 7.13 (d, 2H, J 7 Hz); 3.70-3.30 (m, 2H);
= 7 =

3.20-3.00(m, 2H); 3.00-2.70 2H); 2.70-2.40 (m, 2H);
(m, p ' WO 00/35451 PCT/US99/30332 2.30-2.10 (m, 1H); 2.10-1.90 (m, 2H); 1.90-1.40 (m, 5H);
1.40-1.00 (m, 3H); 0.96 (t, 3H, J = 7 Hz).
O / ' O v '' w ~~
~N O + .., ~N~N 0 H H H H
H
)H
t0 /
O
Part G: preparation of erythro-cis-1-[3-(3-acetylphenylaminocarbonylamino)-n-prop-1-yl]-4-benzyl-a-ethylpiperidinemethanol and erythro-cis-1-[3-(3-acetylphenylaminocarbonylamino)-n-prop-1-yl]-2-[1-(3-acetylphenylaminocarbonyloxy)-n-prop-1-yl)-4-benzylpiperidine Erythro-cis-1-(3-amino-n-prop-1-yl)-4-benzyl-a-ethylpiperidinemethanol (120 mg, 0.41 mmol, 1 eq.) was dissolved in 5 mL of THF at 25 °C under Nz then 3-acetylphenyl isocyanate added neat. After 1 hour the solvent was removed in vacuo to yield an oil. Purified by flash chromatography in 100 EtOAc to 4:1 chloroform/MeOH.
Isolated mono-addition product (product A) along with an additional bis-addition product (product B). Prouct A
yielded 81 mg of an oil. Yield = 43~. Product B yielded 43 mg of an oil.
Product A NMR (300 MHz, CDC1~) 8 7.86 (bs, 1H); 7.73 (d, 1H, J = 7 Hz); 7.60 (s, 1H); 7.56 (d, 1H, J = 7 Hz); 7.40-7.15 (m, 4H); 7.12 (d, 2H, J = 7 Hz); 6.30-6.05 (m, 1H); 4.00-3.80 (m, 1H); 3.50-3.30 (m, 1H); 3.30-2.90 (m, 5H); 2.60-2.40 (m, 2H); 2.57 (s, 3H); 2.30-2.10 (m, 1H); 2.10-1.90 (m, 2H); 1.80-1.40 (m, 5H); 1.30-1.05 (m, 2H); 0.94 (t, 3H, J = 7 Hz).
Product B NMR (300 MHz, CDC13) ~ 10.80-10.60 (m, 1H); 8.20-8.00 (m, 1H) ; 7.91 (bs, lei) ; 7.80-7.18 (m, 9H) ; 7.11 (d, 2H, J = 7 Hz); 6.20-6.00 (m, 1H); 5.20-5.00 (m, 1H); 3.50-3.00 (m, 4H); 2.57 (s, 3H); 2.56 (s, 3H); 2.55-2.00 (m, 5H); 2.00-1.00 (m, lOH); 1.00-0.80 (m, 3H) Product A was separated into its enantiomers employing a Daicel Chiral Pack AD column, eluting with 0.1%
diethylamine in methanol. (-)-isomer [a]DZ5 (c - 0.300 g/dL, MeOH) - -14.9°. (+)-isomer [Ct]DZ5 (c = 0.290 g/dL, MeOH) -+20.2°.
The following compounds can be synthesized by the methods discussed previously:

TABLE 3b.

O'1 61 -,~~3 6 / .~ R3 O 1 ,' 3 ~N~r' 2 l''N 2 N H H ~~'' N , OH H H
OH
c d O 1 ' ~ 3 ~N~N 2 H
0~~
'1 \
O ~ ~ R3 Ri /
a Cores R1 R2 R2a, R2b R3 M+1 319 a,b H CH3 ~ --- 3-COCH3 438 320 a,b H CH3 -- 4-N02 441 321 a,b H CH3CH2 ---~ 3-COCH3 452 322 c H --- CH3, CH3 3-COCH3 452 323 a,b H CH3CH2CH2 --- 3-COCH3 466 Rz Ri a b 6 / ~ R3 O 6 / ~3R3 O i ~. t 3 1 w. ~
N~N 2 ~N~N 2 ' H H H
H
OH
/ R~R2b 0 ~ ~ R3 R1 m 324 a,b H (CH3)2CH --- 3-COCH3 466 325 a,b H CH3CH2CH2CH2 --- 3-COCH3 480 326 a,b H (CH3)2CHCH2 --- 3-COCH3 480 327 d,e H CH3CH2 --- 3-COCH3 613 328 d,e H CH3CH2~CH2 --- 3-COCH3 627 329 d,e H (CH3)2CH --- 3-COCH3 627 I

330 d,e H CH3CH2CH2CH2 --- 3-COCH3 641 I

331 d,e H (CH3)2CHCH2 --- ~COCH3 641 ~ ~ ~

Example 332 Part A Pret~aration of N-cyano-N'-3-methoxvohenvlcarbamimidic acid phenyl ester ~N
O_ 'N \ O~
m-Anisidine (4.56 mL, 4.06 mmol, 1 eq.), and diphenylcyanocarbonimidate (967 mg, 4.06 mmol, 1 eq.) were mixed and refluxed in acetonitrile under N2 for 1 hour.
Solids precipitated. The reaction was worked up by filtering off the solids. Obtained 580 mg as product.
M.P. - 170.0 - 171.0 °C. NMR (300 MHz, DMSO-ds) 8 8.70 -8.50 (m, 1H); 7.43 (t, 2H, J = 7 Hz); 7.40 - 7.20 (m, 2H);
7.14 (d, 2H, J = 7 Hz); 7.00 - 6.80 (m, 2H); 6.80 - 6.70 (m, 1H); 3.80 (s, 3H).
Part B Preparation of N " -cvano-N'-(3-f4-(4-f luorobenzyl ) t~iperidinel propel-N- ( 3-methoxvphenyl )__quanidine r ...,..,.v u. .

N~ i NON N ~ O~
3-(4-(4-fluorophenylmethyl)piperidin-1-yl)propylamine, (synthesized in a similar fashion to the previously described des-fluoro compound) (53 mg, 0.20 mmol, 1 eq.) and the product from Part A (50 mg, 0.20 mmol, 1 eq.) were mixed and refluxed in 2-propanol under Nz for 1 hour. The reaction was stripped and the residue then purified over silica gel in 100 ~ ethyl acetate followed by 8:2 chloroform/methanol. Obtained 55 mg of off-white solids as product. NMR (300 MHz, CDC1,) b 7.33 (t, 1H, J = 7 Hz);
7.10 - 6.90 (m, 4H); 6.90 - 6.80 (m, 3H); 3.83 (s, 3H);
3.50 - 3.35 (m, 2H); 2.90 - 2.70 (m, 2H); 1.50 - 1.20 (m, 3H). Mass Spec detects 424 (M+H).
Example 334 Part A: Preparation of f(Methvlthio)(3-acetylphenvl amino)lmethylenepropanedinitrile N
~S N
O
(Bis(methylthio)methylene]propanedinitrile 3.00 g, 17.6 mmol, 1 eq.), and 3~amino-acetophenone (2.38 g, 17.6 mmol, 1 eq.), were mixed and refluxed under N2 in ethanol for 16 hours. Solids precipitated while cooling to 25 °C.
The solids were filtered. Obtained 1.86 g of tan solids.
M.P. - 165.0 - 166.5 °C. NMR (300 MHz, DMSO-ds) 8 10.66 (m, 1H); 7.90 - 7.80 (m, 2H); 7.60 - 7.50 (m, 2H); 2.60 (s, 3H); 2.54 (s, 3H).

Part B: Preparation of 2-((3-acetylanilino)({3-(4-(4-fluorobenzyl)-1-piperidinyl]propyl) amino)methylene]malononitrile N\ , N
~I
N N N
O
3-(4-(4-fluorophenylmethyl)piperidin-1-yl)propylamine, 49 mg, 0.194 mmol, 1 eq.) and the product from Part A (50 mg, 0.194 mmol, 1 eq.) were mixed then stirred under N2 overnight. The reaction was stripped and the residue purified over chloroform/methanol. Obtained 17 mg of a white amphorphous solid. NMR (300 MHz, CDC13) ~ 7.82 (d, 1H, J = 7 Hz); 7.73(s, 1H); 7.51 (t, 1H, J= 7 Hz); 7.34 (d, 1H, J = 7Hz); 7.10-6.80 (m, 4H); 3.28 (m, 2H); 2.62 (s, 3H); 2.64-2.40 (m,2H); 2.40-2.25 (m, 2H); 2.05-1.70 (m, 2H); 1.70-1.35 (m, 3H); 1.20-0.80 (m, 2H).
Mass Spec detects 460 (M+H).
Example 335 Part A: Preparation of N-(1-(methylthio)-2-nitroethenyl]-3-acetylbenzenamine H
/S N

A neat mixture of 1,1-bismethylthio-2-nitroethylene (6.5 g, 38.5 mmol, 10 eq) and 3-aminoacetophenone (0.5 g, 3.85 mmol, 1eq) was melted together and heated at 140° C for four hours. The mixture was cooled to room temperature, then subjected to flash chromatography, eluting with 50~

.,.._.~ ,., ' WO 00/35451 PCT/US99/30332 ethyl acetate/hexanes, to yield 0.63 g of a yellow powder as product. Yield = 65~. NMR (300 MHz, CDC1,) b 11.82 (bs, 1H), 7.95-7.91 (m, 2H), 7.59-7.48 (m, 2H), 6.73 (s, 1H), 2.65 (s, 3H), 2.41 (s, 3H).
Part B: Preparation of 1-(3-{[(E)-1-((-[4-(4-fluorobenzyl)-1-piperidinyl]propyl)amino)-2-nitroethylenyl]amino)phenyl)ethanone H H
F, / N N N
OZN
To a suspension of N-[1-(methylthio)-2-nitroethenyl]-3-acetylbenzenamine (0.30 g, 1.19 mmol, 1.00 eq) in 20 ml of methanol was added 3-(4-fluorobenzyl)piperidin-1-yl)propylamine (0.31 g, 1.25 mmol, 1.05 eq), and the mixture was stirred at room temperature. After three days, a colorless solution was observed. The solvent was removed in-vacuo, and the residue was subjected to flash chromatography, eluting with 10~ methanol/chloroform, to yield 0.38 g of an orange glass as product. Yield = 70~.
NMR (300 MHz, CDClj) b 10.51 (bs, 1H) , 7.92 (d, 1H, j - 8 Hz), 7.72 (bs, 1H), 7.54 (dd, 1H, j - 8 Hz, 8 Hz), 7.35 (bd, 1H), 6.90-6.88 (m, 5H), 6.17 (s, 1H), 3.54 (bs, 2H), 2.92-2.84 (m, 2H), 2.63 (s, 3H), 2.51 (m, 2H), 1.99-1.91 (m, 4H), 1.55-1.50 (m, 3H), 0.88-0.85 (m, 2H). MS (ESI) detects (M+H)' - 455.
The following compounds can be prepared by procedures described previously:
Table 3c Table 3c \ H H \
N~N~N~R F ~ ~ ""..~N~N
Z 3 z R3 F \ \ Z
~ ~w ~ N ~".~ vN
H H F I ~N~'N'R3 ,,N~N~ H H
Z R3 d F ~ i ",.-~N
H H
\ ',,,N Z N~R3 Core Z R3 Mass Spec M+1 332 a N-CN 3-methoxyphenyl 424 333 i a N-CN 3-acetylphenyl 460 334 I a C(CN)2 3-acetylphenyl 460 335 a CHN02 3-acetylphenyl 455 336 b N-CN 3-acetylphenyl 436 337 b ~ C(CN)23-acetylphenyl 460 338 b I NCONH23-acetylphenyl 454 339 I b CHN02 3-acetylphenyl 455 340 b N-CN 3,5-diacetylphenyl 478 341 b NCONH2 3,5-diacetylphenyl 496 342 b NC02CH3 3,5-diacetylphenyl 511 343 b C(CN)2 3,5-diacetylphenyl 344 b N-CN 3-(1-methyl-1H- 476 tetrazol-5-yl)phenyl 345 b ' C(CN)2 3-(1-methyl-1H- 500 tetrazol-5-yl)phenyl 346 b NCONH2 3-(1-methyl-1H- 494 tetrazol-5-yl)pheny7.

347 b ( N-CN 2,4-dimethoxy-phenyl 454 348 b N-CN 5-acetyl-2-methoxy- 466 phenyl 349 d I N-CN 3-(1-methyl-1H- 4gg tetrazol-5-yl)phenyl 350 c N-CN ~ phenyl 44~

351 c N-CN 3-acetylphenyl 490 352 c I N-CN 3-cyanopneyl 473 353 c N-CN 2,4-dimethoxyphenyl 508 354 c N-CN 2,5-dimethoxyphenyl 508 355 ' N-CN 5-acetyl-2-methoxy- 520 c phenyl 356 c N-CN 2,4-dimethylphenyl 476 357 ~ N-CN 4-(1-methyl-1H- 530 c tetrazol-5-yl)phenyl 358 c N-CN 4-(1-propyl-1H- 558 tetrazol-5-yl)phenyl 359 c N-CN 5,6,7,8-tetrahydro- 502 naphthy-2-yl-phenyl I

360 ~ c N-CN 4-(4-morpholinyl)- 533 phenyl 361 C N-CN 2,5-dimethylphenyl 362 c N-CN 4-hydroxy-2-methylphenyl 363 c N-CN 2-methylphenyl 364 ~ c N-CN 2-phenylethyl 365 c N-CN 1-adamantyl 366 c N-CN 2-adamantyl 367 c C(CN)2 3-acetylphenyl 514 368 c C(CN)2 5-acetyl-2-methoxy- 544 phenyl 369 c CHN02 3-acetylphenyl 509 370 a CHN02 3-acetylphenyl 560 I

371 a N-CN 3,5-diacetylphenyl 583 372 a N-CN 3-acetylphenyl 541 373 a N-CN 4-(1-propyl-1H- 581 tetrazol-5-yl)phenyl The following tables contain representative examples of the present invention, and may be prepared by procedures described above, or methods familiar to one skilled in the art. Each entry in each table is intended to be paired with each formulae at the start of the table. For example, Entry 1 in Table 4 is intended to be paired with each of formulae la-44.
TABLE 4*
G H H
G~N~. ~ R3 /~Nw/~. N N_ R G'~N~ ~ R3 N N ~ 3 N' _ N' H H p H H
la 2a 3a H H
N ~ R ~~~N~ N N. N
C~,~ ~/''N N z R3 ~ ~~N.R3 H H p H H
lb 2b 3b H H
G~Nw/''N~NR3 G~N~N~N_R3 G~N~N~N'R3 H H p H H

G/~N~ G~N ~N~
a H ~ H G a H
H~' Ia R3 ~ nI R3 HNY IS R3 8a 0O 9a ~ 10 O
G~,~N~ ~~,~N ~N
a H T H G ~ H
HNYN. R3 ~'N. R3 HNYIvL R3 8b O 9b O 11 O
1 H ~ H
HN O N; R3 HN~N,R3 12a 13a O ' H ~ H
~~~ R3 ~~~R

12b O 13b O
G~N~ ~N
H G ~ H
f Is R3 HNY N. R3 G
HN ~
R3 ~ R3 16a O 17a O
HN N- ~ IH~L
R3 ~ R3 16b O 17b N
G~ ~ H R~N

R3 ~ R3 G'~N~N~MR3 G/~N~~N~~R3 H H H H
20a 21a O
~~~ N~ N.R3 O~~n~, ~ R3 H H H H
20b 21b R~~~N~N_R2 R~~N~N.R2 G/~N~ N N. R 6;~~N.~ N N_ ~N H N N.
R3 G ~ Y R3 H OH
G/~N H N N_ C~N N N. ~N N N_ R3 ~ R3 G ~ Y R3 Me O Me 0 Me O

H ~ H
G~N H N N. N~N N_R3 G N~N~N.R3 ~- Y R3 Y
iPrO iPrO iPrO

G~~ H H H C~~ H H H ~ H H H
N~N~N.R3 N~N~N.R3 G N~N N_R3 iBuO iBuO iB 0 G~ H H H C n H H H Q
N~N~N_R3 ;~ ,N~N~N_R3 H H H R
G N~N~N.
Ph O Ph 0 36 37 Ph O

OH H N. G~~ H H N, ~N H H N.
R3 ~ R3 G ~ R3 Ph 0 Ph 0 Ph 0 H ~ ~~,~ H H N. ~N H H N.
R3 ~ R3 G ~ R3 Ph O ph O p O

Entry G ~ R3 1 4-F-Ph Ph 2 4-F-Ph 3-CN-Ph 3 4-F-Ph 3-COCH3-Ph 4 4-F-Ph 3-C02Me-Ph 4-F-Ph 3-C02Et-Ph 6 4-F-Ph 3-C02H-Ph 7 4-F-Ph 3-CONH2-Ph 8 4-F-Ph 3-CONHMe-Ph 9 4-F-Ph 3-F-Ph 4-F-Ph 3-C1-Ph 11 4-F-Ph 3-Br-Ph 12 4-F-Ph 3-N02-Ph 13 4-F-Ph 3-NH2-Ph 14 4-F-Ph 3-NI3Me-Ph 4-F-Ph 3-NMe2-Ph 16 4-F-Ph 3-NHCOCH3-Ph 17 4-F-Ph 3-S02NH2-Ph 18 4-F-Ph 3-S02NHMe-Ph 19 4-F-Ph 3-CF3-Ph 4-F-Ph 3-OCH3-Ph 21 4-F-Ph 3-OPh-Ph 22 4-F-Ph 3-OCF3-Ph 23 4-F-Ph 3-SCH3-Ph 24 4-F-Ph 3-SOCH3-Ph 4-F-Ph 3-S02CH3-Ph i ,. .. w.w~...,...... ..

26 4-F-Ph 3-OH-Ph 2~ 4-F-Ph 3-CH20H-Ph 2 8 4 -F- Ph 3 -CHOHCH3 -Ph 29 4-F-Ph 3-COH(CH3)2-Ph 30 4-F-Ph 3-CHOHPh-Ph 31 4-F-Ph 3-CH3-Ph 32 4-F- Ph 3-C2H5-Ph 33 4-F-Ph 3-iPr-Ph 34 4-F-Ph 3-tBu-Ph 35 4-F-Ph 3-Ph-Ph 36 4-F-Ph 3-CH2Ph-Ph 3~ 4-F-Ph 3-CH2C02Me-Ph 38 4-F-Ph 3-(1- i eridin 1)-ph 39 4-F-Ph 3-(1- rrolidin 1)-Ph 40 4-F-Ph 3-(2-imidazolyl)-Ph 41 4-F-Ph 3-(1-imidazol 1)-Ph 42 4-F-Ph 3-(2-thiazol 1)-Ph 43 4-F-Ph 3-(3- razol 1)-Ph 44 4-F-Ph 3-(1- razolyl)-Ph 45 4-F-Ph 3-(1-tetrazol 1)-Ph 46 4-F-Ph 3-(5-tetrazol 1)-Ph 4~ 4-F-Ph 3-(2- yrid 1)-Ph 4g 4-F-Ph 3-(2-thienyl)-Ph 49 4-F-Ph 3-(2-furan 1)-Ph 50 4-F-Ph 4-CN-Ph 51 4-F-Ph 4-COCH3-Ph 52 4-F-Ph 4-C02Me-Ph 53 4-F-Ph 4-C02Et-Ph 54 4-F-Ph 4-C02H-Ph 55 4-F-Ph 4-CONH2-Ph 56 4-F-Ph 4-CONHMe-Ph 5~ 4-F-Ph 4-CONHPh-Ph 58 4-F-Ph 4-NHCONH2-Ph 59 4-F-Ph 4-F-Ph 60 4-F-Ph 4-C1-Ph 61 4-F-Ph 4-Br-Ph 62 4-F-Ph 4-N02-Ph 63 4-F-Ph 4-NH2-Ph 64 4-F-Ph 4-NHMe-Ph 65 4-F-Ph 4-NMe2-Ph 66 4-F-Ph 4-NHCOCH3-Ph 4-F-Ph 4-S02NH2-Ph 68 4-F-Ph 4-S02NHMe-Ph 69 4-F-Ph 4-CF3-Ph ~0 4-F-Ph 4-OCH3-Ph 4-F-Ph 4-OPh-Ph ~2 4-F-Ph 4-OCF3-Ph ~3 4-F-Ph 4-SCH3-Ph ~4 4-F-Ph 4-SOCH3-Ph ~5 4-F-Ph 4-S02CH3-Ph 4-F-Ph 4-OH-Ph 4-F-ph 4-CH20H-Ph ~8 4-F-Ph 4-CHOHCH3-Ph 79 4-F-Ph 4-COH(CH3)2-Ph 80 4-F-Ph 4-CH3-Ph 81 4-F-Ph 4-C2H5-Ph 82 4-F-Ph 4-iPr-Ph 83 4-F-Ph 4-tBu-Ph 84 4-F-Ph 4-Ph-Ph 85 4-F-Ph 4-CH2Ph-Ph 86 4-F-Ph 4-CH2C02Me-Ph 87 4-F-Ph 4-(1- i eridinyl)-Ph 88 4-F-Ph 4-(1-pyrrolidin 1)-Ph 89 4-F-Ph 4-(2-imidazolyl)-Ph 90 4-F-Ph 4-(1-imidazol 1)-Ph 91 4-F-Ph 4-(2-thiazol 1)-Ph 92 4-F-Ph 4-(3- razolyl)-Ph 93 4-F-Ph 4-(1-pyrazolyl)-Ph 94 4-F-Ph 4-(1-tetrazol 1)-Ph 95 4-F-Ph 4-(5-tetrazolyl)-Ph 96 4-F-Ph 4-(2-p rid 1)-Ph 97 4-F-Ph 4-(2-thienyl)-Ph 98 4-F-Ph 4-(2-furanyl)-Ph 99 4-F-Ph 2-CN-Ph 100 4-F-Ph 2-COCH3-Ph 101 4-F-Ph 2-C02Me-Ph 102 4-F-Ph 2-C02Et-Ph 103 4-F-Ph 2-C02H-Ph 104 4-F-Ph 2-CONH2-Ph 105 4-F-Ph 2-CONHMe-Ph 106 4-F-Ph 2-F-Ph 107 4-F-Ph 2-Cl-Ph 108 4-F-Ph 2-Br-Ph 109 4-F-Ph 2-N02-Ph 110 4-F-Ph 2-NH2-Ph 111 4-F-Ph 2-NHMe-Ph 112 4-F-Ph 2-NMe2-Ph I13 4-F-Ph 2-NHCOCH3-Ph 114 4-F-Ph 2-S02NH2-Ph 115 4-F-Ph 2-S02NHMe-Ph 116 4-F-Ph 2-CF3-Ph 117 4-F-Ph 2-OCH3-Ph 118 4-F-Ph 2-OPh-Ph 119 4-F-Ph 2-OCF3-Ph 120 4-F-Ph 2-SCH3-Ph 121 4-F-Ph 2-SOCH3-Ph 122 4-F-Ph 2-S02CH3-Ph 123 4-F-Ph 2-OH-Ph 124 4-F-Ph 2-CH20H-Ph 125 4-F-Ph 2-CHOHCH3-Ph 126 4-F-Ph 2-COH(CH3)2-Ph 127 4-F-Ph 2-CHOHPh-Ph 128 4-F-Ph 2-CH3-Ph 129 4-F-Ph 2-C2H5-Ph 130 4-F-Ph 2-iPr-Ph . 131 4-F-Ph 2-tBu-Ph ._ 132 4-F-Ph 2-Ph-Ph 133 4-F-P_h 2-CH2Ph-Ph 134 4-F-Ph __ 2-CH2C02Me-Ph 135 4-F-Ph 2- (1- it~eridin 1 ) -Ph 136 4-F-Ph 2-(1- rrolidin 1)-Ph 137 4-F-Ph 2-(2-imidazolyl)-Ph 138 4-F~Ph 2-(1-imidazolyl)-Ph 139 4-F-Ph 2-(2-thiazol 1)-Ph 140 4-F-Ph 2-(3- razol 1)-Ph 141 4-F-Ph 2-(1- razol 1)-Ph 142 4-F-Ph 2-(1-tetrazolyl)-Ph 143 4-F-Ph 2-(5-tetrazol 1)-Ph 144 4-F-Ph 2-(2- rid 1)-Ph 145 4-F-Ph 2-(2-thien 1)-Ph 146 4-F-Ph 2- (2-furan 1) -Ph 147 4-F-Ph 2,4-diF-Ph 148 4-F-Ph 2,5-diF-Ph 149 4-F-Ph 2,6-diF-Ph 150 4-F-Ph 3,4-diF-Ph 151 4-F-Ph 3,5-diF-Ph 152 4-F-Ph 2,4-diCl-Ph 153 4-F-Ph 2,5-diCl-Ph 154 4-F-Ph 2,6-diCl-Ph 155 4-F-Ph 3,4-diCl-Ph 156 4-F-Ph 3,5-diCl-Ph 157 4-F-Ph 3,4-diCF3-Ph 158 4-F-Ph 3,5-diCF3-Ph 159 4-F-Ph 5-C1-2-Me0-Ph 160 4-F-Ph 5-C1-2-Me-Ph 161 4-F-Ph 2-F-5-Me-Ph 162 4-F-Ph 2-F-5-N02-Ph 163 4-F-Ph 3,4-OCH20-Ph 164 4-F-Ph 3,4-OCH2CH20-Ph 165 4-F-Ph 2-Me0-4-Me-Ph 166 4-F-Ph 2-Me0-5-Me-Ph 167 4-F-Ph 1-na hth 1 168 4-F-Ph 2-na hth 1 169 4-F-Ph 2-thienyl 170 4-F-Ph 3-thien 1 171 4-F-Ph 2-furan 1 172 4-F-Ph 3-furan 1 173 4-F-Ph 2- rid 1 174 4-F-Ph 3- rid 1 175 4-F-Ph 4- yrid 1 176 4-F-Ph 2-indol 1 177 4-F-Ph 3-indol 1 178 4-F-Ph 5-indolyl 179 4-F-Ph 6-indol 1 180 4-F-Ph 3-indazol 1 181 4-F-Ph 5-indazol 1 182 4-F-Ph 6-indazol 1 183 4-F-Ph 2-imidazol 1 184 ~ 4-F-Ph 3 pyrazolyl 185 4-F-Ph 2-thiazol 1 186 4-F-Ph 5-tetrazolyl 187 4-F-Ph 2-benzimidazolyl 188 4-F-Ph 5-benzimidazolyl 189 4-F-Ph 2-benzothiazol 1 190 4-F-Ph 5-benzothiazolyl 191 4-F-Ph 2-benzoxazol 1 192 4-F-Ph 5-benzoxazol 1 193 4-F-Ph 1-adamantyl 194 4-F-Ph 2-adamantyl 195 4-F-Ph t-Bu 196 2-F-Ph 3-CN-Ph 197 2-F-Ph 3-COCH3-Ph 198 2-F-Ph 3-C02Me-Ph 199 2-F-Ph 3-C02Et-Ph 200 2-F-Ph 3-C02H-Ph 201 2-F-Ph 3-CONH2-Ph 202 2-F-Ph 3-F-Ph 203 2-F-Ph 3-C1-Ph 204 2-F-Ph 3-NH2-Ph 205 2-F-Ph 3-S02NH2-Ph 206 2-F-Ph 3-CF3-Ph 207 2-F-Ph 3-OCH3-Ph 208 2-F-Ph 3-OEt-Ph 209 2-F-Ph 3-OCF3-Ph 210 2-F-Ph 3-S02CH3-Ph 211 2-F-Ph 3-OH-Ph 212 2-F-Ph 3-CH3-Ph 213 2-F-Ph 3-C2H5-Ph 214 2-F-Ph 4-CN-Ph 215 2-F-Ph 4-COCH3-Ph 216 2-F-Ph 4-C02Me-Ph 217 2-F-Ph 4-C02Et-Ph 218 2-F-Ph 4-C02H-Ph 219 2-F-Ph 4-CONH2-Ph 220 2-F-Ph 4-F-Ph 221 2-F-Ph 4-C1-Ph 222 2-F-Ph 4-NH2-Ph 223 2-F-Ph 4-S02NH2-Ph 224 2-F-Ph 4-CF3-Ph 225 2-F-Ph 4-OCH3-Ph 226 2-F-Ph 4-OEt-Ph 227 2-F-Ph 4-OCF3-Ph 228 - 2-F-Ph 4-S02CH3-Ph 229 2-F-Ph 4-OH-Ph 230 2-F-Ph 4-CH3-Ph 231 2-F-Ph 4-C2H5-Ph 232 2-F-Ph 2,4-diF-Ph 233 2-F-Ph 2,5-diF-Ph 234 2-F-Ph 3,4-diF-Ph 235 2-F-Ph 3,5-diF-Ph 236 2-F-Ph 2,4-diCl-Ph 237 2-F-Ph 2,5-diCl-Ph . .. , ."..

238 2-F-Ph 3,4-diCl-Ph 239 2-F-P_h 3,5-diCl-Ph 240 2-F-Ph 3,4-OCH20-Ph 241 2-F-Ph 3,4-OCH2CH20-Ph 242 2-F-Ph 2-thien 1 _243 2-F-Ph 2-furan 1 244 2-F--Ph 2-p rid 1 245 2-F-Ph 4- id 1 246 2-F-Ph 2-imidazolyl 247 2-F-Ph 3- razol 1 248 2-F-Ph 2-thiazolyl 249 2-F-Ph 5-tetrazol 1 250 2-F-Ph 1-adamant 1 251 2,4-diF-Ph 3-CN-Ph 252 2,4-diF-Ph 3-COCH3-Ph 253 2,4-diF-Ph 3-C02Me-Ph 254 2,4-diF-Ph 3-C02Et-Ph 255 2,4-diF-Ph 3-C02H-Ph 256 2,4-diF-Ph 3-CONH2-Ph 257 2,4-diF-Ph 3-F-Ph 258 2,4-diF-Ph 3-C1-Ph 259 2,4-diF-Ph 3-NH2-Ph 260 2,4-diF-Ph 3-S02NH2-Ph 261 2,4-diF-Ph 3-CF3-Ph 262 2,4-diF-Ph 3-OCH3-Ph 263 2,4-diF-Ph 3-OEt-Ph 264 2,4-diF-Ph 3-OCF3-Ph 265 2,4-diF-Ph 3-S02CH3-Ph 266 2,4-diF-Ph 3-OH-Ph 267 2,4-diF-Ph 3-CH3-Ph 268 2,4-diF-Ph 3-C2H5-Ph 269 2,4-diF-Ph 4-CN-Ph 270 2,4-diF-Ph 4-COCH3-Ph 271 2,4-diF-Ph 4-C02Me-Ph 272 2,4-diF-Ph 4-C02Et-Ph 273 2,4-diF-Ph 4-C02H-Ph 274 2,4-diF-Ph 4-CONH2-Ph 275 2,4-diF-Ph 4-F-Ph 276 2,4-diF-Ph 4-C1-Ph 277 2,4-diF-Ph 4-NH2-Ph 278 2,4-diF-Ph 4-S02NH2-Ph 279 2,4-diF-Ph 4-CF3-Ph 280 2,4-diF-Ph 4-OCH3-Ph 281 2,4-diF-Ph 4-OEt-Ph 282 2,4-diF-Ph 4-OCF3-Ph 283 2,4-diF-Ph 4-S02CH3-Ph 284 2,4-diF-Ph 4-OH-Ph 285 2,4-diF-Ph 4-CH3-Ph 286 2,4-diF-Ph 4-C2H5-Ph 287 2,4-diF-Ph 2,4-diF-Ph 288 2,4-diF-Ph 2,5-diF-Ph 289 2,4-diF-Ph 3,4-diF-Ph 290 2,4-diF-Ph 3,5-diF-Ph 291 2,4-diF-Ph 2,4-diCl-Ph 292 2,4-diF-Ph 2,5-diCl-Ph 293 2,4-diF-Ph 3,4-diCl-Ph 294 2,4-diF-Ph 3,5-diCl-Ph 295 2,4-diF-Ph 3,4-OCH20-Ph 296 2,4-diF-Ph 3,4-OCH2CH20-Ph 297 2,4-d,iF-Ph 2-thienyl 298 2,4-diF-Ph 2-furan 1 299 2,4-diF-Ph 2-p rid 1 300 2,4-diF-Ph 4- rid 1 301 2,4-diF-Ph 2-imidazolyl 302 2,4-diF-Ph 3- razol 1 303 2,4-diF-Ph 2-thiazolyl 304 2,4-diF-Ph 5-tetrazol 1 305 2,4-diF-Ph 1-adamantyl 306 4-C1-Ph Ph 307 4-C1-Ph 3-CN-Ph 308 4-C1-Ph 3-COCH3-Ph 309 4-C1-Ph 3-C02Me-Ph 310 4-Cl-Ph 3-C02Et-Ph 311 4-C1-Ph 3-C02H-Ph 312 4-Cl-Ph 3-CONH2-Ph 313 4-C1-Ph 3-CONHMe-Ph 314 4-C1-Ph 3-F-Ph 315 4-C1-Ph 3-C1-Ph 316 4-C1-Ph 3-Br-Ph 317 4-C1-Ph 3-N02-Ph 318 4-Cl-Ph 3-NH2-Ph 319 4-C1-Ph 3-NHMe-Ph 320 4-C1-Ph 3-NMe2-Ph 321 4-C1-Ph 3-NHCOCH3-Ph 322 4-Cl-Ph 3-S02NH2-Ph 323 4-C1-Ph 3-S02NHMe-Ph 324 4-C1-Ph 3-CF3-Ph 325 4-Cl-Ph 3-OCH3-Ph 326 4-Cl-Ph 3-OPh-Ph 327 4-Cl-Ph 3-OCF3-Ph 328 4-C1-Ph 3-SCH3-Ph 329 4-Cl-Ph 3-SOCH3-Ph 330 4-C1-Ph 3-S02CH3-Ph 331 4-Cl-Ph 3-OH-Ph 332 4-C1-Ph 3-CH20H-Ph 333 4-C1-Ph 3-CHOHCH3-Ph 334 4-C1-Ph 3-COH(CH3)2-Ph 335 4-C1-Ph 3-CHOHPh-Ph 336 4-C1-Ph 3-CH3-Ph 337 4-C1-Ph 3-C2H5-Ph 338 4-C1-Ph 3-iPr-Ph 339 4-C1-Ph 3-tBu-Ph 340 4-Cl-Ph 3-Ph-Ph 342 4-Cl-Ph 3-CH2Ph-Ph 342 4-C1-Ph 3-CH2C02Me-Ph 343 4-Cl-Ph 3-(1-piperidinyl)-Ph WO 00/35451 PCTlUS99/30332 344 ~ 4-C1-Ph 3-(1-pyrrolidinyl)-Ph 345 4-C1-Ph 3-(2-imidazolyl)-Ph 346 _ 3-(1-imidazol 1)-Ph 4-C1-Ph 347 4-C1-Ph 3-(2-thiazol 1)-Ph 348 4-C1-Ph 3-(3- razolyl)-Ph 349 4-C1-Ph 3-(1-pyrazol 1)-Ph 350 4-Cl--Ph _ 3-(1-tetrazol 1)-Ph 351 4-C1-Ph 3-(5-tetrazolyl)-Ph 352 4-C1-Ph 3-(2- rid 1)-Ph 353 4-C1-Ph 3-(2-thienyl)-Ph 354 4-C1-Ph 3-(2-furan 1)-Ph 355 4-C1-Ph 4-CN-Ph 356 4-C1-Ph 4-COCH3-Ph 357 4-C1-Ph 4-C02Me-Ph 358 4-C1-Ph 4-C02Et-Ph 359 4-C1-Ph 4-C02H-Ph 360 4-C1-Ph 4-CONH2-Ph 361 4-C1-Ph 4-CONHMe-Ph 362 4-C1-Ph 4-CONHPh-Ph 363 4-C1-Ph 4-NHCONH2-Ph 364 4-C1-Ph 4-F-Ph 365 4-C1-Ph 4-C1-Ph 366 4-C1-Ph 4-Br-Ph 367 4-C1-Ph 4-N02-Ph 368 4-C1-Ph 4-NH2-Ph 369 4-C1-Ph 4-NHMe-Ph 370 4-C1-Ph 4-NMe2-Ph 371 4-C1-Ph 4-NHCOCH3-Ph 372 4-Cl-Ph 4-S02NH2-Ph 373 4-C1-Ph 4-S02NHMe-Ph 374 4-C1-Ph 4-CF3-Ph 375 4-C1-Ph 4-OCH3-Ph 376 4-Cl-Ph 4-OPh-Ph 377 4-C1-Ph 4-OCF3-Ph 378 4-C1-Ph 4-SCH3-Ph 379 4-C1-Ph 4-SOCH3-Ph 380 4-C1-Ph 4-S02CH3-Ph 381 4-C1-Ph 4-OH-Ph 382 4-C1-Ph 4-CH20H-Ph 383 4-C1-Ph 4-CHOHCH3-Ph 384 4-C1-Ph 4-COH(CH3)2-Ph 385 4-C1-Ph H3-Ph 386 4-C1-Ph _ 4-C2H5-Ph 387 4-C1-Ph 4-iPr-Ph 388 4-C1-Ph 4-tBu-Ph 389 4-C1-Ph 4-Ph-Ph 390 4-C1-Ph _ 4-CH2Ph-Ph 391 4-C1-Ph 4-CH2C02Me-Ph 392 4-C1-Ph 4-(1- i eridin 1)-Ph 393 4-C1-Ph 4-(1- rrolidin 1)-Ph 394 4-C1-Ph 4-(2-imidazol 1)-Ph 395 4-C1-Ph 4-(1-imidazol 1)-Ph 396 4-C1-Ph 4-(2-thiazolyl)-Ph 397 4-Cl-Ph 4-(3- razol 1)-Ph 398 4-Cl-Ph 4-(1-pyrazol 1)-Ph 399 4-Cl-Ph 4-(1-tetrazolyl)-Ph 400 4-C1-Ph 4-(5-tetrazol 1)-Ph 401 4-C1-Ph 4-(2- rid 1)-Ph 402 4-C1-Ph 4-(2-thien 1)-Ph 403 4-Cl-Ph 4-(2-furanyl)-Ph 404 4-Cl-Ph 2-CN-Ph 405 4-C1-Ph 2-COCH3-Ph 406 4-C1-Ph 2-C02Me-Ph 407 4-Cl-Ph 2-C02Et-Ph 408 4-Cl-Ph 2-C02H-Ph 409 4-C1-Ph 2-CONH2-Ph 410 4-Cl-Ph 2-CONHMe-Ph 411 4-Cl-Ph 2-F-Ph 412 4-C1-Ph 2-C1-Ph 413 4-C1-Ph 2-Br-Ph 414 4-Cl-Ph 2-N02-Ph 415 4-C1-Ph 2-NH2-Ph 416 4-Cl-Ph 2-NHMe-Ph 417 4-Cl-Ph 2-NMe2-Ph 418 4-C1-Ph 2-NHCOCH3-Ph 419 4-C1-Ph 2-S02NH2-Ph 420 4-C1-Ph 2-S02NHMe-Ph 421 4-C1-Ph 2-CF3-Ph 422 4-Cl-Ph 2-OCH3-Ph 423 4-Cl-Ph 2-OPh-Ph 424 4-C1-Ph 2-OCF3-Ph 425 4-C1-Ph 2-SCH3-Ph 426 4-Cl-Ph 2-SOCH3-Ph 427 4-C1-Ph 2-S02CH3-Ph 428 4-C1-Ph 2-OH-Ph 429 4-C1-Ph 2-CH20H-Ph 430 4-C1-Ph 2-CHOHCH3-Ph 431 4-C1-Ph 2-COH(CH3)2-Ph 432 4-C1-Ph 2-CHOHPh-Ph 433 4-C1-Ph 2-CH3-Ph 434 4-Cl-Ph 2-C2H5-Ph 435 4-C1-Ph 2-iPr-Ph 436 4-C1-Ph 2-tBu-Ph 437 4-C1-Ph 2-Ph-Ph 438 4-C1-Ph 2-CH2Ph-Ph 439 4-Cl-Ph 2-CH2C02Me-Ph 440 4-C1-Ph 2-(1- i eridin 1)-Ph 441 4-C1-Ph 2-(1- rrolidin 1)-Ph 442 4-C1-Ph 2-(2-imidazol 1)-Ph 443 4-C1-Ph 2-(1-imidazol 1)-Ph 444 4-C1-Ph 2-(2-thiazolyl)-Ph 445 4-C1-Ph 2-(3- yrazol 1)-Ph 446 4-C1-Ph 2-(1- razol 1)-Ph 447 4-C1-Ph 2-(1-tetrazolyl)-Ph 448 4-C1-Ph 2-(5-tetrazol 1)-Ph 449 4-C1-Ph 2-(2-pyridyl)-Ph . ~~.., 450 _ 4-C1-Ph_ 2-(2-thienyl)-Ph 451 4-C1-Ph 2-(2-furan 1)-Ph 452 4-Cl-Ph 2,4-diF-Ph 453 4-C1-Ph 2,5-diF-Ph 454 4-C1-Ph 2,6-diF-Ph 455 4-Cl-Ph 3,4-diF-Ph 456 4-Ci-Ph 3,5-diF-Ph 45? 4-C1-Ph 2,4-diCl-Ph 458 4-C1-Ph 2,5-diCl-Ph 459 4-C1-Ph 2,6-diCl-Ph 460 4-C1-Ph 3,4-diCl-Ph 461 4-C1-Ph 3,5-diCl-Ph 462 4-C1-Ph 3,4-diCF3-Ph 463 4-C1-Ph 3,5-diCF3-Ph 464 4-C1-Ph 5-C1-2-Me0-Ph 465 4-C1-Ph 5-C1-2-Me-Ph 466 4-C1-Ph 2-F-5-Me-Ph 467 4-C1-Ph 2-F-5-N02-Ph 468 4-C1-Ph 3,4-OCH20-Ph 469 4-C1-Ph 3,4-OCH2CH20-Ph 470 4-C1-Ph 2-Me0-4-Me-Ph 471 4-C1-Ph 2-Me0-5-Me-Ph 472 4-C1-Ph 1-naphth 1 473 4-C1-Ph 2-na hth 1 474 4-C1-Ph 2-thien 1 475 4-Cl-Ph 3-thien 1 476 4-Cl-Ph 2-furan 1 477 4-Cl-Ph 3-furanyl 478 4-C1-Ph 2- rid I

479 4-C1-Ph 3- rid 1 480 4-C1-Ph 4- rid 1 481 4-C1-Ph 2-indol 1 482 4-CI-Ph 3-indol 1 483 4-C1-Ph 5-indolyl 484 4-C1-Ph 6-indol 1 485 4-C1-Ph 3-indazol 1 486 4-C1-Ph 5-indazol 1 487 4-C1-Ph 6-indazol 1 488 4-C1-Ph 2-imidazol 1 489 4-C1-Ph 3- razol 1 490 4-C1-Ph 2-thiazol 1 491 4-C1-Ph 5-tetrazol 1 492 4-C1-Ph 2-benzimidazol 1 493 4-C1-Ph 5-benzimidazol 1 494 4-C1-Ph 2-benzothiazol 1 495 4-C1-Ph 5-benzothiazol 1 496 4-C1-Ph 2-benzoxazol 1 497 4-C1-Ph 5-benzoxazol 1 498 4-C1-Ph 1-adamant 1 499 4-C1-Ph 2-adamantyl 500 4-C1-Ph t-Bu 501 2-C1-Ph 3-CN-Ph 502 I 2-C1-Ph 3 COCH3 Ph 503 2-C1-Ph 3-C02Me-Ph 504 2-C1-Ph 3-C02Et-Ph 505 2-C1-Ph 3-C02H-Ph 506 2-C1-Ph 3-CONH2-Ph 507 2-Cl-Ph 3-F-Ph 508 2-C1-Ph 3-C1-Ph 509 2-C1--Ph 3-NH2-Ph 510 2-C1-Ph 3-S02NH2-Ph 511 2-C1-Ph 3-CF3-Ph 512 2-Cl-Ph 3-OCH3-Ph 513 2-C1-Ph 3-OEt-Ph 514 2-C1-Ph 3-OCF3-Ph 515 2-C1-Ph 3-S02CH3-Ph 516 2-C1-Ph 3-OH-Ph 517 2-C1-Ph 3-CH3-Ph 518 2-C1-Ph 3-C2H5-Ph 519 2-Cl-Ph 4-CN-Ph 520 2-C1-Ph 4-COCH3-Ph 521 2-Cl-Ph 4-C02Me-Ph 522 2-C1-Ph 4-C02Et-Ph 523 2-C1-Ph 4-C02H-Ph 524 2-C1-Ph 4-CONH2-Ph 525 2-C1-Ph 4-F-Ph 526 2-C1-Ph 4-C1-Ph 527 2-C1-Ph 4-NH2-Ph 528 2-C1-Ph 4-S02NH2-Ph 529 2-C1-Ph 4-CF3-Ph 530 2-Cl-Ph 4-OCH3-Ph 531 2-Cl-Ph 4-OEt-Ph 532 2-C1-Ph 4-OCF3-Ph 533 2-C1-Ph 4-S02CH3-Ph 534 2-C1-Ph 4-OH-Ph 535 2-C1-Ph 4-CH3-Ph 536 2-C1-Ph 4-C2H5-Ph 537 2-Cl-Ph 2,4-diF-Ph 538 2-C1-Ph 2,5-diF-Ph 539 2-C1-Ph 3,4-diF-Ph 540 2-C1-Ph 3,5-diF-Ph 541 2-Cl-Ph 2,4-diCl-Ph 542 2-C1-Ph 2,5-diCl-Ph 543 2-Cl-Ph 3,4-diCl-Ph 544 2-C1-Ph 3 , 5-diCl-Ph 545 2-C1-Ph 3,4-OCH20-Ph 546 2-C1-Ph 3,4-OCH2CH20-Ph 547 2-C1-Ph 2-thien 1 548 2-C1-Ph 2-furan 1 549 2-Cl-Ph 2- yridyl 550 2-C1-Ph 4- yridyl 551 2-C1-Ph 2-imidazol 1 552 2-C1-Ph 3- razol 1 553 2-C1-Ph 2-thiazolyl 554 2-C1-Ph 5-tetrazolyl 555 2-C1-Ph 1-adamantyl 556 2,4-diCl-Ph 3-CN-Ph 557 2,4-diCl-Ph 3-COCH3-Ph 558 2,4-diCl-Ph 3-C02Me-Ph 559 2,4-diCl-Ph 3-C02Et-Ph 560 2,4-diCl-Ph 3-C02H-Ph 561 2,4-diCl-Ph 3-CONH2-Ph 562 2,4-diCl-Ph 3-F-Ph 563 2,4-diCl-Ph 3-C1-Ph 564 2,4-diCl-Ph 3-NH2-Ph 565 2,4-diCl-Ph 3-S02NH2-Ph 566 2,4-diCl-Ph 3-CF3-Ph 567 2,4-diCl-Ph 3-OCH3-Ph 568 2,4-diCl-Ph 3-OEt-Ph 569 2,4-diCl-Ph 3-OCF3-Ph 570 2,4-diCl-Ph 3-S02CH3-Ph 571 2,4-diCl-Ph 3-OH-Ph 572 2,4-diCl-Ph 3-CH3-Ph 573 2,4-diCl-Ph 3-C2H5-Ph 574 2,4-diCl-Ph 4-CN-Ph 575 2,4-diCl-Ph 4-COCH3-Ph 576 2,4-diCl-Ph 4-C02Me-Ph 577 2,4-diCl-Ph 4-C02Et-Ph 578 2,4-diCl-Ph 4-C02H-Ph 579 2,4-diCl-Ph 4-CONH2-Ph 580 2,4-diCl-Ph 4-F-Ph 581 2,4-diCl-Ph 4-C1-Ph 582 2,4-diCl-Ph 4-NH2-Ph 583 2,4-diCl-Ph 4-S02NH2-Ph 584 2,4-diCl-Ph 4-CF3-Ph 585 2,4-diCl-Ph 4-OCH3-Ph 586 2,4-diCl-Ph 4-OEt-Ph 587 2,4-diCl-Ph 4-OCF3-Ph 588 2,4-diCl-Ph 4-S02CH3-Ph 589 2,4-diCl-Ph 4-OH-Ph 590 2,4-diCl-Ph 4-CH3-Ph 591 2,4-diCl-Ph 4-C2H5-Ph 592 2,4-diCl-Ph 2,4-diF-Ph 593 2,4-diCl-Ph 2,5-diF-Ph 594 2,4-diCl-Ph 3,4-diF-Ph 595 2,4-diCl-Ph 3,5-diF-Ph 596 2,4-diCl-Ph 2,4-diCl-Ph 597 2,4-diCl-Ph 2,5-diCl-Ph 598 2,4-diCl-Ph 3,4-diCl-Ph 599 2,4-diCl-Ph 3,5-diCl-Ph 600 2,4-diCl-Ph 3,4-OCH20-Ph 601 2,4-diCl-Ph 3,4-OCH2CH20-Ph 602 2,4-diCl-Ph 2-thien 1 603 2,4-diCl-Ph 2-furan 1 604 2,4-diCl-Ph 2- rid 1 605 2,4-diCl-Ph 4- rid 1 606 2,4-diCl-Ph 2-imidazolyl 607 2,4-diCl-Ph 3- razol 1 608 2,4-diCl-Ph 2-thiazol 1 241.

609 2,4-diCl-Ph 5-tetrazolyl 610 2,4-diCl-Ph 1-adamantyl 611 3-OCH3-Ph 3-CN-Ph 612 3-OCH3-Ph 3-COCH3-Ph 613 3-OCH3-Ph 3-C02Me-Ph 614 3-OCH3-Ph 3-C02Et-Ph 615 3-OCH3-Ph 3-C02H-Ph 616 3-OCH3-Ph 3-CONH2-Ph 617 3-OCH3-Ph 3-F-Ph 618 3-OCH3-Ph 3-C1-Ph 619 3-OCH3-Ph 3-NH2-Ph 620 3-OCH3-Ph 3-S02NH2-Ph 621 3-OCH3-Ph 3-CF3-Ph 622 3-OCH3-Ph 3-OCH3-Ph 623 3-OCH3-Ph 3-OEt-Ph 624 3-OCH3-Ph 3-OCF3-Ph 625 3-OCH3-Ph 3-S02CH3-Ph 626 3-OCH3-Ph 3-OH-Ph 627 3-OCH3-Ph 3-CH3-Ph 628 3-OCH3-Ph 3-C2H5-Ph 629 3-OCH3-Ph 4-CN-Ph 630 3-OCH3-Ph 4-COCH3-Ph 631 3-OCH3-Ph 4-C02Me-Ph 632 3-OCH3-Ph 4-C02Et-Ph 633 3-OCH3-Ph 4-C02H-Ph 634 3-OCH3-Ph 4-CONH2-Ph 635 3-OCH3-Ph 4-F-Ph 636 3-OCH3-Ph 4-C1-Ph 637 3-OCH3-Ph 4-NH2-Ph 638 3-OCH3-Ph 4-S02NH2-Ph 639 3-OCH3-Ph 4-CF3-Ph 640 3-OCH3-Ph 4-OCH3-Ph 641 3-OCH3-Ph 4-OEt-Ph 642 3-OCH3-Ph 4-OCF3-Ph 643 3-OCH3-Ph 4-S02CH3-Ph 644 3-OCH3-Ph 4-OH-Ph 645 3-OCH3-Ph 4-CH3-Ph 646 3-OCH3-Ph 4-C2H5-Ph 647 3-OCH3-Ph 2,4-diF-Ph 648 3-OCH3-Ph 2,5-diF-Ph 649 3-OCH3-Ph 3,4-diF-Ph 650 3-OCH3-Ph 3,5-diF-Ph 651 3-OCH3-Ph 2,4-diCl-Ph 652 3-OCH3-Ph 2,5-diCl-Ph 653 3-OCH3-Ph 3,4-diCl-Ph 654 3-OCH3-Ph 3,5-diCl-Ph 655 3-OCH3-Ph 3,4-OCH20-Ph 656 3-OCH3-Ph 3,4-OCH2CH20-Ph 657 3-OCH3-Ph 2-thien 1 658 3-OCH3-Ph 2-furanyl 659 3-OCH3-Ph 2-pyridyl 660 3-OCH3-ph 4- rid 1 661 3-OCH3-ph 2-imidazolyl 662 3_-OCH3-Ph 3- razol 1 663 3-OCH3-Ph 2-thiazol 1 664 3-OCH3-Ph 5-t.etrazolyl 665 3-OCH3-Ph 1-adamant 1 666 2-thien 1 3-CN-Ph 667 2-thien 1 3-COCH3-Ph 668 2-thien 1 3-F-Ph 669 2-thien 1 _ - 3-C1-Ph 670 2-thien 1 3-NH2-Ph 671 2-thien 1 - 3-OCH3-Ph 672 2-thien 1 3-OH-Ph 673 2-thien 1 4-CN-Ph 674 2-thien 1 4-COCH3-Ph 675 2-thien 1 4-F-Ph 676 2-thienyl 4-C1-Ph 677 2-thien 1 4-NH2-Ph 678 2-thien 1 4-OCH3-Ph 679 2-thien 1 4-OH-Ph 680 2-thien 1 3 , 4-diF-Ph 681 2-thien 1 3,5-diF-Ph 682 2-thien 1 3,4-diCl-Ph 683 2-thien 1 3,5-diCl-Ph 684 2-thien 1 3,4-OCH20-Ph 685 2-thien 1 3,4-OCH2CH20-Ph 686 3-thien 1 3-CN-Ph 687 3-thien 1 3-COCH3-Ph 688 3-thien 1 3-F-Ph 689 3-thien 1 3-C1-Ph 690 3-thien 1 3-NH2-Ph 691 3-thien 1 3-OCH3-Ph 692 3-thien 1 3-OH-Ph 693 3-thien 1 4-CN-Ph 694 3-thien 1 _ 4-COCH3-Ph 695 3-thien 1 4-F-Ph 696 3-thien 1 4-C1-Ph 697 3-thien 1 4-NH2-Ph 698 3-thien 1 4-OCH3-Ph 699 3-thien 1 4-OH-Ph 700 3-thien 1 3,4-diF-Ph -701 3-thien 1 3,5-diF-Ph 702 3-thien 1 3,4-diCl-Ph 703 3-thien 1 3,5-diCl-Ph 704 3-thienyl 3,4-OCH20-Ph 705 3-thien 1 3,4-OCH2CH20-Ph 706 2-furan 1 3-CN-Ph 707 2-furan 1 3-COCH3-Ph 708 2-furan 1 3-F-Ph 709 2-furan 1 3-C1-Ph 710 2-furan 1 3-NH2-Ph 711 2-furan 1 3-OCH3-Ph 712 2-furan 1 3-OH-Ph 713 2-furan 1 4-CN-Ph 714 ~ 2-furanyl j 4-COCH3-Ph 715 2-furan 1 4-F-Ph 716 2-furan 1 4-C1-Ph 717 2-furan 1 4-NH2-Ph 718 2-furan 1 4-OCH3-Ph 719 2-furanyl 4-OH-Ph 720 2-furan 1 3,4-diF-Ph 721 2-furanyl 3,5-diF-Ph 722 2-furanyl 3,4-diCl-Ph 723 2-furanyl 3,5-diCl-Ph 724 2-furanyl 3,4-OCH20-Ph 725 2-furan 1 3,4-OCH2CH20-Ph 726 3-furanyl 3-CN-Ph 727 3-furanyl 3-COCH3-Ph 7_28_ 3-furanyl 3 -F-Ph 729 3-furanyl 3-Cl-Ph 730 3-furan 1 3-NH2-Ph 732 3-furan 1 3-OCH3-Ph 732 3-furan 1 3-OH-Ph 733 3-furanyl 4-CN-Ph 734 3-furan 1 4-COCH3-Ph 735 3-furan 1 4-F-Ph 736 3-furan 1 4-C1-Ph 737 3-furan 1 4-NH2-Ph 738 3-furan 1 4-OCH3-Ph 739 3-furan 1 4-OH-Ph 740 3-furanyl 3,4-diF-Ph 741 3-furan 1 3,5-diF-Ph 742 3-furanyl 3,4-diCl-Ph 743 3-furan 1 3,5-diCl-Ph 744 3-furan 1 3,4-OCH20-Ph 745 3-furanyl 3,4-OCH2CH20-Ph 746 2- ridyl 3-CN-Ph 747 2- yrid 1 3-COCH3-Ph 748 2- rid 1 3-F-Ph 749 2-pyridyl 3-C1-Ph 750 2-pyrid 1 3-NH2-Ph 751 2- rid 1 3-OCH3-Ph 752 2- rid 1 3-OH-Ph 753 2- ridyl 4-CN-Ph 754 2- yrid 1 4-COCH3-Ph 755 2- rid 1 4-F-Ph 756 2- rid 1 4-Cl-Ph 757 2- yrid 1 4-NH2-Ph 758 2- rid 1 4-OCH3-Ph 759 2- rid 1 4-OH-Ph 760 2- yrid 1 3,4-diF-Ph 761 2-pyrid 1 3,5-diF-Ph 762 2- ridyl 3,4-diCl-Ph 763 2- rid 1 3,5-diCl-Ph 764 2-p rid 1 3,4-OCH20-Ph 765 2-pyridyl 3,4-OCH2CH20-Ph 766 3- rid 1 3-CN-Ph 767 3-pyridyl 3-COCH3-Ph 768 3- rid rl 3-F-Ph 769 3-pyridyl 3-C1-Ph 770 3- rid 1 3-NH2-Ph 771 3- rid 1 3-OCH3-Ph 772 3- rid 1 3-OH-Ph 773 3- rid 1 4-CN-Ph 774 3- ridyl 4-COCH3-Ph 775 3- rid 1 4-F-Ph 776 3- rid 1 4-C1-Ph 777 3- ridyl 4-NH2-Ph 778 3- rid 1 4-OCH3-Ph 779 3- rid 1 4-OH-Ph 780 3- rid 1 3,4-diF-Ph 781 3- rid 1 3,5-diF-Ph 782 3- ridyl 3,4-diCl-Ph 783 3- rid 1 3,5-diCl-Ph 784 3-p rid 1 3,4-OCH20-Ph 785 3- rid 1 3,4-OCH2CH20-Ph 786 4- rid 1 3-CN-Ph 787 4- yridyl 3-COCH3-Ph 788 4- rid 1 3-F-Ph 789 4- rid 1 3-Cl-Ph 790 4- ridyl 3-NH2-Ph 791 4- rid 1 3-OCH3-Ph 792 4-p ridyl 3-OH-Ph 793 4- rid 1 4-CN-Ph 794 4-pyrid 1 4-COCH3-Ph 795 4- rid 1 4-F-Ph 796 4- rid 1 4-C1-Ph 797 4- rid 1 4-NH2-Ph 798 4-p rid 1 4-OCH3-Ph 799 4- rid 1 4-OH-Ph 800 4- rid 1 3,4-diF-Ph 801 4- rid 1 3,5-diF-Ph 802 4- ridyl 3,4-diCl-Ph 803 4- rid 1 3,5-diCl-Ph 804 4- rid 1 3,4-OCH20-Ph 805 4- rid 1 3,4-OCH2CH20-Ph 806 3-indol 1 3-CN-Ph 807 3-indol 1 3-COCH3-Ph 808 3-indol 1 3-F-Ph 809 3-indol 1 3-C1-Ph 810 3-indol 1 3-NH2-Ph 811 3-indol 1 3-OCH3-Ph 812 3-indol 1 3-OH-Ph 813 3-indol 1 4-CN-Ph 814 3-indol 1 4-COCH3-Ph 815 3-indol 1 4-F-Ph 816 3-indol 1 4-C1-Ph 817 3-indol 1 4-NH2-Ph 818 3-indol 1 4-OCH3-Ph 819 3-indol 1 4-OH-Ph 820 3-indolyl 3,4-diF-Ph 821 3-indol 1 3,5-diF-Ph _ 822 3-indolyl 3,4-diCl-Ph 823 3-indolyl 3,5-diCl-Ph 824 3-indolyl 3,4-OCH20-Ph 825 3-indol 1 3,4-OCH2CH20-Ph 826 5-indol 1 3-CN-Ph 827 5-indolyl 3-COCH3-Ph 828 5-indol 1 3-F-Ph 829 5-indol 1 3-Cl-Ph 830 5-indol 1 3-NH2-Ph 831 5-indolyl 3-OCH3-Ph 832 5-indolyl 3-OH-Ph 833 5-indol 1 4-CN-Ph 834 5-indol 1 4-COCH3-Ph 835 5-indolyl 4-F-Ph 836 5-indol 1 4-C1-Ph 837 5-indol 1 4-NH2-Ph 838 5-indolyl 4-OCH3-Ph 839 5-indolyl 4-OH-Ph 840 5-indol 1 3,4-diF-Ph 841 5-indolyl 3,5-diF-Ph 842 5-indol 1 3,4-diCl-Ph 843 5-indolyl 3,5-diCl-Ph 844 5-indol 1 3,4-OCH20-Ph 845 5-indolyl 3,4-OCH2CH20-Ph 846 5-indazolyl 3-CN-Ph 847 5-indazolyl 3-COCH3-Ph 848 5-indazol 1 3-F-Ph 849 S-indazol 1 3-C1-Ph 850 5-indazol 1 3-NH2-Ph 851 5-indazolyl 3-OCH3-Ph 852 5-indazol 1 3-OH-Ph 853 5-indazol 1 4-CN-Ph 854 5-indazol 1 4-COCH3-Ph 855 5-indazolyl 4-F-Ph 856 5-indazol 1 4-Cl-Ph 857 5-indazol 1 4-NH2-Ph 858 5-indazol 1 4-OCH3-Ph 859 5-indazolyl 4-OH-Ph 860 5-indazolyl 3,4-diF-Ph 861 5-indazol 1 3,5-diF-Ph 862 5-indazolyl 3,4-diCl-Ph 863 5-indazolyl 3,5-diCl-Ph 864 5-indazol 1 3,4-OCH20-Ph 865 5-indazol 1 3,4-OCH2CH20-Ph 866 5-benzimidazol 1 3-CN-Ph 867 5-benzimidazol 1 3-COCH3-Ph 868 5-benzimidazolyl 3-F-Ph 869 5-benzimidazol 1 3-Cl-Ph 870 5-benzimidazol 1 3-NH2-Ph _871 5-benzimidazolyl 3-OCH3-Ph 872 5-benzimidazolyl 3-OH-Ph 873 5-benzimidazolyl 4-CN-Ph ,... ~a....

8?4 5-benzimidazol 1 4-COCH3-Ph 8?5 5-benzimidazol 1 4-F-Ph 8?6 5-benzimidazolyl 4-C1-Ph 8?7 5-benzimidazol 1 4-NH2-Ph 8?8 5-benzimidazol 1 4-OCH3-Ph 879 5-benzimidazol 1 4-OH-Ph 880 5-benzimidazol 1 3,4-diF-Ph 881 5-benzimidazolyl 3,5-diF-Ph 882 5-benzimidazol 1 3,4-diCl-Ph 883 5-benzimidazol 1 3,5-diCl-Ph 884 5-benzimidazol 1 3,4-OCH20-Ph 885 5-benzimidazol 1 3,4-OCH2CH20-Ph 886 5-benzothiazol 1 3-CN-Ph 88? 5-benzothiazol 1 3-COCH3-Ph 888 5-benzothiazolyl 3-F-Ph 889 5-benzothiazol 1 3-C1-Ph 890 5-benzothiazol 1 3-NH2-Ph 891 5-benzothiazol 1 3-OCH3-Ph 892 5-benzothiazol 1 3-OH-Ph 893 5-benzothiazolyl 4-CN-Ph 894 5-benzothiazol 1 4-COCH3-Ph 895 5-benzothiazol 1 4-F-Ph 896 5-benzothiazol 1 4-Cl-Ph 897 5-benzothiazolyl 4-NH2-Ph 898 5-benzothiazol 1 4-OCH3-Ph 899 5-benzothiazol I 4-OH-Ph 900 5-benzothiazol 1 3,4-diF-Ph 901 5-benzothiazol 1 3,5-diF-Ph 902 5-benzothiazol 1 3,4-diCl-Ph 903 5-benzothiazol 1 3,5-diCl-Ph 904 5-benzothiazol 1 3,4-OCH20-Ph 905 5-benzothiazol 1 3,4-OCH2CH20-Ph 906 5-benzoxazol 1 3-CN-Ph 907 5-benzoxazol 1 3-COCH3-Ph 908 5-benzoxazol 1 3-F-Ph 909 5-benzoxazol 1 3-C1-Ph 910 5-benzoxazol 1 3-NH2-Ph 911 5-benzoxazolyl 3-OCH3-Ph 912 5-benzoxazol 1 3-OH-Ph 913 5-benzoxazol 1 4-CN-Ph 914 5-benzoxazol 1 4-COCH3-Ph 915 5-benzoxazol 1 4-F-Ph 916 5-benzoxazol 1 4-C1-Ph 917 5-benzoxazol 1 4-NH2-Ph 918 5-benzoxazol 1 4-OCH3-Ph 919 5-benzoxazol 1 4-OH-Ph 920 5-benzoxazol 1 3,4-diF-Ph 921 5-benzoxazolyl __ 3,5-diF-Ph 922 5-benzoxazolyl ~ 3,4-diCl-Ph 923 5-benzoxazol 1 3,5-diCl-Ph 924 5-benzoxazol 1 3,4-OCH20-Ph 925 5-benzoxazolyl 3 4-OCH~~u~n-p~, TABLE 6*

HN'l N-R3 HN ~ N.R HN~ N.R3 H F H ~. H
R a R a R a HN~ H R3 HN~ N-R3 HN'l N Ra CY ' " ~ H v H

is a R R a Ot C1 ~ HN~N-R3 r H

O O
F ~ .R' a ~ R3 HN H ~ HN

CI

is p is ~' 3 7 ~'rG~~~ H N ~ N ~R
H

HNJ~N-R3 ° HN~N.R3 H H

4 a ~~N_R
H
~ p F F
!, 11 ~' ,N, R3 ~ R3 ~H R1a ~ H

F
R a Rla 13 C1 HN H_R 15 C1 ~ C
s 17 ~ R3 N H R R1 a ~ H
C 1~~~~~ C

is R a ~...

DEMANDES OU BREVETS VOLUMINEUX
LA PRESENTS PARTIE DE CETTE DEMANDS OU CE BREVET
COMPREND PLUS D'UN TOME_ ~
CECI EST LE TOME _ ~'DE c1 NOTE: Pour les tomes additionels, veuillez contacier le Bureau canadien des brevets ' JUMBO APPL:ICATIONS/PATE~1TS
THIS SECTION OF THE APPUCATIONIPATENT CONTAINS MORE
THAN ONE VOLUME
THIS IS VOLUME ~ -- DF _ , WOTE: For additional volumes ~piease contact'the Canadian Patent Ufif~ca ~ _ ~ < ~'-

Claims (49)

What is Claimed is:
1. A compound of formula (I):
or stereoisomers or pharmaceutically acceptable salts thereof, wherein:
M is absent or selected from CH2, CHR5, CHR13, CR13R13, and CR5R13;
Q is selected from CH2, CHR5, CHR13, CR13R13, and CR5R13;
J, K, and L are independently selected from CH2, CHR5, CHR6, CR6R6 and CR5R6;
with the provisos:
1) at least one of M, J, K, L, or Q contains an R5;
and 2) when M is absent, J is selected from CH2, CHR5, CHR13, and CR5R13;
Z is selected from O and S;
E is - (CHR7) - (CHR9)~ - (CHR11) - ;
R1 and R2 are independently selected from H, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)r C3-6 cycloalkyl, and a (CH2)r-C3-10 carbocyclic residue substituted with 0-5 R a;
R a, at each occurrence, is selected from C1-4 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)r C3-6 cycloalkyl, Cl, Br, I, F, (CF2)r CF3, NO2, CN, (CH2)r NR b R b, (CH2)r OH, (CH2)r OR c, (CH2)r SH, (CH2)r SR c, (CH2)r C(O)R b, (CH2)r C(O)NR b R b, (CH2)r NR b C(O)R b, (CH2)r C(O)OR b, (CH2)r OC (O)R c, (CH2)r CH(=NR b)NR b R b, (CH2)r NHC(=NR b)NR b R b, (CH2)r S(O)p R c, (CH2)r S(O)2NR b R b, (CH2)r NR b S(O)2R c, and (CH2)r phenyl;
R b, at each occurrence, is selected from H, C1-6 alkyl, C3-6 cycloalkyl, and phenyl;
R c, at each occurrence, is selected from C1-6 alkyl, C3-6 cycloalkyl, and phenyl;
alternatively, R2 and R3 join to form a 5, 6, or 7-membered ring substituted with 0-3 R a;
R3 is selected from a (CR3'R3")r-C3-10 carbocyclic residue substituted with 0-5 R15 and a (CR3'R3")r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R15;
R3' and R3", at each occurrence, are selected from H, C1-6 alkyl, (CH2)r C3-6 cycloalkyl, and phenyl;
R4 is absent, taken with the nitrogen to which it is attached to form an N-oxide, or selected from C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)r C3-6 cycloalkyl, (CH2)q C(O)R4b, (CH2)q C(O)NR4a R4a', (CH2)q C(O)OR4b, and a (CH2)r-C3-10 carbocyclic residue substituted with 0-3 R4c;
R4a and R4a', at each occurrence, are selected from H, C1-6 alkyl, (CH2)r C3-6 cycloalkyl, and phenyl;
R4b, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, (CH2)r C3-6 cycloalkyl, C2-8 alkynyl, and phenyl;

R4c, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-6 cycloalkyl, Cl, F, Br, I, CN, NO2, (CF2)r CF3, (CH2)r OC1-5 alkyl, (CH2)r OH, (CH2)r SC1-5 alkyl, (CH2)r NR4aR4a', and (CH2)r phenyl;
alternatively, R4 joins with R7, R9, or R11 to form a 5, 6 or 7 membered piperidinium spirocycle or pyrrolidinium spirocycle substituted with 0-3 R a;
R5 is selected from a (CR5'R5")t-C3-10 carbocyclic residue substituted with 0-5 R16 and a (CR5'R5")t-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R16;
R5' and R5", at each occurrence, are selected from H, C1-6 alkyl, (CH2)r C3-6 cycloalkyl, and phenyl;
R6, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)r C3-6 cycloalkyl, (CF2)r CF3, CN, (CH2)r NR6a R6a', (CH2)r OH, (CH2)r OR6b, (CH2)r SH, (CH2)r SR6b, (CH2)r C(O)OH, (CH2)r C(O)R6b, (CH2)r C(O)NR6a R6a', (CH2)r NR6d C(O)R6a (CH2)r C(O)OR6b, (CH2)r OC(O)R6b, (CH2)r S(O)p R6b, (CH2)r S(O)2NR6a R6a', (CH2)r NR6d S(O)2R6b, and (CH2)t phenyl substituted with 0-3 R6c;
R6a and R6a', at each occurrence, are selected from H, C1-6 alkyl, C3-6 cycloalkyl, and phenyl substituted with 0-3 R6c;
R6b, at each occurrence, is selected from C1-6 alkyl, C3-6 cycloalkyl, and phenyl substituted with 0-3 R6c;
R6c, at each occurrence, is selected from C1-6 alkyl, C3-6 cycloalkyl, Cl, F, Br, I, CN, NO2, (CF2)r CF3, (CH2)r OC1-alkyl, (CH2)r OH, (CH2)r SC1-5 alkyl, and (CH2)r NR6d R6d;

R6d, at each occurrence, is selected from H, C1-6 alkyl, and C3-6 cycloalkyl;
with the proviso that when any of J, K, or L is CR6R6 and R6 is halogen, cyano, nitro, or bonded to the carbon to which it is attached through a heteroatom, the other R6 is not halogen, cyano, or bonded to the carbon to which it is attached through a heteroatom;
R7 at each occurrence, is selected from H or alternatively R7 joins with R4 to form a 5, 6, or 7 membered piperidinium spirocycle or pyrrolidinium spirocycle substituted with 0-3R a;
R9 at each occurrence, is selected from H or alternatively R9 joins with R4 to form a 5, 6, or 7 membered piperidinium spirocycle or pyrrolidinium spirocycle substituted with 0-3R a;
R11 at each occurrence, is selected from H, C1-6alkyl, C2-8alkenyl, C2-8alkynyl, and a (CH2)r-C3-10 carbocyclic residue substituted with 0-5 R11c, or alternatively R11 joins with R4 to form a 5, 6, or 7 membered piperidinium spirocycle or pyrrolidinium spirocycle substituted with 0-3R a;
R11a and R11a', at each occurrence, are selected from H, C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, a (CH2)r-C3-10 carbocyclic residue substituted with 0-5 R11e, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R11e;
R11b, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, a (CH2)r-C3-6 carbocyclic residue substituted with 0-2 R11e, and a (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R11e;
R11c, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)r C3-6 cycloalkyl, Cl, Br, I, F, (CF2)r CF3, NO2, CN, (CH2)r NR11f R11f, (CH2)r OH, (CH2)r OC1-4 alkyl, (CH2)r SC1-4 alkyl, (CH2)r C(O)OH, (CH2)r C(O)R11b, (CH2)r C(O)NR11f R11f, (CH2)r NR11f C(O)R11a, (CH2)r C(O)OC1-4 alkyl, (CH2)r OC(O)R11b, (CH2)r C(=NR11f)NR11f R11f, (CH2)r NHC(-NR11f)NR11f R11f, (CH2)r S(O)p R11b, (CH2)r S(O)2NR11f R11f, (CH2)r NR11f S(O)2R11b, and (CH2)r phenyl substituted with 0-3 R11e;
R11e, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-6 cycloalkyl, Cl, F, Br, I, CN, NO2, (CF2)r CF3, (CH2)r OC1-5 alkyl, OH, SH, (CH2)r SC1-alkyl, (CH2)r NR11f R11f, and (CH2)r phenyl;
R11f, at each occurrence, is selected from H, C1-6 alkyl, and C3-6 cycloalkyl;
R13, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-6 cycloalkyl, (CF2)w CF3, (CH2)q NR13a R13a', (CH2)q OH, (CH2)q OR13b, (CH2)q SH, (CH2)q SR13b, (CH2)w C(O)OH, (CH2)w C(O)R13b, (CH2)w C(O)NR13a R13a', (CH2)q NR13d C(O)R13a, (CH2)w C(O)OR13b, (CH2)q OC(O)R13b, (CH2)w S(O)p R13b, (CH2)w S(O)2NR13a R13a', (CH2)q NR13d S(O)2R13b and (CH2)w-phenyl substituted with 0-3 R13c;
R13a and R13a', at each occurrence, are selected from H, C1-6 alkyl, C3-6 cycloalkyl, and phenyl substituted with 0-3 R13c.
R13b, at each occurrence, is selected from C1-6 alkyl, C3-6 cycloalkyl, and phenyl substituted with 0-3 R13c;

R13c, at each occurrence, is selected from C1-6 alkyl, C3-6 cycloalkyl, Cl, F, Br, I, CN, NO2, (CF2)r CF3, (CH2)r OC1-alkyl, (CH2)r OH, (CH2)r SC1-5 alkyl, and (CH2)r NR13d R13d;
R13d, at each occurrence, is selected from H, C1-6 alkyl, and C3-6 cycloalkyl;
R15, at each occurrence, is selected from C1-8 alkyl, (CH2)r C3-6 cycloalkyl, Cl, Br, I, F, NO2, CN, (CHR')r NR15a R15a', (CHR')r OH, (CHR')r O (CHR')r R15d, (CHR')r SH, (CHR')r C(O)H, (CHR')r S(CHR')r R15d, (CHR')r C(O)OH, (CHR')r C(O) (CHR')r R15b, (CHR')r C(O)NR15a R15a', (CHR')r NR15f C(O) (CHR')r R15b, (CHR')r NR15f C(O)NR15f R15f, (CHR')r C(O)O(CHR')r R15d, (CHR')r OC(O)(CHR')r R15b, (CHR')r C (=NR15f)NR15a R15a', (CHR')r NHC(=NR15f)NR15f R15f, (CHR')r S(O)p(CHR')r R15b, (CHR')r S(O)2NR15a R15a', (CHR')r NR15f S(O)2(CHR')r R15b, C1-6 haloalkyl, C2-8 alkenyl substituted with 0-3 R', C2-8 alkynyl substituted with 0-3 R', (CHR')r phenyl substituted with 0-3 R15e, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R15e;
R', at each occurrence, is selected from H, C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)r C3-6 cycloalkyl, and (CH2)r phenyl substituted with R15e;
R15a and R15a', at each occurrence, are selected from H, C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, a (CH2)r-C3-10 carbocyclic residue substituted with 0-5 R15e, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R15e;

R15b, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, a (CH2)r-C3-6 carbocyclic residue substituted with 0-3 R15e, and (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R15e;
R15d, at each occurrence, is selected from C2-8 alkenyl, C2-8 alkynyl, C1-6 alkyl substituted with 0-3 R15e a (CH2)r-C3-10 carbocyclic residue substituted with 0-3 R15e, and a (CH2)r5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R15e;
R15e, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)r C3-6 cycloalkyl, Cl, F, Br, I, CN, NO2, (CF2)r CF3, (CH2)r OC1-5 alkyl, OH, SH, (CH2)r SC1-5 alkyl, (CH2)r NR15f R15f, and (CH2)r phenyl;
R15f, at each occurrence, is selected from H, C1-6 alkyl, C3-6 cycloalkyl, and phenyl;
R16, at each occurrence, is selected from C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)r C3-6 cycloalkyl, Cl, Br, I, F, NO2, CN, (CHR')r NR16a R16a', (CHR')r OH, (CHR')r O(CHR')r R16d, (CHR')r SH, (CHR')r C(O)H, (CHR')r S(CHR')r R16d, (CHR')r C(O)OH, (CHR')r C(O)(CHR')r R16b, (CHR')r C(O)NR16a R16a', (CHR')r NR16f C(O)(CHR')r R16b, (CHR')r C(O)O(CHR')r R16d, (CHR')r OC(O)(CHR')r R16b, (CHR')r C(=NR16f)NR16a R16a', (CHR')r NHC(=NR16f)NR16f R16f, (CHR')r S(O)p(CHR')r R16b, (CHR')r S(O)2NR16a R16a', (CHR')r NR16f S(O)2(CHR')r R16b, C1-6 haloalkyl, C2-8 alkenyl substituted with 0-3 R', C2-8 alkynyl substituted with 0-3 R', and (CHR')r phenyl substituted with 0-3 R16e;
R16a and R16a', at each occurrence, are selected from H, C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, a (CH2) r-C3-10 carbocyclic residue substituted with 0-5 R16e, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R16e;
R16b, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, a (CH2)r C3-6 carbocyclic residue substituted with 0-3 R16e, and a (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R16e;
R16d, at each occurrence, is selected from C2-8 alkenyl, C2-8 alkynyl, C1-6 alkyl substituted with 0-3 R16e, a (CH2)r-C3-10 carbocyclic residue substituted with 0-3 R16e, and a (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R16e;
R16e, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)r C3-6 cycloalkyl, Cl, F, Br, I, CN, NO2, (CF2)r CF3, (CH2)r OC1-5 alkyl, OH, SH, (CH2)r SC1-5 alkyl, (CH2)r NR16f R16f, and (CH2)r phenyl;
R16f, at each occurrence, is selected from H, C1-5 alkyl, and C3-6 cycloalkyl, and phenyl;
v is selected from 1 and 2;
t is selected from 1 and 2;
w is selected from 0 and 1;
r is selected from 0, 1, 2, 3, 4, and 5;
q is selected from 1, 2, 3, 4, and 5; and p is selected from 0, 1, 2, and 3.
2. The compound of claim 1, wherein:
R4 is absent, taken with the nitrogen to which it is attached to form an N-oxide, or selected from C1-8 alkyl, (CH2)r C3-5 cycloalkyl, and (CH2)r-phenyl substituted with 0-3 R4c;
R4c, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-6 cycloalkyl, Cl, F, Br, I, CN, NO2, (CF2)r CF3, (CH2)r OC1-5 alkyl, (CH2)r OH, (CH2)r SC1-5 alkyl, (CH2)r NR4a R4a' and (CH2)r phenyl;
alternatively, R4 joins with R7, R9, or R11 to form a 5, 6 or 7 membered piperidinium spirocycle or pyrrolidinium spirocycle substituted with 0-3 R a;
R1 and R2 are independently selected from H and C1-4 alkyl;
R6, at each occurrence, is selected from C1-4 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)r C3-6 cycloalkyl, (CF2)r CF3, CN, (CH2)r OH, (CH2)r OR6b, (CH2)r C(O)R6b, (CH2)r C(O)NR6a R6a', (CH2)r NR6d C(O)R6a and (CH2)t phenyl substituted with 0-3 R6c;
R6a and R6a', at each occurrence, are selected from H, C1-6 alkyl, C3-6 cycloalkyl, and phenyl substituted with 0-3 R6c' R6b, at each occurrence, is selected from C1-6 alkyl, C3-6 cycloalkyl, and phenyl substituted with 0-3 R6c;
R6c, at each occurrence, is selected from C1-6 alkyl, C3-6 cycloalkyl, Cl, F, Br, I, CN, NO2, (CF2)r CF3, (CH2)r OC1-alkyl, (CH2)r OH, (CH2)r SC1-5 alkyl, and (CH2)r NR6d R6d;

R6d, at each occurrence, is selected from H, C1-6 alkyl, and C3-6 cycloalkyl;
R13, at each occurrence, is selected from C1-4 alkyl, C3-5 cycloalkyl, (CH2)NR13a R13a', (CH2)OH, (CH2)OR13b, (CH2)w C(O)R13b, (CH2)w C(O)NR13a R13a', (CH2)NR13d C(O)R13a, (CH2)w S(O)2NR13a R13a', (CH2)NR13d S(O)2R13b, and (CH2)w-phenyl substituted with 0-3 R13c;
R13a and R13a', at each occurrence, are selected from H, C1-6 alkyl, C3-6 cycloalkyl, and phenyl substituted with 0-3 R13c;
R13b, at each occurrence, is selected from C1-6 alkyl, C3-6 cycloalkyl, and phenyl substituted with 0-3 R13c;
R13c, at each occurrence, is selected from C1-6 alkyl, C3-6 cycloalkyl, Cl, F, Br, I, CN, NO2, (CF2)r CF3, (CH2)r OC1-alkyl, (CH2)r OH, and (CH2)r NR13d R13d;
R13d, at each occurrence, is selected from H, C1-6 alkyl, and C3-6 cycloalkyl;
v is selected from 1 and 2;
q is selected from 1, 2, and 3; and r is selected from 0, 1, 2, and 3.
3. The compound of claim 2, wherein:
R3 is selected from a (CR3'H)r-carbocyclic residue substituted with 0-5 R15, wherein the carbocyclic residue is selected from phenyl, C3-6 cycloalkyl, naphthyl, and adamantyl; and a (CR3'H)r-heterocyclic system substituted with 0-3 R15, wherein the heterocyclic system is selected from pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, indolinyl, isoindolyl, isothiadiazolyl, isoxazolyl, piperidinyl, pyrrazolyl, 1,2,4-triazolyl, 1,2,3-triazolyl, tetrazolyl, thiadiazolyl, thiazolyl, oxazolyl, pyrazinyl, and pyrimidinyl; and R5 is selected from (CR5'H)t-phenyl substituted with 0-5 R16; and a (CR5'H)t-heterocyclic system substituted with 0-3 R16, wherein the heterocyclic system is selected from pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, indolinyl, isoindolyl, isothiadiazolyl, isoxazolyl, piperidinyl, pyrrazolyl, 1,2,4-triazolyl, 1,2,3-triazolyl, tetrazolyl, thiadiazolyl, thiazolyl, oxazolyl, pyrazinyl, and pyrimidinyl.
4. The compound of claim 3, wherein the compound of formula (I) is:
R16, at each occurrence, is selected from C1-8 alkyl, (CH2)r C3-6 cycloalkyl, CF3, Cl, Br, I, F, (CH2)r NR16a R16a', NO2, CN, OH, (CH2)r OR16d, (CH2)r C(O)R16b, (CH2)r C(O)NR16aR16a', (CH2)r NR16f C(O)R16b, (CH2)r S(O)p R16b, (CH2)r S(O)2NR16a R16a', (CH2)r NR16f S(O)2R16b, and (CH2)r phenyl substituted with 0-3 R16e;

R16a and R16a', at each occurrence, are selected from H, C1-6 alkyl, C3-6 cycloalkyl, and (CH2)r phenyl substituted with 0-3 R16e;
R16b, at each occurrence, is selected from H, C1-6 alkyl, C3-6 cycloalkyl, and (CH2)r phenyl substituted with 0-3 R16e;
R16d, at each occurrence, is selected from C1-6 alkyl and phenyl;
R16e, at each occurrence, is selected from C1-6 alkyl, Cl, F, Br, I, CN, NO2, (CF2)r CF3, OH, and (CH2)r OC1-5 alkyl;
and R16f, at each occurrence, is selected from H, and C1-5 alkyl.
5. The compound of claim 3, wherein the compound formula (I) is:
R16, at each occurrence, is selected from C1-8 alkyl, (CH2)r C3-6 cycloalkyl, CF3, Cl, Br, I, F, (CH2)r NR16a R16a', NO2, CN, OH, (CH2)r OR16d, (CH2)r C(O)R16b, (CH2)r C(O)NR16a R16a', (CH2)r NR16f C(O)R16b, (CH2)r S(O)p R16b, (CH2)r S(O)2NR16a R16a', (CH2)r NR16f S(O)2R16b, and (CH2)r phenyl substituted with 0-3 R16e;
R16a and R16a', at each occurrence, are selected from H, C1-6 alkyl, C3-6 cycloalkyl, and (CH2)r phenyl substituted with 0-3 R16e;

R16b, at each occurrence, is selected from H, C1-6 alkyl, C3-6 cycloalkyl, and (CH2)r phenyl substituted with 0-3 R16e;
R16d, at each occurrence, is selected from C1-6 alkyl and phenyl;
R16e, at each occurrence, is selected from C1-6 alkyl, Cl, F, Br, I, CN, NO2, (CF2)r CF3, OH, and (CH2)r OC1-5 alkyl;
and R16f, at each occurrence, is selected from H, and C1-5 alkyl.
6. The compound of claim 4, wherein:
R5 is CH2phenyl substituted with 0-3 R16;
E i s -CH2-(CH2)-(CH2);
r is selected from 0, 1, and 2.
7. The compound of claim 5, wherein:
E is -CH2-(CHR9)-CHR11;
R5 is CH2phenyl substituted with 0-3 R16; and r is selected from 0, 1, and 2.
8. The compound of claim 6, wherein:
J is selected from CH2 and CHR5;
K is selected from CH2 and CHR5;
L is selected from CH2 and CHR5;

R3 is a C3-10 carbocyclic residue substituted with 0-3 R15, wherein the carbocyclic residue is selected from cyclopropyl, cyclopentyl, cyclohexyl, phenyl, naphthyl and adamantyl, and a (CR3'H)r-heterocyclic system substituted with 0-3 R15, wherein the heterocyclic system is selected from pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, indolinyl, isoindolyl, isothiadiazolyl, isoxazolyl, piperidinyl, pyrrazolyl, 1,2,4-triazolyl, 1,2,3-triazolyl, tetrazolyl, thiadiazolyl, thiazolyl, oxazolyl, pyrazinyl, and pyrimidinyl; and R15, at each occurrence, is selected from C1-8 alkyl, (CH2)r C3-6 cycloalkyl, CF3, Cl, Br, I, F, (CH2)r NR15a R15a', NO2, CN, OH, (CH2)r OR15d, (CH2)r C(O)R15b, (CH2)r C(O)NR15a R15a', (CH2)r NR15f C(O)R15b, (CH2)r S(O)p R15b, (CH2)r S(O)2NR15a R15a', (CH2)r NR15f S(O)2R15b, (CH2)r phenyl substituted with 0-3 R15e, and a (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R15e;
R15a and R15a', at each occurrence, are selected from H, C1-6 alkyl, C3-6 cycloalkyl, and (CH2)r phenyl substituted with 0-3 R15e;
R15b, at each occurrence, is selected from H, C1-6 alkyl, C3-6 cycloalkyl, and (CH2)r phenyl substituted with 0-3 R15e;
R15d, at each occurrence, is selected from C1-6 alkyl and phenyl;

R15e, at each occurrence, is selected from C1-6 alkyl, Cl, F, Br, I, CN, NO2, (CF2)r CF3, OH, and (CH2)r OC1-5 alkyl;
and R15f, at each occurrence, is selected from H, and C1-5 alkyl.
9. The compound of claim 7, wherein:
K is selected from CH2 and CHR5;
L is selected from CH2 and CHR5;
R3 is a C3-10 carbocyclic residue substituted with 0-3 R15, wherein the carbocyclic residue is selected from cyclopropyl, cyclopentyl, cyclohexyl, phenyl, naphthyl and adamantyl, and a (CR3'H)r-heterocyclic system substituted with 0-3 R15, wherein the heterocyclic system is selected from pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, indolinyl, isoindolyl, isothiadiazolyl, isoxazolyl, piperidinyl, pyrrazolyl, 1,2,4-triazolyl, 1,2,3-triazolyl, tetrazolyl, thiadiazolyl, thiazolyl, oxazolyl, pyrazinyl, and pyrimidinyl; and R15, at each occurrence, is selected from C1-8 alkyl, (CH2)r C3-6 cycloalkyl, CF3, Cl, Br, I, F, (CH2)r NR15a R15a', NO2, CN, OH, (CH2)r OR15d, (CH2)r C(O)R15b, (CH2)r C(O)NR15a R15a', (CH2)r NR15f C(O)R15b, (CH2)r S(O)p R15b, (CH2)r S(O)2NR15a R15a', (CH2)r NR15f S(O)2R15b, (CH2)r phenyl substituted with 0-3 R15e, and a (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R15e;

R15a and R15a', at each occurrence, are selected from H, C1-6 alkyl, C3-6 cycloalkyl, and (CH2)r phenyl substituted with 0-3 R15e;
R15b, at each occurrence, is selected from H, C1-6 alkyl, C3-6 cycloalkyl, and (CH2)r phenyl substituted with 0-3 R15e;
R15d, at each occurrence, is selected from C1-6 alkyl and phenyl;
R15e, at each occurrence, is selected from C1-6 alkyl, Cl, F, Br, I, CN, NO2, (CF2)r CF3, OH, and (CH2)r OC1-5 alkyl;
and R15f, at each occurrence, is selected from H, and C1-5 alkyl
10. The compound of claim 3, wherein:
M is absent or selected from CH2;
Q is CH2;
J is CH2;
K and L are independently selected from CH2 and CHR5;
Z is O;
R1 is H;
R2 is H;
R3 is a C3-10 carbocyclic residue substituted with 0-3 R15, wherein the carbocyclic residue is selected from cyclopropyl, cyclopentyl, cyclohexyl, phenyl, naphthyl and adamantyl, and a (CR3'H)r-heterocyclic system substituted with 0-3 R15, wherein the heterocyclic system is selected from pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, indolinyl, isoindolyl, isothiadiazolyl, isoxazolyl, piperidinyl, pyrrazolyl, 1,2,4-triazolyl, 1,2,3-triazolyl, tetrazolyl, thiadiazolyl, thiazolyl, oxazolyl, pyrazinyl, and pyrimidinyl; and R5 is selected from a CH2-C3-10 carbocyclic residue substituted with 1-5 R16 and a heterocyclic system substituted with 0-3 R15, wherein the heterocyclic system is selected from pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, indolinyl, isoindolyl, isothiadiazolyl, isoxazolyl, piperidinyl, pyrrazolyl, 1,2,4-triazolyl, 1,2,3-triazolyl, tetrazolyl, thiadiazolyl, thiazolyl, oxazolyl, pyrazinyl, and pyrimidinyl
11. The compound of claim 1 and pharmaceutically acceptable salt forms thereof, wherein the compound of formula (I) is selected from:
N-(2-hydroxymethylphenyl)-N'-[3-[4-(phenylmethyl)-1-piperidinyl]propyl]urea, N-(3-carboethoxyphenyl)-N'-[3-[4-(phenylmethyl)-2-piperidinyl]propyl]urea, N-(3-cyanophenyl)-N'-[3-[4-(phenylmethyl)-1-piperidinyl]
propyl]urea, N-[4-(benzyloxy)phenyl]-N'-[3-[4-(phenylmethyl)-1-piperidinyl]propyl]urea, N-(3-iodophenyl)-N'-[3-[4-(phenylmethyl)-1-piperidinyl]
propyl]urea, N-(3-methoxyphenyl)-N'-[3-(4-(phenylmethyl)-1-piperidinyl]
propyl]urea, N-phenyl-N'-[3-[4-(phenylmethyl)-1-piperidinyl]propyl]urea, N-(4-carboethoxyphenyl)-N'-[3-[4-(phenylmethyl)-1-piperidinyl]propyl]urea, N-(4-fluorophenyl)-N'-[3-[4-(phenylmethyl)-1-piperidinyl]
propyl]urea, N-(2-methoxyphenyl)-N'-[3-[4-(phenylmethyl)-1-piperidinyl]propyl]urea, N-(4-methoxyphenyl)-N'-[3-[4-(phenylmethyl)-1-piperidinyl]propyl]urea, N-(3-cyanophenyl)-N'-[3-[4-(4-fluorophenylmethyl)-1-piperidinyl]propyl]urea, N-(4-fluorophenyl)-N'-[3-[4-(4-fluorophenylmethyl)-1-piperidinyl]propyl]urea, N-(4-carboethoxyphenyl)-N'-[3-[4-(4-fluorophenylmethyl)-1-piperidinyl]propyl]urea, N-(3-cyanophenyl)-N'-[3-(4-((3,4-methylenedioxy)phenylmethyl)-1-piperidinyl]propyl]urea, N-(3-methoxyphenyl)-N'-[3-[4-(4-fluorophenylmethyl)-1-piperidinyl]propyl]urea, N-(3-carboethoxyphenyl)-N'-[3-[4-((3,4-methylenedioxy) phenylmethyl)-1-piperidinyl]propyl]urea, N-(3-methoxyphenyl)-N'-[3-[4-((3,4-methylenedioxy) phenylmethyl)-1-piperidinyl]propyl]urea, N-(3-methoxyphenyl)-N'-[3-[4-((3-methoxy)phenylmethyl)-1-piperidinyl]propyl]urea, N-(3-cyanophenyl)-N'-[3-[4-(4-fluorophenylmethyl)-1-methyl-1-piperidinium]propyl]urea iodide, N-(4-cyanophenyl)-N'-[3-(4-(phenylmethyl)-1-piperidinyl]
propyl]urea, N-(4-fluorophenyl)-N'-[3-[4-((3,4-methylenedioxy) phenylmethyl)-1-piperidinyl]propyl]urea, N-(4-fluorophenyl)-N'-[3-[4-(2,4-bisfluorophenylmethyl)-1-piperidinyl]propyl]urea, N-(3-methoxyphenyl)-N'-[3-[4-(2,4-bisfluorophenylmethyl)-1-piperidinyl]propyl]urea, N-(3-cyanophenyl)-N'-[3-[4-(2,4-bisfluorophenylmethyl)-1-piperidinyl]propyl]urea, N-(phenylmethyl)-N'-[3-[4-(4-fluorophenylmethyl)-1-piperidinyl]propyl]urea, N-[1-(2-phenylethyl)]-N'-(3-[4-(4-fluorophenylmethyl)-1-piperidinyl]propyl]urea, N-(2-fluorophenyl)-N'-[3-[4-(4-fluorophenylmethyl)-1-piperidinyl]propyl]urea, N-(3-fluorophenyl)-N'-[3-[4-(4-fluorophenylmethyl)-1-piperidinyl]propyl]urea, N-(cyclohexyl)-N'-[3-[4-(4-fluorophenylmethyl)-1-piperidinyl]propyl]urea, N-[1-[trans-2-phenylcyclopropyl]-N'-[3-[4-(4-fluorophenyl-methyl)-1-piperidinyl]propyl]urea, N-(3-methoxyphenyl)-N'-[3-[4-(4-methylphenylmethyl)-1-piperidinyl]propyl)urea, N-(3-cyanophenyl)-N'-[3-[4-(4-methylphenylmethyl)-1-piperidinyl]propyl]urea, N-(3-cyanophenyl)-N'-(3-[4-(4-chlorophenylmethyl)-1-piperidinyl]propyl)urea, N-(3-methoxyphenyl)-N'-[3-[4-(3-methoxyphenylmethyl)-1-piperidinyl]propyl]urea, N-(3-cyanophenyl)-N'-[3-[4-(3-methoxyphenylmethyl)-1-piperidinyl]propyl]urea, N-(4-fluorophenyl)-N'-[3-[4-(3-methoxyphenylmethyl)-1-piperidinyl]propyl)urea, N-(4-carboethoxyphenyl)-N'-[3-[4-(3-methoxyphenylmethyl)-1-piperidinyl]propyl]urea, N-(3-cyanophenyl)-N'-[3-[4-(2-fluorophenylmethyl)-1-piperidinyl]propyl]urea N-(3-fluorophenyl)-N'-(3-[4-(3-methoxyphenylmethyl)-1-piperidinyl]propyl]urea, N-(3-carboethoxyphenyl)-N'-[3-[4-(3-methoxyphenylmethyl)-1-piperidinyl]propyl]urea, N-[3-acetylphenyl]-N'-[3-[4-(4-fluorophenylmethyl)-1-piperidinyl]propyl]urea, N-[3-(alpha-hydroxyethyl)phenyl]-N'-[3-[4-(4-fluorophenyl-methyl)-1-piperidinyl]propyl]urea, N-[4-acetylphenyl]-N'-[3-[4-(4-fluorophenylmethyl)-1-piperidinyl]propyl]urea, N-(3-methoxyphenyl)-N'-[3-[4-(phenylmethyl)-1-piperidinyl]
propyl]urea, cis-N-(3-methoxyphenyl)-N'-(3-[2,4-bis(phenylmethyl)-1-piperidinyl]propyl]urea, N-(3-acetylphenyl)-N'-[3-[4-(4-fluorophenylmethyl)-1-piperidinyl]propyl]urea, N-(3-methoxyphenyl)-N'-(3-[4-(4-fluorophenylmethylidenyl)-1-piperidinyl]propyl]urea, N-(4-acetylphenyl)-N'-[3-[4-(4-fluorophenylmethyl)-1-piperidinyl]propyl]urea, N-(3-(1-hydroxyethyl)phenyl)-N'-[3-[4-(4-fluorophenylmethyl)-1-piperidinyl]propyl]urea hydrochloride, N-(3-acetylphenyl)-N'-[3-[4-(4-fluorophenylmethyl)-3-(phenylmethyl)-1-piperidinyl]propyl]urea, N-(4-fluorophenyl)-N'-[3-[4-(4-fluorophenylmethyl)-3-(phenylmethyl)-1-piperidinyl]propyl]urea, N-(3-methoxyphenyl)-N'-[3-[4-(4-fluorophenylmethyl)-3-(phenylmethyl)-1-piperidinyl]propyl]urea, N-(2-isopropylphenyl)-N'-[3-[4-(4-fluorophenylmethyl)-1-piperidinyl]propyl]urea, N-(2-trifluoromethylphenyl)-N'-[3-[4-(4-fluorophenylmethyl)-Z-piperidinyl]propyl]urea, N-(3-chlorophenyl)-N'-[3-[4-(4-fluorophenylmethyl)-1-piperidinyl]propyl]urea, N-(3-trifluoromethylphenyl)-N'-[3-[4-(4-fluorophenylmethyl)-1-piperidinyl]propyl]urea, N-(2-chlorophenyl)-N'-[3-[4-(4-fluorophenylmethyl)-2-piperidinyl]propyl]urea, N-(2,4-difluororophenyl)-N'-[3-[4-(4-fluorophenylmethyl)-1-piperidinyl]propyl]urea, N-(3-cyanophenyl)-N'-[3-[4-(4-fluorophenylmethyl)-1-piperidinyl]propyl]urea, hydrochloride, N-(3-cyanophenyl)-N'-[3-[4-(naphth-1-ylmethyl)-1-piperidinyl]propyl]urea, N-(4-fluorophenyl)-N'-[3-[4-(naphth-1-ylmethyl)-1-piperidinyl)propyl]urea, N-(3-methoxyphenyl)-N'-[3-[4-(naphth-1-ylmethyl)-1-piperidinyl]propyl]urea, N-(3-cyanophenyl)-N'-[3-[4-(3-methylphenylmethyl)-1-piperidinyl]propyl)urea, N-(3-methoxyphenyl)-N'-[3-[4-(3-methylphenylmethyl)-1-piperidinyl]propyl]urea, N-(4-cyanophenyl)-N'-[3-[4-(4-fluorophenylmethyl)-1-piperidinyl]propyl]urea, N-(4-fluorophenyl)-N'-[3-[4-(4-chlorophenyl)methyl-1-piperidinyl]propyl]urea, N-(3-methoxyphenyl)-N'-[3-[4-(4-chlorophenyl)methyl-1-piperidinyl]propyl]urea, N-(3-cyanophenyl)-N'-[3-[4-(3,4-bisfluorophenyl)methyl-1-piperidinyl]propyl]urea, N-(3-methoxyphenyl)-N'-[3-[4-(3,4-bisfluorophenyl)methyl-1-piperidinyl]propyl]urea, N-(4-fluorophenyl)-N'-[3-[4-(3,4-bisfluorophenyl)methyl-1-piperidinyl]propyl]urea, N-(3-methoxyphenyl)-N'-[3-[4-(3-fluorophenyl) methyl-1-piperidinyl]propyl]urea, N-(3-cyanophenyl)-N'-(3-[4-(3-chlorophenyl)methyl-1-piperidinyl]propyl]urea, N-(3-methoxyphenyl)-N'-[3-[4-(3-carbomethoxyphenyl)methyl-1-piperidinyl]propyl]urea, N-(3-cyanophenyl)-N'-[3-[4-(3-carbomethoxyphenyl)methyl-1-piperidinyl]propyl]urea, N-(3-acetylphenyl)-N'-[3-[4-(4-fluorophenyl)methyl-1-piperidinyl]propyl]urea, N-(3,5-diacetylphenyl)-N'-[3-[3-(4-fluorophenyl)methyl-1-piperidinyl]propyl]urea, N-(3-acetylphenyl)-N'-[3-[3-(4-fluorophenyl)methyl-1-piperidinyl]propyl]urea, N-(3,5-diacetylphenyl)-N'-[3-[4-(4-fluorophenyl)methyl-1-piperidinyl]propyl]urea, N-(3-cyanophenyl)-N'-[1-phenyl-3-[4-(4-fluorophenylmethyl)-1-piperidinyl]propyl]urea, N-(3-methoxyphenyl)-N'-[1-phenyl-3-[4-(phenylmethyl)-1-piperidinyl]propyl]urea, N-(3-cyanophenyl)-N'-[1-phenyl-3-[4-(phenylmethyl)-1-piperidinyl]propyl]urea, N-(1-adamantyl)-N'-[1-phenyl-3-[4-(phenylmethyl)-1-piperidinyl]propyl]urea, N-(4-fluorophenyl)-N'-[1-phenyl-3-[4-(phenylmethyl)-1-piperidinyl]propyl]urea N-(3-carboethoxyphenyl)-N'-[3-[3-(phenylmethyl)-1-piperidinyl]propyl]urea, N-(3-cyanophenyl)-N'-[3-[3-(phenylmethyl)-1-piperidinyl]propyl]urea, N-(4-fluorophenyl)-N'-[3-[3-(phenylmethyl)-1-piperidinyl]propyl]urea, N-phenyl-N'-[3-[3-(phenylmethyl)-1-piperidinyl]propyl)urea, N-(1-adamantyl)-N'-[3-[3-(phenylmethyl)-1-piperidinyl]propyl]urea, N-(3-methoxyphenyl)-N'-[3-[3-(phenylmethyl)-1-piperidinyl]propyl)urea, N-(4-carboethoxyphenyl)-N'-[3-[3-(phenylmethyl)-1-piperidinyl]propyl]urea, N-phenyl-N'-[3-[3-(4-fluorophenyl)methyl-1-piperidinyl]propyl]urea, N-(3-cyanophenyl)-N'-[3-[3-(4-fluorophenyl)methyl-1-piperidinyl]propyl]urea, N-(1-adamantyl)-N'-[3-[3-(4-fluorophenyl)methyl-1-piperidinyl)propyl]urea, N-(3-methoxyphenyl)-N'-[3-[3-(4-fluorophenyl)methyl-1-piperidinyl)propyl)urea, N-(3-carboethoxyphenyl)-N'-[3-[3-(4-fluorophenyl)methyl-1-piperidinyl]propyl)urea, N-(4-fluorophenyl)-N'-[3-[3-(4-fluorophenyl)methyl-1-piperidinyl]propyl]urea, N-(3-cyanophenyl)-N'-[3-[3-[2-(phenyl)ethyl]-1-piperidinyl)propyl)urea, N-(3-carboethoxyphenyl)-N'-[3-[3-[2-(phenyl)ethyl]-1-piperidinyl]propyl)urea, N-(4-carboethoxyphenyl)-N'-[3-[3-[2-(phenyl)ethyl]-1-piperidinyl]propyl]urea, N-(4-fluorophenyl)-N'-[3-[3-[2-(phenyl)ethyl]-1-piperidinyl)propyl)urea, N-phenyl-N'-[3-[3-(2-(phenyl)ethyl]-1-piperidinyl]propyl)urea, N-(1-adamantyl)-N'-[3-[3-(2-(phenyl)ethyl)-1-piperidinyl]propyl)urea, N-(3-methoxyphenyl)-N'-[3-[3-[2-(phenyl)ethyl]-1-piperidinyl]propyl]urea, N-phenyl-N'-[3-[3-(4-fluorophenyl)methyl]-1-pyrrolinyl]propyl]urea, N-(3-cyanophenyl)-N'-[3-[3-(4-fluorophenyl)methyl-1-pyrrolinyl]propyl]urea, N-(3-methoxyphenyl)-N'-[3-[3-(4-fluorophenyl)methyl-1-pyrrolinyl]propyl]urea, N-(4-fluorophenyl)-N'-[3-[3-(4-fluorophenyl)methyl-1-pyrrolinyl]propyl]urea, N-(3-carboethoxyphenyl)-N'-[3-[3-(4-fluorophenyl)methyl-1-pyrrolinyl]propyl]urea, N-(4-carboethoxyphenyl)-N'-[3-[3-(4-fluorophenyl)methyl-1-pyrrolinyl]propyl]urea, N-(1-adamantyl)-N'-[3-[3-(4-fluorophenyl)methyl-1-pyrrolinyl]propyl]urea, N-phenyl-N'-[3-[3-(2-fluorophenyl)methyl-1-piperidinyl]propyl]urea, N-(3-cyanophenyl)-N'-[3-[3-(2-fluorophenyl)methyl-1-piperidinyl]propyl]urea, N-(3-methoxyphenyl)-N'-[3-[3-(2-fluorophenyl)methyl-1-piperidinyl]propyl]urea, N-(4-fluorophenyl)-N'-[3-[3-(2-fluorophenyl)methyl-1-piperidinyl]propyl]urea, N-(3-methoxyphenyl)-N'-[3-[3-(3-fluorophenyl)methyl-1-piperidinyl]propyl]urea, N-(3-cyanophenyl)-N'-[3-[3-(3-fluorophenyl)methyl-1-piperidinyl]propyl]urea, N-(4-fluorophenyl)-N'-[3-[3-(3-fluorophenyl)methyl-1-piperidinyl]propyl]urea N-[3-(1-methyltetrazol-5-yl)phenyl]-N'-[3-[4-(4-fluorophenylmethyl)-1-piperidinyl]propyl]urea, N-[3-(1-methyltetrazol-5-yl)phenyl] -N'-[3-[3-(4-fluorophenylmethyl)-1-piperidinyl]propyl]urea, N-[3,5-bis(1-methyltetrazol-5-yl)phenyl]-N'-[3-[4-(4-fluorophenylmethyl)-1-piperidinyl]propyl)urea, N-[3,5-bis(1-methyltetrazol-5-yl)phenyl]-N'-[3-[3-(4-fluorophenylmethyl)-1-piperidinyl]propyl]urea, N-[4-(1-methyltetrazol-5-yl)phenyl]-N'-[3-[4-(4-fluorophenylmethyl)-1-piperidinyl]propyl]urea, and N-[4-(1-methyltetrazol-5-yl)phenyl]-N'-[3-[3-(4-fluorophenylmethyl)-1-piperidinyl)propyl]urea.
12. The compound of claim 1 and pharmaceutically acceptable salt forms thereof, wherein the compound of formula (I) is selected from:
N-(1-adamantyl)-N'-[3-[4-(phenylmethyl)-1-piperidinyl]
propyl)urea, and N-[1-(trans-2-phenylcyclopropyl))-N'-[3-[4-(phenylmethyl)-1-piperidinyl]propyl)urea.
13. The compound of claim 1 and pharmaceutically acceptable salt forms thereof, wherein the compound of formula (I) is selected from:
N-(3-methoxyphenyl)-N'-[3,-[1,4-bis(phenylmethyl)-1-piperidinium]propyl]urea bromide, N-(3-cyanophenyl)-N'-[3-[1,4-bis(phenylmethyl)-1-piperidinium]propyl]urea bromide, N-(3-methoxyphenyl)-N'-[3-[1-methyl-4-(phenylmethyl)-2-piperidinium]propyl]urea bromide, N-(3-cyanophenyl)-N'-[3-[1-methyl-4-(phenylmethyl)-1-piperidinium]propyl]urea bromide, N-(3-cyanophenyl)-N'-[3-[1-(carbomethoxymethyl)-4-(phenylmethyl)-1-piperidinium]propyl]urea bromide, N-(4-fluorophenyl)-N'-[3-[1-methyl-4-(phenylmethyl)-1-piperidinium]propyl]urea bromide, N-(4-fluorophenyl)-N'-[3-[1,4-bis(phenylmethyl)-1-piperidinium]propyl]urea bromide, N-(4-fluorophenyl)-N'-(3-[1-(carbomethoxymethyl)-4-(phenylmethyl)-2-piperidinium]propyl]urea bromide, N-(3-cyanophenyl)-N'-[3-[1-(cyanomethyl)-4-(phenylmethyl)-1-piperidinium]propyl)urea bromide, N-(3-cyanophenyl)-N'-[3-[1-(phenylcarbonylmethyl)-4-(phenylmethyl)-1-piperidinium]propyl)urea bromide, N-(2-methoxyphenyl)-N'-[3-[1-methyl-4-(phenylmethyl)-1-piperidinium]propyl]urea bromide, N-(4-methoxyphenyl)-N'-[3-[1-methyl-4-(phenylmethyl)-1-piperidinium]propyl]urea bromide, N-(3-methoxyphenyl)-N'-[3-[1-oxo-4-(phenylmethyl)-1-piperidinium]propyl]urea, and N-(3-methoxyphenyl)-N'-[3-[1-methyl-4-(phenylmethyl)-1-piperidinium]propyl]urea iodide.
14. The compound of claim 1 and pharmaceutically acceptable salt forms thereof, wherein the compound of formula (I) is selected from:
N-(3-cyanophenyl)-N'-[4-[4-(phenylmethyl)-1-piperidinyl) butyl]urea, N-(3-acetylphenyl)-N'-[4-[4-(4-fluorophenylmethyl)-1-piperidinyl]butyl]urea, N-(3,5-diacetylphenyl)-N'-[4-[4-(4-fluorophenylmethyl)-1-piperidinyl)butyl]urea, N-(3-cyanophenyl)-N'-[4-[4-(4-fluorophenylmethyl)-1-piperidinyl]butyl]urea, N-(3-acetylphenyl)-N'-[4-[3-(4-fluorophenylmethyl)-1-piperidinyl]butyl]urea, N-(3,5-diacetylphenyl)-N'-[4-[3-(4-fluorophenylmethyl)-1-piperidinyl]butyl]urea, N-(3-cyanophenyl)-N'-[4-[3-(4-fluorophenylmethyl)-1-piperidinyl)butyl]urea, N-(3-methoxyphenyl)-N'-[4-[3-(4-fluorophenylmethyl)-1-piperidinyl]butyl]urea, N-(4-fluorophenyl)-N'-[4-[3-(4-fluorophenylmethyl)-1-piperidinyl]butyl]urea, N-phenyl-N'-[4-[3-(4-fluorophenylmethyl)-1-piperidinyl]butyl]urea,N-[3-(2-methyltetrazol-5-yl)phenyl]-N'-[4-[4-(4-fluorophenylmethyl)-1-piperidinyl)butyl]urea, N-[3-(1-methyltetrazol-5-yl)phenyl]-N'-[4-[3-(4-fluorophenylmethyl)-1-piperidinyl)butyl]urea, N-[3,5-bis(1-methyltetrazol-5-yl)phenyl]-N'-[4-[4-(4-fluorophenylmethyl)-1-piperidinyl)butyl]urea, N-[3,5-bis(1-methyltetrazol-5-yl)phenyl]-N'-[4-[3-(4-fluorophenylmethyl)-1-piperidinyl]butyl]urea, N-(3-carbomethoxyphenyl)-N'-[4-[4-(phenylmethyl)-1-piperidinyl]butyl]urea, N-(3-iodophenyl)-N'-[4-[4-(phenylmethyl)-1-piperidinyl]butyl] urea, N-[1-(4-benzyloxyphenyl)]-N'-[4-[4-(phenylmethyl)-1-piperidinyl]butyl]urea, N-(1-adamantyl)-N'-[4-[4-(phenylmethyl)-1-piperidinyl]butyl]urea, N-(3-methoxyphenyl)-N'-[4-[4-(phenylmethyl)-2-piperidinyl]butyl]urea, N-phenyl-N'-[4-[4-(phenylmethyl)-1-piperidinyl)butyl]urea, N-(3-methoxyphenyl)-N'-[4-[4-(phenylmethyl)-1-piperidinyl]butyl)urea, N-(4-carbomethoxyphenyl)-N'-[4-[4-(phenylmethyl)-1-piperidinyl]butyl]urea, N-(4-cyanophenyl)-N'-[4-[4-(phenylmethyl)-1-piperidinyl]
butyl]urea, N-(3-acetylphenyl)-N'-{(2Z)-4-[3-(4-fluorobenzyl)-1-piperidinyl]-2-butenyl}urea, N-(3-acetylphenyl)-N'-{(2E)-4-[3-(4-fluorobenzyl)-1-piperidinyl]-2-butenyl}urea, N-(3-cyanophenyl}-N'-{(2Z)-4-[3-(4-fluorobenzyl)-1-piperidinyl]-2-butenyl}urea, N-(4-fluorophenyl)-N'-{(2Z)-4-[3-(4-fluorobenzyl)-1-piperidinyl]-2-butenyl}urea, and N-(3-acetylphenyl)-N'-{4-[3-(4-fluorobenzyl)-1-piperidinyl]-2-butynyl}urea
15. A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of claim 1-14.
16. A method for modulation of chemokine receptor activity comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 1-14.
17. A method for treating or preventing inflammatory diseases, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 1-14.
18. A method for treating or preventing asthma, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 1-14.
19. A compound of formula (I):

or stereoisomers or pharmaceutically acceptable salts thereof, wherein:
M is absent or selected from CH2, CHR5, CHR13, CR13R13, and CR5R13;
Q is selected from CH2, CHR5, CHR13, CR13R13, and CR5R13 J, K, and L are independently selected from CH2, CHR5, CHR6, CR6R6 and CR5R6;
with the provisos:
1) at least one of M, J, K, L, or Q contains an R5;
and 2) when M is absent, J is selected from CH2, CHR5, CHR13, and CR5R13;
Z is selected from NR1a, CHCN, CHNO2, and C(CN)2;
R1a is selected from H, C1-6 alkyl, C3-6 cycloalkyl, CONR1b R1b, OR1b, CN, NO2 , and (CH2)w phenyl ;
R1b is independently selected from H, C1-3 alkyl, C3-6 cycloalkyl, and phenyl;

E is -(CR7R8)-(CR9R10)v-(CR11R12)-, R1 and R2 are independently selected from H, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)r C3-6 cycloalkyl, and a (CH2)r-C3-10 carbocyclic residue substituted with 0-5 R a;
R a, at each occurrence, is selected from C1-4 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)r C3-6 cycloalkyl, Cl, Br, I, F, (CF2)r CF3, NO2, CN, (CH2)r NR b R b, (CH2)r OH, (CH2)r OR c, (CH2)r SH, (CH2)r SR c, (CH2)r C(O)R b, (CH2)r C(O)NR b R b, (CH2)r NR b C(O)R b, (CH2)r C(O)OR b, (CH2)r OC(O)R c, (CH2)r CH(=NR b)NR b R b, (CH2)r NHC(=NR b)NR b R b, (CH2)r S(O)p R c, (CH2)r S(O)2NR b R b, (CH2)r NR b S(O)2R c, and (CH2)r phenyl;
R b, at each occurrence, is selected from H, C1-5 alkyl, C3-6 cycloalkyl, and phenyl;
R c, at each occurrence, is selected from C1-6 alkyl, C3-6 cycloalkyl, and phenyl;
alternatively, R2 and R3 join to form a 5, 6, or 7-membered ring substituted with 0-3 R a;
R3 is selected from a (CR3'R3")r-C3-10 carbocyclic residue substituted with 0-5 R15 and a (CR3'R3")r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R15;
R3' and R3", at each occurrence, are selected from H, C1-6 alkyl, (CH2)r C3-6 cycloalkyl, and phenyl;
R4 is absent, taken with the nitrogen to which it is attached to form an N-oxide, or selected from C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)r-C3-6 cycloalkyl, (CH2)a C(O)R4b, (CH2)q C(O)NR4a R4a', (CH2)q C(O)OR4b, and a (CH2)r-C3-10 carbocyclic residue substituted with 0-3 R4c;
R4a and R4a', at each occurrence, are selected from H, C1-6 alkyl, (CH2)r C3-6 cycloalkyl, and phenyl;
R4b, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, (CH2)r C3-6 cycloalkyl, C2-8 alkynyl, and phenyl;
R4c, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-6 cycloalkyl, Cl, F, Br, I, CN, NO2, (CF2)r CF3, (CH2)r OC1-5 alkyl, (CH2)r OH, (CH2)r SC1-5 alkyl, (CH2)r NR4a R4a', and (CH2)r phenyl;
alternatively, R4 joins with R7, R9, or R11 to form a 5, 6 or 7 membered piperidinium spirocycle or pyrrolidinium spirocycle substituted with 0-3 R a;
R5 is selected from a (CR5'R5")t-C3-10 carbocyclic residue substituted with 0-5 R16 and a (CR5'R5")t-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R16.
R5' and R5", at each occurrence, are selected from H, C1-6 alkyl, (CH2)r C3-5 cycloalkyl, and phenyl;
R6, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)r C3-5 cycloalkyl, (CF2)r CF3, CN, (CH2)r NR6a R6a', (CH2)r OH, (CH2)r OR6b, (CH2)r SH, (CH2)r SR6b, (CH2)r C(O)OH, (CH2)r C(O)R6b, (CH2)r C(O)NR6a R6a', (CH2)r NR6d C(O)R6a, (CH2)r C(O)OR6b, (CH2)r OC(O)R6b, (CH2)r S(O)p R6b, (CH2)r S(O)2NR6a R6a' (CH2)r NR6d S(O)2R6b, and (CH2)t phenyl substituted with 0-3 R6 c;
R6a and R6a', at each occurrence, are selected from H, C1-6 alkyl, C3-6 cycloalkyl, and phenyl substituted with 0-3 R6c.
R6b, at each occurrence, is selected from C1-6 alkyl, C3-6 cycloalkyl, and phenyl substituted with 0-3 R6c;
R6c, at each occurrence, is selected from C1-6 alkyl, C3-6 cycloalkyl, Cl, F, Br, I, CN, NO2, (CF2)r CF3, (CH2)r OC1-alkyl, (CH2)r OH, (CH2)r SC1-5 alkyl, and (CH2)r NR6d R6d;
R6d, at each occurrence, is selected from H, C1-6 alkyl, and C3-6 cycloalkyl;
R7, is selected from H, C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)q OH, (CH2)q SH, (CH2)a OR7d, (CH2)q SR7d, (CH2)q NR7a R7a', (CH2)r C(O)OH, (CH2)r C(O)R7b, (CH2)r C(O)NR7a R7a', (CH2)q NR7a C(O)R7a, (CH2)q NR7a C(O)H, (CH2)r C(O)OR7b, (CH2)q OC(O)R7b, (CH2)q S(O)p R7b, (CH2)q S(O)2NR7a R7a', (CH2)a NR7a S(O)2R7b, C1-6 haloalkyl, a (CH2)r-C3-10 carbocyclic residue substituted with 0-3 R7c, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R7c;
R7a and R7a', at each occurrence, are selected from H, C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, a (CH2)r-C3-10 carbocyclic residue substituted with 0-5 R7e, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R7e;
R7b, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, a (CH2)r-C3-6 carbocyclic residue substituted with 0-2 R7e, and a (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R7e;

R7c, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)r C3-6 cycloalkyl, Cl, Br, I, F, (CF2)r CF3, NO2, CN, (CH2)r NR7f R7f, (CH2)r OH, (CH2)r OC1-4 alkyl, (CH2)r SC1-4 alkyl, (CH2)r C(O)OH, (CH2)r C(O)R7b, (CH2)r C(O)NR7f R7f, (CH2)r NR7f C(O)R7a, (CH2)r C(O)OC1-4 alkyl, (CH2)r OC(O)R7b, (CH2)r C(=NR7f)NR7f R7f, (CH2)r S(O)R7b, (CH2)r NHC(=NR7f)NR7f R7f, (CH2)r S(O)2NR7f R7f, (CH2)r NR7f S(O)2R7b, and (CH2)r phenyl substituted with 0-3 R7e;
R7d, at each occurrence, is selected from C1-6 alkyl substituted with 0-3 R7e, alkenyl, alkynyl, and a C3-10 carbocyclic residue substituted with 0-3 R7c;
R7e, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-6 cycloalkyl, Cl, F, Br, I, CN, NO2, (CF2)r CF3, (CH2)r OC1-5 alkyl, OH, SH, (CH2)r SC1-alkyl, (CH2)r NR7f R7f, and (CH2)r phenyl;
R7f, at each occurrence, is selected from H, C1-6 alkyl, and C3-6 cycloalkyl;
R8 is selected from H, C1-6 alkyl, C3-6 cycloalkyl, and (CH2)r phenyl substituted with 0-3 R8a;
R8a, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-6 cycloalkyl, Cl, F, Br, I, CN, NO2, (CF2)r CF3, (CH2)r OC1-5 alkyl, OH, SH, (CH2)r SC1-alkyl, (CH2)r NR7f R7f, and (CH2)r phenyl;
alternatively, R7 and R8 join to form C3-7 cycloalkyl, or =NR8b;
R8b is selected from H, C1-6 alkyl, C3-6 cycloalkyl, OH, CN, and (CH2)r-phenyl;

R9, is selected from H, C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, F, Cl, Br, I, NO2, CN, (CH2)r OH, (CH2)-SH, (CH2)r OR9d, (CH2)r SR9d, (CH2)r NR9aR9a', (CH2)r C(O)OH, (CH2)r C(O)R9b, (CH2)r C(O)NR9a R9a', (CH2)r NR9a C(O)R9a (CH2)r NR9a C(O)H, (CH2)r NR9a C(O)NHR9a, (CH2)r C(O)OR9b, (CH2)r OC(O)R9b, (CH2)r OC(O)NHR9a, ( (CH2)r S(O)p R9b (CH2)r S(O)2NR9a R9a', (CH2)r NR9a S(O)2R9b, C1-6 haloalkyl, a (CH2)r-C3-10 carbocyclic residue substituted with 0-5 R9c, and a (CH2)r-5-20 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R9c;
R9a and R9a', at each occurrence, are selected from H, C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, a (CH2)r-C3-10 carbocyclic residue substituted with 0-5 R9e, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R9e;
R9b, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, a (CH2)r-C3-6 carbocyclic residue substituted with 0-2 R9e, and a (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R9e;
R9c, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)r C3-6 cycloalkyl, Cl, Br, I, F, (CF2)r CF3, NO2, CN, (CH2)r NR9f R9f, (CH2)r OH, (CH2)r OC1-4 alkyl. (CH2)r SC1-4 alkyl, (CH2)r C(O)OH, (CH2)r C(O)R9b, (CH2)r C(O)NR9f R9f, (CH2)r NR9f C(O)R9a, (CH2)r C(O)OC1-4 alkyl, (CH2)r OC(O)R9b, (CH2)r C(=NR9f)NR9f R9f, (CH2)r S(O)p R9b (CH2)r NHC(=NR9f)NR9f R9f, (CH2)r S(O)2NR9f R9f, (CH2)r NR9f S(O)2R9b, and (CH2)r phenyl substituted with 0-3 R9e;

R9d, at each occurrence, is selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, a C3-10 carbocyclic residue substituted with 0-3 R9c, and a 5-6 membered heterocyclic system containing 1-4 heteroatoms selected from the group consisting of N, O, and S
substituted with 0-3 R9c;
R9e, at each occurrence, is selected from C1-6 alkyl, alkenyl, C2-8 alkynyl, (CH2)r C3-6 cycloalkyl, Cl, F, Br, I, CN, NO2, (CF2)r CF3, (CH2)r OC1-5 alkyl , OH, SH, (CH2)r SC1-5 alkyl, (CH2)r NR9f R9f, and (CH2)r phenyl;
R9f, at each occurrence, is selected from H, C1-6 alkyl, and C3-6 cycloalkyl;
R10, is selected from H, C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, F, Cl, Br, I, NO2, CN, (CH2)r OH, (CH2)r OR10d.
(CH2)r SR10d, (CH2)r NR10a R10a', (CH2)r C(O)OH, (CH2)r C(O)R10b, (CH2)r C(O)NR10a R10a', (CH2)r NR10a C(O)R10a, (CH2)r NR10a C(O)H, (CH2)r C(O)OR10b, (CH2)r OC(O)R10b.
(CH2)r S(O)p R10b, (CH2)r S(O)2NR10a R10a', (CH2)r NR10a S(O)2R10b, C1-6 haloalkyl, a (CH2)r-C3-10 carbocyclic residue substituted with 0-5 R10c, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R10c;
R10a and R10a', at each occurrence, are selected from H, C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, a (CH2)r-C3-10 carbocyclic residue substituted with 0-5 R10e, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R10e;
R10b, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, a (CH2)r-C3-6 carbocyclic residue substituted with 0-2 R10e, and a (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R10e;
R10c at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)r C3-5 cycloalkyl, Cl, Br, I, F, (CF2)r CF3, NO2, CN, (CH2)r NR10f R10f (CH2)r OH, (CH2)r OC1-4 alkyl, (CH2)r SC1-4 alkyl, (CH2)r C(O)OH, (CH2)r C(O)R10b (CH2)r C(p)NR10f R10f, (CH2)r NR10f C(O)R10a (CH2)r C(O)OC1-4 alkyl, (CH2)r OC(O)R10b (CH2)r C(=NR10f)NR10f R10f, (CH2)r S(O)p R10b (CH2)r NHC(=NR10f) NR10f R10f, (CH2)r S(O)2NR10f R10f, (CH2)r NR10f S(O)2R10b, and (CH2)r phenyl substituted with 0-3 R10e;
R10d at each occurrence, is selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, a C3-10 carbocyclic residue substituted with 0-3 R10c, and a 5-6 membered heterocyclic system containing 1-4 heteroatoms selected from the group consisting of N, O, and S
substituted with 0-3 R10c.
R10e, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)r C3-5 cycloalkyl, Cl, F, Br, I, CN, NO2, (CF2)r CF3, (CH2)r OC1-5 alkyl, OH, SH, (CH2)r SC1-5 alkyl, (CH2)r NR10f R10f and (CH2)r phenyl;
R10f at each occurrence, is selected from H, C1-6 alkyl, and C3-6 cycloalkyl;
alternatively, R9 and R10 join to form C3-7 cycloalkyl, 5-6-membered cyclic ketal, or =O;
with the proviso that when R10 is -OH, R9 is not halogen, cyano, or bonded to the carbon to which it is attached through a heteroatom;

R11, is selected from H, C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)q OH, (CH2)q SH, (CH2)q OR11d, (CH2)q SR11d, (CH2)q NR11a R11a', (CH2)r C(O)OH, (CH2)r C(O)R11b, (CH2)r C(O)NR11a R11a', (CH2)q NR11a C(O)R11a, (CH2)q NR11a C(O)NHR11a, (CH2)r C(O)OR11b. (CH2)q OC(O)R11b, (CH2)q S(O)p R11b, (CH2)q S(O)2NR11a R11a', (CH2)q NR11a S(O)2R11b, C1-6 haloalkyl, a (CH2)r-C3-10 carbocyclic residue substituted with 0-5 R11c, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R11c;
R11a and R11a', at each occurrence, are selected from H, C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, a (CH2)r-C3-10 carbocyclic residue substituted with 0-5 R11e, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R11e;
R11b at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, a (CH2)r-C3-6 carbocyclic residue substituted with 0-2 R11e, and a (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R11e;
R11c, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)r C3-6 cycloalkyl, Cl, Br, I, F, (CF2)r CF3, NO2, CN, (CH2)r NR11f R11f, (CH2)r OH, (CH2)r OC1-4 alkyl, (CH2)r SC1-4 alkyl, (CH2)r C(O)OH, (CH2)r C(O)R11b, (CH2)r C(O)NR11f R11f, (CH2)r NR11f C(O)R11a, (CH2)r C(O)OC1-4 alkyl, (CH2)r OC(O)R11b, (CH2)r C(=NR11f)NR11f R11f, (CH2)r NHC(=NR11f)NR11f R11f, (CH2)r S(O)p R11b, (CH2)r S(O)2NR11f R11f, (CH2)r NR11f S(O)2R11b and (CH2)r phenyl substituted with 0-3 R11e-R11d, at each occurrence, is selected from C1-6 alkyl substituted with 0-3 R11e, C2-5 alkenyl, C2-6 alkynyl, and a C3-10 carbocyclic residue substitutes with 0-3 R11c.
R11e at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-6 cycloalkyl, Cl, F, Br, I, CN, NO2, (CF2)r CF3, (CH2)r OC1-5 alkyl, OH, SH, (CH2)r SC1-alkyl, (CH2)r NR11f R11f, and (CH2)r phenyl;
R11f, at each occurrence, is selected from H, C1-6 alkyl, and C3-6 cycloalkyl;
R12 is selected from H, C1-6 alkyl, (CH2)q OH, (CH2)r C3-6 cycloalkyl, and (CH2)t phenyl substituted with 0-3 R12a;
R12a at each occurrence, is selected from C1-5 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-6 cycloalkyl, Cl, F, Br, I, CN, NO2, (CF2)r CF3, (CH2)r OC1-5 alkyl, OH, SH, (CH2)r SC1-5 alkyl, (CH2)r NR9f R9f, and (CH2)r phenyl;
alternatively, R11 and R12 join to form C3-7 cycloalkyl;
R13, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-6 cycloalkyl, (CF2)w CF3, (CH2)NR13a R13a', (CH2)OH, (CH2)OR13b, (CH2)SH, (CH2)SR13b, (CH2)w C(O)OH, (CH2)w C(O)R13b, (CH2)w C(O)NR13aR13a', (CH2)NR13d C(O)R13a, (CH2)w C(O)OR13b, (CH2)OC(O)R13b, (CH2)w S(O)p R13b, (CH2)w S(O)2NR13a R13a', (CH2)NR13d S(O)2R13b, and (CH2)w-phenyl substituted with 0-3 R13c;
R13a and R13a', at each occurrence, are selected from H, C1-6 alkyl, C3-6 cycloalkyl, and phenyl substituted with 0-3 R13c;
R13b at each occurrence, is selected from C1-6 alkyl, C3-6 cycloalkyl, and phenyl substituted with 0-3 R13c;
R13c, at each occurrence, is selected from C1-6 alkyl, C3-6 cycloalkyl, Cl, F, Br, I, CN, NO2, (CF2)r CF3, (CH2)r OC1-alkyl, (CH2)r OH, (CH2)r SC1-5 alkyl, and (CH2)r NR13d R13d;
R13d, at each occurrence, is selected from H, C1-6 alkyl, and C3-6 cycloalkyl;
R15, at each occurrence, is selected from C1-8 alkyl, (CH2)r C3-6 cycloalkyl, Cl, Br, I, F, NO2, CN, (CHR')r NR15a R15a', (CHR')r OH, (CHR')r O(CHR')r R15d, (CHR')r SH, (CHR')r C(O)H, (CHR')r S(CHR')r R15d, (CHR')r C(O)OH, (CHR')r C(O)(CHR')r R15b, (CHR')r C(O)NR15a R15a', (CHR')r NR15f C(O)(CHR')r R15b, (CHR')r NR15f C(O)NR15f R15f(CHR')r C(O)O(CHR')r R15d, (CHR')r OC(O)(CHR')r R15b, (CHR')r C(=NR15f)NR15a R15a', (CHR')r NHC(=NR15f)NR15f R15f, (CHR')r S(O)p(CHR')r R15b, (CHR')r S(O)2NR15a R15a', (CHR')r NR15f S(O)2(CHR')r R15b, C1-6 haloalkyl, C2-8 alkenyl substituted with 0-3 R', C2-8 alkynyl substituted with 0-3 R', (CHR')r phenyl substituted with 0-3 R15e, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R15e;
R', at each occurrence, is selected from H, C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)r C3-6 cycloalkyl, and (CH2)r phenyl substituted with R15e;
R15a and R15a', at each occurrence, are selected from H, C1-5 alkyl, C2-8 alkenyl, C2-8 alkynyl, a (CH2)r-C3-10 carbocyclic residue substituted with 0-5 R15e, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R15e;

R15b at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, a (CH2)r-C3-6 carbocyclic residue substituted with 0-3 R15e, and (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R15e;
R15d, at each occurrence, is selected from C2-8 alkenyl, C2-8 alkynyl, C1-6 alkyl substituted with 0-3 R15e, a (CH2)r-C3-10 carbocyclic residue substituted with 0-3 R15e, and a (CH2)r5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R15e;
R15e, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)r C3-6 cycloalkyl, Cl, F, Br, I, CN, NO2, (CF2)r CF3, (CH2)r OC1-5 alkyl, OH, SH, (CH2)r SC1-5 alkyl, (CH2)r NR15f R15f, and (CH2)r phenyl ;
R15f, at each occurrence, is selected from H, C1-6 alkyl, C3-5 cycloalkyl, and phenyl;
R16, at each occurrence, is selected from C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)r C3-6 cycloalkyl, Cl, Br, I, F, NO2, CN, (CHR')r NR16a R16a', (CHR')r OH, (CHR')r O(CHR')r R16d, (CHR')r SH, (CHR')r C(O)H, (CHR')r S(CHR')r R16d, (CHR')r C(O)OH, (CHR')r C(O)(CHR')r R16b, (CHR')r C(O)NR16a R16a', (CHR')r NR16f C(O)(CHR')r R16b, (CHR')r C(O)O(CHR')r R16d, (CHR)r OC(O)(CHR')r R16b, (CHR')r C(=NR16f)NR16a R16a', (CHR')r NHC(=NR16f)NR16f R16f, (CHR')r S(O)p(CHR')r R16b, (CHR')r S(O)2NR16a R16a', (CHR')r NR16f S(O)2 (CHR')r R16b, C1-6 haloalkyl, C2-8 alkenyl substituted with 0-3 R', C2-8 alkynyl substituted with 0-3 R', and (CHR')r phenyl substituted with 0-3 R16e.
R16a and R16a', at each occurrence, are selected .from H, C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, a (CH2)r-C3-10 carbocyclic residue substituted with 0-5 R16e, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R16e;
R16b at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, a (CH2)r C3-6 carbocyclic residue substituted with 0-3 R16e, and a (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R16e;
R16d, at each occurrence, is selected from C2-8 alkenyl, C2-8 alkynyl, C1-6 alkyl substituted with 0-3 R16e a (CH2)r-C3-10 carbocyclic residue substituted with 0-3 R16e, and a (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R16e;
R16e at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)r C3-6 cycloalkyl, Cl, F, Br, I, CN, NO2, (CF2)r CF3, (CH2)r OC1-5 alkyl, OH, SH, (CH2)r SC1-5 alkyl, (CH2)r NR16f R16f, and (CH2)r phenyl;
R16f, at each occurrence, is selected from H, C1-5 alkyl, and C3-6 cycloalkyl, and phenyl;
v is selected from 0, 1, and 2;
t is selected from 1 and 2;
w is selected from 0 and 1;
r is selected from 0, 1, 2, 3, 4, and 5;
q is selected from 1, 2, 3, 4, and 5; and p is selected from 1, 2, and 3.
20. The compound of claim 19, wherein:
R4 is absent, taken with the nitrogen to which it is attached to form an N-oxide, or selected from C1-8 alkyl, (CH2)r C3-6 cycloalkyl, and (CH2)r-phenyl substituted with 0-3 R4c;
R4c, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-6 cycloalkyl, Cl, F, Br, I, CN, NO2, (CF2)r CF3, (CH2)r OC1-5 alkyl, (CH2)r OH, (CH2)r SC1-5 alkyl, (CH2)r NR4a R4a' and (CH2)r phenyl;
alternatively, R4 joins with R7, R9, or R11 to form a 5, 6 or 7 membered piperidinium spirocycle or pyrrolidinium spirocycle substituted with 0-3 R a;
R1 and R2 are independently selected from H and C1-4 alkyl;
R6, at each occurrence, is selected from C1-4alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)r C3-6 cycloalkyl, (CF2)r CF3, CN, (CH2)r OH, (CH2)r OR6b, (CH2)r C(O)R6b, (CH2)r C(O)NR6a R6a', (CH2)r NR6d C(O)R6a, and (CH2)t phenyl substituted with 0-3 R6c;
R6a and R6a', at each occurrence, are selected from H, C1-6 alkyl, C3-6 cycloalkyl, and phenyl substituted with 0-3 R6c;
R6b, at each occurrence, is selected from C1-6 alkyl, C3-6 cycloalkyl, and phenyl substituted with 0-3 R6c;
R6c, at each occurrence, is selected from C1-6 alkyl, C3-6 cycloalkyl, Cl, F, Br, I, CN, NO2, (CF2)r CF3, (CH2)r OC1-alkyl, (CH2)r OH, (CH2)r SC1-5 alkyl, and (CH2)r NR6d R6d;

R6d, at each occurrence, is selected from H, C1-6 alkyl, and C3-6 cycloalkyl;
R7, is selected from H, C1-3 alkyl, (CH2)r C3-5 cycloalkyl, (CH2)q OH, (CH2)a OR7d, (CH2)q NR7aR7a', (CH2)r C(O)R7b, (CH2)r C(O)NR7aR7a', (CH2)q NR7a C(O)R7a, C1-6 haloalkyl, (CH2)r phenyl with 0-2 R7c;
R7a and R7a', at each occurrence, are selected from H, C1-6 alkyl, (CH2)r C3-5 cycloalkyl, a (CH2)r phenyl substituted with 0-3 R7e;
R7b, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)r C3-6 cycloalkyl, (CH2)r phenyl substituted with 0-3 R7e;
R7c, at each occurrence, is selected from C1-4 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)r C3-5 cycloalkyl, Cl, Br, I, F, (CF2)r CF3, NO2, CN, (CH2)r NR7f R7f, (CH2)r OH, (CH2)r OC1-4 alkyl, (CH2)r C(O)R7b, (CH2)r C(O)NR7f R7f, (CH2)r NR7f C(O)R7 a, (CH2)r S(O)p R7b, (CH2)r S(O)2NR7f R7f, (CH2)r NR7f S(O)2R7b, and (CH2)r phenyl substituted with 0-2 R7e;
R7d, at each occurrence, is selected from C1-6 alkyl, (CH2)r C3-6 cycloalkyl, (CH2)r phenyl substituted with 0-3 R7e;
R7e, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-6 cycloalkyl, Cl, F, Br, I, CN, NO2, (CF2)r CF3, (CH2)r OC1-5 alkyl, OH, SH, (CH2)r SC1-alkyl, (CH2)r NR7f R7f, and (CH2)r phenyl;
R7f, at each occurrence, is selected from H, C1-5 alkyl, and C3-6 cycloalkyl;
R8 is H or joins with R7 to form C3-7 cycloalkyl or =NR8b;

R11, is selected from H, C1-6 alkyl, (CH2)r C3-5 cycloalkyl, (CH2)q OH, (CH2)q OR11d, (CH2)q NR11aR11a', (CH2)r C(O)R11b, (CH2)r C(O)NR11aR11a', (CH2)q NR11a C(O)R11a, C1-6 haloalkyl, (CH2)r phenyl with 0-2, R11c, (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R15;
R11a and R11a', at each occurrence, are selected from H, C1-6 alkyl, (CH2)r C3-6 cycloalkyl, a (CH2)r phenyl substituted with 0-3 R11e.
R11b, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)r C3-6 cycloalkyl, (CH2)r phenyl substituted with 0-3 R11e.
R11c, at each occurrence, is selected from C1-4 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)r C3-5 cycloalkyl, Cl, Br, I, F, (CF2)r CF3, NO2, CN, (CH2)r NR11f R11f, (CH2)r OH, (CH2)r OC1-4 alkyl, (CH2)r C(O)R11b, (CH2)r C(O)NR11f R11f, (CH2)r NR11f C(O)R11a, (CH2)r S(O)p R11b, (CH2)r S(O)2NR11f R11f, (CH2)r NR11f S(O)2R11b, and (CH2)r phenyl substituted with 0-2 R11e.
R11d, at each occurrence, is selected from C1-6 alkyl, (CH2)r C3-5 cycloalkyl, (CH2)r phenyl substituted with 0-3 R11e.
R11e, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-6 cycloalkyl, Cl, F, Br, I, CN, NO2, (CF2)r CF3, (CH2)r OC1-5 alkyl, OH, SH, (CH2)r SC1-alkyl, (CH2)r NR11f R11f, and (CH2)r phenyl;
R11f, at each occurrence, is selected from H, C1-5 alkyl and C3-6 cycloalkyl;
R12 is H or joins with R11 to form C3-7 cycloalkyl;

R13, at each occurrence, is selected from C1-4 alkyl, C3-6 cycloalkyl, (CH2)NR13a R13a', (CH2)OH, (CH2)OR13b, (CH2)w C(O)R13b (CH2)w C(O)NR13aR13a', (CH2)NR13d C(O)R13a, (CH2)w S(O)2NR13a R13a', (CH2)NR13d S(O)2R13b, and (CH2)w-phenyl substituted with 0-3 R13c;
R13a and R13a', at each occurrence, are selected from H, C1-6 alkyl, C3-6 cycloalkyl, and phenyl substituted with 0-3 R13c R13b, at each occurrence, is selected from C1-6 alkyl, C3-6 cycloalkyl, and phenyl substituted with 0-3 R13c.
R13c, at each occurrence, is selected from C1-6 alkyl, C3-6 cycloalkyl, Cl, F, Br, I, CN, NO2, (CF2)r CF3, (CH2)r OC1-alkyl, (CH2)r OH, and (CH2)r NR13d R13d;
R13d at each occurrence, is selected from H, C1-6 alkyl, and C3-6 cycloalkyl;
v is selected from 1 and 2;
q is selected from 1, 2, and 3; and r is selected from 0, 1, 2, and 3.
21. The compound of claim 20, wherein:
R3 is selected from a (CR3'H)r-carbocyclic residue substituted with 0-5 R15, wherein the carbocyclic residue is selected from phenyl, C3-6 cycloalkyl, naphthyl, and adamantyl; and a (CR3'H)r-heterocyclic system substituted with 0-3 R15, wherein the heterocyclic system is selected from pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, indolinyl, isoindolyl, isothiadiazolyl, isoxazolyl, piperidinyl, pyrrazolyl, 1,2,4-triazolyl, 1,2,3-triazolyl, tetrazolyl, thiadiazolyl, thiazolyl, oxazolyl, pyrazinyl, and pyrimidinyl; and R6 is selected from (CR5'H)t-phenyl substituted with 0-5 R16; and a (CR5'H)t-heterocyclic system substituted with 0-3 R16, wherein the heterocyclic system is selected from pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, isoindolyl, piperidinyl, pyrrazolyl, 1,2,4-triazolyl, 1,2,3-triazolyl, tetrazolyl, thiazolyl, oxazolyl, pyrazinyl, and pyrimidinyl.
22. The compound of claim 21, wherein the compound of formula (I) is:

R16, at each occurrence, is selected from C1-8 alkyl, (CH2)r C3-6 cycloalkyl, CF3, Cl, Br, I, F, (CH2)r NR16a R16a', NO2, CN, OH, (CH2)r OR16d, (CH2)r C(O)R16b, (CH2)r C(O)NR16a R16a', (CH2)r NR16f C(O)R16b, (CH2)r S()p R16b (CH2)r S(O)2NR16a R16a', (CH2)r NR16f S(O)2R16b and (CH2)r phenyl substituted with 0-3 R16e.
R16a and R16a', at each occurrence, are selected from H, C1-6 alkyl, C3-6 cycloalkyl, and (CH2)r phenyl substituted with 0-3 R16e;

R16b, at each occurrence, is selected from H, C1-6 alkyl, C3-6 cycloalkyl, and (CH2)r phenyl substituted with 0-3 R16e.
R16d, at each occurrence, is selected from C1-6 alkyl and phenyl;
R16e at each occurrence, is selected from C1-6 alkyl, Cl, F, Br, I, CN, NO2, (CF2)r CF3, OH, and (CH2)r OC1-5 alkyl;
and R16f at each occurrence, is selected from H, and C1-5 alkyl.
23. The compound of claim of claim 21, wherein the compound of formula (I) is:

R16, at each occurrence, is selected from C1-8 alkyl, (CH2)r C3-6 cycloalkyl, CF3, Cl, Br, I, F, (CH2)r NR16a R16a', NO2, CN, OH, (CH2)r OR16d, (CH2)r C(O)R16b, (CH2)r C(O)NR16a R16a', (CH2)r NR16f C(O)R16b (CH2)r S(O)p R16b, (CH2)r S(O)2NR16a R16a', (CH2)r NR16f S(O)2R16b, and (CH2)r phenyl substituted with 0-3 R16e;
R16a and R16a', at each occurrence, are selected from H, C1-6 alkyl, C3-6 cycloalkyl, and (CH2)r phenyl substituted with 0-3 R16e;
R16b, at each occurrence, is selected from H, C1-6 alkyl, C3-6 cycloalkyl, and (CH2)r phenyl substituted with 0-3 R16e;

R16d, at each occurrence, is selected from C1-6 alkyl and phenyl;
R16e, at each occurrence, is selected from C1-6 alkyl, C1, F, Br, I, CN, NO2, (CF2)rCF3, OH, and (CH2)rOC1-5 alkyl;
and R16f, at each occurrence, is selected from H, and C1-5 alkyl.
24. The compound of claim 22, wherein:
R5 is CH2phenyl substituted with 0-3 R16;
E is -CH2- (CR9R10) - (CR11R12);
R9, is selected from H, C1-6 alkyl, (CH2)rC3-6 cycloalkyl, F, Cl, CN, (CH2)rOH, (CH2)rOR9d, (CH2)rNR9aR9a', (CH2)rOC(O) NHR9a, (CH2)rphenyl substituted with 0-5 R9e, and a heterocyclic system substituted with 0-2 R9e, wherein the heterocyclic system is selected from pyridyl, thiophenyl, furanyl, oxazolyl, and thiazolyl;
R9a and R9a', at each occurrence, are selected from H, C1-6 alkyl, C3-6 cycloalkyl, and (CH2)rphenyl substituted with 0-3 R9e;
R9d, at each occurrence, is selected from C1-6 alkyl and phenyl;
R9e, at each occurrence, is selected from C1-6 alkyl, C1, F, Br, I, CN, NO2, (CF2)rCF3, OH, and (CH2)rOC1-5 alkyl;
R10 is selected from H, C1-5 alkyl, OH, and CH2OH;
alternatively, R9 and R10 join to form C3-7 cycloalkyl, 5-6-membered cyclic ketal or =O;

with the proviso that when R10 is -OH, R9 is not halogen, cyano, or bonded to the carbon to which it is attached through a heteroatom;
R11 is selected from H, C1-8 alkyl, (CH2)rphenyl substituted with 0-5 R11e, and a (CH2)r-heterocyclic system substituted with 0-2 R11e, wherein the heterocyclic system is selected from pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, isoindolyl, piperidinyl, pyrrazolyl, 1,2,4-triazolyl, 1,2,3-triazolyl, tetrazolyl, thiazolyl, oxazolyl, pyrazinyl, and pyrimidinyl; and R11e, at each occurrence, is selected from C1-6 alkyl, C1, F, Br, I, CN, NO2, (CF2)rCF3, OH, and (CH2)rOC1-5 alkyl;
R12 is H;
alternatively, R11 and R12 join to form C3-7 cycloalkyl; and r is selected from 0, l, and 2.
25. The compound of claim 23, wherein:
R5 is CH2phenyl substituted with 0-3 R16;
E is -CH2- (CR9R10) - (CR11R12);
R9, is selected from H, C1-6 alkyl, (CH2)rC3-6 cycloalkyl, F, C1, CN, (CH2)rOH, (CH2)r-OR9d, (CH2)rNR9aR9a', (CH2)rOC(O)NHR9a, (CH2)rphenyl substituted with 0-5 R9e, and a heterocyclic system substituted with 0-2 R9e, wherein the heterocyclic system is selected from pyridyl, thiophenyl, furanyl, oxazolyl, and thiazolyl;

R9a and R9a', at each occurrence, are selected from H, C1-6 alkyl, C3_6 cycloalkyl, and (CH2)rphenyl substituted with 0-3 R9e;
R9d, at each occurrence, is selected from Cl-6 alkyl and phenyl;
R9e, at each occurrence, is selected from C1-6 alkyl, C1, F, Br, I, CN, NO2, (CF2)rCF3, OH, and (CH2)rOC1-5 alkyl;
R10 is selected from H, C1-8 alkyl, OH, and CH2OH;
alternatively, R9 and R10 join to form C3-7 cycloalkyl, 5-,6-membered cyclic ketal or =O;
with the proviso that when R10 is -OH, R9 is not halogen, cyano, or bonded to the carbon to which it is attached through a heteroatom;
R11 is selected from H, C1-8 alkyl, (CH2)rphenyl substituted with 0-5 R11e, and a (CH2)r-heterocyclic system substituted with 0-2 R11e, wherein the heterocyclic system is selected from pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, isoindolyl, piperidinyl, pyrrazolyl, 1,2,4-triazolyl, 1,2,3-triazolyl, tetrazolyl, thiazolyl, oxazolyl, pyrazinyl, and pyrimidinyl; and R11e, at each occurrence, is selected from C1-6 alkyl, Cl, F, Br, I, CN, NO2, (CF2)rCF3, OH, and (CH2)rOC1-5 alkyl;
R12 is H;
alternatively, R11 and R12 join to form C3-7 cycloalkyl; and r is selected from 0, 1, and 2.
26. The compound of claim 24, wherein:
J is selected from CH2 and CHR5;
K is selected from CH2 and CHR5;
L is selected from CH2 and CHR5;
R3 is a C3-10 carbocyclic residue substituted with 0-3 R15, wherein the carbocyclic residue is selected from cyclopropyl, cyclopentyl, cyclohexyl, phenyl, naphthyl and adamantyl, and a (CR3'H)r-heterocyclic system substituted with 0-3 R15, wherein the heterocyclic system is selected from pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, indolinyl, isoindolyl, isothiadiazolyl, isoxazolyl, piperidinyl, pyrrazolyl, 1,2,4-triazolyl, 1,2,3-triazolyl, tetrazolyl, thiadiazolyl, thiazolyl, oxazolyl, pyrazinyl, and pyrimidinyl; and R15, at each occurrence, is selected from C1-8 alkyl, (CH2)rC3-6 cycloalkyl, CF3, Cl, Br, I, F, (CH2)rNR15aR15a', NO2, CN, OH, (CH2)rOR15d, (CH2)rC(O)R15b, (CH2)rC(O)NR15aR15a',(CH2)rNR15fC(O)R15b, (CH2)rS(O)pR15b, (CH2)rS(O)2NR15aR15a', (CH2)rNR15fS(O)2R15b, (CH2)rphenyl substituted with 0-3 R15e, and a (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R15e;

R15a and R15a', at each occurrence, are selected from H, C1-6 alkyl, C3-6 cycloalkyl, and (CH2)rphenyl substituted with 0-3 R15e;
R15b, at each occurrence, is selected from H, C1-6 alkyl, C3-6 cycloalkyl, and (CH2)rphenyl substituted with 0-3 R15e;
R15d, at each occurrence, is selected from C1-6 alkyl and phenyl;
R15e, at each occurrence, is selected from C1-6 alkyl, C1, F, Br, I, CN, NO2, (CF2)rCF3, OH, and (CH2)rOC1-5 alkyl;
and R15f, at each occurrence, is selected from H, and C1-5 alkyl.
27. The compound of claim 25, wherein:
K is selected from CH2 and CHR5;
L is selected from CH2 and CHR5;
R3 is a C3-10 carbocyclic residue substituted with 0-3 R15 wherein the carbocyclic residue is selected from cyclopropyl, cyclopentyl, cyclohexyl, phenyl, naphthyl and adamantyl, and a (CR3'H)r-heterocyclic system substituted with 0-3 R15, wherein the heterocyclic system is selected from pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, indolinyl, isoindolyl, isothiadiazolyl, isoxazolyl, piperidinyl, pyrrazolyl, 1,2,4-triazolyl, 1,2,3-triazolyl, tetrazolyl, thiadiazolyl, thiazolyl, oxazolyl, pyrazinyl, and pyrimidinyl; and R15, at each occurrence, is selected from C1-8 alkyl, (CH2)rC3-5 cycloalkyl, CF3, C1, Br, I, F, (CH2)rNR15aR15a' ,NO2, CN, OH, (CH2)rOR15d, (CH2)rC(O) R15b, (CH2)rC(O)NR15aR15a',(CH2)rNR15fC(O)R15b, (CH2)rS(O)pR15b, (CH2)rC(O)NR15aR15a', (CH2)rNR15S(O)2R15b, (CH2)rphenyl substituted with 0-3 R15e, and a (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R15e;
R15a and R15a', at each occurrence, are selected from H, C1-6 alkyl, C3-6 cycloalkyl, and (CH2)rphenyl substituted with 0-3 R15e;
R15b, at each occurrence, is selected from H, C1-6 alkyl, C3-6 cycloalkyl, and (CH2)rphenyl substituted with 0-3 R15e;
R15d, at each occurrence, is selected from C1-6 alkyl and phenyl;
R15e, at each occurrence, is selected from C1-6 alkyl, C1, F, Br, I, CN, NO2, (CF2)rCF3, OH, and (CH2)rOC1-5 alkyl;
and R15f, at each occurrence, is selected from H, and C1-5 alkyl.
28. The compound of claim 1 and pharmaceutically acceptable salt forms thereof, wherein the compound of formula (I) is selected from:
N"-cyano-N-(3-methoxyphenyl)-N'-[3-[4-(phenylmethyl)-1-piperidinyl]propyl]guanidine, N"-cyano-N-(3-methoxyphenyl)-N'-[3-[4-(4-fluorophenylmethyl)-1-piperidinyl]propyl]guanidine.

N-(3-acetylphenyl)- N"-cyano-N'-[3-[4-(4-fluorophenylmethyl)-1-piperidinyl]propyl]guanidine, N-(3-acetylphenyl)-N"-cyano-N'-{3-[(3S)-3-(4-fluorobenzyl)piperidinyl]propyl}guanidine, N"-cyano-N-(3,5-diacetylphenyl)-N'-{3-[(3S)-3-(4-fluorobenzyl)piperidinyl]propyl}guanidine, N"-cyano-N-(3-[(3S)-3-(4-fluorobenzyl)piperidinyl]propyl}-N'-[3-(1-methyl-1H-tetraazol-5-yl)phenyl]guanidine, N"-cyano-N-(2,4-dimethoxyphenyl)-N'-{3-[(3S)-3-(4-fluorobenzyl)piperidinyl]propyl}guanidine, N-(5-acetyl-2-methoxyphenyl)-N"-cyano-N'-{3-[(3S)-3-(4-fluorobenzyl)piperidinyl]propyl}guanidine, N-(3-acetylphenyl)-N"-cyano-N'-{(3R, 4R)-5-[4-(4-fluorobenzyl)piperidinyl]-4-hydroxy-1-methyl-3-pentyl}guanidine, N"-cyano-N-{3-[(3S)-3-(4-fluorobenzyl)piperidinyl]-2-(2E)-propenyl}-N'-[3-(1-methyl-1H-tetraazol-5-yl)phenyl]guanidine, 2-[(3-acetylanilino)({3-[(4-(4-fluorobenzyl)piperidinyl]propyl}amino)methylene]malono nitrite, 2-[ (3-acetylanilino) ({3- [(3S)-3-(4-fluorobenzyl)piperidinyl]propyl}amino)methylene]malono nitrite, 2-[[3-(1-methyl-1H-tetrazol-5-yl)anilino]({3-[(3S)-3-(4-fluorobenzyl)piperidinyl]propyl}amino)methylene]malono nitrite, N-[(E)-(3-acetylanilino) ( {3-[ (3S)-3-(4-fluorobenzyl)piperidinyl]propyl}amino)methylidene]urea N- [ (E) - (3, 5-diacetylanilino) ( {3- [ (3S) -3- (4-fluorobenzyl)piperidinyl]propyl}amino)methylidene]urea , N-[(E)-[3-(1-methyl-1H-tetrazol-5-yl)anilino]({3-[(3S)-3-(4-fluorobenzyl)piperidinyl]propyl}amino)methylidene]urea ' Methyl (E) - (3 , 5-diacetylanilino) ( {3- [ (3S) -3- (4-fluorobenzyl)piperidinyl]propyl}amino)methylidenecarba mate, 1-(3-{ [ (E)-1-({3-[4-(4-fluorobenzyl)piperidinyl]propyl}amino)-2-nitroethenyl]amino}phenyl)ethanone, and 1-(3-{ [ (E)-1-({3-[ (3S)-3-(4-fluorobenzyl)piperidinyl]propyl}amino)-2-nitroethenyl]amino}phenyl)ethanone.
29. A compound of formula (I):
or stereoisomers or pharmaceutically acceptable salts thereof, wherein:
M is absent or selected from CH2, CHR5, CHR13, CR13R13, and CR5R13;
Q is selected from CH2 , CHR5 , CHR13 , CR13R13 , and CR5R13 ;

J, K, and L are independently selected from CH2, CHR5, CHR6, CR6R6 and CR5R6;
with the provisos:
1) at least one of M, J, K, L, or Q contains an R5;
and 2) when M is absent, J is selected from CH2, CHR5, CHR13 , and CR5R13;
Z is selected from NR1a, CHCN, CHNO2, and C(CN)2;
R1a is selected from H, C1-6 alkyl, C3-6 cycloalkyl, CONR1bR1b, OR1b, CN , NO2 , and (CH2)wphenyl;
R1b is independently selected from H, C1-3 alkyl, C3-6 cycloalkyl, and phenyl;
E is selected from:
ring A is a C3-6 carbocyclic residue;
R1 and R2 are independently selected from H, C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)rC3-6 cycloalkyl, and a (CH2)r-C3-10 carbocyclic residue substituted with 0-5 Ra;
Ra, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)rC3-6 cycloalkyl, C1, Br,.I, F, (CF2)rCF3, NO2, CN, (CH2)rNRbRb, (CH2)rOH, (CH2)rORc, (CH2)rSH, (CH2)rSRc, (CH2)rC(O)Rb, (CH2)rC(O)NRbRb, ( CH2 ) rNRbC ( 0 ) Rb , ( CH2 ) rC ( O ) ORb , ( CHI ) rOC ( O ) R~ , ( CH2 ) rCH ( =NRb ) NRbRb , ( CH2 ) rNHC ( =NRb ) NRZ'Rb , ( CH2 ) r S ( 0 ) pR~ , (CH2)rS(O)2NRbRb, (CH2)rNR~'S(O)2R~, and (CH2)rphenyl;
Rb, at each occurrence, is selected from H, C1-6 alkyl, C3-6 cycloalkyl, and phenyl;
R~, at each occurrence, is selected from C1-6 alkyl, C3-5 cycloalkyl, and phenyl;
alternatively, R2 and R3 join to form a 5, 6, or 7-membered ring substituted with 0-3 Ra;
R3 is selected from a (CR3'R3")r-C3-to carbocyclic residue substituted with 0-5 R15 and a (CR3'R3")r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 Rls;
R3' and R3", at each occurrence, are selected from H, C1_s alkyl, (CH2)rC3-6 cycloalkyl, and phenyl;
3 5 '7 R4 is absent, taken with the nitrogen to which it is attached to form an N-oxide, or selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)r C3-6 cycloalkyl, (CH2)q C(O)R4b, (CH2)q C(O)NR4a R4a', (CH2)q C(O)OR4b, and a (CH2)r-C3-10 carbocyclic residue substituted with 0-3 R4c;
R4a and R4a', at each occurrence, are selected from H, C1-6 alkyl, (CH2)r C3-6 cycloalkyl, and phenyl;
R4b, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, (CH2)r C3-5 cycloalkyl, C2-8 alkynyl, and phenyl;
R4c, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-6 cycloalkyl, Cl, F, Br, I, CN, NO2, (CF2)r CF3, (CH2)r OC1-5 alkyl, (CH2)r OH, (CH2)r SC1-5 alkyl, (CH2)r NR4aR4a' and (CH1)r phenyl;
alternatively, R4 joins with R7, R9, or R11 to form a 5, 6 or 7 membered piperidinium spirocycle or pyrrolidinium spirocycle substituted with 0-3 R a.
R5 is selected from a (CR5'R5")t-C3-10 carbocyclic residue substituted with 0-5 R16 and a (CR5'R5")t-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R16.
R5' and R5", at each occurrence, are selected from H, C1-6 alkyl, (CH2)r C3-6 cycloalkyl, and phenyl;
R6, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)r C3-5 cycloalkyl, (CF2)r CF3, CN, (CH2)r NR6a R6a', (CH2)r OH, (CH2)r OR6b, (CH2)r SH, (CH2)r SR6b, (CH2)r C(O)OH, (CH2)r C(O)R6b, (CH2)r C(O)NR6a R6a', (CH2)r NR6d C(O)R6a, (CH2)r C(O)OR6b, (CH2)r OC(O)R6b, (CH2)r S(O)p R6b, (CH2)r S(O)2NR6a R6a', (CH2)r NR6d S(O)2R6b, and (CH2)t phenyl substituted with 0-3 R6c;
R6a and R6a', at each occurrence, are selected from H, C1-6 alkyl, C3-6 cycloalkyl, and phenyl substituted with 0-3 R6c.
R6b, at each occurrence, is selected from C1-6 alkyl, C3-6 cycloalkyl, and phenyl substituted with 0-3 R6c;
R6c, at each occurrence, is selected from C1-6 alkyl, C3-6 cycloalkyl, Cl, F, Br, I, CN, NO2, (CF2)r CF3, (CH2)r OC1-alkyl, (CH2)r OH, (CH2)r SC1-5 alkyl, and (CH2)r NR6d R6d;
R6d, at each occurrence, is selected from H, C1-6 alkyl, and C3-6 cycloalkyl;
R7, is selected from H, C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)q OH, (CH2)q SH, (CH2)q OR7d, (CH2)q SR7d, (CH2)q NR7a R7a', (CH2)r C(O)OH, (CH2)r C(O)R7b, (CH2)r-C(O)NR7a R7a', (CH2)q NR7a C(O)R7a, (CH2)q NR7a C(O)H, (CH2)r C(O)OR7b, (CH2)q OC(O)R7b, (CH2)q S(O)p R7b, (CH2)q S(O)2NR7a R7a', (CH2)q NR7a S(O)2R7b, C1-6 haloalkyl, a (CH2)r-C3-10 carbocyclic residue substituted with 0-3 R7c, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R7c;
R7a and R7a', at each occurrence, are selected from H, C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)r C3-6 cycloalkyl, a (CH2)r-C3-10 carbocyclic residue substituted with 0-5 R7e, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R7e;
R7b, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, a (CH2)r-C3-6 carbocyclic residue substituted with 0-2 R7e, and a (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R7e;
R7c, at each occurrence, is selected from C1-6 alkyl, alkenyl, C2-8 alkynyl, (CH2)r C3-6 cycloalkyl, Cl, Br, I, F, (CF2)r CF3, NO2, CN, (CH2)r NR7f R7f, (CH2)r OH, (CH2)r OC1-4 alkyl, (CH2)r SC1-4 alkyl, (CH2)r C(O)OH, (CH2)r C(O)R7b, (CH2)r C(O)NR7f R7f, (CH2)r NR7f C(O)R7a, (CH2)r C(O)OC1-4 alkyl, (CH2)r OC(O)R7b, (CH2)r C(=NR7f)NR7f R7f, (CH2)r S(O)p R7b.
(CH2)r NHC(=NR7f)NR7f R7f, (CH2)r S(O)2NR7f R7f, (CH2)r NR7f S(O)2R7b, and (CH2)r phenyl substituted with 0-3 R7e;
R7d, at each occurrence, is selected from C1-6 alkyl substituted with 0-3 R7e, alkenyl, alkynyl, and a C3-10 carbocyclic residue substituted with 0-3 R7c;
R7e, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-6 cycloalkyl, Cl, F, Br, I, CN, NO2, (CF2)r CF3, (CH2)r OC1-5 alkyl, OH, SH, (CH2)r SC1-alkyl, (CH2)r NR7f R7f, and (CH2)r phenyl;
R7f, at each occurrence, is selected from H, C1-6 alkyl, and C3-6 cycloalkyl;
R8 is selected from H, C1-6 alkyl, C3-6 cycloalkyl, and (CH2)t phenyl substituted with 0-3 R8a;
R8a, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-6 cycloalkyl, Cl, F, Br, I, CN, NO2, (CF2)r CF3, (CH2)r OC1-5 alkyl, OH, SH, (CH2)r SC1-alkyl, (CH2)r NR7f R7f, and (CH2)r phenyl;
alternatively, R7 and R8 join to form C3-7 cycloalkyl, or =NR8b;

R8b is selected from H, C1-6 alkyl, C3-6 cycloalkyl, OH, CN, and (CH2)r-phenyl;
R9, is selected from H, C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, F, Cl, Br, I, NO2, CN, (CH2)r OH, (CH2)r SH, (CH2)r OR9d, (CH2)r SR9d, (CH2)r N R9a R9a', (CH2)r C(O)OH, (CH2)r C(O)R9b, (CH2)r C(p)NR9a R9a', (CH2)r NR9a C(O)R9a, (CH2)r NR9a C(O)H, (CH2)r NR9a C(O)NHR9a, (CH2)r C(O)OR9b, (CH2)r OC(O)R9b, (CH2)r OC(O)NHR9a, (CH2)r S(O)p R9b, (CH2)r S(O)1NR9a R9a', (CH2)r NR9a S(O)2R9b C1-6 haloalkyl, a (CH2)r-C3-10 carbocyclic residue substituted with 0-5 R9c, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S;
substituted with 0-3 R9c;
R9a and R9a', at each occurrence, are selected from H, C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, a (CH2)r-C3-10 carbocyclic residue substituted with 0-5 R9e, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R9e;
R9b, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, a (CH2)r-C3-6 carbocyclic residue substituted with 0-2 R9e, and a (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R9e R9c, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)r C3-6 cycloalkyl, Cl, Br, I, F, (CF2)r CF3, NO2, CN, (CH2)r NR9f R9f, (CH2)r OH, (CH2)r OC1-4 alkyl, (CH2)r SC1-4 alkyl, (CH2)r C(O)OH, (CH2)r C(O)R9b, (CH2)r C(O)NR9f R9f, (CH2)r NR9f C(O)R9a, (CH2)r C(O)OC1-4 alkyl, (CH2)r OC(O)R9b, (CH2)r C(=NR9f)NR9f R9f, (CH2)r S(O)p R9b, (CH2)r NHC(=NR9f)NR9f R9f, (CH2)=S(O)2NR9f R9f, (CHZ)rNR9fS(O)2R9b, and (CH2)rphenyl substituted with 0-3 R9e;
R9d, at each occurrence, is selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl,, a C3-10 carbocyclic residue substituted with 0-3 R9c, and a 5-6 membered heterocyclic system containing 1-4 heteroatoms selected from the group consisting of N, O, and S
substituted with 0-3 R9c;
R9e, at each occurrence, is selected from C1-6 alkyl, C2-6 alkenyl, C2-8 alkynyl, (CH2)rC3-6 cycloalkyl, C1, F, Br, I, CN, N02, (CF2)rCF3, (CH2)rOCi-5 alkyl, OH, SH, (CH2)rSCl-5 alkyl, (CH2)rNR9fR9f, and (CH2)rphenyl;
R9f, at each occurrence, is selected from H, C1-6 alkyl, and C3-6 cycloalkyl;
R10, is selected from H, C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, F, C1, Br, I, NO2, CN, (CH2)rOH, (CH2)rORl0d, (CH2)rSRl0d (CH2)rNR10aR10a', (CH2)rC(0)OH, ( CH2 ) rC ( O ) RlOb ( CH2 ) rC ( O ) NR10aR10a' , ( CH2 ) rNRlOaC ( O ) RlOa ( CHZ ) rNRi 0aC ( O ) H , ( CH2 ) rC ( O ) ORlOb W CH2 ) rOC ( O ) R10b ( CH2 ) rS ( O ) F,RlOb ( CH2 ) rS ( O ) 2NR10aR10a' .
(CH2)rNR10aS(O)2R10b C1-6 haloalkyl, a (CH2)r-C3-10 carbocyclic residue substituted with 0-5 Rl0c, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, 0, and S, substituted with 0-3 Rl0c;
Rloa and Rl0a' at each occurrence, are selected from H, C1-5 alkyl, C2-8 alkenyl, C2-g alkynyl, a (CH2)r-C3-to carbocyclic residue substituted with 0-5 Rl0e, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, 0, and S, substituted with 0-3 Rl0e;

Rl0b at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, a (CH2)r-C3-5 carbocyclic residue substituted with 0-2 Rl0e, and a (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 Rl0e-Rl0c, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)rC3-6 cycloalkyl, C1, Br, I, F, (CF2)rCF3, NO2, CN, (CH2)rNR10fR10f (CH2);OH, (CH2)rOC1-4 alkyl, (CH2)rSCl-4 alkyl, (CH2)rC(0)OH, (CH2)rC(O)Rl0b (CH2)rC(O)NRlofRl0f, (CH2)rNRl0fC(O)Rl0a (CHZ)rC(O)OC1-4 alkyl, (CH2)rOC(O)Rl0b (CH2)rC(=NRl0f)NR10fR10f (CH2)rS(O)pRl0b (CH2)rNHC(=NRlOf)NR10fR10f (CH2)rS(0)2NR10fR10f (CH2)rNRl0fS(0)2Rl0b, and (CH2)rphenyl substituted with 0-3 R10e.
Rl0d at each occurrence, is selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, a C3-10 carbocyclic residue substituted with 0-3 Rl0c, and a 5-6 membered heterocyclic system containing 1-4 heteroatoms selected from the group consisting of N, O, and S
substituted with 0-3 Rl0c Rl0e, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)rC3-6 cYcloalkyl, C1, F, Br, I, CN, NO2, (CF2)rCF3, (CH2)rOCl-5 alkyl, OH, SH, (CH2)rSCl-5 alkyl, (CH2)rNRlofRl0f, and (CH2)rphenyl;
Rl0f, at each occurrence, is selected from H, C1-5 alkyl, and C3-6 cycloalkyl;
alternatively, R9 and Rl0 join to form C3-7 cycloalkyl, 5-6-membered cyclic ketal or =O;

with the proviso that when R10 is -OH, R9 is not halogen, cyano, or bonded to the carbon to which it is attached through a heteroatom;
R11, is selected from H, C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)q OH, (CH2)q SH, (CH2)q OR11d, (CH2)q SR11d, (CH2)q NR11a R11a', (CH2)r C(O)OH, (CH2)r C(O)R11b, (CH2)r C(O)NR11a R11a', (CH2)q NR11a C(O)R11a, (CH2)q NR11a C(O)NHR11a, (CH2)r C(O)OR11b, (CH2)q OC(O)R11b, (CH2)q S(O)p R11b, (CH2)q S(O)2NR11a R11a', (CH2)q NR11a S(O)2R11b, C1-6 haloalkyl, a (CH2)r-C3-10 carbocyclic residue substituted with 0-5 R11c, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R11c;
R11a and R11a', at each occurrence, are selected from H, C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, a (CH2)r-C3-10 carbocyclic residue substituted with 0-5 R11e, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R11e;
R11b, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, a (CH2)r-C3-6 carbocyclic residue substituted with 0-2 R11e, and a (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R11a, R11c, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)r C3-6 cycloalkyl, Cl, Br, I, F, (CF2)r CF3, NO2, CN, (CH2)r NR11f R11f, (CH2)r OH, (CH2)r OC1-4 alkyl, (CH2)r SC1-4 alkyl, (CH2)r C(O)OH, (CH2)r C(O)R11b, (CH2)r C(O)NR11f R11f, (CH2)r NR11f C(O)R11a, (CH2)r C(O)OC1-4 alkyl, (CH2)r OC(O)R11b, (CH2)r C(=NR11f)NR11f R11f, (CH2)r NHC(=NR11f)NR11f R11f, (CH2)r S(O)p R11b, (CH2)r S(O)2NR11f R11f, (CH2)rNRllfS(O)2Rllb, and (CH2)rphenyl substituted with 0-3 Rlle;
Rlld, at each occurrence, is selected from C1-6 alkyl substituted with 0-3 Rlle, C2-6 alkenyl, C2-6 alkynyl, and a C3-l0 carbocyclic residue substituted with 0-3 Rllc;
Rlle, at each occurrence, is selected from C1-6 alkyl , C2-8 alkenyl, C2-8 alkynyl, C3-6 cycloalkyl, C1, F, Br, I, CN, NO2, (CF2)rCF3, (CH2)rOCl-5 alkyl, OH, SH, (CH2)rSCl-alkyl, (CH2)rNR11fR11f and (CH2)rphenyl;
Rllf, at each occurrence, is selected from H, C1-6 alkyl, and C3-6 cycloalkyl;
R12 is selected from H, C1-6 alkyl, (CH2)qOH, (CH2)rC3-6 cycloalkyl, and (CH2)tphenyl substituted with 0-3 Rl2a.
Rl2a at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-6 cycloalkyl, C1, F, Br, I, CPJ, NO2, (CF2)rCF3, (CH2)rOCl-5 alkyl, OH, SH, (CH2)rSCl-5 alkyl, (CH2)rNR9fR9f, and (CH2)rphenyl;
alternatively, R11 and R12 join to form C3-7 cycloalkyl;
R13, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-6 cycloalkyl, (CF2)wCF3, (CH2) NR13aR13a', (CH2) OH, (CH2) ORl3b (CH2) SH, (CH2)SRl3b (CH2)wC(O)OH, (CH2)wC(O)Rl3b (CH2)wC(O)NR13aR13a', (CH2)NRl3dC(O)Rl3a (CH2)wC(O)ORl3b (CH2)OC(O)Rl3b (CH2)wS(0)pRl3b (CH2)wS(O)2NR13aR13a', (CH2)NRl3dS(O)2R13b, and (CH2)w-phenyl substituted with 0-3 Rl3c;

Rl3a and Rl3a', at each occurrence, are selected from H, C1-6 alkyl, C3-6 cycloalkyl, and phenyl substituted with 0-3 Rl3c;
Rl3b, at each occurrence, is selected from C1-6 alkyl, C3-6 cycloalkyl, and phenyl substituted with 0-3 Rl3c;
Rl3c, at each occurrence, is selected from C1-6 alkyl, C3-6 cycloalkyl, C1, F, Br, I, CN, NO2, (CF2)rCF3, (CH2)rOCl-alkyl, (CHZ)rOH, (CH2)rSCl_5 alkyl, and (CH2)rNR13dR13d;
Rl3d at each occurrence, is selected from H, C1-6 alkyl, and C3-6 cycloalkyl;
R14, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)rC3-5 cycloalkyl, C1, Br, I, F, NO2, CN, (CHR')rNR14aR14a' (CHR')rOH, (CHR')rO(CHR')rRl4d, (CHR')rSH, (CHR')rC(O)H, (CHR') rS (CHR') rRl4d, (CHR') rC(O) OH, (CHR') rC (O) (CHR') rRl4b, (CHR') rC (O) NR14aR14a', (CHR') rNRl4fC (O) (CHR') rRl4b (CHR') rC (O) O (CHR') rRl4d (CHR') rOC (O) ( CHR') rRl4b (CHR') rC (=NR14f)NR14aR14a', (CHR')rNHC(=NRl4f)NR14fR14f (CHR')rS(O)p(CHR')rRl4b (CHR')rS(O)zNR14aR14a'~ (CHR')rNRl4fS(O)2(CHR')rRl4b C1-6 haloalkyl, C2_8 alkenyl substituted with 0-3 R', C2-8 alkynyl substituted with 0-3 R', (CHR')rphenyl substituted with 0-3 Rl4e, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 Rl5e.
R', at each occurrence, is selected from H, C1-6 alkyl, C2 alkenyl, C2-8 alkynyl, (CH2)rC3-6 cYcloalkyl, and (CH?)rphenyl substituted with Rl4e;
Rl4a and Rl4a', at each occurrence, are selected from H, C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, a (CH2)r-C3-10 carbocyclic residue substituted with 0-5 R14e, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R14e;
R14b, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, a (CH2)r-C3-6 carbocyclic residue substituted with 0-3 R14e, and (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R14e;
R14d, at each occurrence, is selected from C2-8 alkenyl, C2-8 alkynyl, C1-6 alkyl substituted with 0-3 R14e a (CH2)r-C3-10 carbocyclic residue substituted with 0-3 R14e and a (CH2)r5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R14e;
R14e, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)r C3-6 cycloalkyl, C1, F, Br, I, CN, NO2, (CF2)r CF3, (CH2)r OC1-5 alkyl, OH, SH, (CH2)r SC1-5 alkyl, (CH2)r NR14f R14f, and (CH2)r phenyl;
R14f, at each occurrence, is selected from H, C1-6 alkyl, C3-6 cycloalkyl, and phenyl;
alternatively, R14 joins with R4 to form a 5, 6 or 7 membered piperidinium spirocycle or pyrrolidinium spirocycle fused to ring A, the spirocycle substituted with 0-3 R a;
R15, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)r C3-6 cycloalkyl, C1, Br, I, F, NO2, CN, (CHR')r NR15a R15a', (CHR')r OH, (CHR')r O(CHR')r R15d, (CHR')r SH, (CHR')r C(O)H, (CHR')r S(CHR')r R15d, (CHR')r C(O)OH, (CHR')r C(O)(CHR')r R15b, (CHR')r C(O)NR15a R15a', (CHR')r NR15f C(O)(CHR')r R15b, (CHR')r C(O)O(CHR')r R15d, (CHR')r OC(O)(CHR')r R15b, (CHR')r C(O)NR15a R15a', (CHR')r C(=NR15f)NR15a R15a', (CHR')r NHC(=NR15f)NR15f R15f, (CHR')r S(O)p(CHR')r R15b, (CHR')r S(O)2NR15a R15a', (CHR')r NR15f S(O)2(CHR')r R15b, C1-6 haloalkyl, C2-8 alkenyl substituted with 0-3 R', C2-8 alkynyl substituted with 0-3 R', (CHR')r phenyl substituted with 0-3 R15e, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R15e;
R15a and R15a', at each occurrence, are selected from H, C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, a (CH2)r-C3-10 carbocyclic residue substituted with 0-5 R15e, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R15e;
R15b, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, a (CH2)r-C3-6 carbocyclic residue substituted with 0-3 R15e, and (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R15e;
R15d at each occurrence, is selected from C2-8 alkenyl, C2-8 alkynyl, C1-6 alkyl substituted with 0-3 R15e, a (CH2)r-C3-10 carbocyclic residue substituted with 0-3 R15e, and a (CH2)r5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R15e;
R15e, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)r C3-6 cycloalkyl, C1, F, Br, I, CN, NO2, (CF2)r CF3, (CH2)r OC1-5 alkyl, OH, SH, (CH2)r SC1-5 alkyl, (CH2)r NR15f R15f, and (CH2)r phenyl;

R15f, at each occurrence, is selected from H, C1-6 alkyl, C3-6 cycloalkyl, and phenyl;
R16, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)r C3-6 cycloalkyl, C1, Br, I, F, NO2, CN, (CHR')r NR16a R16a' (CHR')r OH, (CHR')r O(CHR')r R16d (CHR')r SH, (CHR')r C(O)H, (CHR')r S(CHR')r R16d (CHR')r C(O)OH, (CHR')r C(O)(CHR')r R16b (CHR')r C(O)NR16a R16a', (CHR')r NR16f C(O)(CHR')r R16b, (CHR')r C(O)O(CHR')r R16d, (CHR')r OC(O)(CHR')r R16b, (CHR')r C(=NR16f)NR16a R16a', (CHR')r NHC(=NR16f)NR16f R16f, (CHR')r S(O)p(CHR')r R16b, (CHR')r S(O)2NR16a R16a', (CHR')r NR16f S(O)2(CHR')r R16b, C1-6 haloalkyl, C2-8 alkenyl substituted with 0-3 R', C2-8 alkynyl substituted with 0-3 R', and (CHR')r phenyl substituted with 0-3 R16e;
R16a and R16a', at each occurrence, are selected from H, C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, a (CH2)r-C3-10 carbocyclic residue substituted with 0-5 R16e, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R16e;
R16b, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, a (CH2)r C3-6 carbocyclic residue substituted with 0-3 R16e, and a (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R16e;
R16d, at each occurrence, is selected from C2-8 alkenyl, C2-8 alkynyl, C1-6 alkyl substituted with 0-3 R16e, a (CH2)r-C3-10 carbocyclic residue substituted with 0-3 R16e, and a (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R16e;

R16e, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)r C3-6 cycloalkyl, C1, F, Br, I, CN, NO2, (CF2)r CF3, (CH2)r OC1-5 alkyl, OH, SH, (CH2)r SC1-5 alkyl, (CH2)r NR16f R16f, and (CH2)r phenyl;
R16f, at each occurrence, is selected from H, C1-6 alkyl, and C3-6 cycloalkyl, and phenyl;
g is selected from 0, 1, 2, 3, and 4;
v is selected from 0, 1, and 2;
t is selected from 1 and 2;
w is selected from 0 and 1;
r is selected from 0, 1, 2, 3, 4, and 5;
q is selected from 1, 2, 3, 4, and 5; and p is selected from 1, 2, and 3.
30. The compound of claim 29, wherein:
E is selected from:
and ;
R4 is absent, taken with the nitrogen to which it is attached to form an N-oxide, or selected from C1-8 alkyl, (CH2)r C3-6 cycloalkyl, and (CH2)r -phenyl substituted with 0-3 R4c;
R4c, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-6 cycloalkyl, C1, F, Br, I, CN, NO2, (CF2)r CF3, (CH2)r OC1-5 alkyl, (CH2)r OH, (CH2)r SC1-5 alkyl, (CH2)r NR4a R4a', and (CH2)r phenyl;
alternatively, R4 joins with R7 or R9 to form a 5, 6 or 7 membered piperidinium spirocycle substituted with 0-3 R a;
R1 and R2 are independently selected from H and C1-4 alkyl;
R6, at each occurrence, is selected from C1-4 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)r C3-6 cycloalkyl, (CF2)r CF3, CN, (CH2)r OH, (CH2)r OR6b, (CH2)r C(O)r 6b, (CH2)r C(O)NR6a R6a', (CH2)r NR6d C(O)r 6a, and (CH2)t phenyl substituted with 0-3 R6c;
R6a and R6a', at each occurrence, are selected from H, C1-6 alkyl, C3-6 cycloalkyl, and phenyl substituted with 0-3 R6c;
R6b, at each occurrence, is selected from C1-6 alkyl, C3-6 cycloalkyl, and phenyl substituted with 0-3 R6c;
R6c, at each occurrence, is selected from C1-6 alkyl, C3-6 cycloalkyl, C1, F, Br, I, CN, NO2, (CF2)r CF3, (CH2)r OC1-alkyl, (CH2)r OH, (CH2)r SC1-5 alkyl, and (CH2)r NR6d R6d;

R6d, at each occurrence, is selected from H, C1-6 alkyl, and C3-6 cycloalkyl;
R7, is selected from H, C1-3 alkyl, (CH2)r C3-6 cycloalkyl, (CH2)q OH, (CH2)q OR7d, (CH2)q NR7a R7a', (CH2)r C(O)R7b, (CH2)r C(O)NR7a R7a', (CH2)q NR7a C(O)R7a, C1-6 haloalkyl, (CH2)r phenyl with O-2 R7c;
R7a and R7a', at each occurrence, are selected from H, C1-6 alkyl, (CH2)r C3-6 cycloalkyl, a (CH2)r phenyl substituted with 0-3 R7e;
R7b, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)r C3-cycloalkyl, (CH2)r phenyl substituted with 0-3 R7e;
R7c, at each occurrence, is selected from C1-4 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)r C3-6 cycloalkyl, Cl, Br, I, F, (CF2)r CF3, NO2, CN, (CH2)r NR7f R7f, (CH2)r OH, (CH2)r OC1-4 alkyl, (CH2)r C(O)R7b, (CH2)r C(O)NR7f R7f, (CH2)r NR7f C(O)R7a, (CH2)r S(O)p R7b, (CH2)r S(O)2NR7f R7f, (CH2)r NR7f S(O)2R7b, and (CH2)r phenyl substituted with 0-2 R7e;
R7d, at each occurrence, is selected from C1-6 alkyl, (CH2)r C3-6 cycloalkyl, (CH2)r phenyl substituted with 0-3 R7e;
R7e, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-6 cycloalkyl, C1, F, Br, I, CN, NO2, (CF2)r CF3, (CH2)r OC1-5 alkyl, OH, SH, (CH2)r SC1-alkyl, (CH2)r NR7f R7f, and (CH2)r phenyl;
R7f, at each occurrence, is selected from H, C1-5 alkyl, and C3-6 cycloalkyl;

R8 is H or joins with R7 to form C3-7 cycloalkyl or =NR8b;
R11, is selected from H, C1-6 alkyl, (CH2)r C3-6 cycloalkyl, (CH2)q OH, (CH2)q OR11d (CH2)q NR11a R11a', (CH2)r C(O)r 11b (CH2)r C(O)NR11a R11a', (CH2)q NR11a C(O)R11a, C1-6 haloalkyl, (CH2)r phenyl with 0-2 R11c, (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R15;
R11a and R11a', at each occurrence, are selected from H, C1-6 alkyl, (CH2)r C3-6 cycloalkyl, a (CH2)r phenyl substituted with 0-3 R11e;
R11b at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)r C3-6 cycloalkyl, (CH2)r phenyl substituted with 0-3 R11e;
R11c, at each occurrence, is selected from C1-4 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)r C3-6 cycloalkyl, Cl, Br, I, F, (CF2)r CF3, NO2, CN, (CH2)r NR11f R11f, (CH2)r OH, (CH2)r OC1-4 alkyl, (CH2)r C(O)R11b (CH2)r C(O)NR11f R11f, (CH2)r NR12f C(O)R11a, (CH2)r S(O)p R11b, (CH2)r S(O)2NR11f R11f, (CH2)r NR11f S(O)2R11b, and (CH2)r phenyl substituted with 0-2 R11e;
R11d, at each occurrence, is selected from C1-6 alkyl, (CH2)r C3-6 cycloalkyl, (CH2)r phenyl substituted with 0-3 R11e;
R11e, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-6 cycloalkyl, Cl, F, Br, I, CN, NO2, (CF2)r CF3, (CH2)r OC1-5 alkyl, OH, SH, (CH2)r SC1-alkyl, (CH2)r NR11f R11f, and (CH2)r phenyl;
R11f, at each occurrence, is selected from H, C1-5 alkyl and C3-6 cycloalkyl;

R12 is H or joins with R11 to form C3-7 cycloalkyl;
R13, at each occurrence, is selected from C1-4 alkyl, C3-6 cycloalkyl, (CH2)NR13a R13a', (CH2)OH, (CH2)OR13b, (CH2)w C(O)R13b, (CH2)w C(O)NR13a R13a', (CH2)NR13d C(O)R13a, (CH2)w S(O)2NR13a R13a', (CH2)NR13d S(O)2 R13b, and (CH2)w-phenyl substituted with 0-3 R13c;
R13a and R13a', at each occurrence, are selected from H, C1-6 alkyl, C3-6 cycloalkyl, and phenyl substituted with 0-3 R13c;
R13b, at each occurrence, is selected from C1-6 alkyl, C3-6 cycloalkyl, and phenyl substituted with 0-3 R13c;
R13c at each occurrence, is selected from C1-6 alkyl, C3-6 cycloalkyl, Cl, F, Br, I, CN, NO2, (CF2)r CF3, (CH2)r OC1-alkyl, (CH2)r OH, and (CH2)r NR13d R13d;
R13d at each occurrence, is selected from H, C1-6 alkyl, and C3-6 cycloalkyl;
v is selected from 1 and 2;
q is selected from 1, 2, and 3; and r is selected from 0, 1, 2, and 3.
31. The compound of claim 30, wherein:
ring A is selected from:

R3 is selected from a (CR3'H)r-carbocyclic residue substituted with 0-5 R15, wherein the carbocyclic residue is selected from phenyl, C3-6 cycloalkyl, naphthyl, and adamantyl; and a (CR3'H)r-heterocyclic system substituted with 0-3 R15, wherein the heterocyclic system is selected from pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, indolinyl, isoindolyl, isothiadiazolyl, isoxazolyl, piperidinyl, pyrrazolyl, 1,2,4-triazolyl, 1,2,3-triazolyl, tetrazolyl, thiadiazolyl, thiazolyl, oxazolyl, pyrazinyl, and pyrimidinyl; and R5 is selected from (CR5'H)t-phenyl substituted with 0-5 R16; and a (CR5'H)t-heterocyclic system substituted with 0-3 R16, wherein the heterocyclic system is selected from pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, isoindolyl, piperidinyl, pyrrazolyl, 1,2,4-triazolyl, 1,2,3-triazolyl, tetrazolyl, thiazolyl, oxazolyl, pyrazinyl, and pyrimidinyl.
32. The compound of claim 31, wherein the compound of formula (I) is:

R16, at each occurrence, is selected from C1-8 alkyl, (CH2)r C3-6 cycloalkyl, CF3, Cl, Br, I, F, (CH2)r NR16a R16a', NO2 CN, OH, (CH2)r OR16d, (CH2)r C(O)R16b, (CH2)r C(O)NR16a R16a', (CH2)r NR16f C(O)R16b, (CH2)r S(O)p R16b, (CH2)r S(O)2NR16a R16a', (CH2)r NR16f S(O)2R16b, and (CH2)r phenyl substituted with 0-3 R16e;

R16a and R16a', at each occurrence, are selected from, H, C1-6 alkyl, C3-6 cycloalkyl, and (CH2)r phenyl substituted with 0-3 R16e;

R16b, at each occurrence, is selected from H, C1-6 alkyl, C3-6 cycloalkyl, and (CH2)r phenyl substituted with 0-3 R16e.

R16d, at each occurrence, is selected from C1-6 alkyl and phenyl;

R16e at each occurrence, is selected from C1-6 alkyl, Cl, F, Br, I, CN, NO2, (CF2)r CF3, OH, and (CH2)r OC1-5 alkyl;
and R16f at each occurrence, is selected from H, and C1-5 alkyl.
33. The compound of claim 32, wherein the compound of formula (I) is:

R16, at each occurrence, is selected from C1-8 alkyl, (CH2)r C3-6 cYcloalkyl, CF3, Cl, Br, I, F, (CH2)r NR16a R16a', NO2, CN, OH, (CH2)r OR16d, (CH2)r C(O)R16b, (CH2)r C(O)NR16a R16a', (CH2)r NR16f C(O)R16b (CH2)r S(O)p R16b, (CH2)r S(O)2NR16a R16a', (CH2)r NR16f S(O)2R16b, and (CH2)r phenyl substituted with 0-3 R16e;

R16a and R16a', at each occurrence, are selected from H, C1-6 alkyl, C3-6 cycloalkyl, and (CH2)r phenyl substituted with 0-3 R16e;

R16b at each occurrence, is selected from H, C1-6 alkyl, C3-6 cycloalkyl, and (CH2)r phenyl substituted with 0-3 R16e.

R16d at each occurrence, is selected from C1-6 alkyl and phenyl;

R16e, at each occurrence, is selected from C1-6 alkyl, Cl, F, Br, I, CN, NO2, (CF2)r CF3, OH, and (CH2)r OC1-5 alkyl;
and R16f at each occurrence, is selected from H, and C1-5 alkyl.
34. The compound of claim 32, wherein:
R5 is CH2phenyl substituted with 0-3 R16;
R9, is selected from H, C1-6 alkyl, (CH2)r C3-6 cycloalkyl, F, Cl, CN, (CH2)r OH, (CH2)r OR9d, (CH2)r NR9a R9a', (CH2)r OC(O)NHR9a, (CH2)r phenyl substituted with 0-5 R9e, and a heterocyclic system substituted with 0-2 R9e, wherein the heterocyclic system is selected from pyridyl, thiophenyl, furanyl, oxazolyl, and thiazolyl;

R9a and R9a', at each occurrence, are selected from H, C1-6 alkyl, C3-6 cycloalkyl, and (CH2)r phenyl substituted with 0-3 R9e;

R9d, at each occurrence, is selected from C1-6 alkyl and phenyl;

R9e, at each occurrence, is selected from C1-6 alkyl, Cl, F, Br, I, CN, NO2, (CF2)r CF3, OH, and (CH2)r OC1-5 alkyl;

R10 is selected from H, C1-5 alkyl, OH, and CH2OH;

alternatively, R9 and R10 join to form C3-7 cycloalkyl, 5-6-membered cyclic ketal or =O;

with the proviso that when R10 is -OH, R9 is not halogen, cyano, or bonded to the carbon to which it is attached through a heteroatom;

R11 is selected from H, C1-8 alkyl, (CH2)r phenyl substituted with 0-5 R11e, and a (CH2)r -heterocyclic system substituted with 0-2 R11e, wherein the heterocyclic system is selected from pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, isoindolyl, piperidinyl, pyrrazolyl, 1,2,4-triazolyl, 1,2,3-triazolyl, tetrazolyl, thiazolyl, oxazolyl, pyrazinyl, and pyrimidinyl; and R11e, at each occurrence, is selected from C1-6 alkyl, Cl, F, Br, I, CN, NO2, (CF2)r CF3, OH, and (CH2)r OC1-5 alkyl;

R12 is H;

alternatively, R11 and R12 join to form C3-7 cycloalkyl;

R14, at each occurrence, is selected from C1-8 alkyl, (CH2)r C3-6 cycloalkyl, CF3, Cl, Br, I, F, (CH2)r NR14aR14a', NO2, CN, OH, (CH2)r OR14d, (CH2)r C(O)R14b, (CH2)r C(O)NR14a R14a', (CH2)r NR14f C(O)R14b, (CH2)r S(O)p R14b, (CH2)r S(O)2NR14a R14a', (CH2)r NR14f S(O)2R14b, (CH2)r phenyl substituted with 0-3 R14e.

R14a and R14a' at each occurrence, are selected from H, C1-6 alkyl, C3-6 cycloalkyl, and (CH2)r phenyl substituted with 0-3 R14e, and a (CH2)r -5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R15e;

R14b, at each occurrence, is selected from H, C1-6 alkyl, C3-6 cycloalkyl, and (CH2)r phenyl substituted with 0-3 R14e;

R14d, at each occurrence, is selected from C1-6 alkyl and phenyl;

R14e, at each occurrence, is selected from C1-6 alkyl, Cl, F, Br, I, CN, NO2, (CF2)r CF3, OH, and (CH2)r OC1-5 alkyl;
and R14f, at each occurrence, is selected from H, and C1-5 alkyl; and r is selected from 0, 1, and 2.
35. The compound of claim 33, wherein:
R5 is CH2 phenyl substituted with 0-3 R16;

R9, is selected from H, C1-6 alkyl, (CH2)r C3-6 cycloalkyl, F, Cl, CN, (CH2)r OH, (CH2)r OR9d, (CH2)r NR9a R9a', (CH2)r OC(O)NHR9a, (CH2)r phenyl substituted with 0-5 R9e, and a heterocyclic system substituted with 0-2 R9e, wherein the heterocyclic system is selected from pyridyl, thiophenyl, furanyl, oxazolyl, and thiazolyl;

R9a and R9a', at each occurrence, are selected from H, C1-6 alkyl, C3-6 cycloalkyl, and (CH2)r phenyl substituted with 0-3 R9e;

R9d, at each occurrence, is selected from C1-6 alkyl and phenyl;

R9e, at each occurrence, is selected from C1-6 alkyl, Cl, F, Br, I, CN, NO2, (CF2)r CF3, OH, and (CH2)r OC1-5 alkyl;

R10 is selected from H, C1-8 alkyl, OH, and CH2OH;

alternatively, R9 and R10 join to form C3-7 cycloalkyl, 5-6-membered cyclic ketal or =O;

with the proviso that when R10 is -OH, R9 is not halogen, cyano, or bonded to the carbon to which it is attached through a heteroatom;

R11 is selected from H, C1-8 alkyl, (CH2)r phenyl substituted with 0-5 R11e, and a (CH2)r -heterocyclic system substituted with 0-2 R11e, wherein the heterocyclic system is selected from pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, isoindolyl, piperidinyl, pyrrazolyl, 1,2,4-triazolyl, 1,2,3-triazolyl, tetrazolyl, thiazolyl, oxazolyl, pyrazinyl, and pyrimidinyl; and R11e, at each occurrence, is selected from C1-6 alkyl, Cl, F, Br, I, ON, NO2, (CF2)r CF3, OH, and (CH2)r OC1-5 alkyl;

R12 is H;
alternatively, R11 and R12 join to form C3-7 cycloalkyl;

R14, at each occurrence, is selected from C1-8 alkyl, (CH2)r C3-6 cycloalkyl, CF3, Cl, Br, I, F, (CH2)r NR14aR14a', NO2, CN, OH, (CH2)r OR14d, (CH2)r C(O)R14b, (CH2)r C(O)NR14a R14a', (CH2)r NR14f C(O)R14b, (CH2)r S(O)p R14b, (CH2)r S(O)2NR14a R14a', (CH2)r NR14f S(O)2R14b, (CH2)r phenyl substituted with 0-3 R14e and a (CH2)r -5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R15e.

R14a and R14a' at each occurrence, are selected from H, C1-6 alkyl, C3-6 cycloalkyl, and (CH2)r phenyl substituted with 0-3 R14e.

R14b at each occurrence, is selected from H, C1-6 alkyl, C3-6 cycloalkyl, and (CH2)r phenyl substituted with 0-3 R14e;

R14d, at each occurrence, is selected from C1-6 alkyl and phenyl;

R14e at each occurrence, is selected from C1-6 alkyl, Cl, F, Br, I, CN, NO2, (CF2)r CF3, OH, and (CH2)r OC1-5 alkyl;

R14f at each occurrence, is selected from H, and C1-5 alkyl; and r is selected from 0, 1, and 2.
36. The compound of claim 34, wherein:
J is selected from CH2 and CHR5;

K is selected from CH2 and CHR5;
L is selected from CH2 and CHR5;

R3 is a C3-10 carbocyclic residue substituted with 0-3 R15, wherein the carbocyclic residue is selected from cyclopropyl, cyclopentyl, cyclohexyl, phenyl, naphthyl and adamantyl, and a (CR3'H)r -heterocyclic system substituted with 0-3 R15, wherein the heterocyclic system is selected from pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, indolinyl, isoindolyl, isothiadiazolyl, isoxazolyl, piperidinyl, pyrrazolyl, 1,2,4-triazolyl, 1,2,3-triazolyl, tetrazolyl, thiadiazolyl, thiazolyl, oxazolyl, pyrazinyl, and pyrimidinyl; and R15, at each occurrence, is selected from C1-8 alkyl, (CH2)r C3-5 cycloalkyl, CF3, Cl, Br, I, F, (CH2)r NR15a R15a', NO2, CN, OH, (CH2)r OR15d, (CH2)r C(O)R15b, (CH2)r C(O)NR15a R15a', (CH2)r NR15f C(O)R15b, (CH2)r S(O)p R15b, (CH2)r S(O)2NR15a R15a', (CH2)r NR15f S(O)2R15b, (CH2)r phenyl substituted with 0-3 R15e, and a (CH2)r -5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R15e.

R15a and R15a', at each occurrence, are selected from H, C1-6 alkyl, C3-6 cycloalkyl, and (CH2)r phenyl substituted with 0-3 R15e;

R15b, at each occurrence, is selected from H, C1-6 alkyl, C3-6 cycloalkyl, and (CH2)r phenyl substituted with 0-3 R15e.

R15d, at each occurrence, is selected from C1-6 alkyl and phenyl;

R15e, at each occurrence, is selected from C1-6 alkyl, Cl, F, Br, I, CN, NO2, (CF2)r CF3, OH, and (CH2)r OC1-5 alkyl;
and R15f, at each occurrence, is selected from H, and C1-5 alkyl.
37. The compound of claim 35, wherein:
K is selected from CH2 and CHR5;
L is selected from CH2 and CHR5;

R3 is a C3-10 carbocyclic residue substituted with 0-3 R15, wherein the carbocyclic residue is selected from cyclopropyl, cyclopentyl, cyclohexyl, phenyl, naphthyl and adamantyl, and a (CR3'H)r -heterocyclic system substituted with 0-3 R15, wherein the heterocyclic system is selected from pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, indolinyl, isoindolyl, isothiadiazolyl, isoxazolyl, piperidinyl, pyrrazolyl, 1,2,4-triazolyl, 1,2,3-triazolyl, tetrazolyl, thiadiazolyl, thiazolyl, oxazolyl, pyrazinyl, and pyrimidinyl; and R15, at each occurrence, is selected from C1-8 alkyl, (CH2)r C3-6 cycloalkyl, CF3, Cl, Br, I, F, (CH2)r NR15a R15a', NO2, CN, OH, (CH2)r OR15d, (CH2)r C(O)R15b, (CH2)r C(O)NR15a R15a', (CH2)r NR15f C(O)R15b, (CH2)r S(O)p R15b, (CH2)r S(O)2NR15a R15a', (CH2)r NR15f S(O)2R15b, and (CH2)r phenyl substituted with 0-3 R15e, and a (CH2)r -5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R15e;

R15a and R15a' at each occurrence, are selected from H, C1-6 alkyl, C3-6 cycloalkyl, and (CH2)r phenyl substituted with 0-3 R15e.

R15b, at each occurrence, is selected from H, C1-6 alkyl, C3-6 cycloalkyl, and (CH2)r phenyl substituted with 0-3 R15e.

R15d, at each occurrence, is selected from C1-6 alkyl and phenyl;

R15e at each occurrence, is selected from C1-6 alkyl, Cl, F, Br, I, CN, NO2, (CF2)r CF3, OH, and (CH2)r OC1-5 alkyl;
and R15f at each occurrence, is selected from H and C1-5 alkyl.
38. The compound of claim 29 and pharmaceutically acceptable salt forms thereof, wherein the compound of formula (I) is selected from N"-cyano-N-(3-acetylphenyl)-N'-[(1R,2S)-2-[[(3S)-3-(4 fluorobenzyl)piperidinyl]methyl]cyclohexyl]guanidine, N"-cyano-N-(4-((1H)-1-methyl-tetrazol-5-yl)phenyl)-N'-[(1R,2S)-2-[[(3S)-3-(4-fluorobenzyl)piperidinyl]methyl]cyclohexyl]guanidine, N"-cyano-N-(3-acetylphenyl)-N'-[(1R,2S)-2-[[4-(4-fluorobenzyl)piperidinyl]methyl]cyclohexyl]guanidine, N"-cyano-N-(phenyl)-N'-[(1R,2S)-2-[[4-(4-fluorobenzyl)piperidinyl]methyl]cyclohexyl]guanidine, N"-cyano-N-(phenyl)-N'-[(1R,2S)-2-[[(3S)-3-(4-fluorobenzyl)piperidinyl]methyl]cyclohexyl]guanidine, N"-cyano-N-(3-cyanophenyl)-N'-[(1R,2S)-2-[[(3S)-3-(4-fluorobenzyl)piperidinyl]methyl]cyclohexyl]guanidine, N"-cyano-N-(3-cyanophenyl)-N'-[(1R,2S)-2-[[4-(4-fluorobenzyl)piperidinyl]methyl]cyclohexyl]guanidine, N"-cyano-N-(2,4-dimethoxyphenyl)-N'-[(1R,2S)-2-[[(3S)-3-(4-fluorobenzyl)piperidinyl)methyl]cyclohexyl]guanidine, N"-cyano-N-(2,5-dimethoxyphenyl)-N'-[(1R,2S)-2-[[(3S)-3-(4-fluorobenzyl)piperidinyl]methyl]cyclohexyl]guanidine, N"-cyano-N-(4-((1H)-1-propyl-tetrazol-5-yl)phenyl)-N'-[(1R,2S)-2-[[(3S)-3-(4-fluorobenzyl)piperidinyl]methyl]cyclohexyl]guanidine, N"-cyano-N-(1-adamantyl)-N'-[(1R,2S)-2-[[(3S)-3--(4-fluorobenzyl)piperidinyl]methyl]cyclohexyl]guanidine, N"-cyano-N-(2-adamantyl)-N'-[(1R,2S)-2-[[(3S)-3-(4-fluorobenzyl)piperidinyl]methyl]cyclohexyl]guanidine, N"-cyano-N-(ethoxycarbonylmethyl)-N'-[(1R,2S)-2-[[(3S)-3-(4-fluorobenzyl)piperidinyl]methyl]cyclohexyl]guanidine, N"-cyano-N-(5,6,7,8-tetrahydronaphth-1-yl)-N'-[(1R,2S)-2-[[(3S)-3-(4-fluorobenzyl)piperidinyl]methyl]cyclohexyl]guanidine, N"-cyano-N-(2,4-dimethylphenyl)-N'-[(1R,2S)-2-[[(3S)-3-(4-fluorobenzyl)piperidinyl]methyl]cyclohexyl]guanidine, N"-cyano-N-(2-methoxyphenyl)-N'-[(1R,2S)-2-[[(3S)-3-(4-fluorobenzyl)piperidinyl]methyl]cyclohexyl]guanidine, N"-cyano-N-(2-methyl-4-hydroxyphenyl)-N'-[(1R,2S)-2-[[(3S)-3-(4-fluorobenzyl)piperidinyl]methyl]cyclohexyl]guanidine, N"-cyano-N-(2,5-dimethylphenyl)-N'-[(1R,2S)-2-[[(3S)-3-(4-fluorobenzyl)piperidinyl]methyl]cyclohexyl]guanidine, N"-cyano-N-(2-phenylethyl)-N'-[(1R,2S)-2-[[(3S)-3-(4-fluorobenzyl)piperidinyl]methyl)cyclohexyl]guanidine, N"-cyano-N-(5-acetyl-2-methoxyphenyl)-N'-[(1R,2S)-2-[[(3S)-3-(4-fluorobenzyl)piperidinyl]methyl]cyclohexyl]guanidine, N"-cyano-N-(4-(4-morpholinyl)phenyl]-N'-[(1R,2S)-2-[[(3S)-3-(4-fluorobenzyl)piperidinyl]methyl]cyclohexyl]guanidine, 2-{(3-acetylanilino)[((1R,2S)-2-{[(3S)-3-(4-fluorobenzyl)piperidinyl]methyl}cyclohexyl)amino}methy lene}malonitrile, 2-{(5-acetyl-2-methoxyanilino)[((1R,2S)-2-([(3S)-3-(4-fluorobenzyl)piperidinyl]methyl}cyclohexyl]amino}methy lene)malonitrile, 1-[3-({1-[({(1R,2S)-2-[{3(S)-3-(4-fluorobenzyl)piperidinyl)methyl}cyclohexyl)amino]-2-nitroethenyl}amino)phenyl]ethanone, 1-{3-([1-{(2-[{4-(4-fluorobenzyl)piperidinyl}methyl]phenyl)amino}-2-nitroethenyl]amino)phenyl}ethanone, N"-cyano-N-(3,5-diacetylphenyl)-1-N'-[2-[[4-(4-fluorobenzyl)piperidinyl]methyl)3-(N-methylcarbamoyl)phenyl]guanidine, N"-cyano-N-(3-diacetylphenyl)-1-N'-[2-[[4-(4-fluorobenzyl)piperidinyl]methyl]3-(N-methylcarbamoyl)phenyl]guanidine, and N"-cyano-N-[3-[(1H)-1-methyltetrazol-5-yl]phenyl]-1-N'-[2-[[4-(4-fluorobenzyl)piperidinyl]methyl]3-(N-methylcarbamoyl)phenyl]guanidine.
39. A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound claim 19-38.
40. A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound claim 29.
41. A method for modulation of chemokine receptor activity comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 19-38.
42. A method for modulation of chemokine receptor activity comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 29.
43. A method for treating or preventing inflammatory diseases, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 19-38.
44. A method for treating or preventing inflammatory diseases, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 29.
45. A method for treating or preventing asthma, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 19-38.
46. A method for treating or preventing asthma, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 29.
47. A method for treating or preventing disorders, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 1-18, said disorders being selected from asthma, allergic rhinitis, atopic dermatitis, inflammatory bowel diseases, idiopathic pulmonary fibrosis, bullous pemphigoid, helminthic parasitic infections, allergic colitis, eczema, conjunctivitis, transplantation, familial eosinophilia, eosinophilic cellulitis, eosinophilic pneumonias, eosinophilic fasciitis, eosinophilic gastroenteritis, drug induced eosinophilia, HIV infection, cystic fibrosis, Churg-Strauss syndrome, lymphoma, Hodgkin's disease, and colonic carcinoma.
48. A method for treating or preventing disorders, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 19-38, said disorders being selected from asthma, allergic rhinitis, atopic dermatitis, inflammatory bowel diseases, idiopathic pulmonary fibrosis, bullous pemphigoid, helminthic parasitic infections, allergic colitis, eczema, conjunctivitis, transplantation, familial eosinophilia, eosinophilic cellulitis, eosinophilic pneumonias, eosinophilic fasciitis, eosinophilic gastroenteritis, drug induced eosinophilia, HIV infection, cystic fibrosis, Churg-Strauss syndrome, lymphoma, Hodgkin's disease, and colonic carcinoma.
49. A method for treating or preventing disorders, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of claim 29, said disorders being selected from asthma, allergic rhinitis, atopic dermatitis, inflammatory bowel diseases, idiopathic pulmonary fibrosis, bullous pemphigoid, helminthic parasitic infections, allergic colitis, eczema, conjunctivitis, transplantation, familial eosinophilia, eosinophilic cellulitis, eosinophilic pneumonias, eosinophilic fasciitis, eosinophilic gastroenteritis, drug induced eosinophilia, HIV infection, cystic fibrosis, Churg-Strauss syndrome, lymphoma, Hodgkin's disease, and colonic carcinoma.
CA002350730A 1998-12-18 1999-12-17 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity Abandoned CA2350730A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11271798P 1998-12-18 1998-12-18
US60/112,717 1998-12-18
US16124399P 1999-10-22 1999-10-22
US60/161,243 1999-10-22
PCT/US1999/030332 WO2000035451A1 (en) 1998-12-18 1999-12-17 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity

Publications (1)

Publication Number Publication Date
CA2350730A1 true CA2350730A1 (en) 2000-06-22

Family

ID=26810265

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002350730A Abandoned CA2350730A1 (en) 1998-12-18 1999-12-17 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity

Country Status (4)

Country Link
EP (1) EP1140086A4 (en)
AU (1) AU2057200A (en)
CA (1) CA2350730A1 (en)
WO (1) WO2000035451A1 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6525069B1 (en) 1998-12-18 2003-02-25 Bristol-Myers Squibb Pharma Co. N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
ATE308985T1 (en) 1999-05-18 2005-11-15 Teijin Ltd REMEDIES AND PREVENTION FOR CHEMOKINE-RELATED DISEASES
EP1201239A4 (en) 1999-08-04 2004-12-08 Teijin Ltd Cyclic amine ccr3 antagonists
SE9902987D0 (en) 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
US6784200B2 (en) 2000-10-13 2004-08-31 Bristol-Myers Squibb Pharma Company Bicyclic and tricyclic amines as modulators of chemokine receptor activity
AU1201101A (en) 1999-10-15 2001-04-30 Du Pont Pharmaceuticals Company Bicyclic and tricyclic amines as modulators of chemokine receptor activity
CA2384240A1 (en) 1999-10-15 2001-04-26 Dean A. Wacker Benzylcycloalkyl amines as modulators of chemokine receptor activity
CO5300399A1 (en) 2000-02-25 2003-07-31 Astrazeneca Ab HETEROCICLIOCS CONTAINING NITROGEN, PROCESS FOR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AR028947A1 (en) * 2000-06-20 2003-05-28 Astrazeneca Ab NEW COMPOUNDS
AR028948A1 (en) 2000-06-20 2003-05-28 Astrazeneca Ab NEW COMPOUNDS
WO2001098268A2 (en) 2000-06-21 2001-12-27 Bristol-Myers Squibb Pharma Company Piperidine amides as modulators of chemokine receptor activity
AU2001273129A1 (en) 2000-06-30 2002-01-14 Bristol-Myers Squibb Pharma Company N-ureidoheterocycloaklyl-piperidines as modulators of chemokine receptor activity
AU2001290143A1 (en) 2000-09-29 2002-04-08 Glaxo Group Limited Morpholin-acetamide derivatives for the treatment of inflammatory diseases
DE60130684T2 (en) 2000-12-19 2008-08-14 F. Hoffmann-La Roche Ag SUBSTITUTED PYRROLIDINES AS CCR-3 RECEPTOR ANTAGONISTS
WO2002051414A1 (en) * 2000-12-22 2002-07-04 Takeda Chemical Industries, Ltd. Medicinal compositions for oral use
GB0104050D0 (en) 2001-02-19 2001-04-04 Astrazeneca Ab Chemical compounds
AR035230A1 (en) 2001-03-19 2004-05-05 Astrazeneca Ab BENCIMIDAZOL COMPOUNDS, PROCESS FOR PREPARATION, PHARMACEUTICAL COMPOSITION, PROCESS FOR THE PREPARATION OF SUCH PHARMACEUTICAL COMPOSITION, AND USES OF THESE COMPOUNDS FOR THE PREPARATION OF MEDICINES
GB0107228D0 (en) 2001-03-22 2001-05-16 Astrazeneca Ab Chemical compounds
SE0101038D0 (en) 2001-03-23 2001-03-23 Astrazeneca Ab Novel compounds
SE0103818D0 (en) 2001-11-15 2001-11-15 Astrazeneca Ab Chemical compounds
CN1321115C (en) 2001-11-30 2007-06-13 霍夫曼-拉罗奇有限公司 Piperazine derivatives for use as CCR-3 receptor antagonists in the treatment of asthma
EP1453804B1 (en) 2001-11-30 2007-08-22 F. Hoffmann-La Roche AG Ccr-3 receptor antagonists vii
US6977265B2 (en) 2001-11-30 2005-12-20 Roche Palo Alto Llc Piperidine CCR-3 receptor antagonists
TW200303304A (en) 2002-02-18 2003-09-01 Astrazeneca Ab Chemical compounds
WO2004028530A1 (en) 2002-09-26 2004-04-08 Bristol-Myers Squibb Company N-substituted heterocyclic amines as modulators of chemokine receptor activity
EP1604981A4 (en) 2003-03-14 2008-12-24 Ono Pharmaceutical Co Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient
JP4710606B2 (en) 2003-04-18 2011-06-29 小野薬品工業株式会社 Spiropiperidine compounds and pharmaceutical uses thereof
KR101120414B1 (en) 2003-04-24 2012-04-12 인사이트 코포레이션 Aza spiro alkane derivatives as inhibitors of metalloproteases
US7351720B2 (en) 2003-06-12 2008-04-01 Bristol-Myers Squibb Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US7291744B2 (en) 2003-11-13 2007-11-06 Bristol-Myers Squibb Company N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity
SE0400208D0 (en) 2004-02-02 2004-02-02 Astrazeneca Ab Chemical compounds
PE20060598A1 (en) 2004-09-13 2006-08-21 Ono Pharmaceutical Co HETEROCYCLE DERIVATIVE CONTAINING NITROGEN AS ANTAGONIST OF CCR5 CHEMOKINE
US20110052612A1 (en) 2005-05-31 2011-03-03 Ono Pharmaceutical Co., Ltd. Spiropiperidine compound and medicinal use thereof
TW200738634A (en) 2005-08-02 2007-10-16 Astrazeneca Ab New salt
ES2427989T3 (en) 2005-10-28 2013-11-05 Ono Pharmaceutical Co., Ltd. Compound containing a basic group and its use
PL1961744T3 (en) 2005-11-18 2013-09-30 Ono Pharmaceutical Co Basic group-containing compound and use thereof
RU2008140144A (en) 2006-03-10 2010-04-20 Оно Фармасьютикал Ко., Лтд. (Jp) NITROGEN CONTAINING HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL PRODUCT INCLUDING SUCH DERIVATIVE AS AN ACTIVE INGREDIENT
US8618122B2 (en) 2006-05-16 2013-12-31 Ono Pharmaceutical Co., Ltd. Compound having acidic group which may be protected, and use thereof
WO2008016006A1 (en) 2006-07-31 2008-02-07 Ono Pharmaceutical Co., Ltd. Compound having cyclic group bound thereto through spiro binding and use thereof
WO2010129351A1 (en) 2009-04-28 2010-11-11 Schepens Eye Research Institute Method to identify and treat age-related macular degeneration

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3988294A (en) * 1974-03-11 1976-10-26 R. T. Vanderbilt Company, Inc. Surface coating compositions containing antimicrobic ureas
JP2826826B2 (en) * 1988-04-11 1998-11-18 日本ケミファ株式会社 Alkylenediamine derivative
FR2641278B1 (en) * 1989-01-05 1991-03-22 Lipha PIPERIDINES, METHODS OF PREPARATION AND MEDICAMENTS CONTAINING THEM
FI97540C (en) * 1989-11-06 1997-01-10 Sanofi Sa Process for the preparation of therapeutically useful aromatically substituted piperidine and piperazine derivatives
IL99320A (en) * 1990-09-05 1995-07-31 Sanofi Sa Arylalkylamines, their preparation and pharmaceutical compositions containing them
DE69131842T2 (en) * 1990-10-05 2000-07-27 Ajinomoto Kk Piperidine derivatives and their use as antiarrhythmic agents
DK60893D0 (en) * 1993-05-26 1993-05-26 Novo Nordisk As PIPERIDE INGREDIENTS, THEIR PREPARATION AND USE
US5668151A (en) * 1995-06-07 1997-09-16 Bristol-Myers Squibb Company Dihydropyridine NPY antagonists: piperidine derivatives
GB9523526D0 (en) * 1995-11-17 1996-01-17 Zeneca Ltd Therapeutic compounds
IL125658A0 (en) * 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
PT1131291E (en) * 1998-11-17 2005-01-31 Hoffmann La Roche ANTAGONISTS III OF THE 4-AROIL-PIPERIDIN-CCR-3 RECEPTOR

Also Published As

Publication number Publication date
WO2000035451A1 (en) 2000-06-22
AU2057200A (en) 2000-07-03
EP1140086A1 (en) 2001-10-10
EP1140086A4 (en) 2002-04-03

Similar Documents

Publication Publication Date Title
CA2350730A1 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6444686B1 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6780857B2 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6521592B2 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6486180B1 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
CA2346933A1 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6525069B1 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6605623B1 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
CA2413421A1 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
CA2413274A1 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6897234B2 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
MXPA01006148A (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
AU2001271359A1 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity

Legal Events

Date Code Title Description
FZDE Discontinued